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Abstract
The cyclic adenosine monophosphate (cAMP) signalling pathway is centrally 
involved in the regulation of cell function by many extracellular messengers. 
Signalling through the cAMP pathway is involved in the acute regulation of 
numerous metabolic processes ineluding glucose and lipid metabolism, 
neurotransmission and membrane trafficking. The cAMP pathway also functions to 
affect gene expression and can thereby mediate the long term control of processes 
such as cell growth and differentiation.
Every stage in the cAMP signalling pathway is mediated by a family of enzymes.
This provides opportunities for cell type and developmental stage specific variations 
in the control of the cAMP signalling, dependant upon the particular isoforms of each 
of the components of the cAMP pathway that are expressed in a given cell. In 
addition, each stage in the cAMP pathway is able to interact with components of 
other intracellular signalling pathways and this allows for a cell to modulate its 
response to any one stimuli depending upon the other stimulatory inputs that it 
receives.
f
An important aspect of intracellular signalling is the spatial organisation of the 
components of the various pathways within the 3 dimensional cell interior. The 
paradigm for the spatial organisation of signalling proteins as a regulatory factor 
arose with the identification of protein domains that mediated the rapid clustering of 
tyrosine kinases around activated insulin receptors. It has since become apparent that 
the regulated targeting of a wide variety of signalling proteins to specific subcellular 
locations is an essential feature of much of the signalling that occurs within 
eukaryotic cells.
In chapter 3 of this thesis I have shown that the type 4 phosphodiesterase (PDE4) 
splice variant PDE4D4 can interact specifically with Src homology 3 (SH3) domains 
in vitro. HSPDE4D4 showed a selectivity for the SH3 domains that it could interact 
with and bound most str ongly to the SH3 domains of the tyrosyl kinases Src, Lyn, 
Fyn and Abl and also the SH3 domain of the cytoskeletal protein fodrin. In contrast 
it did not bind to a number of other SH3 domains that were tested. .
In chapter 4 of this thesis I have shown for the first time that it is possible to express 
both full length HSPDE4D4 and also the unique, alternatively spliced, amino 
terminal 166 amino acids of HSPDE4D4 in E.coli as fusion proteins with maltose 
binding protein (MBP) and to purify these species to near homogeneity by affinity 
chromatography. I used these purified fusion proteins to demonstrate a direct 
protein-protein interaction between the alternatively spliced, amino terminal region 
of HSPDE4D4 and the SH3 domain of Lyn kinase.
By engineering a recognition site for a high fidelity viral protease (TEV) into the 
MBP-HSPDE4D4 fusion protein, I was able to separate proteolytically the MBP and 
the HSPDE4D4 moieties and, for the first time, to perform a limited characterisation 
of highly purified, full length HSPDE4D4. This species migrated on SDS-PAGE 
with and apparent Mw of 12 IkDa and catalysed the hydrolysis of cAMP with a Km 
of 2.3pM and an apparent Vmax of 3490pmol/min/mg.
In chapter 5 of this thesis I have mapped sub-regions within the amino terminal of 
RNPDE4A5 that are involved in the interaction with SH3 domains, in the subcellular 
targeting and in the regulation of the catalytic activity of this isoform. My data 
suggest that the extreme amino terminal region, residues 1-10, of RNPDE4A5 are 
important in the interaction of this isoform with the SH3 domain of Lyn kinase. The 
region between residues 218-259 of RNPDE4A5 appears to be involved in both the 
subcellular targeting and the regulation of the catalytic activity of this enzyme.
In chapter 6 of this thesis I have shown that 2 highly conserved regions of sequence 
called Upstream Conserved Regions 1 and 2 (UCRl and UCR2) that characterise the 
amino terminal regions of all long PDE4 isoforms can bind to one another. I have 
shown that this interaction is stabilised by electrostatic bonds between specific 
residues located in the carboxyl terminal portion of UCRl and the amino terminal 
portion of UCR2. This interaction can be regulated by the phosphoiylation of a serine 
residue that lies within the amino terminal region of UCRl and forms a consensus 
recognition site for protein kinase A (PKA).
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1. Introduction
1.1 Cyclic nucleotide signalling pathways
The cyclic nucleotides 3’,5’ cyclic adenosine monophosphate (cAMP) and 3’,5’ 
cyclic guanosine monophosphate (cGMP) are ubiquitous second messengers in 
mammalian cells. They are both small, stable molecules that are well suited to their 
roles in intracellular signalling.
The precursors of each of these molecules, adenosine triphosphate (ATP) and 
guanosine triphosphate (GTP) for cAMP and cGMP respectively, are important 
molecules within cells where their hydrolysis provides free energy to drive anabolic 
reactions and, in the case of GTP, also serves as a timing mechanism for many 
processes. Due to the importance of their roles, the intracellular concentrations of 
these precursor molecules are kept constantly high by homeostatic mechanisms 
within cells. Due to the high levels of ATP and GTP, in normal cells, the cyclases 
that generate cAMP and cGMP can always operate at Vmax when activated. This 
means that a cells responsiveness to signalling through these pathways is not directly 
dependent on the availability of nucleotide triphosphate.
Unlike their precursor molecules, neither cAMP nor cGMP are themselves substrates 
in any major metabolic pathways. This allows for their concentrations to be 
independently controlled within cells.
1.1.1 The cAMP signalling pathway
Many hoimones and gi'owth factors act through the cAMP signalling pathway to 
regulate a diverse range of physiological processes in their target cells. These include 
both acute regulation of various metabolic processes such as glucose and lipid 
metabolism, neurotransmission, membrane trafficking and also the long term control 
of processes such as cell growth and differentiation (37, 44).
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1.1.1.1 Overview o f the cAMP signalling pathway
The cAMP signalling pathway can be thought of as beginning at the cell surface, 
with the binding of an extracellular signalling molecule to a specific, transmembrane 
receptor protein, expressed on the plasma membrane of a target cell. The signal is 
transmitted across the membrane as a conformational change in the receptor protein 
that allows a heterotrimeric guanine nucleotide binding regulatory protein (G- 
protein) to associate with the cytoplasmic domain of the receptor. This G-protein is 
in its guanosine diphosphate (GDP) bound (inactive) state but, upon its interaction 
with an activated receptor it exchanges its bound GDP for a molecule of GTP. This 
exchange results in the disassociation of the G-protein from the receptor and also of 
the GTP bound a  subunit from the py dimer of the G-protein, Both the GTP bound a  
subunit and the py dimer of the G-protein are active signalling molecules and interact 
with downstream elements in the pathway. An important example of such a 
downstream element is adenylyl cyclase, a membrane-bound enzyme that catalyses 
the synthesis of the second messenger, cAMP. All known adenylyl cyclases are 
activated by GTP bound a  subunits of Gs G-proteins (see section 1.1.1.2). The major 
action of cAMP in a cell is to bind to and activate protein kinase A (PKA) which, in 
turn, phosphorylates downstream proteins and thereby regulates their function. The 
degradation and inactivation of cAMP is catalysed by 3’5’ cyclic nucleotide 
phosphodiesterase (PDE) activity which catalyses the hydrolysis of cAMP to AMP 
{Figure 1.1).
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LI. 1.2 Agonist stimulation o f G~protein coupled, heptahelical receptors
Persistent stimulation of cells leads to receptor desensitisation. This occurs by 
numerous mechanisms that operate at the transcriptional, translational and protein 
levels (113). Classically these processes have been regarded as mechanisms to 
dampen a cells responsiveness to strong or persistent stimulations and thereby to 
increase the range over which changes in the intensity of stimulation can be detected. 
Recent evidence, however, suggests that the mechanisms which operate at the protein 
level may function as “pathway switching” as well as “pathway desensitising” 
mechanisms (113).
1-5M.B.Beard Introduction
A large family of G-protein coupled receptors (GPCRs) transmit signals from many 
different extracellular messengers across the plasma membrane to G-proteins (196,
■243). This family of receptors all display a high degree of structural similarity and of 
membrane topology. The primary sequence of each member contains 7 putative 
membrane spanning domains of 22-28 hydrophobic residues, connected by a series 
of extracellular and cytoplasmic loops. The amino terminal region of these receptors 
is located on the extracellular side of the membrane, is of variable length and can be 
glycosolated. The carboxyl terminal region is intracellular and is often a substrate for 
phosphorylation and regulation by kinases such as PKA, protein kinase C (PKC) and 
G-protein coupled receptor kinases (GRKs) (67, 97).
Activation of this class of receptor causes a conformational change that is transmitted 
across the plasma membrane to the intracellular domain of the receptor. This allows 
the cytoplasmic region of the receptor to bind to a G-protein. The receptor bound G- 
protein then undergoes a conformational change that serves to allow the exchange of 
a molecule of GDP, bound to the a  subunit of the G-protein, for GTP. The primary 
site on the GPCR that interacts with G-proteins has been mapped to the third 
cytoplasmic loop (163) although the carboxyl tail region of the GPCR is also of 
major importance in regulating the coupling of G-proteins to GPCRs. It has recently 
been suggested that GPCRs may adopt multiple, ligand specific, conformations that 
interact with G-proteins differently depending on which extracellular messenger 
activated the receptor (195).
1
Both PKA, activated by Gs coupled receptors, and PKC, activated by Gq coupled 
receptors, can phosphorylate GPCRs (113). Phosphorylation by either one of these 
kinases can lead to a conformational change in the receptor that alters its ability to 
interact with G-proteins. Usually the effect of such phosphorylation is to inhibit the 
interaction between the receptor and the G-protein and thereby to dampen 
(desensitise) signalling through that receptor. In at least one case, however, this type 
of phosphorylation leads to a change in the class of coupled G-protein rather than to a 
simple desensitisation or the receptor (43).
■
When expressed in HEK 293 (human embryonic kidney) cells, p2-adrenergic 
receptors (p2-AR) can activate ERKl and ERK2 by a G-protein (Gi) py subunit, Ras 
dependent pathway (43). This activation of MAP kinase signalling is, however, also 
dependent on the activation of PKA as H89, an inhibitor of PKA, can block the 
activation of MAP kinase signalling in this system. The reason that PKA activation is 
necessary for the activation of MAP kinase signalling in this system seems to be that 
PKA regulates the class of G-protein that the p2-AR receptor preferentially couples 
to. Phosphorylation of a PKA site within the third cytoplasmic loop of the receptor 
increases its interaction with the Gi class of G-proteins and decreases its interaction 
with the Gs class of G-proteins. For the P2-AR receptor to activate MAP kinase 
signalling downstream of the activated Gi G-protein Py subunit dimer then, it must 
first activate, and be phosphorylated by, PKA. It therefore appears that, in this 
system, signalling from the p2-AR can be switched from a Gs G-protein coupled 
cAMP, PKA pathway to a Gi G-protein coupled MAP kinase pathway. This is 
achieved by the PKA dependent phosphorylation of the receptor (43).
Another major, protein level mechanism for the desensitisation of GPCRs is a 2-step 
process that begins with the phosphorylation of the receptor by a G-protein receptor 
specific kinase (GRK). This modification increases the affinity of the GPCR for a 
class of binding proteins called arrestins (113). The binding of an an estin to the 
carboxyl terminal region of the GPCR sterically inhibits receptor interaction with G- 
proteins, thereby causing desensitisation. The bound arrestin also leads to receptor 
internalisation by clathrin coated vesicles (113). The internalisation of receptors by 
this mechanism is necessary both for their resensitisation, which is achieved by
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receptor déphosphorylation and also for the activation of ERKl and ERK2 by the 
GPCRs that couple to this pathway (130). The latter appears to involve the formation 
of a multi-protein signalling complex around the internalised receptor. The assembly 
of multi-protein signalling complexes around internalised GPCRs can be considered 
as being analogous to the complexes that form around activated tyrosine kinase 
receptors in the more classical tyrosine kinase signalling pathways.
It appears that, as with every other step in the cAMP signalling pathway, the 
activated receptor provides opportunities for crosstalk between a variety of signalling 
pathways. It is easy to imagine the exquisite control of cell function that could be 
achieved by the temporally co-ordinated activation and desensitisation of a number 
of different pathways that even this single stage of the complete cAMP signalling 
pathway alone can allow for.
1.1.1.3 heterotrimeric G-proteins
The heterotrimeric G-proteins are a subset of a larger family of GTP binding 
proteins. They are composed of an a  subunit (40-5OkDa) that can reversibly 
associate with a (3y subunit dimer (35 and 8kDa for p and y respectively). At least 20 
different isoforms of the a  subunit, 5 of the p subunit and 7 of the y subunit are 
known to exist. This allows for a potential 700 or more distinct G-protein trimers. In 
fact, however, certain combinations of subunits seem to be preferred and only a 
fraction of the theoretically possible trimers have been shown to occur (155).
The a  subunit of the heterotrimeric G-proteins contains the both the guanine 
nucleotide binding site and the site that defines the specificity of interaction between 
the individual G-protein and receptor proteins. Indeed G-protein holoenzymes are 
most often thought of as being defined by their a  subunit. The interaction between a 
G-protein heterotrimer and an activated receptor catalyses the exchange of a bound 
molecule of GDP on the a  subunit of the G-protein for GTP. This exchange 
promotes the disassociation of the a  subunit from both the receptor and from the py 
subunit dimer. Both of these released species are active in signalling. The released py 
subunits of G-proteins can variously interact with certain isofonns of adenylyl
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cyclase, with ras and with phospholipase C. The GTP-bound a  subunits variously 
interact with adenylyl cyclases, with phospholipase C and with certain ion channels. 
Thus, for example, Gs a  shows specificity for adenylyl cyclase activation and Gq a  
shows specificity for PLC activation (242).
In addition to their actions on downstream signalling molecules all G-protein a  
subunits have measurable GTPase activity in vitro and catalyse the gradual 
hydrolysis of the bound GTP to GDP (242). Free a  subunits in the GDP-bound state 
are not themselves active as signalling molecules. They do, however, serve to 
sequester and inactivate free Py dimers thus reforming the holoenzyme. The 
hydrolysis of GTP by the G-protein a  subunit therefore serves as a “timing 
mechanism” for the activation of the G-protein. In the case of the Gi, and possibly 
other classes of, G-proteins the rate of GTP hydrolysis by the released a  subunit is 
regulated by a class of binding proteins called regulators of G-protein signalling 
(RGS) (52).
LI. 1.4 Adenylyl cyclases
Adenylyl cyclases are a family of membrane bound enzymes that catalyse the 
conversion of ATP into cAMP. Nine different mammalian genes encoding adenylyl 
cyclases (classes I-IX) have so fai' been cloned and there is some evidence for 
alternative splicing within these forms (91, 242). The protein sequences of these 
forms all share homology with one another (approximately 50%) and suggest a 
conserved structure composed of 2 transmembrane regions (Ml and M2) that each 
comprise 6 membrane spanning helices connected by short loops. The Ml and M2 
regions are separated from one another by a much larger cytoplasmic loop (Cl). The 
carboxyl terminal tail of these proteins (02) is also cytoplasmic and is well 
conseiwed between the forms (91).
The transmembrane regions of adenylyl cyclase are topologically similar to certain 
ion channels and ATP dependent transporters (85, 109). This has lead to the 
speculation that these regions of the protein may themselves have some transporter or 
ion channel activity . Indeed the adenylyl cyclase of Paramecium does function as a
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voltage dependent K  channel when reconstituted into artificial bilayers (192), 
however no conclusive evidence to support any such activity of a mammalian 
adenylyl cyclase has yet been reported.
The large cytoplasmic regions of mammalian adenylyl cyclases show much higher 
sequence conservation than do the membrane spanning regions (approximately 90% 
homology at the amino acid level). These regions of the protein can be further 
subdivided into Cla, Clb, C2a and C2b. Of these subregions Cl a and C2a are 
homologous to one another and contain the catalytic site of the enzyme (91). The 
Clb subregion is large, poorly conserved between different cyclases, and contains, 
isoform specific regulatory sites. The C2b region of adenylyl cyclases does not have 
an identified function and is extremely short in several of the isoforms.
As yet no 3 dimensional structure for an intact adenylyl cyclase has been reported.
The active sites of these enzymes are, however, entirely contained within the 
intracellular domains C la and C2a. Soluble, regulated, adenylyl cyclase activity can 
be reconstituted by expressing either a tethered Cla-C2a species or by expressing 
C la and C2a individually and then mixing them. The C2a region alone also exhibits 
some forskolin stimulated cyclase activity although this is greatly reduced compared 
to that of either the Cla-C2a heterodimer or to the native enzyme (253).
Crystal structures for both the C2a homodimer and the Cla-C2a heterodimer have 
been reported (230, 253). These species each form similar, wreath like structures in 
which the catalytic residues line a central cleft. The residues that are involved in both 
substrate binding and in the catalysis are shared between the C la and the C2a 
moieties of the heterodimer. This fact is important in understanding the regulation of 
adenylyl cyclases. Its significance is that any agent that affects the relative 
orientation of these 2 domains is a potential regulator of their activity (91). An 
important example of such a regulatory molecule is forskolin; which strongly 
activates all mammalian adenylyl cyclases except for type IX. Forskolin binds to a 
hydrophobic pocket at one end of the central cleft that contains the catalytic site of 
the enzyme and causes activation by moving the elements of the active site together 
(91). The forskolin binding site is very strongly conserved between adenylyl cyclase
1-9M.B.Beard Introduction
I
■I
types I-VIII and this has lead to speculation that a forskolin-like, physiological 
regulator of adenylyl cyclase activity may exist.
The characteristics and regulatory properties of the various mammalian adenylyl 
cyclases differ. All of the isoforms so far identified are activated by the a  subunit of 
Gs G-proteins. In contrast to this there is a deal of variation in the regulation of these 
isoforms by Gi, Go, Gz a  subunits, by G-protein |3y dimers and by other regulators 
such as Ca^  ^calmodulin and PKC {Table 1.1.1).
'x5}„
I
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Effect of regulators
Adenylyl
cyclase
Splice
variants
Chromosome
location
Ca2+ G-protein
Py
subunits
Gi
G-protein 
a subunit
PKC PKA
AC-I 7pI2-7pl3 activates inhibits inhibits activates unknown
AC-II 5pl5.3 no change activates
(+aGs)
no change activates unknown
AC-m* 2p22-2p24 activates
(+aGs)
no change unknown activates unknown
AC-IV 1 4q ll.2 no change activates
(+aGs)
no change no
change
/inhibits
unknown
AC-V 2 3qI3.2-3q2] inhibits no change inhibits no
change
/activates
inhibits
AC-Vl 2 12ql2-I2ql3 inliibits no change inhibits no
change
/activates
inhibits
AC-VII 16ql2-16ql3 no change activates unknown unknown
(activates
.....  ) ... .
unknown
AC-IIX 8q24.2 activates inhibits inhibits unknown unknown
AC-IX inhibits no change unknown unknown unknown
Table l.Ll:Differential regulation o f the multiple forms o f adenylyl cyclase
The table summarises the modes o f regulation o f the known forms o f adenylyl 
cyclase.  ^AC-III is inhibited by phosphorylation by CAMK~II 
Table adapted from (85).
M.B.Beard Introduction l-Il
1.1.1,5 Inactivation o f intracellular cAMP
The major mechanism for the inactivation of cAMP within cells is provided by 
members of the cyclic nucleotide phosphodiesterase (PDE) superfamily of enzymes. 
These enzymes catalyse the hydrolysis of the internal cyclic phosphodiester bond of 
a cyclic nucleotide to generate the cognate 5’ nucleotide monophosphate. Within this 
enzyme superfamily members of the PDEl, PDE2, PDE3, PDE4, PDE7, PDE8 and 
PDE 10 enzyme families have cAMP phosphodiesterase. Most of these families are 
composed of the products from more than a single gene and additional diversity 
arises from alternative splicing. The various cAMP PDEs are expressed in a cell and 
developmental stage specific fashion; also the total cAMP hydrolytic capacity of any 
one cell invariably represents the combined activities of a number of different PDEs. 
This allows for very fine control of the degradation of cAMP. The properties if the 
various PDEs are discussed in detail in sections 1.2 and 1.3.
In addition to inactivation by PDEs, intracellular cAMP and cGMP can be exported 
from certain cell types. This has been shown to be able to occur by facilitated 
diffusion across the plasma membrane of human erythrocytes and also by a 
hormonally regulated, energy dependent transport system that is known to operate in 
pigeon erythrocytes, rat 06 glioma cells, human fibroblasts (normal and 
transformed), human astrocytoma cells, MDCK (dog kidney epithelial) cells and rat 
reticulocytes (23, 77-79, 246). There is, however, little published research on this 
aspect of cyclic nucleotide regulation and the importance of cyclic nucleotide export 
in the regulation of intracellular signalling remains uncleai'.
1.LL6 Protein kinase A
The major intracellular sensor of cAMP in eukaryotic cells is PKA. The inactive, 
holoenzyme form of this protein kinase is a heteroteti'amer (RgCg) that is composed 
of 2 catalytic (C) subunits that are bound to a regulatory (R) subunit dimer. Multiple 
forms of both the C and the R subunits occur and these are differentially expressed in 
tissues.
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Three isoforms of C subunit have been identified: a  p and y. These share homology 
with one another (93% homology between Ca and Cp, 83% homology between Ca 
and Cy, 79% between Cp and Cy at the amino acid level) and also with the catalytic 
subunits of all other eukaryotic protein kinases (240). The various forms of C subunit 
are differentially expressed between tissues. The Ca and Cp foims each have a broad 
tissue distribution. Ca is ubiquitously expresses and is the most abundant of the C 
subunit isofoims. Cp is generally expressed at lower levels than Ca but is enriched in 
neuronal tissue (191). The Cy form has a much more restricted distribution and is 
only readily detected in primate testis (9). The substrate specificities of the Ca and 
Cp isoforms, as defined by in vitro phosphorylation assays, are identical to each 
another and are very similar to that of Cy. The relevanee of the multiplicity and the 
differential expression of these C subunit isoforms to the regulation of signal 
transduction is therefore unclear.
Four isoforms of R subunit have been identified, these are fiiither subdivided into 2 
classes (RI and RII): RIa, Rip, R lla and RIip. The classifieation of PKA 
holoenzymes (into types I and II) is defined by the class of R subunit dimer to which 
the C subunits are bound. All of the R subunits share homology with one other. They 
occur in normal tissues as stable homodimers that form via a dimérisation domain 
located within the amino terminal of these subunits (184). In addition to the 
dimérisation domain each R subunit contains 2 cAMP binding sites that are located 
within the carboxyl terminal third of the polypepeptide and a pseudosubstrate, 
regulatory region that binds to and inhibits the active site of a C subunit in the 
holoenzyme. The binding of a molecule of cAMP to each of the 4 cAMP binding 
sites on the R subunit dimer of the PKA holoenzyme causes a conformational change 
in the protein that results in the dissociation and activation of the 2 bound C subunits.
The various isoforms of R subunit show tissue specific patterns of expression and 
have distinct subcellular localisations. The RI class of R subunits are predominantly 
located in the cytosolic compartment of cells. RIa is expressed in almost all tissues 
whereas Rip is predominantly expressed in brain, testis and placenta. The RII class 
of R subunits are predominantly located to the particulate fractions of cells. The 
targeting of these isoforms is mediated by their specific binding to members of
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the A kinase anchoring protein (AKAP) class of binding proteins (see section 
1.4.2.1). R lla has a broad tissue distribution whilst RIIp is detected predominantly in 
brain, testis and placenta (129).
In addition to the cAMP regulated pool of PKA holoenzyme another, cAMP 
independent, pool of PKA C subunit has been identified in rabbit lung cytosol (256). 
This pool of C subunit is maintained in an inactive state by binding to IicB-a or IkB- 
p in a multiprotein complex comprising the transcription factor NFkB, its regulatory 
protein IkB and the PKA C subunit. The activation and, translocation to the nucleus, 
of NFkB is regulated by signalling pathways that lead to the phosphorylation, 
ubiquitination and degradation of IkB. This results in the release of both NFkB and 
of active PKA C subunit. The released PKA C subunit then phosphorylates and 
activates the transcriptional activation activity of NFkB.
LI. 1.7 PICA independent signalling through cAMP
Although most of the effects of cAMP on cell function ai*e downstream of activated 
PKA, several examples of signalling through cAMP that are independent of PKA 
mediated phosphorylation have been reported.
The RIIp subunit dimer of PKA, in its cAMP bound state, can bind directly to the 
cAMP responsive element (CRE) in the promoter region of cAMP responsive genes 
and can activate transcription independently of the classical CREB/ATF class of 
CRE binding transcription factors (219).
Cyclic AMP can bind to and directly regulate members of the eyclic nucleotide gated 
class of ion channels; examples of this form of signalling by cAMP include olfactory 
adaptation (110) and the modulation of cardiac pacemaker activity (51). Cyclic AMP 
can also bind to and directly regulate the activity of GLUT4 glucose transporters in 
transfected Chinese hamster ovary (CHO) cells (170). Another protein that is directly 
regulated by cAMP in this manner is the guanine nucleotide exchange factor Epac 
(exchange protein directly activated by cAMP) (181). Guanine nucleotide exchange 
factors are a family of enzymes that catalyse the exchange of GDP for GTP on G-
1-14M.B.Beard Introduction
proteins. In the cAMP bound state Epac can activate the small, Ras like GTPase 
Rapl by catalysing the exchange of bound GDP for GTP on Rapl. In its GTP bound 
(active) state Rap-1 can interact with downstream molecules such as B-raf and so 
feed into the mitogen activated kinase (MAP/ERK) signalling pathway (20).
1.2 The 3^ 5^  cyclic nucleotide phosphodiesterase (PDE) superfamily
The 3’5’ cyclic nucleotide phosphodiesterases (PDEs) compose a large and complex 
enzyme superfamily. On the basis of sequence homology this superfamily can be 
broadly divided into 2 distinct classes. Class I PDEs all contain a conserved region of 
approximately 250 residues, normally located towards the carboxyl terminal end of 
the molecule. This region contains the catalytic site of the enzyme and is the only 
region of sequence that is common to all class I PDEs. All known mammalian PDEs 
are members of class I. Class II PDEs do not contain any single identifiable 
conserved unit such as the 250 residue region that is present in the class I enzymes. 
Rather they share homology with one another throughout the entire length of the 
molecule. Members of this class of PDE include the yeast PDE I gene product and 
the Dictyostelium discoideum phosphodiesterase.
At present mammalian PDEs are classified into 10 enzyme families each of which 
comprises the products from up to 4 related but distinct genes. Many of these genes 
have of multiple start sites for transcription that are controlled by distinct (possibly 
tissue specific) promoters and therefore encode multiple, alternatively spliced, 
mRNAs (83, 238). This generates a further level complexity in the classification of 
this enzyme family {Table 1.1.2).
A  standardised nomenclature for describing mammalian PDEs has been devised (8). 
The name of each isoenzyme is constmcted from: (a) 2 letters indicating the source 
species (HS - Homo sapiens or RN - Rattus norvégiens for example); (b) PDE for 
cyclic nucleotide phosphodiesterase; (c) an arabic numeral for the gene family; (d) a 
single letter for the gene; (e) an arabic number for the splice variant; (f) a single letter 
for the report.
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The classification of mammalian PDEs is, nowadays, based primarily on sequence 
homology. Before the widespread availability of sequence information for PDE 
isoenzymes, however, PDE activities were classified according to their biochemical 
and phaimacological characteristics. These were each assigned a descriptive name 
and a roman numeral that alluded to their order of elution from ion exchange 
chromatography columns (87). These various classes of PDE activities roughly 
correspond to individual gene families, as defined by their sequence homology.
Many authors continue to use both the formal and the descriptive nomenclature when 
referring to a PDE family (the cAMP specific, rolipram sensitive PDE4 gene family 
or the Ca2+ calmodulin dependent PDEl gene family, for example).
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1.2.1 The PDEl enzyme family
The PDEl enzyme family is composed of the products from 3 homologous genes (A,
B and C). There is evidence for alternative splicing of the mRNA from each of these 
genes. Three splice variants of PDEl A (128, 213, 214) and 5 splice variants of 
PDE 1C (128, 248, 249) have been characterised. RNase protection assays suggest the 
presence of alternatively spliced PDE IB species (10).
The pattern of splicing of the forms PDE1C4 and PDE1C5 is especially interesting 
because this deviates from the 5’ domain swaps usually seen for other PDE splice 
variants. The open reading frames (ORFs) of the PDE1C4 and PDEl 05 
complementary DNA (cDNA) sequences are identical with the differences being 
confined to their 3 ’ untranslated regions. These differences may be important in the 
post transcriptional regulation of these mRNAs (248).
The various PDEl isoenzymes are differentially expressed in tissues. For instance 
PDElAl, PDEIBI and PDEs 101-5 all show distinct patterns of expression in brain 
whilst PDE1A2 is enriched in heart and lung (128, 248, 249).
1.2.1.1 Regulation o f PDEl
PDEl isoforms can catalyse the hydrolysis of both cAMP and cGMP at physiological 
concentrations. The PDEl A and PDE IB forms each exhibit a Km for cAMP that is 
approximately 10 fold higher than that for cGMP whereas the Km of PDE 10 
isoenzymes for cAMP and cGMP are approximately equivalent (7).
All PDEl enzymes are stimulated by Oa^^/calmodulin binding to one or more 
regulatory calmodulin binding domains located within the amino terminal of the 
protein. The PDEl family of enzymes therefore represents an obvious point of 
crosstalk between the cyclic nucleotide and the Oa^  ^signalling pathways. The 
catalytic activity of PDEl is stimulated at least 10 fold by the binding of calmodulin 
and this is due, almost exclusively, to an increase in Vmax with little change in Km 
(7). The mechanism of activation seems to be that calmodulin binding relieves
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inhibition of the catalytic site of the enzyme by an inliibitoiy domain that is located 
near to the calmodulin binding domain in the amino terminal of PDEl (214).
The splice variant PDE1A2 exhibits a higher affinity for Ca^Vcalmodulin than do the 
other PDEl isoenzymes. This is because this splice variant contains a second 
calmodulin binding domain within an alternatively spliced region at its amino 
terminal (214).
PDEl enzymes are subject to regulation by phosphorylation. PDEl A l, PDE1A2 and 
PDE IB are all substrates for phosphorylation by PKA (202). PDE IB can also be 
phosphoiylated by CaM kinase II (75). Phosphorylation of these isoforms appears to 
reduce their affinity for Ca^^^/calmodulun and therefore reduces their activity. The 
phosphoiylation of PDEl by PKA therefore has the potential to form a positive 
feedback loop in which cAMP activates PKA which then phosphorylates PDEl 
reducing its activity and leading to an increase in the level of cAMP. An increase in 
the level of intracellular Ca^  ^could terminate this feedback loop by increasing the 
concentration of Ca^^ /^calmodulin. It has been suggested that such a positive feedback 
loop may operate in post synaptic terminals to amplify signals that cause a small 
increase in intracellular cAMP (7). Nevertheless, the state of phosphorylation and 
regulation in intact cells remains to be established
The dephosphorylation of PDEl isoforms is mediated by the Ca^Vcalmodulin 
dependent phosphatase (calcineurin) (7, 202).
Evidence for the transcriptional regulation of PDEl comes from studies that 
investigated the induction of this class of PDE in CHO cells. No PDEl activity is 
detectable in unstimulated CHO cells, however, stimulation with the phorbol ester 
phorbol 12-myiistate 13-acetate (PMA); stimulation with agonists for endogenous 
P2-purinoceptors, for lysophosphatidic acid receptors or for thrombin receptors leads 
to the transient induction of a PDEl that has been identified by reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis as PDEIB. This induction then seems 
to depend upon PKC aetivation. Consistent with this the transient transfection of 
CHO cells to overexpress specific isoforms of protein kinase C (PKC), PKCa or
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PKCe but not PKCpl nor PKCy leads to the transient induction of PDEIB (217,
218).
1.2.2 The PDE2 enzyme family
Members of the PDE2 enzyme family catalyse the hydrolysis of both cAMP and 
cGMP. The catalytic activity of these enzymes is stimulated by low (sub pM) 
concentrations of cGMP. This is an allosteric regulation, mediated by a cGMP 
binding site that is located within the amino terminal region of the protein. The 
stimulation is due to an increase in Vmax with little change in Km. That the 
allosteric, cGMP binding site is distinct from the catalytic site of the enzyme can be 
demonstrated by its separation from the catalytic site by limited proteolysis of the 
enzyme (220). The catalytic region of PDE2 can also bind cGMP, although with 
lower affinity than can the allosteric binding site.
In addition to their regulation by cGMP there is evidence that PDE2 may be 
regulated by phosphorylation. A PDE2 associated with the Golgi-endosomal fr action 
of rat liver is rapidly and transiently activated downstream of PKCa following 
stimulation with PMA (66).
Only 1 gene encoding PDE2 has so far been identified (212). Alternative splicing of 
mRNA from this gene gives rise to at least 3 splice variants (PDE2A1, PDE2A2 and 
PDE2A3) that diverge in their amino terminal regions (182). Both soluble and 
membrane-associated forms of PDE2 activity have been identified and it is likely that 
the individual splice variants have different subcellular localisations.
Members of the PDE2 enzyme family have been implicated in the control of the 
basal Ca^  ^current in human although not rat cardiomyocytes (177); in signalling 
within a subset of olfactory neurones (101); in the regulation of human platelet 
aggregation, by antagonising the accumulation of cAMP and henee the inhibition of 
aggregation that follows inhibition of PDE3 by intracellular cGMP, (50).
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1.2.3 The PDE3 enzyme family
Members of the PDE3 enzyme family can catalyse the hydrolysis of both cAMP and 
cGMP. These enzymes have high affinity for both of these cyclic nucleotides; Km 
values for the hydrolysis of both cAMP and cGMP are in the range O.l-O.SgM. The 
value of Vmax for the hydrolysis of cAMP by PDE3 is, however, approximately 10 
fold higher than that for the hydrolysis of cGMP. For this reason, the PDE3 family of 
enzymes are considered to function as cAMP specific PDEs (48, 134).
L2.3.1 Regulation o f PDE3 by cGMP
Although cGMP is not considered to be a physiological substrate for PDE3, the high 
affinity with which it binds to these enzymes means that it acts as a competitive 
inhibitor of cAMP hydrolysis by PDE3. For this reason the PDE3 enzyme family is 
also referred to as the cGMP inhibited PDE family. Several of the physiological 
effects of cGMP arise at, least in part, from its ability to inhibit PDE3 and thereby to 
increase intracellular levels of cAMP. Examples of this include the stimulation of 
renin secretion downstream of nitric oxide (NO) in kidney (111) and the synergistic 
effects on the inhibition of platelet aggregation by agents that increase cAMP and 
those that increase cGMP (50). The latter example is especially interesting because 
PDE2, as well as PDE3, is present in platelets. In this system the actions of these 2 
classes of PDE in response to cGMP appear to antagonise one another with PDE2 
limiting the accumulation of cAMP that follows the inhibition of PDE3.
1.2.3.2 Structure o f PDE3
Two separate genes encoding PDE3 have been identified and, localised, in humans, 
to chromosomes 12 and 11 for PDE3A and PDE3B respectively (143). There is 
evidence for alternative splicing of the PDE3A gene. This appears to generate 2 
forms of the protein, the shorter of which is a truncated version of the longer (103).
The organisation of the primary structures of PDE3 follows a pattern typical for 
members of the PDE superfamily. The catalytic region, that is conserved between all 
mammalian PDE classes, is located towards the carboxyl terminal end of the
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molecule and the amino terminal region of the molecules is involved in the 
subcellular targeting and the regulation of the protein.
Uniquely amongst PDEs the catalytic region of PDE3 contains a 44 amino acid insert 
region that is not present in other classes of PDE. Furthermore, although this insert is 
present in both PDE3 A and PDE3B proteins, the sequence of this region is poorly 
conserved between the 2 genes. Although deletion of the 44 amino acid insert in 
PDE3 increases the homology of the catalytic region to those of other PDE classes, 
mutants of PDE3A in which this insert was deleted were found to be catalytically 
inactive (33, 229). The mutation of putative p turn forming residues that at the 
beginning and the end of this 44 amino acid insert also reduced the catalytic activity 
of the enzyme (229). These results suggest that the PDE3 specific insert region is 
important in maintaining the structure of the catalytic site of PDE3 enzymes.
The amino terminal regions of both PDE3A and PDE3B contain a hydrophobic 
region of sequence that, based upon hydrophobicity plots and secondary stmcture 
predictions, may contain several transmembrane, helical regions (48). It has been 
suggested that this region of the protein may constitute a membrane association 
domain that is involved in the membrane association of PDE3 (103, 115). Recent 
work in the laboratoiy of M. Houslay, using mutated forms of PDE3B in which this 
putative membrane association domain was deleted suggest, however, that this region 
is not necessary for the association of PDE3 with the particulate fraction of 
transfected COS-7 cells. Rather, it seems, sequence within the region that links this 
hydrophobic region to the catalytic domain of PDE3 (residues 267-613 in PDE3B) is 
involved in the membrane association of this enzyme [G. Rena personal 
communication].
1.2.3.3 The acute regulation o f PDE3 by phosphorylation
PDE3 can be acutely activated by hormones in a number of systems (174). These 
activations seem to be due to phosphorylation of the PDE on serine. The in vivo site 
of phosphorylation has been mapped to Ser^ gg (in PDE3B). This residue is located 
within a PKA consensus motif in the amino terminal of PDE3. Interestingly, 
although this serine appears to be the in vivo site of phosphorylation both by PKA 
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and by an unidentified insulin stimulated kinase (see below) it is not the site that is 
most efficiently phosphorylated by PKA in vitro (175). In these assays Ser^ ?^ of 
solubilised, rat adipocyte PDE3B was most efficiently phosphorylated by PKA. This 
residue does not, however, become modified in intact cells (174). This discrepancy 
may reflect a conformational change in the PDE upon its association with 
membranes of perhaps differences between the interaction of PDE3 with additional 
regulatory factors in intact and in broken cells.
The stimulation of intact adipocytes, hepatocytes or platelets with agents that 
activate adenylyl cyclase and increase intracellular cAMP leads to the rapid 
phosphorylation and activation of PDE3 (134). This activation appears to be due to 
the direct phosphorylation of PDE3 by PKA and probably functions as a negative 
feedback loop that limits the accumulation of cAMP.
In addition to PKA this serine in PDE3 is also a substrate for an insulin stimulated 
kinase that lies downstream of phosphatidylinositol 3 kinase (PI3K) in adipocytes, 
platelets and liver (127, 203,204). The pathway appears to be a major mechanism by 
which insulin reduces the intracellular cAMP concentration in these cells to 
antagonise the effects of agents that promote lipolysis and glycogenolysis. A similar 
pathway, downstream of activated insulin like growth factor 1 (IGFl) receptors, also 
operates in pancreatic islet (3 cells to attenuate insulin secretion (255). This forms an 
elegant negative feedback loop in which insulin secreted by (3 cells stimulates the 
release of IGFl by the liver that then activates IGFl receptors on the p cells and 
inhibits insulin secretion.
It seems likely that PDE3 is also acutely regulated by phosphorylation on residues 
other than Ser^ o^ . It has been proposed that at least 2, interacting sites of 
phosphorylation exist in the rat liver dense vesicle associated PDE3. Phosphoiylation 
at one of these sites results in an activation of the enzyme whereas phosphorylation at 
the other site does not activate the enzyme but can prevent modification of the 
activating site (105). Also, a membrane associated PDE3 present in frog ventricle 
cells is inactivated, downstream of activated glucagon receptors via a pertussis toxin 
sensitive G-protein (21).
X"
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1,2,4 The PDE4 enzyme family
The PDE4 enzyme family was initially identified as a PDE activity, resolved by ion 
exchange chromatography that specifically hydrolysed cAMP but not cGMP (87).
This family of enzymes are potently and specifically inhibited by the antidepressant 
drug, rolipram. Indeed endogenous PDE4 activity is fi*equently defined as “that 
cAMP PDE activity which is inhibited by lOpM rolipram”.
The PDE4 gene family is composed of the products from 4 homologous genes (A, B,
C and D) that are located on 3 chromosomes (4A and 4C on chromosome 19, 4B on 
chromosome 1 and 4D on chromosome 5 in humans) (83, 86). Distinct 
transcriptional start sites coupled with the alternative splicing of mRNAs leads to the 
production of multiple splice variants fi om each of these genes. The splicing of all 
known, active PDE4s follows the typical pattern for PDE splicing and takes the form 
of 5’ domain swaps. This results in splice variants from each PDE4 gene that all 
share an identical primary structure within the catalytic region and the carboxyl 
terminal end of the proteins but that diverge in their amino termini. There is 
considerable evidence that the various PDE4 isoenzymes are differentially expressed 
(15-17, 83, 87, 140, 225).
An exception to the usual pattern of splicing is the human PDE4A splice variant 
HSPDE4A8A (2EL). This species is alternatively spliced at 2 points to produce an 
mRNA that has a unique 5’ end and that also contains a 34bp insert within the region 
that would otherwise encode the catalytic region of the protein. The 34bp insert 
causes a shift in the reading firame of the sequence, relative to those of other 
PDE4As. This results in the occurrence of an in firame stop codon just downstream of 
the insert and leads to the production of a tmncated, catalytically inactive protein 
(83).
1.2.4.1 The dunce PDE o f Drosophila melanogaster
The mammalian PDE4s are highly homologous to the dunce PDE of Drosophila 
melanogaster. This gene was the first PDE to be cloned fiom any species and was
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used as a probe to isolate the first mammalian PDE4 cDNA in a screen of a rat brain 
cDNA library (47).
Insights into the functions of mammalian PDE4s have been gained from studies of 
the Drosophila dunce PDE. Flies that are deficient in the dunce PDE exhibit 
deficiencies in learning and memory and are also sterile, suggesting a role for the 
dunce PDE in these functions (46). These deficiencies in dunce- flies can be rescued 
by the expression of a mammalian PDE4 (45). This is consistent with the notion that 
cAMP signalling and, specifically, the actions of the dunce PDE are involved in 
regulating processes such as long term potentiation and synaptic plasticity.
Furthennore it seems likely that at least some of these functions will be conserved in 
mammalian PDE4s.
Despite the high degree of homology between the dunce PDE and mammalian 
PDE4s, the PDE4 specific inhibitors rolipram and RO-20-1724 do not inhibit the 
dunce PDE. Another PDE4 specific inhibitor, denbufylline, does inhibit the dunce 
PDE, although with a lower potency than with which it inhibits mammalian PDE4s 
(IC50 values of l-3pM  and of 0.1-0.22pM for the inhibition o f Drosophila and of 
mammalian PDE4 respectively) (13). The structural differences in the catalytic 
regions of these enzymes that account for these differences in inhibitor specificity are 
unclear. It is perhaps significant, however, that the conformation of the active site of 
PDE4 can be post translationally modulated by PKA action and that this modulation 
can be detected as a change in sensitivity to inhibition by rolipram (82). Certain other 
specific inhibitors of PDE4, such as RS-25344 and RS-33793, also interact 
differently with the different forms of the enzyme (2). Other specific PDE4 
inhibitors, such as SB207499 and trequinsin, seemingly do not differentiate between 
these different forms of the enzyme (see section 1.3.6) (2, 141).
1.2.5 The PDE5 enzyme family
To date only 1 PDE5 gene has been identified. This, however, appears to encodes 2 
splice variants (42, 138, 251). The PDE5 enzyme family has recently been the focus 
of much attention because it is the molecular target of sildenafil, the active ingredient 
of the anti erectile dysfunction dmg, Viagra™ (see section 1.2.5.1).
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It is also uncleai' whether or not the binding of cGMP to the allosteric sites in PDE5 
has a direct effect on the conformation of the catalytic site of the enzyme. The 
binding of cGMP analogues that are specific for the catalytic site to PDE5 stimulates 
the binding of cGMP to the allosteric sites (42). This shows that the conformation of 
the PDE5 active site can affect the confonnation of the allosteric cGMP binding 
sites. It therefore seems likely that ligand at the allosteric site may be able to 
influence the conformation of the catalytic site.
The catalytic region of PDE5 contains 2 putative Zn^  ^binding sequences of the form 
HX3HX„(E/D) and bound Zn^  ^is necessary for the catalytic activity of PDE5. These 
putative Zn^  ^binding motifs are conserved in all known mammalian PDEs and are 
homologous to the single Zn^  ^binding motif of metalloproteases.
PDE5 exists as a homodimer. It is highly specific for cGMP, the hydrolysis of which 
it catalyses approximately 100 times more efficiently than it does that of cAMP.
Each subunit of the PDE5 holoenzyme contains 2 allosteric cGMP binding sites that 
are located within the amino terminal region of the protein. These are distinct from 
the catalytic region of the protein and they share homology with the allosteric cGMP 
binding sites in PDE2, PDE6 and PDEIO (231).
The binding of cGMP to the allosteric sites of PDE5 is a necessary prerequisite for 
the phosphorylation of the protein by PKG on Ser^ .^ This phosphoiylation stimulates 
the catalytic activity of PDE5 and may represent a negative feedback loop that 
regulates cGMP levels (24, 25). The same site in PDE5 is also a substrate for 
phosphorylation by PKA in vitro (42). It is, however, unclear whether or not PDE5 is 
an in vivo substrate of PKA as, for Ser’  ^ to be available to be modified, cGMP must 
be bound to the allosteric sites on PDE5. Under these conditions one would expect 
PKG to be active.
I1.2.5.1 PDE5 as the target o f sildenafil
The PDE5 enzyme family has recently received much attention because it is the 
molecular target of sildenafil, the active ingredient of Pfizer’s anti erectile 
dysfunction drug, Viagra™. Sildenafil is potent and highly specific inhibitor of PDE5 
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(236). It has long been appreciated that elevation of intracellular cGMP causes 
relaxation of vascular smooth muscle. It was therefore envisaged that compounds, 
such as PDE5 inhibitors, that could increase levels of cGMP would be of potential 
therapeutic value in the treatment of conditions such as hypertension and angina. 
Indeed, the effects of sildenafil on penile erectility were first noticed during a clinical 
trial conducted to determine its efficacy as a treatment for angina (42). The reason 
that sildenafil acts more specifically on penile erectile smooth muscle compared to 
smooth muscle that controls general circulation is not well understood.
1.2.6 The PDE6 enzyme family
The PDE6 enzyme family are the photoreceptor PDEs. This is a cGMP specific 
family of PDEs that are expressed in photoreceptor rod and cone cells. The inactive, 
holoenzyme form of PDE6 is a heterotetramer composed of 2 catalytic and 2 
regulatory subunits. In rod cells the 2 large, homologous catalytic subunits (a  and (3) 
and 1 inhibitory subunit (y) are expressed (65, 70). Usually these subunits assemble 
into a aPY2 heterotetramer although (1 2 ^ 2  and p2T2 heterotetrameric forms have also 
recently been demonstrated. In cone cells the heterotetramer is composed of 2 
identical catalytic subunits (a ’) complexed with 2 inhibitory subunits (y). The cone 
cell a \  catalytic subunit is the product of a homologous but distinct gene fiom the 
rod cell a  and p catalytic subunits (118, 123).
PDE6 enzymes are predominantly peripherally membrane associated enzymes. This 
association is due to méthylation or isoprenylation of a site within the carboxyl 
terminal region of the catalytic subunits (11, 117). A fraction of the PDE6 in both rod 
and in cone cells is, however, present in the soluble fraction. This fi action of the 
PDE6 is associated with a 17kDa polypepeptide that has been called the PDE6 5 
subunit (117). This subunit does not effect the catalytic activity of the PDE but it 
prevents membrane association by directly interacting with the modified carboxyl 
terminal. The physiological significance of the partial solubilisation of PDE6 is 
unclear. It has, however, been suggested that this may function as some sort of a 
desensitisation mechanism by removing the PDE6 catalytic subunits from their site 
of action (64).
M.B.Beard Intioduction 1-28
Each catalytic subunit of PDE6 contains 2 noncatalytic, allosteric cGMP binding 
sites that are located amino terminally to the catalytic region of the PDE (123). These 
sites are homologous to the noncatalytic cGMP binding sites of PDE2, PDE5 and 
PDEIO. The binding of cGMP at these allosteric sites may affect the interaction of 
the catalytic subunits with the inhibitory y subunits. Certainly the interaction of y 
subunits with the catalytic subunits affects interaction between cGMP and its 
allosteric binding sites (71). It is therefore possible that the function of the allosteric 
cGMP binding sites on PDE6 is to regulate the activation of the PDE by transducin.
1.2.6.1 The role o f PDE6 in photoreception
PDE6 functions as a major effector enzyme in the photodetection cascade in both rod 
and cone cells. The light receptor in these cells is rhodopsin, a member of the 
heptahelical, G protein coupled, transmembrane class of receptor proteins.
Rhodopsin contains the chromophore 1 l-cf^-Retinal as a prosthetic group. When it 
absorbs a photon of light the chromophore isomorises to all-^raws-Retinal and this 
causes a conformational change in the protein. This conformational change allows 
rhodopsin to catalyse the exchange of GDP for GTP on a heterotiimeric G protein 
(transducin). The GTP bound transducin a  subunit, in turn, binds to the inhibitoiy y 
subunits of PDE6, causing their dissociation from the holoenzyme and the activation 
of the PDE6 catalytic subiunits. This activation of PDE6 causes a reduction in 
intracellular cGMP concentration and consequently the closure of cGMP gated Na^ 
channels in the cell membrane. This results in a hyperpolarisation of the plasma 
membrane (221). It is interesting that photosensitive cells, unlike other excitable cell 
types, convert the initial stimulation into a hyperpolarisation rather than a 
depolarisation of the plasma membrane.
1.2.7 The PDE7 enzyme family
The existence of a PDE7 enzyme family was originally suggested by the detection of 
a novel, cAMP specific PDE activity present in preparations of hepatocytes and liver 
that was insensitive to any of the known PDE inhibitors including IB MX, a broad 
range PDE inhibitor (112). Since that time 2 IBMX insensitive, cAMP PDE enzyme
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families (PDE7 and PDE8) have been identified. The activity resolved by Lavan et al 
was most similar to the PDE enzyme family that is now designated PDE8.
To date 1 gene that encodes 2 splice variants of PDE7 (PDE7A1 and PDE7A2) has 
been identified in humans and in mice. These enzymes have a high affinity for cAMP 
(Km 0. l-0.2pM), do not hydrolyse cGMP and are insensitive to known effectors of 
other PDE enzyme families. Notably PDE7 is insensitive to rolipram and to RO-20- 
1724, inhibitors of the cAMP specific PDE4 family. It also shows a relatively low 
sensitivity to IBMX (IC50 30|aM).
The first of the PDE7 splice variants to be cloned, HSPDE7A1, was isolated jfrom a 
human glioblastoma cDNA library by its ability to rescue a PDE deficient strain of 
yeast from heat shock (142). Subsequently this cDNA was used to probe cDNA 
libraries to isolate the murine MMPDE7A2 enzyme from mouse then the human 
HSPDE7A2 enzyme from skeletal muscle (12, 72).
The 2 splice variants of HSPDE7A differ from each other only in their amino 
terminal regions. The kinetic characteristics of these 2 splice variants are very similar 
to one another but their subcellular localisations differ markedly. HSPDE7A1 
partitions between the particulate and the soluble factions of cells whereas 
HSPDE7A2 is exclusively located in the particulate fraction (72). The subcellular 
targeting of HSPDE7A2 is mediated by the hydrophobic character and modifications 
of its 20 residue, alternatively spliced amino terminus.
A functional role of HSPDE7A1 in regulating T cell activation has recently been 
identified (116). The full activation of CD4 and possibly of other classes of T cells 
requires stimulation of both the T cell receptor CD3 complex (TCR-CD3) and also 
the CD28 costimulatory receptor. One effect of this costimulation is that the steady 
state protein levels of HSPDE7A1 in these cells are increased. This increase in 
HSPDE7A1 is necessary for the activation as antisense oligonucleotides that 
specifically inhibit HSPDE7A1 expression also prevent T cell activation. The 
increase in HSPDE7A1 levels seems to allow proliferation by suppressing 
intracellular levels of cAMP. This prevents the activation of PKA activation that 
occurs downstream of TCR-CD3 receptor stimulation in the absence of CD28 
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receptor costimulation. Stimulation of the TCR-CD3 receptor in the absence of CD28 
receptor stimulation promotes T cell anergy or apotosis (96). This seems to result 
from the antiproliferative effects of activated PKA.
1.2.8 The PDE8 enzyme family
The PDE8 enzyme family was identified in the modern way, by searching expressed 
sequence tag (EST) databases for sequences with homology to known PDE 
sequences. The identified EST clones were then sequenced in their entirety and 
assembled into single sequences. The open reading frames (ORFs) generated by this 
strategy were all open at their 5’ ends so the technique of rapid amplification of 
cDNA ends (5’ RACE) was used to extend the sequences. The existence of the 
deduced sequences was then confirmed by RT-PCR of the entire ORE from tissues 
(63, 76,208).
At least 2, possibly 3, distinct genes encode PDE8 and there is evidence for 
alternative splicing within the 5’ region of at least one of these genes (HSPDE8A)
(63). The members of this PDE enzyme family are high affinity, cAMP specific 
PDEs with a sub pM Km for cAMP. The Vmax of PDE8 isoforras is approximately 
10-fold lower than that of PDE4 isoforms. These characteristics of high affinity for 
substrate together with relatively low Vmax values suggest that PDE8 may function 
to maintain low background cAMP levels whilst PDE4 may serve to rapidly reverse 
transient increases in cAMP concentration that occur during signalling.
The PDE8 enzyme family is pharmacologically distinct from other PDE enzyme 
families. This family of enzymes is insensitive to most known effectors of other PDE 
families including rolipram, RO-20-1724, cGMP and IBMX (208). Surprisingly, 
however, PDE8 is sensitive to dipyiidamole (IC50 4.5pM), which was previously 
considered to be an inhibitor of cGMP but not cAMP specific PDEs.
1.2.9 The PDE9 enzyme family
The PDE9 enzyme family was identified by searching EST databases for sequences 
homologous to known PDE sequences. To date 1 gene encoding PDE9 has been
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identified in both mouse and in humans. The presence of a 60 residue insert within 
the amino terminal region of the human PDE9 clone (HSPDE9A2) that is not 
conserved in the mouse sequence (MMPDE9A1) suggests that there may be at least 2 
splice variants from this gene (62, 209).
The PDE9 enzyme family specifically hydrolyses cGMP with very high affinity (Km 
70-170nM) this is the highest affinity for cGMP of any PDE identified to date. The 
Vmax of the reaction catalysed by PDE9 is also high, being approximately 2 fold 
higher than that for the hydrolysis of cAMP by PDE4. PDE9 does not catalyse the 
hydrolysis of cAMP at physiological concentrations (Km 230pM) and it is 
insensitive to many known inhibitors of other PDE families including rolipram, 
vinpocetine, sildenafil and IBMX. It is, however sensitive to the PDE5 inhibitor 
zaprinast ( IC50 35pM). Unlike the other known cGMP specific PDE families (PDE2, 
PDE5 and PDE6), the putative regulatory, amino terminal region of PDE9 does not 
contain allosteric cGMP binding sites (62,209).
1.2.10 The PDEIO enzyme family
As in the identification of the PDE8 and the PDE9 enzyme families, the PDEIO 
enzyme family was identified by screening an EST database (210). To date only 1 
cDNA encoding a murine PDEIO (MMPDEIOA) has been cloned. This cDNA 
contains the a complete OFR and is predicted to encode a 779 residue protein.
Northern blot analysis reveals that PDEIO RNA is most prevalent in testis and in 
brain (210).
When expressed in Sf9 cells, MMPDEIOA has the characteristics of a dual 
specificity PDE that hydrolyses cAMP with a Km of 0.05 pM and cGMP with a Km 
of 3pM. The cGMPxAMP Vmax ratio of this enzyme is 4.7. It is therefore possible 
that PDEIO may function in vivo to regulate cGMP signalling. Indeed it is possible 
that PDEIO could be regulated by cAMP acting as a competitive inhibitor of cGMP 
hydrolysis in a manner analogous to the regulation of cAMP hydrolysis by PDE3 by 
cGMP (210). Unlike PDE8 and PDE9, PDEIO is sensitive to inhibition by the broad 
range PDE inhibitor IBMX (IC50 2.6pM).
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The amino terminal region of PDEIO contains 2 regions homologous to the allosteric 
cGMP binding sites present in PDE2, PDE5 and PDE6. These motifs in 
MMPDEIOA are, however, imperfectly conserved and binding assays suggest that 
the affinity of the noncatalytic cGMP binding motifs in PDEIO is lower than that of 
these motifs in the other cGMP specific PDE enzyme families (210).
1.3 Molecular biology and biochemistry of the PDE4 enzyme family
The PDE4 enzyme family is composed of 4 distinct but related genes each of which 
encodes multiple splice variants. At least 18 distinct splice variants of PDE4 exist 
(14, 85, 87). Splicing of PDE4 mRNAs predominantly takes the form of 5’ domain 
swaps and leads to the production of isoenzymes that have distinct amino termini but 
share identical primary structures within their carboxyl termini. The spliced amino 
termini of PDE4 isoenzymes appear to function as regulatory domains of the 
proteins. Effects on both the conformation and the activity of the catalytic region (82, 
140, 197, 200) and on the subcellular targeting and protein-protein interactions of the 
PDE (162, 194, 252) have been demonstrated.
1.3.1 The primary structure of PDE4
Sequence aligmnents of the deduced primary structures for the active PDE4 
isoenzymes reveal that these proteins share a common overall structure {Figure 1.2). 
The catalytic region of the enzyme, that is conserved between all class I PDEs, is 
located towards the carboxyl teiminal end of the molecule. In addition to the catalytic 
region there are 2 other regions of sequence that are highly conserved between all of 
the mammalian PDE4 gene families and the dunce PDE of Drosophila; these regions 
are located amino terminal to the catalytic region and are called Upstream Conserved 
Regions 1 and 2 (UCRl and UCR2) (see section 6.1) (14). The regions of sequence 
that lie between UCRl and UCR2 and between UCR2 and the catalytic region appear 
to be hypervariable. They are not consei^ed between the 4 PDE4 genes and nor are 
they well conserved between homologous PDE4 genes in different species. These 
regions have been called Linker Regions 1 and 2 (LRl and LR2) respectively (141).
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The regions of sequence that lie carboxyl terminal to the catalytic regions of PDE4s 
are poorly conserved between the PDE4 gene families but they are invariant between 
the active splice variants within each gene family. This region of PDE4s contains 
sequences that have been suggested to be involved in dimérisation of PDE4 isoforms 
(108). It is possible that sequences contained within the extreme carboxyl terminal 
regions of PDE4s may confer, as yet unidentified, gene family specific properties on 
the enzymes.
The sequences at the extreme amino termini of PDE4 isoforms are extremely 
divergent between the 4 gene families and also between different isoenzymes within 
a single gene family. The amino terminal regions of individual PDE4 isoenzymes are 
involved in regulating the activity of the catalytic region (140,201), in defining the 
subcellular localisation of the enzyme (194) and in mediating protein-protein 
interactions (162,252).
There ar e 2 major points of alternative mRNA splicing within mammalian PDE4s.
The position of the first (most 5’) of the splice points in mammalian PDE4s 
corresponds to the 5’ end of the third exon of the dunce gene of Drosophila^ where it 
is also the site of extensive alternative splicing. The coding sequence at this splice 
junction corresponds to the consensus F(E/D)(AW)(E/D)NG. The second major 
splice junction lies at the 5’ end of the sequence that encodes UCR2. The consensus 
protein sequence at this point is EE(A/S/T)(G/C/Y)(L/Q)(Q/K)LA (14). There are 2 
cases in which the splicing of PDE4s diverges fi’om this pattern. The first of these is 
the PDE4A isoform PDE4A1, in which splicing occurs 3’ to the second of the major 
splice junctions, at the beginning of the second of the 3 exons that encode UCR2 of 
PDE4A. The second example of isoenzymes that diverge from the usual pattern of 
splicing are PDE4D1 and PDE4D2. The splicing of these isoforms occurs 5’ to the 
second of the major PDE4A splice junctions (14).
The positions of the splice junctions in relation to the conserved regions, UCRl and
UCR2, in PDE4 isoforms allows for the informal classification of these isoenzymes
into so called long and short forms. Thus long form splice variants contain both
UCRl and UCR2 whereas short form splice variants that contain only UCR2. In the
cases of the short form splice variants PDE4A1 and FDE4D2 not only do these 
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isoforms lack UCRl but also the amino terminal portion of UCR2 {Figure 1.2 and 
Figure 1.3).
Long Form Splice Junction
Short Form Splice Junction (2) 
Short Form Splice Junction (1)
Figure 1,2: The domain structure of a typical mammalian PDE4
The figure shows a diagrammatic representation o f the typical domain structure o f 
PDE4 isoenzymes. Within each PDE4 enzyme family multiple splice variants arise 
through the alternative splicing o f mRNA. Typically the alternative splicing takes the 
form o f 5 ' domain swaps. This results in splice variants form each PDE4 gene that 
share a common catalytic region and extreme carboxyl terminus but that diverge in 
their amino termini. The positions o f the major points o f splicing in PDE4s are 
indicated by arrvws. Also shown are regions o f sequence that are highly conserved 
between each o f the mammalian PDE4 enzyme families and the Dunce PDE o f 
Drosophila. These are upstream conserved regions 1 and 2 (UCRl and ÜCR2) and 
the catalytic region (catalytic).
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...... .er s...s....khlwrqprtp iriqqrgysdA MEPPTVPSER SLSLSLPGPR EGQATLKPPP QHLWRQPRTP IRIQQRGYSD
B  MKKSR SVMTVMADDN VKDYFECSLS KSYSSSSNTL GIDLWRGRRCC .MENLGVGEG AEACSRLSRS RGRHSMTRAP KHLWRQPRRP IRIQQRFYSD
....a... ar. .d.s......... swp.s.A SAERAERERQ PHRPIERADA MDTSDRPGLR TTRMSWPSSF HGTGTGSGGA
B CSGNLQLPPL SQRQSERART PEGDG........ISRPTTL PLTTLPSIAIC PDKSAG........... CRE RDLSPRPERR KSRRSWPVS.  .D ........................................... MMHVNNFPF
UCRl
101 150...S.r.Fdv eNG..pSpGR spLDpqaSpg .Gl.l.A.fp .hSQRRESFL
A GGGSSRRFEA ENGPTPSPGR SPLDSQASP. .GLVLHAG.A ATSQRRESFLB TTVSQECFDV ENG..PSPGR SPLDPQASSS AGLVLHATFP GHSQRRESFL
C ...SCRRFDL ENGL..SCGR RALDPQSSPG LGRIMQAPVP .HSQRRESFLD RRHSWICFDV DNG..TSAGR SPLDPMTSPG SGLILQANF. VHSQRRESFL
UCRl
151 200
YRSDSDYdlS PKaMSRNSSv aS..Hg.DlI VTPFAQVLAS LR.VR.NfaaA YRSDSDYDMS PKTMSRNSSV TSEAHAEDLI VTPFAQVLAS LRSVRSNFSL
B YRSDSDYDLS PKAMSRNSSL PSEQHGDDLI VTPFAQVLAS LRSVRNNFTI
C YRSDSDYELS PKAMSRNSSV ASDLHGEDMI VTPFAQVLAS LRTVRSNVAAD YRSDSDYDLS PKSMSRNSSI ASDIHGDDLI VTPFAQVLAS LRTVRNNFAA
LRl UCR2
201 250
Ltnlq...sn KrsP.gn.p. vnkatp.Eet yQkLA.ETLe ELDWCLdQLEA LTNVPV.PSN KRSPLGGFTP VCKATLSEET CQQLARETLE ELDWCLEQLEB LTNLHG.TSN KRSPAASQPP VSRVNPQEES YQKLAMETLE ELDWCLDQLEC LARQQCLGAA KQGPVGNPSS SNQLPPAEDT GQKLALETLD ELDWCLDQLED LTNLQDRAPS KRSPMCNQPS INKATITEEA YQKLASETLE ELDWCLDQLE
UCR2
251 300T1QT..SVSE MASnKFKRmL NRELTHLSEm SRSGNQVSEy ISnTFLDkQnA TMQTYRSVSE MASHKFKRML NRELTHLSEM SRSGNQVSEY ISTTFLDKQN
B TIQTYRSVSE MASNKFKRML NRELTHLSEM SRSGNQVSEY ISNTFLDKQNC TLQTRHSVGE MASNKFKRIL NRÉLTHLSET SRSGNQVSEY ISRTFLDQQTD TLQTRHSVSE MASNKFKRML NRELTHLSEM SRSGNQVSEF ISNTFLDKQH
LR2 Catalytic
301 350eVEiPspTqk erekkk.p qpMsqIs G.kkLmHSsSA EVEIPSPTMK EREKQQAPRP RPSQPPPPPV PHLQPMSQIT GLKKLMHSNS
B DVEIPSPTQK DREKKKKQ QLMTQIS GVKKLMHSSS
C EVELPKVTAE EAP QPMSRIS GLHGLCHSASD EVEIPSPTQK EKEKKKRP MSQIS GVKKLMHSSS
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Catalytic351
LnnssipRFG VkT.qE..LA kELEdlNKWG Ln.F.vadys
400gnRpLTcImy
A LNNSNIPRFG VKTDQEELLA QELENLNKWG LNIFCVSDYA GGRSLTCIMYB LNNTSISRFG VNTENEDHLA KELEDLNKWG LNIFNVAGYS HNRPLTCIMYC LSSATVPRFG VQTDQEEQLA KELEDTNKWG LDVFKVADVS GNRPLTAIIFD LTNSSIPRFG VKTEQEDVLA KELEDVNKWG LHVFRIAELS GNRPLTVTMH
401.IFQERDLLK tFrlpvDTli
Catalytic
TY..tLEdHY HadVAYHNsl 450HAADVaQSTHA MIFQERDLLK KFRIPVDTMV TYMLTLEDHY HADVAYHNSL HAADVLQSTHB AIFQERDLLK TFRISSDTFI TYMMTLEDHY HSDVAYHNSL HAADVAQSTH
C SIFQERDLLK TFQIPADTLA TYLLMLEGHY HANVAYHNSL HAADVAQSTHD TIFQERDLLK TFKIPVDTLI TYLMTLEDHY HADVAYHNNI HAADWQSTH
451VLL.TPAL.A VFTDLEILAA
Catalytic
.FA.AIHDVD HPGVSNQFLI 500NTNSelALMYA VLLATPALDA VFTDLEILAA LFAAAIHDVD HPGVSNQFLI NTNSELALMYB VLLSTPALDA VFTDLEILAA IFAAAIHDVD HPGVSNQFLI NTNSELALMY
C VLLATPALEA VFTDLEILAA LFASAIHDVD HPGVSNQFLI NTNSDVALMYD VLLSTPALEA VFTDLEILAA IFASAIHDVD HPGVSNQFLI NTNSELALMY
501NDeSVLENHH LAVGFKLLQe
Catalytic
enCDIFqNL. kkQRqsLRkM 550VIDmVLATDMA NDESVLENHH LAVGFKLLQE DNCDIFQNLS KRQRQSLRKM VIDMVLATDMB NDESVLENHH LAVGFKLLQE EHCDIFMNLT KKQRQTLRKM VIDMVLATDMC NDASVLENHH LAVGFKLLQA ENCDIFQNLS AKQRLSLRRM VIDMVLATDMD NDSSVLENHH LAVGFKLLQE ENCDIFQNLT KKQRQSLRKM VIDIVLATDM
551SKHMnLLADL KTMVETKKVT
Catalytic
SsGVLLLDNY sDRIQVL.Nm 600VHCADLSNPT
A SKHMTLLADL KTMVETKKVT SSGVLLLDNY SDRIQVLRNM VHCADLSNPTB SKHMSLLADL KTMVETKKVT SSGVLLLDNY TDRIQVLRNM VHCADLSNPT
C SKHMNLLADL KTMVETKKVT SLGVLLLDNY SDRIQVLQNL VHCADLSNPTD SKHMNLLADL KTMVETKKVT SSGVLLLDNY SDRIQVLQNM VHCADLSNPT
601KpLeLYRQWT DRIM.EFFqQ
Catalytic
GDrERErGme ISPMCDKHtA 650SVEKSQVGFI
A KPLELYRQWT DRIMAEFFQQ GDRERERGME ISPMCDKHTA SVEKSQVGFIB KSLELYRQWT DRIMEEFFQQ GDKERERGME ISPMCDKHTA SVEKSQVGFI
C KPLPLYRQWT DRIMAEFFQQ GDRERESGLD ISPMCDKHTA SVEKSQVGFID KPLQLYRQWT DRIMEEFFRQ GDRERERGME ISPMCDKHNA SVEKSQVGFI
651DYIvHPLWET WADLVhPDAQ
Catalytic
dlLDTLEDNR eWYqS.IpqS 700PSpppdee.rA DYIVHPLWET WADLVHPDAQ EILDTLEDNR DWYYSAIRQS PSPPPEEESRB DYIVHPLWET WADLVQPDAQ DlLDTLEDNR NWYQSMIPQS PSPPLDEQNR
C DYIAHPLWET WADLVHPDAQ DLLDTLEDNR EWYQSKIPRS PSDLTNPERDD DYIVHPLWET WADLVHPDAQ DlLDTLEDNR EWYQSTIPQS PSPAPDDPEE
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Catalytic
750..g.qglp.k FQFELTLeEe eeed.e....A GPGHPPLPDK FQFELTLEEE EEEEISMAQI PCTAQEALTA QGLSGVEEALB ..DCQGLMEK FQFELTLDEE DSEGPE___C G.....PDR FQFELTLEEA EEEDEE___D ..GRQGQTEK FQFELTLEED GESDTE.... .............KDSGSOV
751
e y . . . . a d a k  . l . . . u . e . .  e . . l e . d . e
800
. ± ................a .  . . d ......................A DATIAWEASP AQESLEVMAQ EASLEAELEA VYLTQQAQST GSAPVAPDEF3 EGÎISYFSSTK TLCVIDPENR DSLGETDID. . . lATEDKSP VDT......C EGEETALAKE ALELPDTELL SPEAGPDPGD LPLDNQRT............
D EEDTSCSDSK TLCTQDSEST EIPLDEOVEE EAVGEEEESO PEACVIDDRS
001  050
A SSREEFWAV SHSSPSALAL QSPLLPAWRT LSVSEHAPGL PGLPSTAAEV
3  ......................................................................................................................................................
C .................................       , .
D PDT.................................................
851  090
A EAQREHQAAK RACSACAGTF GEDTSALPAP GGGGSGGDPT
3  ..................................................................................................................
C .........................................D .........................................
Figure 1.3: Alignment n f  the deduced amintt acid sequences o f  cDNAs for the 4 
human FDF4 genes
The figure shows an alignment, made using the GCG PILEUP multiple aligfiment 
software, o f the PDE4 isoforms HSPDE4À4, HSPDE4BI, HSPDE4CI ana 
HSPDE4D3. The regions o f sequence coloured in green are regions conserved 
between all PDE4s and the Lhtnce PDE o f Drosophila. These are UCRl (residues 
141-200 in HSPDE4A4B), UCR2 (residues 224 302 in HSPDE4A4B) and the 
catalytic region (residues 332 688 in HSPDE4A4B). The positions o f the 
hypervariable regions LRl (residues 201-223 in HSPDE4A4B) and LR2 (residues 
303-331 in HSPDE4A4B are also shown.
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1.3.2 The PDE4A enzyme family
13.2.1 PDE4A1
I
There are currently thought to be at least 6 different, endogenously occurring splice 
variants of PDE4A. In the cases of a number of these splice variants their expression 
has been detected in one of either the rat or humans but not in both. This may be due 
either to genuine species differences between these organisms or it may simply 
reflect the fact that the homologous isoenzyme in the other species has not yet been 
cloned.
.The human PDE4A gene locus has been characterised and finely mapped to a region 
of chromosome 19 p i3.2 between the genes encoding TYK2 and the low density 
lipoprotein receptor. The HSPDE4A gene spans 50kb and is composed of at least 17 
exons. The upstream conserved regions UCRl and UCR2 are each encoded by 3 
exons (exons 2, 3 and 4 and exons 6, 7 and 8 respectively). The hypervariable 
regions LRl and LR2 are encoded by 2 and 1 exons (exons 4 and 5 and exon 8 
respectively). The catalytic region of the enzyme is primarily encoded by 5 exons 
(exons 10, 11, 12, 13 and 14) with some additional contribution from exon 15 (225).
The first cDNA encoding a mammalian PDE4 to be cloned was the rat PDE4A splice 
variant RNPDE4A1. This clone was isolated from a rat brain cDNA libraiy. It 
encodes for a protein of 610 amino acids with a predicted Mw of 68kDa (47).
Antibodies raised against deduced amino acid sequences contained within the 
carboxyl terminal region of RNPDE4A1 detect a 73kDa immunoreactive species that 
is expressed endogenously in cerebellum (201) and also in other regions of brain 
(140). This 73kDa endogenous species migrates with a slightly higher apparent Mw 
than that predicted from the deduced protein sequence of RNPDE4A1. It is likely, 
however, to represent native RNPDE4A1 as it co migrates exactly with the novel 
immunoreactive species that is present in COS cells transiently transfected to express 
recombinant RNPDE4A1. Indeed, anomalous migration on SDS-PAGE is a common 
feature of PDE4 isoforms (16, 87, 108). This may be attributable to stretches of 
negatively charged amino acids that lie within the catalytic region of PDE4 enzymes
- iand that may affect the ratio of SDS binding to these proteins (87).
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Northern blot analysis suggests that the endogenous expression of RNPDE4A1 is 
confined to brain(201). Immunological analysis show that within brain RNPDE4A1 
is expressed in the brain stem, the cerebellum, the hippocampus, the striatum, the 
cortex, the midbrain and the hypothalamus (140). RNPDE4A1 is the only PDE4A 
species detected in cerebellum (140, 201).
The subcellular localisation of RNPDE4A1 has been studied in brain and also in a 
number of transfected, model systems using both biochemical and confocal 
microscopic analyses. In all of the systems investigated full length RNPDE4A1 
exists as a membrane-bound protein that is associated predominantly with the 
cytosolic faces of the plasma membrane and the Golgi (possibly endocytotic) 
apparatus (171, 200, 201). The association of RNPDE4A1 with these membranous 
structures is not disrupted by washing with buffers containing high concentrations of 
salt. It is, however, disrupted by washing with buffers containing even very low 
concentrations of the non-ionic detergent triton X-Î00 (200, 201). This suggests that 
the interaction of RNPDE4A1 with these structures may be predominantly 
hydrophobic in nature.
The alternatively spliced amino terminal 23 amino acids of RNPDE4A1 are both
necessary and sufficient for the regulated, subcellular targeting of this protein. That
this region of RNPDE4A1 is necessary for its subcellular targeting was shown by
examining the localisation of the engineered species Met^^RD 1. This species, a
tmncation of RNPDE4A1 that lacks the first 25 amino acids of the full length
protein, has an entirely cytosolic subcellular localisation in transfected COS-1 and
COS-7 cells (200). That the spliced, amino terminal region of RNPDE4A1 is
sufficient for its subcellular targeting was shown by examining the subcellular
localisation of chimeric constructs between the alternatively spliced, amino terminal
region of RNPDE4A1 and the normally cytosolic, bacterial protein chloramphenicol
acetyltransferase (CAT). Constructs in which the extreme amino terminal 25 residues
of RNPDE4A1 were expressed as an amino terminal fusion protein with CAT were
associated with the particulate fractions of transfected COS cells. This is in marked
contrast to the entirely cytosolic subcellular localisation of native CAT and of
regions of RNPDE4A1, other than that between residues 1-25, expressed as fusion
proteins with CAT (194).
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The 3 dimensional structure of a 25 residue peptide corresponding to the alternatively 
spliced, amino terminal region of RNPDE4A1 has been determined by nuclear 
magnetic resonance (NMR) (207). This peptide folds into 2 well ordered regions that 
are separated by a mobile hinge region. The most amino terminal of the 2 ordered 
regions is formed by the residues Leu^-Cys^\ These residues fold into a amphipathic 
a  helix in which the non polar residues (Leu\ Ala"*, Phe^, and Phe^) are concentrated 
along one edge. The region Cys^ -^Pro*"* appears to be highly mobile implying that it 
forms a hinge region in the structure. The region Pro‘'*-Lys^ '^  forms the second of the 
2 ordered regions of the peptide and can itself be resolved into 2 identifiable 
domains. The residues Pro^ "^ ~Trp^ ® fold into a compact, globular structure formed 
principally from large, hydrophobic residues. The folding of this region forces the 
hydrophobic residue Vail7 out into the solvent. This exposed residue has the 
potential to help stabilise specific interactions with other molecules. The residues 
Asp^-Arg^^ form a polar helix and it is likely that in the intact protein this helical 
region may extend fuilher downstream.
There are no features obvious from either the amino acid sequence or the NMR 
structure of the spliced amino terminal region of RNPDE4A5 that would be expected 
to insert into the phospholipid bilayer of a membrane. Neither is there any evidence 
that this region of RNPDE4A1 is modified by palmitoylation or by myristolyation 
(201). The mechanism by which this protein sequence can specifically target proteins 
to membranous structures within cells is likely therefore to involve its binding to 
some unidentified anchoring molecule. At present it seems more likely that this 
anchoring molecule is a specific phospholipid than a protein. This is because in vitro 
translated RNPDE4A1 is still able to associate with a membrane fraction from COS- 
7 cells even after the membrane fraction has been treated with proteases or has been 
boiled [Scotland and others, manuscript in preparation].
■e
L3.2.2 HSPDE4A4 (RNPDE4A5)
The human PDE4A splice variant HSPDE4A4B and its homologue in the rat
RNPDE4A5 are long PDE4A isofonns. As such they contain both UCRl and UCR2.
These isoforms each have an alternatively spliced region of approximately 110
unique residues at their extreme amino terminus. This region is the only sequence 
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that is unique to this PDE4A splice variant and it is likely to be responsible for the 
isoenzyme specific properties of these forms.
Immunological analysis shows that RNPDE4A5 is differentially expressed in various 
regions of rat brain. It is detected in the hippocampus, the striatum, the cortex, the 
midbrain and the hypothalamus but not in the brain stem, the pituitary gland nor the 
cerebellum (140). Both endogenously in brain and in a number of different 
transfected cell lines (COS-1, COS-7, HEK and Rat-1 cells), RNPDE4A5 partitions 
between the soluble and the particulate cell fractions (140). This subcellular 
distribution is also seen with the human homologue, HSPDE4A4B in transfected, 
model systems (93).
The particulate fractions of these proteins are not solubilised by repeated washing 
with buffers containing high concentrations of salt, the non-ionic detergent triton X- 
100 nor both salt and this detergent. This has lead to the speculation that these 
isoenzymes may interact with some element of the cytoskeleton (86, 93, 140). This 
hypothesis is further supported by immunofluoresent confocal microscopic analysis 
of the subcellular' distributions of RNPDE4A5 and HSPDE4A4B in transfected cells. 
These analyses show that a high concentration of these proteins are localised into foci 
(ruffles) at the cell margins. This distribution is reminiscent of those seen for the 
actin associated, cytoskeletal proteins fodrin and cortactin (86, 93).
The alternatively spliced, amino terminal regions of RNPDE4A5 and of 
HSPDE4A4B are rich in proline and arginine residues and each contains 3 
identifiable motifs that conform to the PxxP consensus sequence for interaction with 
SH3 domains (see section 1.5.1.1). Both RNPDE4A5 and HSPDE4A4B are able to 
specifically interact, in vitro^ with certain SH3 domains expressed as fusion proteins 
with glutathione S-transferase (GST). Furthermore co-immunoprecipitation 
experiments show that RNPDE4A5 and HSPDE4A4B can interact with full length 
Src and Lyn kinases (141, 162).
The interaction between RNPDE4A5 and SH3 domains has an absolute requirement 
for the alternatively spliced, amino terminal region of the protein; other rat PDE4A 
splice variants and amino terminal truncations of RNPDE4A5 that do not contain the 
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unique, amino terminal region do not interact with SH3 domains (see section 5.2.2) 
(162). It is likely that the most amino terminal of the 3 PxxP motifs present in this 
splice variant is directly involved in mediating the interaction between RNPDE4A5 
and SH3 domains (see section 5.2.2).
The alternatively spliced, extreme amino terminal region of HSPDE4A4B is also 
able to interact with SH3 domains (141). The interaction of HSPDE4A4B with SH3 
domains appears to be more complicated than that of the rat isoform RNPDE4A5.
This is because, in addition to the 3 putative SH3 domain binding motifs that are 
present within the alternatively spliced region of these proteins, there is another 
proline and arginine rich stretch of sequence within LR2 of the human but not of the 
rat isoenzyme that can interact with SH3 domains. The interaction between LR2 of 
HSPDE4A4B and an SH3 domain in vitro causes a change in the conformation of the 
catalytic site of HSPDE4A4B that can be detected by a change in its sensitivity to 
inhibition by rolipram. It has been suggested that a similar, in vivo interaction 
between HSPDE4A4B and an SH3 domain may function as a regulatory mechanism 
for this PDE and as a point of crosstalk between cAMP and tyrosine kinase signalling 
pathways (141).
The alternatively spliced, amino terminal region of RNPDE4A5 can be 
proteolytically cleaved from the enzyme during apoptosis in both the rat-1 fibroblast 
and the PCI2 cell lines [Huston and others, manuscript in preparation]. This is due to 
the specific proteolysis of RNPDE4A5 by caspase-3, a downstream effector of 
appopotsis. The site of cleavage conforms to the consensus recognition motif for 
caspase-3 and lies at the carboxyl terminal end of the alternatively spliced unique, 
amino terminal region of RNPDE4A5. Cleavage of RNPDE4A5 at this site abolishes 
its ability to interact with SH3 domains and, truncations that mimic the cleaved 
product have a different subcellular distribution from full length RNPDE4A5 as 
assessed by confocal microscopy [Huston and others, manuscript in preparation].
A functional role for the murine homologue of RNPDE4A5, MMRNPDE4A5 in
regulating differentiation of the 3T3-F442A fibroblast cell line has been identified
(132). Stimulation by growth hormone (GH) is an essential prerequisite for the
differentiation of 3T3-F442A fibroblasts into adipocytes. The activated GH receptor 
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interacts with the cytosolic tyrosine kinase JAK-2 to initiate a number of signalling 
cascades. This results in the cells exiting from the cell cycle and becoming primed 
for differentiation. Elevated levels of intracellular cAMP are then important for the 
subsequent differentiation of the primed cells. In addition to priming 3T3-F442A 
fibroblasts for differentiation stimulation by growth honnone also causes an acute 
activation of MMPDE4A5 in these cells. This antagonises subsequent increases in 
intracellular cAMP levels and so antagonises the differentiation process. This 
stimulation of MMPDE4A5 in 3T3-F442A fibroblasts is downstream of JAK-2 and 
of p70S6 kinase and it appears to involve a post translatational modification, 
probably phosphorylation, of this PDE form (132).
L3.2J RNPDE4A8
The splice variant RNPDE4A8 is a long PDE4A isoform that was initially cloned 
from a rat testes cDNA library. The cDNA encodes for a 763 amino acid protein that 
includes an alternatively spliced, extreme amino terminal region of 21 residues that is 
not conserved in any other splice variant (16). When expressed in heterologous 
systems (COS-7 and MA-10 cells), RNPDE4A8 migrates on SDS-PAGE as a single 
band of 98±1.4kDa (16, 152). RNAse protection analysis suggests that RNPDE4A8 
may be exclusively expressed in testis and immunoblotting of this tissue with 
antisera specific for PDE4A demonstrates the presence of a 97±2kDa 
immunoreactive species that is likely to be endogenous RNPDE4A8 (16). A similar 
immunoreactive species is also present in extracts from human ejaculated 
spermatozoa suggesting that a human homologue of RNPDE4A8 is also expressed in 
this tissue (152).
The expression of RNPDE4A8 is restricted to the testis and is developmentally 
regulated in maturing spermatozoa. A number of other components of the cAMP 
signalling pathway also have testis specific isoforms that aie differentially expressed 
during the differentiation of spermatozoa. This suggests that the cAMP signalling 
pathway may regulate some tissue specific function in these cells (152).
ir
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1.3.2.4 HSPDE4A10 (OlfRDl), rPDE66 and TM3
There is evidence for the existence of 3 further long form splice variants from the 
PDE4A gene.
The splice variant PDE4A10 is the full length sequence represented by a partial 
cDNA clone (Olf-RDl) that was first isolated from rat olfactory bulb RNA. This 
sequence has recently been cloned [G. Rena and others, manuscript in preparation] 
but the protein has not yet been fully characterised.
The cDNA rPDE66 was isolated form a rat lung cDNA library. A preliminaiy 
characterisation of protein product from this cDNA expressed in COS-7 cells has 
been undertaken [J. O’Donnell and others, manuscript in preparation]. The 
endogenous expression of this splice variant, however, has not yet been 
demonstrated.
A human PDE4A cDNA, called TM3 (HSPDE4A5) that is distinct from other 
PDE4A sequences has also been cloned (13). This cDNA appeared to encode for a 
novel long form PDE4A splice variant in that it contains sequences for UCRl and 
UCR2. The sequence at the extreme 3’ end of the TM3 cDNA clone, however, bears 
no homology to any known PDE. Rather, it has been suggested that, the 3’ region of 
this clone is the inverted 3 ’ end of a cDNA derived form another gene and that these 
2 cDNAs became inappropriately ligated during the cloning process (225). The 
existence of a unique 5' exon, that encodes for novel sequence found in the TM3 
cDNA clone, in PDE4A genomic sequence suggests however that a cDNA closely 
resembling TM3 may nevertheless be transcribed (225).
1.3.2.5 HSPDE4A8 (2EL)
The cDNA encoding HSPDE4A8 (2EL) was cloned from a human T-cell Jurkat 
cDNA library. This clone contains 2 regions of sequence that are not found in other 
PDE4A isoforms. These are a novel 5’ end and also a 34bp insert within the region 
that encodes the catalytic region of other PDE4A isoforms. The 34bp insert causes a 
frame shift in the ORE of the cDNA, compared to those of other PDE4A splice
I
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variants, and brings a downstream stop codon into frame. This can be expected to 
cause the premature termination of the expressed protein and to result in a 
catalytically inactive species (83). Exons that encode both of the novel regions of 
sequence present in the HSPDE4A8 clone have been identified within the human 
PDE4A gene locus. This supports the hypothesis that HSPDE4A8 is a genuine 
PDE4A splice variant (225).
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Figure 1.4: Rat PDE4A mRNA splice variants
The figure shows a diagrammatic representation o f the mRNAs that are Jmown to be 
encoded by the rat PDE4A gene. Regions o f sequence that are conserved between all 
mammalian PDE4 genes and the dunce PDE o f Drosophila (UCRl, UCR2 and the 
catalytic region) are shown as boxes. Regions o f alternatively spliced sequence that 
are unique to each splice variant are shown as dark bars. The splice variants shown 
are: 66, the recently cloned rPDE66; AS, RNPDE4A5A (accession number L27057); 
AID, RNPDE4A10 (OlfRDl); A8, RNPDE4A8A (accession number L36467); Al, 
RNPDE4A1A (accession number M26715).
NB. This diagram is not drawn to scale. I
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Figure 1.5: Human PDE4A mRNA splice variants
The figure shows a diagrammatic representation o f the mRNAs that are known to be 
encoded by the human PDE4A gene. Regions o f sequence that are conserved 
between all mammalian PDE4 genes and the dunce PDE o f Drosophila (UCRl, 
UCR2 and the catalytic region) are shown as boxes. Regions o f alternatively spliced 
sequence that are unique to each splice variant are shown as dark bars. The splice 
variants shown are: A4. HSPDE4A4B (accession number L20965); AlO the recently 
clonedHSPDE4A10, TM3, HSPDE4A5 (TM3, accession number L20967); Al, 
HSPDE4A1 (accession number NM 006202); A8, HSPDE4A8 (2EL accession 
number U18088).
NB. This diagram is not drawn to scale.
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1.3.3 The PDE4B enzyme family
To date 4 splice variants from the PDE4B gene have been identified. Each of these 
has been cloned from either or both the human and the rat. There are 2 long form 
splice variants PDE4BI (human clone TM72, rat clone DPD) (13, 38) and PDE4B3 
(rat clone rPDE74) (92); and 2 short form splice variants PDE4B2 (human clones 
PDE32 and HPB106, rat clones ratPDE4 and RPDE18) (13, 17, 139, 160, 228) and 
PDE4B4 (human clone HBP102) (160). There is evidence that different PDE4B 
splice valiants are differentially expressed between brain regions (126).
The recombinant PDE4B splice variants HSPDE4B1, HSPDE4B2 and HSPDE4B3 
have each been expressed and characterised in COS-7 cells. In this system these 
enzymes all have broadly similar kinetic characteristics that are typical of members 
of the PDE4 enzyme. There are, however, several differences in specific 
characteristics, such as the Vmax and the sensitivity to inhibition by rolipram 
between these isofonns. There are also differences between the cytosolic and the 
particulate populations of individual splice variants. Such differences are likely to be 
related to specific functions of these isoenzymes (92).
The subcellular localisations of the splice variants HSPDE4B1, HSPDE4B2 and 
HSPDE4B3 were examined in transfected COS-7 cells. In this system all of these 
splice variants were found to partition between the particulate and the soluble cell 
fractions, with 30-40% of each splice variant present in the particulate fractions. The 
mode of association of each of these splice variants with particulate cell fractions, 
however, appears to be quite different as each showed very different susceptibility to 
solubilisation by buffers containing either or both the detergent Triton X-100 and 
high concentrations of NaCl. Furthermore the populations of each individual splice 
variant that were associated with the low speed (PI) and the high speed (P2) pellet 
fractions also showed different susceptibility to solubilisation by the various buffers 
(92).
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1.3.3.1 Phosphorylation o f PDE4B
The short form PDE4B splice variant HSPDE4B2 is phosphorylated on 2 serine 
residues (Ser"^ ®^ and Seri®®) when expressed in Sf9 cells or in yeast but not when 
expressed in E.coli (114). This region of the protein is conserved between all of the 
known PDE4B splice variants and it is likely that these too are similarly modified. 
These serine residues lie within consensus motifs for phosphorylation by mitogen 
activated protein kinase (MAPK/ERK) and by casein kinase II respectively. A 
truncated form of HSPDE4B2B expressed in and purified form E.coli is a substrate 
for phosphorylation by MAPK in vitro (114). This purified HSPDE4B2B species 
was phosphorylated by MAPK on Seri®\ No effects of this phosphoiylation on the 
kinetic characteristics of the enzyme were reported, however, this was not rigorously 
investigated and the function of phosphorylation, by MAPK, at this site is, as yet, 
unclear (114).
1.3.4 The PDE4C enzyme family
The PDE4C gene family is the least well characterised of all the PDE4 gene families. 
To date there is evidence for 3 PDE4C splice variants (58, 165). The best 
characterised of these is the human PDE4C splice variant HSPDE4C2 that was 
isolated from the U87 glioblastoma cell line by 5’RACE and RT-PCR. This cDNA 
clone encodes a predicted protein of 605 amino acids that migiates with an apparent 
Mw of 80kDa when expressed in COS-1 cells or yeast. The interaction of this splice 
variant with rolipram differed between the 2 expression systems, with high affinity 
binding of rolipram being detected for the COS-1 cell but not for the yeast expressed 
enzyme (165). This indicates that the enzyme can adopt more than one active 
conformation, which are distinguished by their interaction with rolipram (see section
1.3.6).
No endogenous PDE4C isoform has yet been detected at the protein level but RT- 
PCR has been used to detect the expression of PDE4C message in a number of cell 
and tissue types including rat parotid gland (94) and heart (107). The levels of 
PDE4C message in heart appeared to be altered following treatment of the animals
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with 7-oxo-prostacyclin (107). This suggests that the expression of PDE4C may be 
hormonally regulated in this tissue.
1.3.5 The PDE4D enzyme family
To date 5 distinct splice variants from the PDE4D gene have been identified {Figure
1.6). There are 2 short form splice variants, PDE4D1 (159, 226) and PDE4D2 (99, 
159). In addition there are 3 long form splice variants, PDE4D3 (199), PDE4D4 (14, 
15, 98) and PDE4D5 (15). These splice variants have all been identified both in 
humans and in the rat. The cDNA sequence for the rat form of PDE4D5, however, 
has not yet been cloned and the evidence for the existence of this isoenzyme is solely 
immunological.
1.3.5.1 Short form PDE4D splice variants, PDE4D1 and PDE4D2
The primary structures of the 2 short form splice variants from the PDE4D gene, 
PDE4D1 and PDE4D2 are very similar to one another, the only difference being a 78 
residue extension at the extreme amino terminal of PDE4D1 that is not present in 
PDE4D2. Each of these splice variants has been extensively characterised in 
transfected COS-7 cells. In this model system these splice variants each exhibit 
kinetic characteristics typical of PDE4 isoforms: a low Km for cAMP, an 
insensitivity to cGMP or to Ca^  ^calmodulin and a sensitivity to inhibition by 
rolipram (15, 227). The 2 proteins both have a predominantly cytosolic subcellular 
localisation in transfected COS-7 cells, approximately 94% of the protein 
fractionating with the S2 cell fraction and also in FRTL-5 thyroid cells (98). Both 
HSPDE4D1 and HSPDE4D2 migrate on SDS-PAGE with similar apparent Mw’s of 
68±lkDa(15).
The mRNAs that encode PDE4D1 and PDE4D2 are transcribed from the same start 
site and their expression is controlled by the same promoter (146, 238). The promoter 
that controls the expression of these 2 splice variants contains cAMP responsive 
elements and is regulated by hormones that act through the cAMP signalling pathway 
in a number of different cell types including Sertoli cells (227) and the FRTL-5
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thyroid cell line (238). The induction of these splice variants in response to hormonal 
stimulation appears to be involved in the long term desensitisation of the cells (98).
13.5.2 Long form PDE4D splice variants PDE4D3, PDE4D4 and PDE4D5
The primary structures of the long form PDE4D splice variants, PDE4D3, PDE4D4 
and PDE4D5, differ from one another only in their alternatively spliced amino- 
teiminal regions {Figure 1.6). These splice variants have been expressed and 
characterised in transfected COS-7 cells (15). As with the short form PDE4D splice 
variants each has catalytic characteristics typical for a member of the PDE4 
superfamily. All of the long PDE4D isoforms partition between the cytosolic and the 
particulate fractions of transfected COS-7 cells (15) and a similar distribution has 
also been observed for endogenous, long PDE4D splice variants in FRTL-5 thyroid 
cells (98).
1.3.5.3 Phosphorylation o f PDE4D3 by PKA
The long form PDE4D splice variant PDE4D3 is a substrate for phosphorylation by 
PKA in vitro (2, 197). This isoform also becomes phosphorylated and activated in 
response to agents that act to increase intracellular cAMP and activate PKA in vivo in 
FRTL-5 thyroid cells (122, 197), COS-1 cells (82), U937 promonocyte cells (2) and 
vascular smooth muscle cells (124).
The phosphorylation of PDE3D3 by PKA produces an approximately 3 fold increase 
in activity that is due to a change in Vmax but not in Km of the enzyme. This 
phosphorylation also generates an increase in affinity for Mg^  ^and a change in 
sensitivity to inhibition by rolipram (82, 197).
Two residues in PDE4D3 (Ser*  ^and Seri"^ ) become phosphorylated by PKA (197). 
Mutational analysis has shown that phosphorylation at Ser^ "*, in the absence of 
phosphorylation at Ser^ ,^ is sufficient to engender activation of the enzyme and the 
changes in sensitivity to both Mg^  ^and to rolipram (82, 197). A model in which 
modification at Seri‘S disrupts at least 2 distinct intramolecular bonds to cause both
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the activation of and the change in sensitivity to rolipram of PDE4D3 has been 
proposed on the basis of mutational analysis (82).
This model proposes that Ser^ '^  and the adjacent Glu^  ^are each involved in making 
bonds that influence the structure of the catalytic site of the enzyme. It has been 
suggested that GW is involved in forming an ion pair that constrains the activity of 
the enzyme and that the introduction of a negative charge by the phosphorylation of ■ i.Ser^ '^  would disrupt this interaction and cause an activation (82). In addition to this 
Seri'* has been suggested to be involved in forming a hydrogen bond with another, 
unidentified residue in the protein (82). The disruption of this hydrogen bond has 
been suggested not to affect the catalytic activity of the enzyme but to influence the 
conformation of the active site in such a way that can be detected by a change in 
affinity for rolipram (82).
The functional consequences of phosphorylation at Seri  ^are not known. A change in 
the electrophoretic mobility of HSPDE4D3 on SDS-PAGE that occurs upon its 
phosphorylation by PKA has, however, been linked to the phosphorylation of 
PDE4D3 in certain cells (98) but not observed in others (82).
; ';r
13.5A  Phosphorylation o f PDE4D3 by ERK
The PDE4 isoforms PDE4D3 and PDE4D5 have been shown to be substrates for 
phosphoiylation and regulation by the MAP kinase ERK2 (81). These proteins are 
phosphorylated by ERK2 both in vitro and in vivo on a single serine residue (Ser^ ^® in 
HSPDE4D3) that is located within the carboxyl terminal region of the molecule and 
lies within a consensus motif of the form PXn(S/T)P for phosphoiylation by ERKs
The phosphoiylation of PDE4D3 by ERK2 causes an inactivation of the enzyme that 
can be reversed either by dephosphorylation by PPl or by a further phosphoiylation 
at the PKA site located within UCRl (Ser^ '* in HSPDE4D3) (81). It has been 
suggested that the PKA phosphorylation may provide a negative feedback loop 
whereby activation of ERK2 causes an inhibition of long foim PDE4s, leading to an 
increase in intracellular cAMP, the activation of PKA and the subsequent 
phosphorylation and reactivation of the PDEs (81).
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L3.5.5 PDE4D4
The long form PDE4D splice variant HSPDE4D4 was initially isolated from a human 
fetal brain cDNA library as an incomplete cDNA that was open at its 5’ end (13).
Full length cDNA sequences for PDE4D4 have subsequently been cloned from both 
humans and the rat (15, 98). This splice variant differs, at the level of primary 
structure, from the other long PDE4D splice variants solely in its alternatively 
spliced, amino terminal region {Figure 1.6). The expression of this splice variant 
appears to be largely restricted to brain (15) although mRNA encoding RNPDE4D4 
has been detected by RT-PCR in the FRTL-5 thyroid cell line (98).
The alternatively spliced, amino terminal region of PDE4D4 comprises 152 amino 
acids. This region of HSPDE4D4 contains long stretches of extremely proline rich 
sequence that might be expected to fold into a left handed PPII helical structure. This 
region of the protein is also unusually rich in histidine residues. The primary 
structure of this region of HSPDE4D4 is somewhat reminiscent of sequences that 
participate in specific protein-protein interactions and, in this thesis, I present 
evidence that PDE4D4 can interact, at least in vitro, with specific SH3 domains (see 
chapter 3).
1.3.5.6 Interaction ofPDE4D5 with RACK
The long fonn PDE4D splice variant HSPDE4D5 differs, at the level of primary 
structure, fr om the other long PDE4D splice variants solely in its alternatively 
spliced, amino terminal region.
A yeast 2 hybrid screen that used the unique, alternatively spliced region of 
HSPDE4D5 as a bait identified a potential interaction between HSPDE4D5 and 
protein called, receptor for activated C kinase 1 (RACKl) (252). The interaction 
between RACKl and HSPDE4D5 was subsequently confirmed as being a genuine 
protein-protein interaction that occurs both in vitro and in vivo (252).
RACK 1 is a 36kDa protein which was first identified as one of several proteins, 
present in the detergent insoluble fr action of heart and brain that can bind to activated
I
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protein kinase C (PKC) (145). This protein was cloned from a rat brain cDNA library 
and found to belong to the superfamily of WD40 motif containing proteins (180).
The structure of another WD40 motif protein (the G protein p subunit) has been 
solved; the G protein p subunit has a propeller like structure in which the blades of 
the propeller are formed by the repeating WD40 motifs. Other WD40 motif proteins 
such as RACK 1 are presumed to adopt a similar conformation (211). In both RACK 
1 and the G protein p subunit the WD40 motifs are involved in mediating protein- 
protein interactions.
The interaction between PDE4D5 and RACKl is due to a specific, high affinity, 
direct binding of these 2 proteins and not due to each protein binding to a third 
bridging protein. A short stretch of sequence found within amino acids 19-50 and 
that is contained within the alternatively spliced amino-terminal region of PDE4D5 is 
necessary for the interaction of PDE4D5 with RACK 1. The mutation of any 1 of 4 
amino acids (N22, P23, W24 or N26) within this region to alanine is sufficient to 
completely abolish the interaction with RACK 1. This suggests that this region is the 
major site of interaction between the 2 proteins (252).
In addition to PDE4D5 and PKC, RACKl can interact with the cytoplasmic domain 
of the integrin p subunit(121) and with Src kinase (30). In the cases of PKC and the 
integrin p subunit interaction with RACK 1 is not constitutive but requires activation 
by phosphatidylserine and Ca^  ^in the case of PKC and by stimulation of the cells by 
phorbol esters (which would also be expected to activate PKC) in the case of the 
integrin p subunit. In the cases of PDE4D5 and of Src kinase the interaction with 
RACK 1 appears to be constitutive.
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Figure 1.6: Mammalian PDE4D mRNA splice variants
The figure shows a diagrammatic representation o f the mJRNAs that are known to be 
encoded by the mammalian PDE4A gene. Regions o f sequence that are conserved 
between all mammalian PDE4 genes and the dunce PDE o f Drosophila (UCRl, 
UCR2 and the catalytic region) are shown as boxes. Regions o f alternatively spliced 
sequence that are unique to each splice variant are shown as dark bars. The dashed 
line indicates a region o f sequence that is absent from the PDE4D2 mRNA. The 
splice variants shown are:Dl, PDE4D1 (accession numbers U79571 andL27060for 
the human and rat sequences respectively); D2 PDE4D2 (accession numbers 
S:1059275 and U09456for the human and rat sequences respectively); D3, PDE4D3 
(accession numbers L20970 and U09457for the human and rat sequences 
respectively); D4, PDE4D4 (accession numbers L20962 and AF031373 for the 
human and rat sequences respectively); D5, PDE4D5 (accession number S:1059276 
for the human sequence).
NB. This diagram is not drawn to scale.
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1.3.6 Inhibition of PDE4 isoforms by rolipram: evidence for distinct 
conformational states
The antidepressant drug, rolipram (4-[3"(cyclopentoxyl)"4-methoxyphenyl]2- 
pyrrolidone) is a specific inhibitor of the PDE4 enzyme family (158). The structural 
similarities between rolipram and cAMP, together with the kinetic characteristics of 
the inhibition suggest that rolipram binds at or near to the catalytic site of PDE4 
isoenzymes and functions as a competitive inhibitor. Rolipram is widely considered 
to be the archetypal PDE4 specific inhibitor; indeed PDE4 activity is often defined as 
the PDE enzyme activity within a preparation that is inhibited by lOpM rolipram. 
Rolipram has been tested in clinical trials as an antidepressant drug but its adverse 
side effects, which include emesis and nausea, limit its therapeutic utility.
Despite its limited therapeutic utility the interaction between rolipram and PDE4 
continues to receive considerable attention. This is largely because certain 
discrepancies between a model of simple competitive inhibition and the data 
obtained for the effect of rolipram on various preparations of PDE4 suggest that 
specific long form PDE4 isoenzymes may be able to adopt more than 1 
conformational state and that these can be distinguished by differences in their 
interaction with rolipram (6, 141, 215, 233).
A high affinity (low nM) rolipram binding site is present in preparations of brain and 
certain, although by no means all, other tissues. There is good evidence that this high 
affinity rolipram binding site is a property of the PDE4 enzyme as high affinity 
rolipram binding is co expressed with recombinant PDE4 in yeast (234). The high 
affinity rolipram binding shows marked sterioselectivity with a 20 fold greater 
affinity for the R-(-) enantiomer than for the S~(+) enantiomer of rolipram. In 
contrast to this the inhibitory potency of rolipram against PDE4 usually lies in the 
0.1-2.0pM range and little stereoselectivity between the R-(-) and S-(+) enantiomers 
of rolipram is apparent (215, 216). Furthermore many peripheral tissues that are rich 
in PDE4 activity do not display high affinity rolipram binding (87).
Despite the apparent differences between the high affinity binding and the inhibitory 
action of rolipram on PDE4 a number of lines of evidence suggest there is only a 
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single rolipram binding site on each PDE4 subunit. Firstly, as rolipram is structurally 
similar to cAMP, one might expect that any additional rolipram binding site within a 
PDE4 molecule would be contained in a domain of a similar size and with some 
homology to the catalytic domain. In PDE2, PDE5, PDE6 and PDE 10, for instance, 
the allosteric cGMP binding site is clearly identifiable as sharing homology with the 
catalytic domain (87). There are, however, no regions of sequence outside of the 
catalytic region of PDE4s that are obvious candidates for forming an additional 
rolipram binding site. Secondly, rolipram binding assays performed using 
HSPDE4B2 purified to homogeneity show that the stochiometry of binding does not 
exceed Imol rolipram per mol of PDE. This supports the hypothesis of a single 
rolipram binding site on PDE4 (178, 179).
A number of different models have been proposed that could account for the 
discrepancies between the binding of and the inhibition by rolipram of PDE4 (87,
215). Most of these models involve the existence of at least 2 distinct conformational 
states of the PDE, each of which exhibits a different affinity for rolipram. An 
attractive hypothesis is that the interconversion between possible conformers may be 
controlled by some type of molecular switch, such as a phosphorylation or by a 
protein-protein interaction. This notion is consistent with the observations that 
vanadyl-glutathione complexes can cause an activation of and an increase in the 
affinity for rolipram of PDE4 from guinea pig eosinophil membranes (104). It is 
plausible that these effects are due to a thiol group modification of either the PDE or 
an associated protein that tiiggers a conformational change in the PDE and results in 
the accumulation of a conformer exhibiting high affinity rolipram binding (87). Also 
PDE4D3, expressed in either Sf9 cells or MA 10 cells, appears to exist as 2 distinct 
conformers each of which has a different sensitivity to inhibition by rolipram. The 
interconversion of the enzyme between these conformational states appeal's to be 
regulated in some way as phosphorylation by PKA specifically activates high affinity 
rolipram binding form but does not perturb the amount of the low rolipram affinity 
conformer (2). Finally the between a proline and arginine rich motif, located within 
LR2 of HSPDE4A4B, and the SH3 domain of a Src family tyrosyl kinase (Src or Lyn 
kinase) causes a change in the sensitivity of this PDE to inhibition by rolipram (141).
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There is evidence to suggest that different conformers of PDE4 may have distinct 
physiological functions (215). This raises the possibility of developing conformer 
specific PDE4 inhibitors that might be expected to have a more specific action (fewer 
side effects) than currently available PDE4 inhibitors.
The structural determinants of the rolipram sensitivity of PDE4 isoenzymes have 
been mapped to a 109 amino acid region located at the carboxyl teiminus of the 
PDE4 catalytic domain (4). This region of PDE4 is relatively well conserved between 
PDE4 and other PDE gene families. Both residues that are specific to PDE4 
isoenzymes and also those that are conseiwed between PDE4 and, for instance, PDE3 
were identified as being important determinants for inhibition by rolipram. In 
general, mutation of residues that are important for sensitivity to rolipram and that 
are also conserved in the PDE3 gene family resulted in the largest changes in the 
affinity of the enzyme for cAMP. This supports the hypothesis that the catalytic site 
of PDE4 is closely liked to the rolipram binding site and that changes in the 
conformation of the active site can markedly affect its interaction with rolipram.
1.4 Src family tyrosyl protein kinases
The Src family tyrosyl kinases are a family of non receptor protein tyrosine kinases.
In mammals 8 Src family tyrosyl kinases have so far been identified: Src, Fyn, Yes, 
Lck, Hck, Lyn, Fyr and Blk. These proteins range between 52-62 kDa in size and 
certain of the family members occur as multiple forms due to alternative mRNA 
splicing (Fgr, Lyn and Hck) or to posttranslational modification (Lck) {Table 1.3).
All of the Src family tyrosyl kinases share a common domain stmcture composed of 
a myristalated, amino terminal membrane localisation (SH4) domain; a unique 
domain that is between 45-85 amino acids and is not conseiwed between the various 
family members, an SH3 domain (see section 1.5.1.1); an SH2 domain (see section 
1.5.1); a linker region; the tyrosine kinase catalytic region and a conseiwed carboxyl 
terminal region that contains a regulatory tyrosine residue (Y527 in chicken Src).
The crystal structures of human Src (247), chicken Src (244) and human Hck (206) 
have recently been determined and this has provided insights into the regulation of
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these enzymes. The inactive conformation of Src family tyrosyl kinases is stabilised 
by multiple intramolecular interactions including an interaction between a 
phosphorylated regulatory tyrosine residue within the carboxyl terminal region of the 
kinase and its SH2 domain and an interaction between the SH3 domain and a region 
within the small lobe of the kinase domain. Full activation of Src family tyrosyl 
kinases therefore requires the disruption of both the intramolecular SH2 and SH3 
domain interactions to allow the reorganisation of the kinase into its active 
conformation.
Src family tyrosyl kinases become activated following the stimulation of cells with a 
number of hormones and growth factors that activate receptors with intrinsic tyrosine 
kinase activity such as the platelet derived growth factor receptor (PDGFR) (49). Src 
family kinases are also activated downstream of antigen receptor complexes, that 
lack intrinsic tyrosine kinase activity, in lymphoid cells (88). The roles of the various 
Src family tyrosyl kinases in signalling downstream of activated receptors are not 
well understood and appear to vary between different cell types and even 
downstream of different receptors within a single cell type. Src, for instance, 
functions differently downsteram of activated a  and p PDGFRs in several cell lines 
(49). Also, different family members appear able to substitute for one another in 
knockout cell lines. Stimulation of a Src' murine fibroblast cell line by plalatelet 
derived growth factor (PDGF) was still able to innitate mitogenesis, however kinase 
inactive mutants of Src functioned as dominant negatives when expressed in these 
cells. This was presumably due to competition between the mutant Src and other 
endodgenous Src family tyrosyl kinases that were sufficient to support signalling in 
the Src' cells (22). Despite these difficulties it is clear that Src family tyrosyl kinases 
are recruited to activated receptors by an interaction between their SH2 domain and 
phosphoiylated tyrosine residues on the receptor and that, at least in the case of 
mitogenic signalling in murine fibroblasts, a functional SH3 domain on the Src 
family kinase is required for further signalling to downstream elements of the 
pathway (22, 49).
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Src family tyrosyl kinase Molecular mass of protein (kDa)
Src 60
Yes 62
Fyn 59
Fgr 55/53"
Lyn 56/53"
Lck 56 (58,60,62....)"
Hck 59/56"
Blk 55
Table 1.3: Molecular masses o f the mammalian Src family tyrosyl kinases
Abbreviations two forms due to alternative mRNA splicing or alternative 
translational initiation sites
Multiple forms due to posttranslational modification 
Table adapted from (150)
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1.5 Protein-protein interactions in signal transduction
Much of the signalling in eukaryotic cells is mediated by the actions of broad 
specificity kinases and phosphatases. Understanding how promiscuous enzymes such 
as these are organised into specific signal transduction pathways represents an 
essential step towards attaining a full knowledge of the control of cell function. 
Although, as with the control of metabolism, the physical separation of pathways into 
membrane-bound intracellular compartments undoubtedly plays an important role in 
the organisation of signalling, many distinct signal transduction pathways do exist 
within a single subcellular compartment. It is difficult to imagine how the integrity of 
these pathways, many of which consist of highly related enzymes exhibiting similar 
substrate specificities, could be maintained solely by variations in enzyme and 
substrate levels.
It is becoming increasingly apparent that regulated protein-protein interactions play 
an important role in the organisation of signalling pathways. The cytosolic 
compartment of a cell is not envisaged as a “soup” of proteins diffusing in free 
solution but, rather, as a highly organised environment where regulated protein- 
protein interactions localise signalling molecules to specific regions and so define the 
pool of substrates on which they can act (60, 168). This model presents the 
opportunity for controlled “crosstalk” between pathways as, depending on the 
juxtaposition of molecules within a given cell type, pathways sharing common 
elements could either interact or operate independently of one another. It also allows 
for differential activation of functionally distinct pathways by a single second 
messenger following the establishment of non-homogeneous distributions of that 
messenger within the cell (85) (see section 1.4.3).
1.5.1 Modular domains for protein-protein interaction
Modular domains for protein-protein interaction occur in a wide number of different 
types of protein. Transcription factors and signalling proteins are 2 important 
examples of proteins that frequently contain domains for protein-protein interaction.
In transcription factors such domains function both to allow the dimérisation of DNA
M.B.Beard Introduction 1-62
1.5.1.1 Src homology 3 (SH3) domains
binding proteins and also to allow the assembly of multi-protein complexes around 
the promoter regions of the genes that they control.
The concept of conserved, modular domains that mediate protein-protein interactions
between signalling molecules arose with the identification of Src homology 2 (SH2)
domains. These domains, which share homology with a region of approximately 100
amino acids towards the amino terminus of Src kinase (amino acids 143-244) (247),
bind to specific phosphotyrosine containing motifs within their target proteins. A
large number of other conserved domains for protein-protein interaction have now
been identified {Table 1.1.4). Such domains form distinct modular units within
proteins and seem to function independently of sunounding sequences. Each type of
domain mediates protein-protein interactions by binding to a short, peptide-like core
motif (74). These motifs are flanked by more variable sequences that also interact
.with the domain to increase the specificity and the affinity of interaction (167).
The domains for protein-protein interaction that occur in signalling proteins fimction 
as regulated docking sites that allow multiprotein complexes to dynamically 
assemble and disassemble during signalling. The recruitment of proteins into such 
complexes appears to be an essential feature of many signalling pathways (133). This 
may be because such complexes serve to enhance the efficiency of signal 
transduction by brining enzymes and their substrates into close proximity. Another 
function of these signalling complexes seems to be in maintaining the integrity of 
discrete signalling pathways by presenting only the appropriate substrates to 
activated enzymes (60). I
Src homology 3 (SH3) domains are a class of modular domain for protein-protein 
interaction that, as with SH2 domains, were first identified in Src kinase. SH3 
domains share homology with a region of approximately 60 amino acids in the 
amino-terminal region of Src kinase (amino acids 83-142) (137). Studies in which 
expression libraries were screened for interacting proteins revealed that SH3 domains 
bind to regions of target proteins that are rich in proline residues and contain the core 
PxxP motif (1). Structural studies and peptide binding assays have revealed that SH3 
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biading sequeacea adopt a haaded polypmlme typo II (PPII) Wical coamrmadoa
and that residues flanking the PxxP motif are also important in stabiKsing the
interaction (61).
It has been proposed that SK3 domain binding sequences may be divided into two 
distinct classes (class I and class II) (205).
I sequences c o t^ m  to the coasegm^s Xi p %  P p %  P 
Class II sequences eon&>mi to the consensus P p Xz- P p X,
A lowercase p indicates a scaffolcüng residue, responsible for stabilising the PPII helix.
This is often found to be a proline residue.
An uppercase P represents a proline residue that contacts the SH3 domain.
Subscripted Xs represent non-conserved residues that also contact the SH3 domain.
The reiduGs represented by Xi and Xi are %pecia*iy noteworthy as these positions
are believed to make contact with a pocket on the SH3 domain that is distinct from 
the proline binding pockets (205). In SH3 domains such as that of Src, this pocket is 
acidic. The Xi or X, positions of ligands for these SH3 domains are therefore usually 
occupied by arginine residues, which fonn a salt bridge with an acidic residue in the 
SH3 domain (D99 in Src kinase), ^ le rea s  the X% position of class I ligands lies on 
the amino-terminal side of the PXXP motif, the Xi - position of class II ligands Is on 
the carboxji-terminal side of the PXXP motif. This difterencs has been suggested to 
cause class 1 and class il sequences to bind to SH3 domains in opposite orientations 
(205),
In addition to its role in mediating intermolecular protein-protein interactions the SH3 
domain of Src kinase engages in an intramolecular with another region in Src kinase. 
This interaction affects the conformation of the tyrosine kinase domain of Src in such 
a way as to constrain its catalytic activity. The intermolecular interaction of the SH3 
domain of Src with another protein is therefore involved in the activation of Src 
tyrosine kinase activity (247).
/. J. J. 2 WW domians
WW domains derive their name from the presence of 2 conserved tryptophan 
residuces that are spaced at either end of these domains. These domains are relatively
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small, compared to other domains that mediate protein-protein interactions, being 
only 35-40 residues in length. They fold into a compact, 3-stranded (3-sheet structure 
that presents a flat surface formed from the conserved residues within the domain.
This provides the site of protein-protein interactions. As with SH3 domains, WW 
domains bind to ligands that contain stretches of proline rich sequences. The 
sequences that bind to WW domains are, however, of a different form to those that 
bind to SH3 domains and confoim to the consensus PPxY or PPLP (29, 168, 222,
223).
1.5.1.3 Phospho tyrosine binding (PTB) domains
Phospho tyrosine binding (PTB) domains are a class of protein-protein interaction 
domains that, although having low sequence homology with one another, all share a 
similar secondary structure. These domains are composed from between 100-150 
residues that fonn 7-stranded p-sheeted structures, capped by a helix at the carboxyl 
terminal end of the domain (74). The PTB domains of She and of insulin receptor 
substrate-1 (IRS-1) bind to sequences that conform to the consensus motif NPxY in 
which the tyrosine residue is phosphorylated (257). Sequences that lie amino 
terminal to the phospho-tyrosine recognition motif also make contact with these 
domains and increase the affinity and specificity of the interaction. Despite their 
name, certain PTB domains can bind to motifs in which the tyrosine residue is not 
phosphorylated. Examples of this include the PTB domains of X I1, Fe65 and Numb 
(19, 254).
1.5.1.4 PDZ domains
PDZ domains are structurally similar to PTB domains. This class of domain binds to 
sequence motifs at the extreme cai'boxyl tenninal end of proteins that confonn to the 
consensus xS/TxV (54). The target proteins that PDZ domains bind to are frequently 
transmembrane receptors or ion channels. All 3 classes of glutamate receptor, for 
example, are recognised by distinct PDZ domain containing proteins. Many PDZ 
proteins contain multiple PDZ domains that can often bind to different target 
proteins. PDZ domains can also frequently heterodimerise with PDZ domains in 
other proteins. This has lead to the speculation that PDZ domain containing proteins 
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may have an important role in mediating the clustering of transmembrane receptors 
and ion channels (168, 235).
1.5.1.5 Pleckstrin homology (PH) domains
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Pleckstrin homology (PH) domains do not mediate protein-protein interactions but 
rather protein-phospholipid interactions. I have, nevertheless, included a brief 
description of PH domains in this section because these domains share a similar 
secondary structure to both PTB and PDZ domains. PH domains occur in a wide 
variety of signalling proteins including certain tyrosine kinases, protein kinase B 
(PKB/AKT) and phospholipase C. This class of protein domain binds to the charged 
headgroups of specific phosphoinositide phospholipids. PH domains may therefore 
function to target proteins to specific regions of cellular membranes that are enriched 
in a specific phospholipids. This would allow for the coupling of phospholipid 
signalling pathways to protein kinase and other signalling pathways within a cell 
(168). An example of this is provided by the PH domain of the Bruton’s tyrosine 
kinase (Btk). This PH domain binds to phosphatidylinositol-3,4,5 triphosphate (PI- 
3,4,5-P;) and so may serve to recruit Btk to areas of membrane where this 
phospholipid is being produced. In so doing it serves to facilitate the interactions of 
Btk with other signalling molecules already present. As Btk contains an SH2 and an 
SH3 domain, in addition to its PH domain, it is possible that Btk may itself then 
recruit other proteins to a forming complex (32),
Ï:
Domain for protein-protein Reference
interaction
BTB domain/ POZ domain (119)
PDZ domain (54, 55, 189, 235)
PH domain (3 ,3 2 )
PT B /PI/SA IN  domain (2 5 4 )(1 9 )(7 4 )(2 5 7 )
SH2 domain (IB, 183,239, 247)
SH3 domain (61, 86, 148, 149, 162, 176, 205, 247)
WD repeat/ beta-tiansducin repeat (120, 156 ,211 ,252)
WW domain/ WWP motiP RSP5 repeat (29, 131 ,222 ,223)
Table 1.1.4: Modular domains for protein-protein interaction that occur in 
signalling proteins
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1.5.2 Protein-protein interactions in cAMP signalling
The role of regulated protein-protein interactions in organising signalling through the 
cAMP, PKA pathway is now well established. A family of functionally related PKA 
anchoring proteins (AKAPs) target the inactive, holoenzyme form of protein kinase 
A (PKA) to specific intracellular locations. Protein serine/threonine phosphatases are 
targeted to substrates and regulated by a variety of binding proteins. Cyclic AMP 
phosphodiesterases also interact with binding proteins which may play a role in the 
targeting and regulation of these molecules.
L5.2.1 Interaction o f PKA with AKAPs
A family of AKAPs target the inactive, holoenzyme form of PKA to specific 
intracellular locations. At least 2 functional domains within AKAPs are involved in 
the targeting of PKA: a PKA regulatory (R) subunit binding region and a second 
region which anchors the AKAP-PKA complex to its specific intracellular location. 
Mutagenesis and deletion experiments have been used to map these domains in 
AKAPs and, on the basis of predictions from sequence data, it has been proposed that 
an acidic, amphipathic helical structure may be an important feature of the PKA 
binding region (184).
PKA holoenzymes are subdivided into type I (containing RIa or Rip R subunit 
isoforms) and type II (containing R lla or RIIp R subunit isoforms) forms of the 
kinase (see section 1.1.1.6). Initially it was thought that only type II forms of PKA 
were targeted by interaction with AKAPs. Recent reports, however, suggest that 
certain AKAPs, such as D-AKAPl, may also target type I forms of PKA (89, 90). 
Although the interaction of RI subunits with most AKAPs is approximately 500 
times weaker than with RII subunits, the Kd for interaction is still in the pM range. 
This is within the physiological concentration range of RI subunits and AKAPs in 
cells. There is evidence to suggest that, under conditions where RII subunit 
concentrations are limiting, RIa subunits may be capable of physiologically relevant 
interactions with AKAPs; for instance, although regulation of skeletal muscle L-type 
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channels by PKA is dependant on the anchoring of PKA by an AKAP, this 
regulation is unaffected in R lla subunit knockout mice (26, 100).
In addition to PKA, certain AKAPs also bind to a variety of other signalling 
molecules. For instance AKAP 79 anchors PKA, the a, pi and pll isoforms of PKC 
and protein phosphatase 2B (PP-2B, or calcineurin) at the postsynaptic densities of 
neurones (36, 106); AKAP 250 (gravin) anchors both PKA and PKC to the cell 
periphery and filopodia of human erythroleukemia cells (153). Functionally distinct 
regions of these AKAPs mediate interaction with each class of ligand and 
simultaneous binding of different ligands can occur. This has lead to speculation that 
these AKAPs may function in a similar way to the scaffolding protein Sterile-5 that 
functions to organise a MAP kinase cascade that is required for mating in 
S.cerevisiae (35, 60). Unlike Sterile-5, however, enzymes targeted by AKAPs are in 
an inactive state when bound (106). Indeed the interaction of a constitutively active 
form of PP-2B with AKAP 79 is sufficient to inhibit this enzyme (36). Interaction 
with AKAPs may therefore serve to localise a pool of signalling molecules in close 
proximity to the process which they control and so facilitate rapid, specific signal 
transduction following activation by second messengers.
1.5.2.2 Protein-protein interactions o f protein serine/threonine phosphatases
Protein phosphatases play important roles in signal transduction and can function as 
positive, as well as negative, regulators of cell function; for instance okadaic acid, an 
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Protein serine/threonine phosphatases catalyse the removal of phosphate groups from 
serine and threonine residues in their substrate phosphoproteins. These enzymes are 
classified into 4 major families (PPl, PP2A, PP2B and PP2C) on the basis of 
differences in substrate specificity, dependence on divalent cations and susceptibility 
specific inhibitors and activators. Molecular cloning has revealed that each family 
consists of multiple isoforms. The PPl, PP2A and PP2B gene families are related to 
one another (40-50% homology) whereas the PP2C family is structurally distinct. In 
addition to the major families, other serine/threonine phosphatase families such as 
PP3 and PPX (which share homology with the PPl and PP2 families) have been 
identified (73).
inhibitor of PP2A, PPl and of several other, more recently cloned, phosphatases 
including PP3 and PPX, blocks the expression of the cdc2 and cyclin A genes 
following serum stimulation of growth arrested cells. This shows that an okadaic acid 
sensitive protein phosphatase activity is necessary for this induction (190).
Compared to the large number of protein kinases that have been identified, many of 
which are extremely specific for the proteins that they can phosphorylate, relatively 
few protein phosphatases have been identified and those that have exhibit wide 
specificities for the phosphoproteins that they will dephosphorylate. This makes the 
problem of organising protein phosphatase activities into discrete pathways even 
more acute than with the organisation of protein kinase activities. Protein-protein 
interactions are an important feature of this organisation. The catalytic subunits of 
PPl, PP2A and PP2B can each interact with an array of distinct binding proteins 
(referred to as regulatory subunits) which seiwe to regulate and target the 
phosphatase. In the case of PPl, for instance, more that 12 regulatory subunits have 
been identified. The regulatory subunits of PPl each contain a motif conforming to 
the consensus (R/K)(V/I)xF which interacts with a conserved regulatoiy subunit 
binding site on the catalytic subunit of PPl (57).
1.5.3 Models for the compartmentalisation of cAMP signalling and potential 
roles for cAMP PDEs
The observation that each of the components of the cAMP signalling pathway can be
specifically targeted to various subcellular locations has lead to the formulation of
the hypothesis that a functional compartmentalisation of cAMP signalling occurs
within cells (39, 60, 85, 184). That is to say, it is proposed that, localised increases in
cAMP concentration at specific points within the 3 dimensional interior of a cell
might be expected to activate the pool of PKA localised in that area without effecting
another, functionally distinct pool of PKA that is localised to a different subcellular
region {Figure 1.7). This hypothesis is broadly similar to the proposed
compartmentalisation of Ca^  ^signalling at the presynaptic junctions of neurones
whereby Ca^  ^entering the cell through voltage sensitive channels localised at the
sites of neurotransmitter release is much more effective at stimulating rapid
exocytosis than is Ca^  ^released from intracellular stores or that enters the cell via an 
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ionophore (185). In the cases of both cAMP and of signalling non-uniform
distributions of these second messengers have been directly visualised in cells 
following stimulation of these pathways (80). These observations lend considerable 
support to the hypothesis that signalling through these second messengers could be 
spatially organised into functionally distinct compartments.
A number of studies (34, 102) have used specific PDE inhibitors to investigate the 
possible role of these enzymes in maintaining the integrity of functionally distinct 
pools of G AMP. Jurevicius et al used the broad specificity PDE inhibitor IBMX to 
demonstrate that during p-adrenergic stimulation of a single frog ventricular 
myocyte, PDE activity limited the spread of localised pools of cAMP. They found 
that, in the absence of PDE inhibition, the selective stimulation of p-adrenergic 
receptors located in one region of the cell lead to a greater increase the local 
concentration of cAMP than it did in the cAMP concentration in distant regions of 
the cell. In the presence of the PDE inhibitor IBMX, however, a more uniform 
increase in the distribution of cAMP within the cell was observed (102).
In another study Chini et al used selective inhibitors of PDE3 and of PDE4 to 
investigate the involvement of these PDE classes in the regulation of cAMP 
signalling in primary cultures of rat kidney mesangial cells. In these cells 2 major 
responses to immunoinflammatory stimulation, accelerated proliferation and the 
generation of reactive oxygen metabolites (ROMs) ar e both inhibited by PKA 
activation downstream of increased cAMP levels.
The selective inhibition of either PDE3 or of PDE4 in these cells leads to an 
increased activation of PKA and the effect of the combined inhibition of both PDE3 
and PDE4 is at least additive with the inhibition of either one alone. Inhibition of 
PDE3 suppressed the accelerated proliferation of these cells whereas inhibition of 
PDE4 did not affect the proliferation. Furthermore the combined inhibition of both 
PDE3 and PDE4, although more efficacious at activating PKA, was no more 
effective at inhibiting proliferation than was the inhibition of PDE3 alone. In contrast 
to this the inhibition of PDE4, but not of PDE3 in these cells suppressed the 
generation of ROMs and, again, the combined inhibition of both PDE3 and PDE4
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was no more efficacious at suppressing ROM generation than was the inhibition of 
PDE4 alone (34).
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Figure 1.7: A model fo r  the compartmentalisation o f  cAM P signalling
The figure is a diagram representing the hypothesised compartmentalisation of 
cAMP signalling within a polarised cell Stimulation of receptors located at one face 
of the cell selectively activates adenyiyl cyclases that are co-localised with the 
receptors. This creates a local increase in the concentration of cAMP that activates 
PKA anchored in that region of the cell (by interaction of RJI subunits with AKAPs 
for instance). The localised increase in cAMP concentration is prevented from 
spreading throughout the cell and activating functionally distinct pools of PKA 
anchored in other regions of the cell interior by the action of specifically localised 
PDE.
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2. Materials and methods
Except where stated otherwise, bio chemicals were obtained either from Fisons or 
from Sigma-Aldrich and were of analytical grade.
2.1 Biochemical techniques
2.1.1 SDS polyacrylamide gel electrophoresis of proteins
2.1.1.1 Tris-glycine SDS PA GE
Tris-glycine SDS PAGE was performed following the discontinuous buffer system 
of Laemmli (188).
■i1
I
Acrylamide concentration* (%) Protein size range (KD)
8 40-200
10 21-100
12 10-40
Table 2,2.1: Effective range o f separation of SDS polyacrylamide gels.
* Molar ratio acrylamide:N,N’-methylenebisacrylamide o f 29:1. Table adapted from  
(7^60.
2.1.1.2 Buffers 
Resolving gel (6-8%)
6- 8% 29:1 acrylamide :N,N'-methylenebisacrylamide mix
0.375M Tris/HCl (pH 8.8)
0.1% SDS
0.1% Ammonium persulfate
0.06% N,N,N',N'-tetramethylethylenediamine (TEMED)
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Resolving gel (10-15%)
10-15% 29:1 acrylamide:N,N'“methylenebisacrylamide mix
0.375M Tris/HCl (pH 8.8)
0.1% SDS
0.1 % Ammonium persulfate
0.04% N,N,N',N'-tetramethylethylenediamine (TEMED)
Butanol saturated water
1:11 Butanol:deionised water (use the top phase)
Stacking gel
5 % 29:1 acrylamide :N,N'"methylenebisacrylamide mix
0.125M Tris/HCl (pH 6.8)
0.1% SDS
0.1% Ammonium persulfate
0.1 % N,N,N*,N'-tetramethylethylenediamine (TEMED)
2X SDS loading buffer (Laemmli buffer)
0.125M Tris/HCl (pH 6.8)
25% Glycerol
4% SDS
0.007% bromophenol blue
5% p-mercaptoethanol (added just prior to use)
5X SDS loading buffer (Hannah sample buffer)
0.26M Tris/HCl (pH 6.7)
55.5% Glycerol
8.8% SDS
11.1% P-mercaptoethanol
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Tris-glycine running buffer
192mM Glycine
25mM Tris
0.15% SDS
2.1.1.3 Preparation o f samples
Samples were diluted either 1:2 with 2X SDS loading buffer or 1:5 with 5X SDS 
loading buffer and heated for 5 minutes at 100°C to denature the proteins.
2.1.1.4 Prépara tion o f standards
Prestained protein molecular weight markers (Bio-Rad) contain the following 
proteins: myosin H chain (200kDa); phosphorylase B (97.4kDa); BSA (68kDa); 
ovalbumin (43kDa); carbonic anhydrase (29kDa); P-lactalbumin (18.4kDa) and 
lysozyme (14.3kDa). The apparent molecular weights varied from batch to batch and 
the precise sizes of the proteins were indicated on any particular figure.
2.1.1.5 Casting and running a tris-glycine gel
The gel apparatus was assembled in accordance with the manufactures instructions. 
A resolving gel of the appropiate percentage for size of proteins to be separated was 
prepared and poured between the plates of the gel kit {Table 2.2.1). Water saturated 
butanol was then layered on top of the resolving gel to produce a even surface and 
exclude oxygen during polymerisation. The gel was allowed to set and the water 
saturated butanol removed, a comb was inserted and the stacking gel poured. When 
the stacking gel had set, the comb was removed and the gel placed in a tank 
containing tris-glycine running buffer. Samples were loaded into the wells and the 
gel was run at a constant current until the dye front reached the bottom of the gel.
2.1.2 High resolution PAGE
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Low molecular weight peptides were separated through high resolution gels 
consisting of a 16.5% separating gel, a 10% spacer gel and a stacking gel, each made 
with a 32:1 acrylamide:N,N'-methylenebisacrylamide ratio.
2.1.2.1 Buffers
Separating gel
16.5% 32:1 acrylamide :N,N’-methylenebisacrylamide mix
IM Tris/HCl (pH 8.45)
0.1% SDS
13.3% Glycerol
0.05% Ammonium persulfate
0.05% N,N,N',N'-tetramethylethylenediamine (TEMED)
Spacer gel
0.1% SDS
0.05% Ammonium persulfate
0.05% N,N,N',N'-tetramethylethylenediamine (TEMED)
Stacking gel
4% 32:1 acrylamide :N,N'-methylenebisacrylamide mix
0.75M Tris/HCl (pH 8.45)
0.75% SDS
0.08% Ammonium persulfate
0.08% N,N,N',N'-tetramethylethylenediamine (TEMED)
Anode buffer
10% 32:1 acrylamide:N,N'-methylenebisacrylamide mix
IM Tris/HCl (pH 8.45)
■s..
I
I
0.2M Tris/HCl (pH 8.9)
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Cathode buffer
O.IM Tris/HCl (pH 8.25)
O.IM Tricine
0.1% SDS
2.1.2.2 Protein low molecular weight markers
Pre-stained low molecular weight markers (Sigma) contained differently coloured 
ovalbumin (yellow, 45kD), carbonic anhydrase (orange, 29kD), trypsin inhibitor 
(green, 20kD), a-Lactalbumin (puiple, 14kD), aprotinin (blue, 6.5kD)
2.1.2.3 Casting and running a high resolution gel
Mini-gel apparatus was assembled according to the manufacturers instructions. The 
separating gel was then poured 4.2cm high and the spacer gel was immediately 
poured on top 1cm high. Water saturated butanol was layered over the top of the 
separator gel. When the gels had set, the water saturated butanol was removed, a 
comb inserted and the stacking gel poured. When this had set, the comb was removed 
and the gel placed into the running tank. The anode and cathode chambers were filled 
with the appropriate buffers, samples (SDS loading buffer), were loaded into the 
wells and the gels were run at 100 volts until the dye front reached the bottom of the 
gel.
2.1.3 Staining of SDS polyacrylamide gels with Coomassie brilliant blue
Coomassie stain
0.025% Coomassie brilliant blue R 250
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Protein bands separated by SDS-PAGE were simultaneously fixed and stained. The 
limit of detection for protein on Coomassie stained gels is 0.3-1.Opg.
2.1.3.1 Buffers
■s..h
%
I
40% Methanol
7% Acetic acid
Destain I
40% Methanol
7% Acetic acid
Destain II
7% Acetic acid
5% Methanol
2.1.3.2 Visualisation o f proteins
Following separation by gel electrophoresis the gel was incubated in at least 5 
volumes of Coomassie stain with gentle shaking at room temperature. The length of 
incubation was from 30 minutes to 4 hours, depending on the thickness of the gel.
Protein bands were then visualised by incubating the stained gel in destain I for 2-4 
hours at room temperature with gentle shaking. Destaining was completed by 
exchanging the destain I for destain II and continuing the incubation for form several 
hours to overnight. After destaining, the gel was rehydrated by incubating in 1% 
glycerol for 30 minutes at room temperature with gentle shaking.
2.1.4 Staining of SDS polyacrylamide gels with silver salts
Greater sensitivity of detection than provided by Coomaissie staining was achieved 
by silver staining, the detection limit for which is 2-5ng protein.
2.1.4.1 Buffers
Destain I
40% Methanol
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7% Acetic acid
Destain II
7% Acetic acid
5% Methanol
Cross-linking solution
10% Glutaraldehyde
DTT (dithiothreitol) solution
0.0005% Dithiothreitol
Silver nitrate solution
0.1 % Silver nitrate
Developing solution
3% Sodium carbonate
0.019% F ormaldehyde
Stop solution
2.3M Sodium citrate
2,1 A.2 Visualisation o f proteins
Following separation by gel electrophoresis the gel was fixed by incubation in 100ml 
destain I for at least 30 minutes at room temperature with gentle shaking. The destain 
I was replaced with 100ml destain II and incubation was continued for 30 minutes. 
The destain II was exchanged for 100ml cross-linking solution and incubated for a 
further 30 minutes. The glutaraldehyde solution was discarded into a sink in a fume
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Clipboard and the gel washed with either several changes of deionised water over 2 
hours or in 21 of deionised water overnight followed by a 30 minute wash in fresh 
deionised water the next day. After its final wash, the gel was incubated in 100ml 
DTT solution for 30 minutes at room temperature, with gentle shaking. The DTT 
solution was removed and the gel drained well but not rinsed before addition of 
100ml silver nitrate solution. Incubation was continued for another 30 minutes then 
the gel was rinsed once under innning deionised water and twice with 50ml of 
freshly prepared developing solution. The gel was then gently shaken in 100ml of the 
developing solution until protein bands appeared slightly lighter than desired. 
Development was then stopped by addition of 5ml stop solution.
Gloves were worn at all stages of the silver staining procedure and dedicated 
sandwich boxes were used for all incubations. This was to protect the gel from 
contaminating proteins.
2.1.5 Drying SDS polyacrylamide gels
Gels were dried on a Bio-Rad gel drier. The gel was placed on the drying surface of 
the drier, on top of a wetted piece of filter paper and covered with cellophane. The 
cover sheet of the drier was then laid over the gel and a vacuum applied so the cover 
sheet made a tight seal over the gel. The lid of the drier was then closed and the gel 
dried at 63°C for 1-2 hours, depending on the thickness of the gel.
2.1.6 Western (Immuno) Blotting
2.1.6.1 Buffers 
Transfer Buffer
192mM Glycine
25mM Tris
20% Methanol
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Tris buffered saline (TBS)
137mM NaCl
20mM Tris pH 7.6
Blocking buffer
137mM NaCl
20mM Tris pH 7.6
5% Skimmed milk powder
Ponceau S stain
0.1% Ponceau S
3% Trichloroacetic acid
2.1.6.2 Transfer o f proteins onto nitrocellulose
Following separation by gel electrophoresis the gel was placed in a cassette on top of 
a piece of nitrocellulose paper, bound by two pieces of Whatman 3MM paper and 
two pieces of sponge. The cassette was assembled whilst submerged in a tray of 
blotting buffer, to exclude air bubbles. It was loaded into the transfer tank with the 
nitrocellulose side of the cassette towards the positive electrode. The tank was filled 
with blotting buffer and the proteins transferred for 1 hour at 1A or overnight at 
0.05A.
2.1.6.3 Visualisation o f transferred proteins
Following transfer the nitrocellulose was rinsed with deionised water and then 
incubated with Ponceau S stain untill the protein bands became visible. The filter was 
then washed with several changes of deionised water. The positions of lanes or 
significant bands such as unstained markers were marked. Ponceau S stain was then 
removed by washing with TBS containing 0.1% Tween-20 before proceeding with 
immunological detection.
2,1.6.4 Immuno-detection using ECL solution (AMERSHAM)
2.1.7 Overlay assay
Purified GST fusion proteins were eluted from the glutathione-Sepharose beads by 3 
incubations in lOOpl elution buffer (lOmM glutathione, 50mM Tris HCl (pH8.0)), 
for at least 10 min. each, end-over-end at 4°C. The 3 eluted fractions were pooled 
and assayed for protein concentration, diluted 1:2 with 2X SDS sample buffer and 
then boiled for 5 min.. The boiled samples were loaded onto a 10% SDS poly­
acrylamide gel (lOpg/lane) which was run at 40mA/gel until the dye front reached 
the bottom. The samples were then transferred from the gel onto a nitrocellulose
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Any unoccupied protein binding sites on the nitrocellulose were blocked by 
incubation in blocking buffer for 1-2 hours at room temperature, with gentle shaking. 
The nitrocellulose was then washed four times with TBS containing 0.1% Tween-20 
for 5 minutes each minutes each. 5'
An antibody specific to the protein of interest (primary antibody), was diluted in
10ml TBS, 1% Skimmed milk powder. The nitrocellulose filter was sealed into a
-polythene bag with the primary antibody and incubated for at least 1 hour at room 
temperature with vigorous shaking. The nitrocellulose was then washed as described 
above.
A secondary, horse radish peroxidase (HRP) conjugated, anti-immunoglobulin.
antibody (IgG) directed against the primary antibody was diluted in 10ml TBS, 1%
Skimmed milk powder. The nitrocellulose was sealed into a polythene bag with the 
secondary antibody and incubated for at least 1 hour at room temperature with 
vigorous shaking. The nitrocelulose was then washed four times in TBS containing 
0.1% Tween-20 for 5 minutes each.
I
The filter was incubated with ECL (Amersham) reagents according to the 
manufacturers instructions. X-ray film (Fuji) was exposed to the nitrocellulose for 
vaiying times depending on the intensity of the signal. The film was then developed 
using a Kodak X-omat.
membrane. The membrane was incubated for Ih at room temperature with gentle 
shaking in 100ml blocking buffer (137mM NaCl, 20mM (Tris pH 7.6), 5% Skimmed 
milk powder). The blocked membrane was washed 4 times over a 20 min. period 
with T-TBS (137mM NaCl, 20mM (Tris pH 7.6), 0.1% Tween-20) and then 
incubated overnight at 4®C with rapid shaking in the presence of 1 pg of either 
purified MBP or of MBP-HSPDE4D4 diluted in 10ml dilution buffer (buffer 
(137mM NaCl, 20mM (Tris pH 7.6), 1% Skimmed milk powder). The membrane 
was then washed as before and incubated for 1 h at room temperature with rapid 
shaking in the presence of an anti-MBP polyclonal antibody (New England Biolabs) 
diluted 1:10000 in dilution buffer. The membrane was then washed as before and 
incubated for 1 h at room temperature with rapid shaking in the presence of 
horseradish peroxidase conjugated anti-rabbit IgG (Sigma) diluted 1:20000 in 
dilution buffer. Finally the membrane was washed again as before and the labelled 
bands were detected according to the Amersham ECL western blotting visualisation 
protocol.
2.1.8 Immunoprécipitation
2.1.8.1 Buffers
Phosphate buffered saline (PBS)
■'ÎÎ.K
:
-I
2.7mM KCl 1
137mM NaCl 3:
4mM Na^HPO^ Î
0.15mM NaH^PO^, pH 7.4 %
3
Radio-immunoprecipitation assay buffer (RIPA buffer)
1
50mM Tris/HCl (pH 8.0) ;i
132mM NaCl a
0.1% SDS 1
1% Triton X-100 'i1;
0.5% Deoxycholate
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22mM NaF
1 ImM Tetra-sodium pyrophosphate
l.lmM  EDTA
5.5mM EGTA
Complete protease inhibitor cocktail
.2.1.8.2 Procedure i
Cells were rinsed once with ice cold PBS and drained before being scraped into 
500pi ice cold RIPA buffer and lysed with 8 strokes of a 26 16 gauge needle attached 
to a disposable syringe. Cell debris were then removed by centrifugation at 12000xg 
for 10 min at 4°C. The cleared lysate was pre-cleared by incubation with 50pl bed 
volume protein-A sepharose 4B fast flow (Amersham) for 1 hour at 4°C with end- 
over-end mixing. The protein-A sepharose was removed by centrifugation at 
12000xg for 10 sec at 4°C and an antibody specific for the species of interest was 
added at a concentration that has previously been established to be optimal for 
immunoprécipitation. The antibody and lysate were incubated together for 1 hour at 
4°C with continual end-over-end mixing to allow immune complexes to form. The 
immune complexes were then precipitated by adding 50pl bed volume protein-A 
sepharose and incubating for a further 1 hour at 4°C with continual end-over-end 
mixing. The protein-A sepharose was harvested by centrifugation at 12000xg for 10 
sec at 4°C, washed 3 times with 500pl ice cold RIPA buffer, a further 1 time with 
500pl ice cold PBS and then transferred to a fresh Eppendorf tube before being 
resuspended in IX SDS sample buffer and boiled for analysis by SDS-PAGE.
2.1.9 Induction and Purification of GST Fusion Proteins
Cultures of Escherichia coU (JM109), transfoimed either with the plasmid pGEX-2T 
(for the production of GST) or with recombinant pGEX-2T containing an SH3 
domain (or another protein binding domain) as an in-frame fusion with GST were 
grown overnight at 37°C, with agitation, in Luria broth (L-broth) (170mM NaCl, 
0.5% (w/v) Bacto-Yeast Extract 1 % (w/v) Bacto-Tryptone) containing lOOpg/ml 
ampicillin. The overnight cultures were used to inoculate larger (400ml) cultures in
the same medium. These were grown at 37°C, with agitation, until the OD. at 
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2.1.10 Induction and Purification of MBP Fusion Proteins
The Escherichia coli (JM109) were transformed with pMAL-c2 (for the production
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600nm reached 0.600 -1.000. Expression of the fusion protein was then induced by 
the addition of isopropyl B-D-thiogalactoside (IPTG) to a final concentration of 
O.lmM. Growth was continued for a further 4-6h, at 37°C, with agitation before the 
bacteria were harvested by centrifugation at 2500g for 5 min. in a refrigerated 
centrifuge. The bacteria were then resuspended in 20ml phosphate buffered saline 
(PBS) supplemented with ImM dithiothreitol (DTT) and a cocktail of protease 
inhibitors (40mg/ml PMSF, 156mg/ml benzamidine, 1 mg/ml apoprotinin, 1 mg/ml 
antipain 1 mg/ml leupeptin, 1 mg/ml pepstatin, dissolved in DMSO). The resuspended 
bacteria were stored at -20°C in conveniently sized aliquots until needed.
Frozen aliquots were rapidly thawed at room temperature. The volume used was 
dependant on the level of expression achieved, which varied widely between 
constructs. In my hands 4ml of resuspended bacteria yielded between 0.4 and 3mg of 
most fusion proteins used. The delfosted bacteria were held on ice and sonicated in 
20 sec. pulses, separated by 30 sec. intervals until cell lysis was complete. The 
sonicate was then subjected to centrifugation for 1 min. at high speed in a benchtop 
centrifuge and the supernatant was transferred to fi*esh tubes. Glutathione-sepharose 
beads equilibrated in PBS containing ImM DTT and protease inhibitor cocktail were 
added to the sample which was then incubated end-over-end for 4-18h at 4°C. I 
routinely added lOOpl bed volume of beads which was sufficient to bind up to about 
3mg fusion protein. Following incubation, the beads were collected by centrifugation 
for 5 sec. at high speed in a benchtop centrifuge and the supernatant was discarded. 
The beads were then held on ice and washed three times with 1ml PBS containing 
ImM DTT and protease inhibitor cocktail over a 15 min. period. The washed beads 
were resuspended as a 25% slurry and assayed for protein concentration.
The induction and purification of MBP fusion proteins was by a method based on 
that already described for the purification of GST fusion proteins but with the 
following differences:
of MBP) or with pMAL~c2 containing the cDNA of interest as an in frame fusion 
protein with MBP.
The L-broth was supplemented with glucose (0.2% w/v) as well as with ampicillin 
(lOOpg/ml).
Expression of the fusion protein was induced by the addition of IPTG to a final 
concentration of 0.3mM. The culture was then shifted to 30°C for the expression of 
the fusion protein.
The sonicate was cleared by centrifugation at 9000g for 30min and the supernatant 
was incubated with amalose resin equilibrated in KHEM containing ImM DTT and 
protease inhibitor cocktail.
The fusion protein was eluted fr om the washed amylose resin by 3 incubations in 1ml 
elution buffer (KHEM supplemented with lOmM maltose), for at least 10 min. each, 
end-over-end at 4°C. The 3 eluted fr actions were pooled and dialysed at 4°C against 
3 600ml batches of dialysis buffer (50mM NaCl, 20mM Tris pH8.0) before being 
snap frozen as aliquots. The aliquots were stored at -80°C until use.
2.1.11 Phosphodiesterase Assay
Phosphodiesterase activity was measured by a two step cAMP hydrolysis assay, 
based on the method developed by Thompson and Appleman [(1971) Biochemistry,
310, 2, 311-316]. In the first step H-cyclic nucleotide (8 position of the adenine or 
guanine ring) was hydrolysed, by the phosphodiesterase activity, to fonn labelled 
nucleotide mono-phosphate. In the second step the nucleotide mono-phosphate ring 
was converted to the corresponding labelled nucleoside by incubation with snake 
venom (which has 5’-nucleotidase activity). Under the conditions used complete 
conversion of nucleotide mono-phosphate to nucleoside occurs within the incubation 
time. Separation of the remaining, unhydrolysed cyclic nucleotide from the 
nucleoside was achieved by a batch binding of the mixture to Dowex 1X8-400 anion 
exchange resin (Sigma): this binds the chai'ged nucleotides, leaving only the
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uncharged nucleosides in the soluble fraction.
2.1.11.1 Buffers
Assay buffer
lOmM MgCl2
20mM Tris/HCl, pH 7.4
Dilution buffer
20mM Tris/HCl, pH7.4
2.1.11.2 Activation o f Dowex 1X8-400 anion exchange resin
2.1.11.3 Assay procedure
The cyclic nucleotide substrate solution for phosphodiesterase activity assays was 
made up in assay buffer as a 2X stock (usually 2pM cAMP) supplemented with 8-'^H 
labelled cyclic nucleotide (0.003 pCi pl"^). Effectors were made up in dilution buffer
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To activate the Dowex 1X8-400, 41 of NaOH (IM) was added to 400g of the resin 
and the mixture was incubated for 15 min at room temperature with gentle mixing. 
The resin was allowed to settle by gravity and the supernatant removed. The resin 
was then extensively washed with distilled water by resuspending the resin in 41 of 
distilled water then allowing it to settle by gravity before removing the supernatant 
(30 washes). After its last wash the resin was resuspended in 41 HCl (IM) and 
incubated for 15 min at room temperature with gentle mixing before being allowed to 
settle by gravity. The resin was then washed with distilled water, as described above, 
until the supernatant had a pH of 3 (approximately 4 washes). The activated resin 
was stored at 4^C as a 1:1 slurry with distilled water until required. Before use in 
phosphodiesterase assays ethanol was added to make a 1:1:1 slurry of 
Dowex: water: ethanol.
■^'1
as a 4X stock. The first step of the assay was performed in a final volume of lOOpl.
This consisted of 50pl 2X substrate solution, 25 pi 4Xeffector solution and 25pi 
sample. In assays where no effector was included 25 pi dilution buffer was added in 
place of the 4X effector solution. Tubes were held on ice until all the additions had
been made then rapidly mixed by vortexing before being incubated at 30^C (usually 
for 10 min). The reaction was stopped by boiling for 2 min to denature the 
phosphodiesterase. The tubes were then cooled on ice.
In stage 2 of the assay 25 pi of Img m f^ snake venom (either Ophiophagus hannah
2.1.12 Kinetic analysis of enzyme activity data
I calculated the values of Km and Vmax by non-linear regression analysis using the 
computer program Hyper 1.02a (Shararewear. Author: J. S. Easterby). This progi'am 
fits data to the hyperbolic form of the Michaelis-Menten equation by first obtaining 
estimates of the Km and Vmax, (using linear regression analysis to fit the data to a 
Hanes plot ([S]/v against [S])) and then using these estimates as starting values for a 
non-linear regression analysis which fits the data directly to a hyperbola.
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or Crotalus atrox venom) (Sigma) was added to the reaction mix from stage 1 of the
assay. Tubes were then rapidly mixed by vortexing and incubated at 30 C for 10 
min. Following incubation the tubes were held on ice and 400pl of a 1:1:1 slurry of 
Dowex : water : ethanol was added. The mixture was incubated on ice for 15 min with 
occasional vortexing and then separated by centrifugation at top speed in a bench top 
centrifuge for 3 min. A 150pl aliquot of the supernatant was then added to 1ml 
scintillation cocktail and counted on a Wallac 1409 liquid scintillation counter.
I calculated values of IC50 for the inhibition of preparations of PDE4 by the inhibitor 
rolipram using the computer program KaleidaGraph. This program fits data to an 
equation describing a sigmoidal curve.
2.1.13 Pull down assay for proteiu-protein interaction
2.1.13.1 Pull down assays with GST—SH3 domain fusion protein as bait
Volumes of slurry containing 400pg immobilised fusion protein were pelleted and 
the supernatants discarded. The pellets were resuspended in crude cytosol from 
transfected COS-7 cells, diluted to a final volume of 200pl in KHEM buffer (50mM 
KCl, 50mM HEPES KOH (pH7.2), lOmM EGTA, 1.92mM MgClg) containing ImM 
DTT and protease inhibitor cocktail. In pull down assays where the “bait” was a 
recombinant PDE overexpressed in COS-7 cells I routinely used cytosol containing 
30 to 40 EU of PDE activity (pmol cAMP hydrolysed/min, with 1 pM cAMP as 
substrate), this was typically 20pg cell protein. The immobilised fusion protein and 
cytosol were incubated together for 10 min. end-over-end at 4°C. The beads were 
then colleeted by centrifugation for 5 sec. at high speed in a benehtop centrifijge and 
the supernatant retained as the unbound fi’aetion. The beads were then held on ice and 
washed three times with 400pi KHEM containing ImM DTT and protease inhibitor 
coektail over a 15 min. period. These washes were pooled along with the unbound 
fraction and aliquots were taken for PDE assay and immunoblotting. The bound PDE 
was eluted fiom the beads by 3 ineubations with lOOpl elution buffer (lOmM 
glutathione, 50mM Tris HCl (pH8.0)), for at least 10 min. each, end-over-end at 4*^ C. 
The 3 eluted fi-actions were pooled and aliquots taken for PDE assay and 
immunoblotting.
2.1.13.2 Pull down assays with MBP—UCRl fusion proteins as bait
50pg of MBP or MBP-UCRl was incubated with sufficient cmde cytosolic extract 
from COS-7 cells to contain 18-20 enzyme units of PDE enzyme activity (pmol 
cAMP hydrolysed/min, with IpM cAMP as substrate), in a total volume of 350pl for 
1 hour end-over-end at 4°C. 50pl (bed volume) of amylose resin, equilibrated in 
KHEM supplemented with DTT and complete protease inhibitor cocktail was then 
added and the incubation was continued for 1 hour more. The resin was then 
collected by centrifugation at 2500xg for 20 sec at room temperature and the 
supernatant was retained as the unbound fi*action. The pelleted resin was held on ice 
and washed 3 times over 15 min, each time with 350pl KHEM supplemented with 
DTT and complete protease inhibitor cocktail. These washes were pooled along with
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the unbound fraction and aliquots were taken for analysis by PDE enzyme assays an 
by immunoblotting. The bound PDE was eluted from the beads by 3 incubations end- 
over-end, for lOmin each at 4°C with 100 pi KHEM supplemented with lOmM 
maltose. The 3 eluted fractions were pooled and aliquots were taken for analysis by 
PDE enzyme assays and by immunoblotting.
2.1.14 ELISA assay for protein—protein interaction
2.1.14J  Buffers
Tween tris buffered saline (T TBS)
lOmM Tris HCl, pH 7.6
137mM NaCl
0.05% (v/v) Tween 20
Blocking buffer
1 % (w/v) Skimmed milk powder in T-TB S
Fixing Buffer
2.7mM KCl
137mM NaCl
4mM Na2HPO^
0.15mM NaH^PO^, pH 7.4
4% (v/v) P araformaldehyde
2.1.14.2 Procedure
1.5pmol of either MBP or of MBP-PDE fusion protein, diluted in 100pi T-TBS was 
incubated in each well of a 96 well microtiter plate for 1 hour at room temperature. 
This allowed the fusion protein to become adsorbed onto the plastic of the microtiter 
plate. The plate was then washed 3 times with 200pl T-TBS per well to remove any 
unbound fusion protein. 200pl blocking buffer was added to each well and the 
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plate was incubated at room temperature for 1 hour to block any unoccupied protein 
binding sites in the wells. The blocked wells were then washed 3 times with 200pl T- 
TBS per well and probed with varying concentrations of GST or of GST-SH3 
domain fusion proteins diluted in lOOpl blocking buffer, for 3 hours at room 
temperature. The plate was then cooled on ice for 2 min and the wells were rapidly 
washed 3 times with 200pl ice cold T-TBS per well. The bound GST fusion protein 
was then fixed by the addition of lOOpl fixing buffer and incubation for 30 min at 
room temperatui'e. The plate was washed 10 times with 200pl T-TBS per well.
Bound GST fusion proteins were detected by the addition of lOOpl per well anti-GST 
polyclonal antisera diluted 1:10000 in blocking buffer for 1 hour at room 
temperature. The plate was then washed 3 times with 200pl T-TBS per well and 
100pi per well alkaline phosphatase conjugated anti-rabbit IgG (Sigma) diluted 
1:2000 in blocking buffer was added for 1 hour at room temperature. The plate was 
then washed a further 3 times with 200pl T-TBS per well and the binding of second 
antibody was detected using the BCIP Microwell 2 Component Phosphatase 
Substrate System (KPL, Maryland, USA), following the manufactures instructions. 
The colour development was quantified using a MRX microtiter plate reader (Dynex 
Technologies) set to read at a wavelength of 630nM.
2.1.15 Quantification of protein (Bradford's assay)
Protein assays were conducted on 96 well microtiter plates. A spectrophotometrie 
standard curve of protein concentration was constructed using 0-7pg bovine serum 
albumin (BSA). These amounts of protein were dissolved in 50pl distilled water. To 
this, 200pl Bio-Rad reagent diluted 1:5 with deionised water was added. The plate 
was incubated for 5 min at room temperature and then the absorbance was read at a 
wavelength of 590nm using a MRX microtiter plate reader (Dynex Technologies). 
Protein concentrations of the samples were determined on the same microtiter plate 
and simultaneously with the standard curve by diluting a known volume of the 
sample in 50pl distilled water, adding 200|li1 Bio-Rad reagent diluted 1:5 with 
distilled water and reading the absorbance in the plate reader. All samples were 
assayed in tiiplicate. Protein concentrations were determined by plotting the standard 
curve and using least squared regression analysis to determine the line of best fit. The
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the SV40 T antigen allows plasmids that contain an S V40 origin of replication to be 
replicated in the COS cell lines (69).
2.2.1.1 Maintenance o f COS-7 cells
COS-7 cells were maintained in continuous culture as a monolayer at 37°C in an 
atmosphere of 5% CO .^ The growth medium was a standard Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 2mM L-glutamine, 10% (v/v) fetal 
calf serum, 1 unit/ml penicillin and Img/ml streptomycin. The COS cell lines have a 
fibroblast like morphology and will shed cells upon reaching confluency. The cells 
were passaged at approximately 90% confluency at which time they were split 1:3- 
1:6. Under this regime the cells needed to be passaged every 2-4 days. Due to the 
willingness of the COS cell lines to support the growth of viruses and the possibility 
of their containing a complete SV40 region these lines were regarded as being 
potentially biohazardous material.
2,2.2 Transient transfection with DAE-Dextran
2.2.2.1 Buffers 
TE buffer
lOmM Tris-HCl pH 7.2
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equation of the line was used to determine the protein concentration of the samples.
2.2 Cell Culture
2.2.1 The COS-7 cell line (ATCC Number: CRL-1651)
The COS cell lines (COS-1, COS-3 and COS-7) are simian (African green monkey) 
kidney cell lines derived from the CV-1 line by transfection with an origin-defective 
mutant of the Simian virus 40 (SV40) virus. The cells contain integrated copies of 
the early region of SV40 encoding the SV40 T antigen. This facilitates the 
overexpression of proteins in these lines by transient transfection as the presence of
ImM EDTA
Transfection medium
DMEM supplemented with
2mM 
10% (v/v) 
1 unnit/ml 
Img/ml 
O.lmM
Glutamine 
Newborn calf serum 
Penicillin 
Streptomycin 
Chloroquine
PBS
2.7mM 
137mM 
4mM 
0.15mM
Shock buffer
KCl
NaCl
NagHPO^
NaHgPO^, pH 7.4
10% (v/v) DMSO in PBS
2.2.2.2 Transfection procedure
The eells were passaged 24 hours before transfection and seeded onto new plates at 
approximately 50% confluency. The cells were transfected with lOpg plasmid DNA 
per 79cm^ plated cells. Prior to transfection the DNA was diluted to 40ng/pl in sterile 
TE buffer, then further diluted 5:9 in sterile DEAE dextran solution (lOmg/ml in 
PBS). This mixture was incubated for 15 min at room temperature to allow the 
formation of DNA-DEAE complexes. The giowth medium was aspirated from the 
cells and replaced with transfection medium. 5ml transfection medium was added for 
every 79cm^ plated cells. The DNA-DEAE dextran mixture was dropped onto the 
cells and mixed by swirling. The eells were then incubated at 37°C in an atmosphere
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of 5% CO2 for 3-4 hours. Following this incubation the cells were shocked with 
DMSO; the transfection medium was removed by aspiration or by pouring, replaced 
with an equal volume of shock buffer and then incubated for exactly 2 min at room 
temprature. The cells were then washed once in PBS, transferred to giowth medium 
and incubated at 37°C for approximately 72 hours in an atmosphere of 5% COj. The 
cells were then harvested. Mock transfections were performed by treating the cells 
exactly as described above but omitting DNA from the mixtures.
2.2.3 Harvesting and subcellular fractionation
2.2.3.1 Buffers 
KHEM
50mM Hepes KOH, pH7.4
50mM KCl
lOmM EGTA
1.92mM MgCl2
2.2.3.2 Harvesting and fractionation by differential centrifugation
Approximately 72 hours after transfection the growth medium was removed from the 
cells. The cells were then rinsed once with 5ml ice cold KHEM per 79cm^ plated 
cells before being incubated for lOmin at 4“C in 2ml ice cold KHEM supplemented 
with ImM DTT and protease inhibitors, per 79cm^ plated cells. The cells were then 
rinsed once more with 1ml ice eold KHEM supplemented with ImM DTT and 
protease inhibitors, per 79cm^ plated cells, drained and harvested by scraping. The 
harvested cells were made up to a known volume (usually 500pl/79cm^ plated cells 
harvested) by the addition of ice cold KHEM supplemented with ImM DTT and 
protease inhibitors and then disrupted by 20 strokes in a Dounce glass on glass 
homogenizer. Lactate dehydrogenase (a marker enzyme for cytosol) assays show that 
this method routinely achieves >96% cell breakage.
The cell homogenate was fractionated by differential centrifiigation to produce a low
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speed (850g) pellet fraction (PI) enriched in nuclear and cytoskeletal components; a 
high speed (lOOOOOg) pellet fraction (P2) enriched in plasma membranes, vesicles 
formed from the Golgi apparatus and the endoplasmic reticulum, lysosomes and 
endosomes; and a high speed (lOOOOOg) supernatant (S2) fraction enriched in 
eytosolic proteins (193).
The P1 pellet fraction was generated by centrifuging the cell homogenate for 5 min at 
850g at 4°C. The P 1 pellet was washed twice by being resuspended in ice cold 
KHEM supplemented with ImM DTT and protease inhibitors and finally 
resuspended in an equal volume of ice cold KHEM supplemented with ImM DTT 
and protease inhibitors to that of the S2 fraction. The P2 pellet fraction and the S2 
fraction were generated by centrifuging the supernatant from the PI pellet for 1 hour 
at lOOOOOg at 4°C. The P2 pellet was washed twice by being resuspended in ice cold 
KHEM supplemented with ImM DTT and protease inhibitors and finally 
resuspended in an equal volume of ice cold KHEM supplemented with ImM DTT 
and protease inhibitors to that of the S2 fraction. Each of the cell fractions was 
aliquoted and snap fr ozen in liquid nitrogen then stored at -80°C until use.
2.2.4 Lactate Dehydrogenase Assay
Lactate dehydrogenase (LDH) activity was assayed by the reverse reaction:
Pyruvate + NADH -> Lactate + NAD
The progi ess of this reaction was performed in a 96 well microtiter plate and the 
conversion of NADH to NAD was measured speetrophotometrically using a MRX 
microtiter plate reader (Dynex Technologies) set at a wavelength of 340nm.
For the measurement of free LDH activity the following reaction was set up:
186pl 0.15M Tris-HCl, pH7.4
7 pi 1 OmM Na pyruvate
7 pi sample to be assayed
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The reaction was started by the addition of 1 Opl 2mM j3-NADH and readings were 
taken at 20sec intervals for 1 Omin.
For the measurement of occluded LDH activity the following reaction was set up:
172pl 0.15M Tris-HCl, pH7.4
7 pi 1 OmM Na pyruvate
14pl 30% Triton X-100
7 pi sample to be assayed
The reaction was started by the addition of lOpl 2mM (3-NADH and readings were 
taken at 20sec intervals for 1 Omin
In all cases the assays were performed in triplicate.
The initial rate of decrease in the absorbance at 340mM was taken to be directly 
proportional to the LDH activity present in the sample.
2.3 Molecular Techniques
2.3.1 Electrophoresis of DNA
23.1.1 Buffers
Tris acetate electrophoresis (TAE) buffer (50X stock)
2M Tris base
IM Aeetic acid
0.05M EDTA
2.3.1.2 Casting an agarose minigel
200 ml IX TAE was prepared for each minigel. 20 ml of agarose suspension was 
made up in IX TAE at the desired concentration (w/v) in a small conical flask and
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the flask was weighed. This suspension was heated in a microwave until the agarose 
dissolved. Once this occurred, the flask was reweighed and made up to the original 
weight with distilled water. 1.7pl ethidium bromide was then added to the molten 
agarose and mixed by swirling before the agarose was poured into the casting tray of 
a minigel apparatus and allowed to set. The remaining TAE was then used to fill the 
tank. Samples were loaded into the wells of the gel after mixing with 6X loading dye 
(Promega) and the gel was run at 75 V.
Range of Separation of linear DNA molecules according to agarose concenti ation. 
Percentage gel Size of fragment (kilobases)
0.9 0.5-7
1.2 0.4-6
1.5 0.2-3
2.0 0. 1-2
2.3.1.3 Recovery o f DNA from agarose gels
The recovery of DNA from agarose gels was achieved using the QIAquick gel 
extraction kit (QIAgen) according to the manufacturers instructions.
2.3.2 Large scale plasmid purification
The large scale purification of plasmid DNA was achieved using either the Promega 
Wizard^^ maxiprep kit or the Qiagen QIAprep maxiprep kit according to the 
manufacturers instructions.
2.3.3 Small scale plasmid purification
The small scale purification of plasmid DNA was achieved using either the Promega 
Wizard™ miniprep kit or the Qiagen QIAprep spin miniprep kit according to the 
manufaeturers instruetions.
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2.3.4 Quantification of DNA and RNA
Both DNA and RNA were quantified spectrophotometricly. A known volume of 
DNA or RNA solution was diluted to 1ml with distilled water and absorbance 
measurements were taken at 260nM and 280nM using a Shimadzu UV-1201 UV-VS 
spectrophotometer blanked on distilled water. The concentration of nucleic acid was 
then calculated using the following approximations:
An absorbance of 1 at 260nM corresponds to 50pg/ml double stranded DNA
37pg/ml single stranded DNA 
40pg/ml single stranded RNA
The ratio between the absorbance measurements at 260nM and 280nM provided an 
indication of the purity of the nucleic acid. In solution, pure DNA and RNA typically 
have A26o:A2go ratios of 1.8 and 2.0, respectively. If the absorbance ratio is 
significantly less than this it indicates that the nucleic acid may be contaminated with 
either phenol or with protein.
2.3.5 Polymerase chain reaction (FCR)
23.5.1 PCR Reaction mix
5 OmM KCl (Supplied lOX in Taq polymerase buffer) ■I'
lOmM Tris HCl (pH9) (Supplied lOX in Taq polymerase buffer)
200pM dATP Î;Ç
200pM dTTP 3
200pM dGTP
200pM dCTP 3
0.5pM 5’ (sense) primer
0.5pM 3’ (antisense) primer
l.SmM MgClz f:
<lpg Template cDNA
5 units Taq DNA polymerase
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2.3.5.2 Procedure
The PCR reaction mix was assembled in a sterile 0.5ml Eppendorf tube and cycled in 
a Techgene theimocycler PCR machine. The cycling conditions were optimised for 
each PCR reaction, typical conditions were:
Segment 1: 2 cycles
Dénaturation 30 sec 94°C 
Annealing 30 sec 3TC 
Extension 30 sec 72°C
Segment 2: 28 cycles
Dénaturation 30 sec 94°C
Annealing 30 sec at 8°C below the predicted melting temperature of the primers 
Extension 30 sec 72°C
2.3.6 Site directed mutagenesis using the QuickChange™ kit
Site directed mutagenesis was performed using the QuickChange^^ kit (Stratagene) 
according to the manufacturers instructions. Briefly, 2 complementary 
oligonucleotides each containing the desired mutation, flanked by unmodified 
sequence were generated and purified by high pressure liquid chromatography 
(HPLC). A series of 3 reactions was set up using various concentrations of template 
DNA (lOng, 25ng and 50ng). The concentration of the complementary primers was 
kept constant, at 125ng of each primer, in all 3 reactions. The components in the 
reactions were as follows:
5pl lOX reaction buffer (supplied with the kit)
xpl template DNA plasmid
125ng sense primer
125ng antisense primer
Ip dNTP mix (supplied with the kit)
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sterile, deionised water to 50pl
2.5 units Pfu DNA ploymerase
The reaction mixes were assembled in sterile 0.5ml Eppendorf tubes and cycled in a 
Techgene thermocycler PCR machine. The cycling conditions were:
Segment 1:1 cycle
Dénaturation 30 sec 95®C
Segment 2:12-18 cycles
Dénaturation 30 sec 95°C 
Annealing 1 min 55^C 
Extension 2 min/kb of template plasmid 68°C
The number of cycles used in segment 2 depended upon the type of mutation desired: 
point mutations 12 cycles, single codon change 16 cycles, multiple codon deletions 
or insertions 18 cycles.
After the temperature cycling the reactions were cooled to below 3TC  then 10 units 
Dpnl restriction enzyme was added to each reaction and the tubes were incubated at 
3>TC for 1 hour. The Dpnl restriction enzyme digests methylated but not non 
methylated DNA. Therefore this digestion serves to degrade the template DNA but 
not the newly synthesised DNA that includes the mutation. After this digestion the 
Dpn~I treated DNA from each of the reactions was used to transform E.coli XLl- 
Blue supercompetent cells (supplied with the kit).
2.3.7 RNA isolation
Pre-weighed tissue was homogenised in Tri-Reagent (1ml per 50-100mg tissue) 
using a sterilised glass homogeniser. Alternatively, one flask of a cell monolayer was 
scraped into 1ml of Tri-Reagent and resuspended with a pipette. The homogenate 
was stored at room temperature for 5 min. It was then transferred in 1ml aliquots to
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sterile Eppendorf tubes. The homogenate was centrifuged at 12000g at 4°C to remove 
the cell membranes, polysaccharides and high molecular weight DNA. The 
supernatant was transferred to a fresh, sterile Eppendorf tube. The RNA and DNA 
were phase separated by the addition of 0.2ml RNAse-free chloroform per 1ml of 
Tri-Reagent. The solution was mixed by vortexing for 15 sec then stored at room 
temp for 3min. Phase partition was brought about by centrifugation at 12000g for 15 
min at 4°C. The aqueous phase was transferred to a fresh, sterile Eppendorf tube and 
the RNA was precipitated by the addition of isopropanol (propan-2-ol): 0.5ml per 
1ml of Tri-Reagent initially used. The precipitation was allowed to continue for 5-10 
min at room temperature before the RNA was pelleted by centrifugation at 12000g 
for 10 min at 4°C. The supernatant was removed by aspiration and the pellet was 
washed in 1ml 75% ethanol. In this state the RNA can be stored for up to a year at - 
20"C.
2.3.8 First strand complementary DNA (cDNA) synthesis
2.3.8.1 buffers
cDNA synthesis reaction mixture
11 pi "Bulk 1 St str and cDNA mix" (supplied with kit)
1 pi DTT solution (supplied with kit)
Ipl "Notl“d(T)l 8" (0.2 pg/pl) primer (supplied with kit) diluted 1:25 with
distilled water 
20pl heat-denatured RNA from 1st tube
First strand cDNA was synthesised using the Pharmacia First-strand cDNA Synthesis 
Kit according the manufacturers instructions. Briefly 5pg of total RNA was made up 
to 20pl with DEPC treated distilled water. This was heated to 65°C in a thermal cycler 
for lOmin then immediately chilled on ice. The "Bulk 1st strand cDNA mix" (supplied 
with the kit) was gently mixed by being pipetted up and down several times and was 
then collected with a brief centrifugation. The cDNA synthesis reaction mixture was 
assembled in a sterile 0.5ml Eppendorf tube that was chilled on ice. The cDNA
2-101M.B.Beard Materials and Methods
synthesis reaction was then incubated at 37®C for 1 hour.
2.3.9 DNA sequencing
DNA sequencing was performed using the ABI PRISM Dye Terminator Cycle 
Sequencing Ready Reaction Kit (Perkin-Elmer Corporation). Plasmid DNA samples 
were prepared for sequencing using the QIAprep spin miniprep kit (Qiagen) and 
resuspended in sterile, deionised water. The plasmid DNA (400ng) was mixed with 
8 pi of the Taq DyeDeoxy Terminator (ABI) reaction premix (supplied with the kit) 
and 3.2pmol of a sequencing primer. The reaction volume was made up to 20pl with 
sterile, deionised water. The sequencing reaction was then subjected to 25 rounds of 
thermal cycling using the following conditions:
Dénaturation 96°C 30 sec
Annealing*  ^ 47°C 15 sec
Extension 60°C 4min
* This segment temperature was variable according to the primer used. The
temperature shown was that used for the T7 sequencing primer 
(taatacgactcactataggg) and the pCR2.1 upstream primer (agctatgaccatgattacg)
After cycling the reaction products were concentrated by ethanol precipitation and 
the pellets sent to the Glasgow University Moleculai- Biology Support Unit for gel 
electrophoresis.
2.3.10 Sequence Aanalysis
Routine DNA and deduced amino acid sequence analysis was performed on the Gene 
Jockey II program. The GCG suite of software was used for similarity searching of 
the nucleotide and protein databases and also for sequence analyses that were not 
available in the Gene Jockey II program.
In all analyses of the deduced amino acid sequences of proteins the initiating 
methionine residue encoded by the cDNA was included in the analysis of the protein
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2.3.11 Restriction digestion of DNA
2.3.13 Ligation of DNA
Double stranded DNA was mixed with lOOng linearised vector DNA at 1:1 and 1:3 
ratios (v/v) of vector:insert DNA and the mixture was made to 19.5pi IX T4 DNA 
ligase buffer by the addition of lOX T4 DNA ligase buffer (supplied with the T4 
DNA ligase. lOX T4 DNA ligase buffer is 3OmM Tris-HCl, pH7.8. lOOmM MgCl^, 
lOOmM DTT, lOmM ATP) and sterile, deionised water. The ligation reaction was 
then started by the addition of 1 unit of T4 DNA ligase (Promega). The reaction was 
incubated at 14“C overnight.
2.3.14 Preparation of competant cells
2.3,14.1 Buffers and media
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All restriction enzyme digest were performed on pure plasmid DNA using restriction 
enzymes supplied either by Promega, by New England Biolabs or by Boehringer 
Mannheim. The incubation conditions were 37°C for a minimum of 1 hour using the 
appropriate buffer supplied by the manufacturer.
2.3.12 Ethanol Precipitation of DNA
To the volume of DNA to be ethanol precipitated, 0.1 volume 3M sodium acetate and 
2 volumes of 100% ethanol were added. The DNA mixed by vortexing and then 
incubated at -80°C for 30 min. The precipitated DNA was centrifuged at 12000g at 
4°C for 1 Omin to pellet the DNA. The supernatant was aspirated and 1ml of 70% 
ethanol added. The DNA was pelleted again by centrifugation at 12000g at room 
temperature for 5min. The supernatant was removed and the pellet allowed to air-dry 
for 5-10 minutes. The DNA was then resuspended in TE buffer or sterile, deionised 
water.
L-broth
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract
1 % (w/v) Bacto-Tryptone
Transformation buffer Rfl
lOOmM 
50mM 
30mM 
lOmM 
15% (w/v)
RbCl
MnC1.4H20 
Potassium acetate
CaCIz-ZHgO
glycerol
pH adjusted to 5.8 with 0.2M acetic acid. 
Filter sterilised through a 0.22p filter.
Transformation buffer R£2
lOmM RbCl
lOmM 3-(N-Morpholino)propane sulphonic acid (MOPS)
75mM CaCl^^HgO
15 % (w/v) glycerol
pH adjusted to 6.8 with 0.2M NaOH.
Filter sterilised through a 0.22p filter.
2.3.14.2 Preparation o f Competent JM 109 or XLl-Blue E.coli
10ml of L-broth was inoculated with a stab fi'om a glycerol stock of either JM109 or 
of XLl-Blue E. coll and grown overnight at 37°C with constant shaking. The next 
day 3ml of this culture was used to inoculate 400ml L-broth and this culture was 
grown at 37“C with constant shaking until the optical density at 550nm was between 
0.5 and 0.55. The culture was divided equally between two sterile 250ml centrifuge 
bottles and cooled on ice for 30 minutes. The cooled culture was then centrifuged at 
2500rpm (95Og) at in a Beckman JA14 rotor for 15min and each pellet was
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resuspended in 20ml of ice-cold transfoimation buffer R fl. The cells were incubated 
on ice for a further 15min before being centrifuged at 2500rpm (950g) for 10 minutes 
in a Beckman JA14 rotor at 4*^ C. The supernatant was removed and the cell pellets 
were each gently resuspended in 3.5ml of transformation buffer Rf2. The 
resuspended cells were pooled and incubated on ice for 15 minutes. The competent 
cells were then snap-frozen in 250pl aliquots and stored at -80°C.
2.3.15 Transformation of E,coH
2.3.15.1 Media 
L-broth
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract
1 % (w/v) Bacto-Tryptone
LB-Agar
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract 
1% (w/v) Bacto-Tiyptone
2% (w/v) Agar
2.3.15.2 Transformation
An aliquot of frozen competent cells was thawed slowly on ice. For each 
transformation a lOOpl aliquot of competent cells was transferred to a chilled, sterile, 
17x100mm tube (Falcon 2059). To each lOOgl aliquot of competent cells, 
approximately lOOng of DNA was added and this was incubated on ice for 30 min. 
The cells were then heat shocked for exactly 45 seconds at 42°C then incubated on 
ice for a further 2 min. 900pl of room temperature L-broth was then added and the 
transformed cells were incubated at 37°C for 30~60min with shaking. 100-500pl of 
the culture was plated on a 10cm agar plate containing a selection antibiotic. The
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plate was incubated at 37°C overnight. The next morning transformed colonies were 
picked and glycerol stocks were made.
2.3.16 Glycerol stocks
A single colony was picked from an agar plate and used to inoculate 10ml of L-broth 
supplemented with a selection antibiotic (usually lOOpg/ml ampicillin). The culture 
was grown overnight at 37°C. The next morning 600pl of the overnight culture was 
transferred into a sterile Eppendorf tube and mixed with 300jal of sterile 45% 
glycerol. The glycerol stock was then stored at -80°C.
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3. Interaction of type 4 phosphodiesterase with SH3 
domains
3,1 Introduction
The rat PDE4A isoenzyme RNPDE4A5 and the human homologue of this protein, 
HSPDE4A4B can interact specifically with certain members of the Src homology 3 
(SH3) class of domains for protein-protein interaction (141, 162).
SH 3 domains comprise a family of homologous, regions of sequence, approximately 
60 residues in length, that occur in a wide variety of proteins (see section 1.4.1.1).
SH3 domains represent genuine protein domains in that they foim independently 
folding structures that appear to be able to fold correctly within a wide variety of 
different contexts and are little affected by the surrounding regions of the proteins in 
which they occur. These domains have a compact p-barrel structure that is formed 
from 5 anti-parallel p-strands. The amino and carboxyl termini of the folded domain 
aie close together in 3 dimensional space. Thus SH3 domains can be thought of 
almost as distinct entities that are covalently linked to the proteins in which they are 
situated (148, 149, 247).
The functional role of SH3 domains is to mediate protein-protein interactions. An 
important role for these domains appears to be the recruitment of signalling proteins 
into multienzyme complexes. In this regard it is noteworthy that proteins which 
contain SH3 domains often also contain other classes of domain for protein-protein 
interactions. All members of the Src family of protein tyrosyl kinases, for instance, 
contain both an SH2 and an SH3 domain. This may serve to allow for the 
simultaneous association of a such a protein with 2 or more binding partners (168).
SH3 domains bind to regions of target proteins that are rich in proline and arginine 
residues. Peptide binding, phage display and crystallographic analyses have 
identified a consensus motif of the form PxxP as being an important determinant of 
binding to SH3 domains (see section 1.4.1) (1, 32, 205). Such sequences adopt a left
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handed polyproUne type II helical conformation that interacts with a highly 
conserved region, consisting mainly of aromatic residues on the surface of the SH3 
domain (149, 205).
The long form PDE4A isoform RNPDE4A5 can interact specifically with certain 
SH3 domains, showing a preference for interaction with the SH3 domains of the Src 
family tyrosyl kinases Lyn and Fyn (162). The interaction of RNPDE4A5 with SH3 
domains has an absolute requirement for the alternatively spliced amino terminal 
region of RNPDE4A5. This region of the protein is rich in proline and arginine 
residues and contains 3 regions of sequence that conform to the PxxP consensus 
motif that has been suggested to be important for binding to SH3 domains {Figure 
3.8). It has been suggested that the 1 or more of the 3 proline rich motifs within the 
amino teiminal region of RNPDE4A5 form the site of interaction between 
RNPDE4A5 and SH3 domains (162).
The human homologue of RNPDE4A5, namely HSPDE4A4B, has also recently been 
shown to interact with SH3 domains (141). In addition to the 3 putative SH3 domain 
binding motifs that are present in the alternatively spliced amino terminal region of 
this isoform, and that are conserved between the rat and the human proteins, there is 
an additional region of sequence that conforms to the motif PxxP present in the 
unspliced, Linker Region 2 (LR2) of human PDE4A. The LR2 of PDE4A appears to 
be hypeiwariable and is not conserved between the rat and the human sequences (see 
section 1.3.2.2) (141). Both an, as yet unidentified, site or sites within the 
alternatively spliced amino terminal region of HSPDE4A4B and also the proline and 
arginine rich region of sequence in the LR2 of human PDE4A can bind to SH3 
domains (141).
In this chapter I will present evidence that a long splice variant of the PDE4D 
enzyme family, namely HSPDE4D4, can also interact with SH3 domains and that 
this interaction is dependent upon the alternatively spliced, amino terminal region of 
HSPDE4D4.
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WRQPRTPIRIQQR 
EPPAAPSERSLS \ / ERSPHRPIERAD
/ / UCRl UCR2 RNPDE4A5
UCRl UCR2 HSPDE4D4
PHHHLPPPPPPSPQPQPQCPLQPPPPPPLPPPPPPP
Figure 3.H: Isoforms o f  PDE4A and 4D contain consensus motifs fo r  SH3 
binding.
The figure shows diagrams representing the amino-terminal regions of RNPDE4A5 
and HSPDE4D4. The alternatively spliced, extreme amino-terminal region of each 
isqfbrm contains proiine rich regions o f sequence, which conform to Known consensus 
motifs for interaction with SH3 domains.
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3.2 Results and discussion
Ï
It had previously been shown that both recombinant RNPDE4A5 (expressed in COS- 
7 cells) and rolipram sensitive, PDE4 activity from the cytosolic fraction of rat brain
can specifically associate with the SH3 domains of Src and Fyn kinases (see section 
3.1) (162). In this study GST fusion proteins of the SH3 domains from Src kinase 
and from Fyn kinase were immobilised on glutathione Sepharose resin and used as 
probes to identify PDEs in the cytosolic fraction of rat brain that could bind to these 
domains (see (162) for a description of the method used).
Immunoblots of the material from rat brain cytosol that bound to the GST-SH3 
domain fusion proteins were performed using antisera specific for each of the PDE4 
gene families. This revealed the presence of PDE4A (162) and PDE4D {Figure 3.9) 
but not of either PDE4B or PDE4C [J. O'Connell, personal communication]. A single 
isoform of PDE4A, namely RNPDE4A5, was detected in the cytosolic fraction of rat 
brain; this isoform was also present in the material that bound to the SH3 domain of 
Src kinase (162).
In these preliminary experiments 3 anti-PDE4D immunoreactive species were 
detected in the cytosolic fraction of rat brain. Each of these species co-migrated on 
SDS-PAGE with one of either recombinant HSPDE4D3, HSPDE4D4 or 
HSPDE4D5 {Figure 3.9). On this basis the 3 immunoreactive species were 
tentatively identified as being the rat homologues of the human HSPDE4D3,
HSPDE4D4 and HSPDE4D5 isofbrms, namely RNPDE4D3, RNPDE4D4 and IRNPDE4D5. Only 1 of the 3 PDE4D species that were present in the rat brain 
cytosol was reproducibly detected in the material that bound to the SH3 domains of 
Src and Fyn kinases at levels above those in the material that bound to GST alone.
This was the species that co-migrated, on SDS-PAGE, with recombinant 
HSPDE4D4 {Figure 3.9).
At the time this work was started the full length cDNA clone of human PDE4D4 had 
only just been isolated and the sequence for the rat homologue of this splice variant 
had not yet been cloned. Inspection of the deduced amino acid sequence of
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HSPDE4D4 revealed that this protein contains proline rich sequences of a form that 
might be expected to interact with SH3 domains. This seemed to support the tentative 
identification of the PDE4D species present in rat brain cytosol and that bound to 
SH3 domains as being the rat homologue of HSPDE4D4.
Aberrant migration on SDS-PAGE is, however, a known feature of many PDE4 
enzymes and at least 2 PDE4 isoforms are known to exhibit shifts in mobility on 
SDS-PAGE following stimulation of cells with various effectors (98, 132). I 
therefore felt that the immunoblot data alone was insufficient evidence to positively 
identify the rat PDE4D isofoim as RNPDE4D4.
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Figure 3.9: Endogenous PDE4D4 from  Rat Brain Cytosol Binds to SH3 Domains
The figure shows an immunoblot of PDE4D species “pulled down ” from rat brain 
cytosol by the SH3 domains of Src and Fyn, expressed as fusion proteins with GST and 
immobilised on glutathione Sepharose. Lanes 1-4 are cytosolic fractions from COS-7 
cells overexpressing HSPDE4D1, HSPDE4D3, HSPDE4D5 and HSPDE4D4 
respectively. Lanes 6-9 are the bound fractions from lOOpg rat brain cytosol 
challenged with GST, GST-Src SH3, GST-Src SH2/3 and GST-Fyn SH3 respectively. 
Lane 11 is 25pg rat brain cytosol. The primary antibody used was the monoclonal 
antibody 61D10E (ICOS) that detects the common region ofPDE4D isoforms. The 
secondary antibody was a horsradish peroxidase conjugated anti-mouse IgG, 
polyclonal antisera (Sigma).
Source: (161)
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3.2.1 RT-PCR of RNP0E4D4 from rat brain
To support the hypothesis that the PDE4D isoform that is present in rat brain cytosol 
and that can interact with the SH3 domains of Src and Fyn kinases was RNPDE4D4, 
the rat homologue of HSPDE4D4,1 decided to confirm the existence of this isoform 
using reverse transcriptase polymerase chain reaction (RT-PCR) analysis of RNA 
isolated fi'om rat brain.
3.2.1.1 Optimisation ofPCR conditions for amplification of PDE4D4
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Primers APIO and API 1, intended to amplify the entire alternatively spliced region 
of PDE4D4, were designed against the known human and, in the case of the 
antisense primer (API 1), rat sequences {Figure 3.10, Table 3.3.1). The plasmid 
pCMVPDE4D4, which contains the complete open reading frame for HSPDE4D4, 
was used as a source of template for the optimisation of PCR conditions.
Reactions were performed to test a range of Mg^  ^and DMSO concentiations and 
various different cycling conditions. The 5’ region of the cDNA encoding 
HSPDE4D4 is rich in guanine (G) and cytosine (C) residues (76% over the target 
region). It is possible the G-C rich character of this template could lead to 
incomplete melting of the DNA and hence poor amplification. In order to address 
this possibility, the melting temperature in these PCR reactions was set at 9TC 
(rather than 96°C, which is commonly used in PCR reactions). Further increases in 
melting temperature were found to cause a decreased signal in control reactions, 
presumably due to instability of Taq polymerase at temperatures in excess of 9TC. 
Conditions of 97“C melting temperature, 0.75mM MgClj and 5% DMSO were found 
to amplify a single band of the predicted size (446 bp) {Figure 3.11). It has 
subsequently found that melting temperatures of 99”C and use of Deep Vent 
polymerase (New England Biolabs) can also improve amplification.
APIO SEIO A P ll  
D 4- 2775 GR6
UCRl UCR2
GR35
4
C ata ly tic  R egion
Start codon  
Stop codon
Figure 3.10: Annealing positions ofprimers designed against PDE4D isoforms.
The figure shows a diagram representing the known isoforms o f PDE4D. The annealing 
positions ofprimers used in the RT-PCR analysis o f these isoforms are indicated by arrows.
Primer Sequence
APIO GAGGCAGAGGGCAGCAGCG
A P l l  CCTCGTTCCAGGGACTCAGGC
SEIO AGCGCTACCTGTACTGTCG
2 7 7 5  ACTTGTTGGAGGCCATCTCAC
A P 4  ATTTTCCG TTC AG AAG G CATTCCTG G
G R 6  CCTG G TTG CCAG ACC GA CTCATTTCA
G R 3 5  G A T C ( C T ) ACATCATG TATTG CA CTG G C
Region o f  splice variant Strand
HSPDE4D4 bp 426-444 Sense
HSPDE4D4 bp 856-876 Antisense
HSPDE4D4 bp 760-778 Sense
HSPDE4D4 bp 1324-1344 Antisense
HSPDE4D3 bp 148-173 Sense
HSPDE4D4 bp 1382-1407 Antisense
HSPDE4D4 bp 1914-1938 Antisense
Table 3.3.1: Primers used in the RT-PCR analysis of PDE4D isoforms.
The table shows the sequences and annealing positions o f the primers used in the RT-PCR 
analysis ofPDE4D isoforms.
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1636
•1018
517, 506 .396 344■298
•220 , 221 •154, 134, 75
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 3.11: Optimisation o f  PCR conditions.
The figure shows products o f PCR reactions performed with a range o f and 
DMSO concentrations. Lanes 1—3 are 1.5juM MgCl2 with 0, 2.5 and 5% DMSO 
respectively. Lanes 5-7 are 3pM MgCl2 with 0, 2.5 and 5Vo DMSO respectively. 
Lanes 8-10 are 5pM MgCli with 0, 2.5 and 5% DMSO respectively. Lanes 12—14 
are 0.75fiM MgCl2 with 0, 2.5 and 5% DMSO respectively. Lanes 4 and 11 contain 
1Kb ladder marker DNA (Gibco). The arrows indicate the molecular wetghts o f the 
bands in the marker lanes.
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3.2.1.2 RT-PCR o f PDE4D4 from rat brain, total RNA
First strand cDNA was synthesised from rat brain, total RNA using MMLV reverse 
transcriptase (First-strand cDNA Synthesis Kit, Pharmacia) and the primer GR35, 
which is specific for PDE4D gene products (see Section 2.3.8). The cDNA was then 
probed for PDE4D4 by PCR, for 30 cycles under the optimised conditions. This 
reaction, however, failed to amplify the predicted 446 bp product.
There are several possible explanations for failing to obtain a signal in the above RT- 
PCR reaction. Amplification of the extreme 5’ region of the PDE4D4 open reading 
frame is problematic even when using good quality plasmid DNA as the template; 
this is possibly due to the G-C rich character of the sequence. PDEs have a low 
abundance in native cells. The corresponding mRNA might also be present at low 
levels, making detection difficult. Furthermore, the sense primer APIO was designed 
against the human sequence and was not degenerate; therefore regions of mismatch 
with the rat sequence were likely. In order to address at least some of these 
possibilities RT-PCR was attempted using the primers SEIO and 2775 {Figure 
3.10, Table 3.3.1). These primers were designed to amplify a 585 bp region of 
PDE4D4 which overlaps the splice junction with PDE4D3 and does not include the 
G-C rich region of sequence at the extreme 5 ’ end of the open reading frame. 
Amplification of RNPDE4D3 using primers AP4 and GR6 {Figure 3.10, Table 3.3.1) 
was performed in parallel to serve as a positive control for the cDNA synthesis 
reaction.
First strand cDNA was synthesised from rat brain total RNA using the primer GR35 
(see section 2.3.8). This cDNA was probed for RNPDE4D4 and for RNPDE4D3 by 
PCR using the primers SEIO and 2775 (RNPDE4D4) and AP4 and GR6 
(RNPDE4D3). Bands of the predicted sizes were amplified by both pairs of primers, 
corresponding to RNPDE4D4 (585 bp) and to RNPDE4D3 (561 bp) {Figure 3.12). 
The products from the RT-PCR amplification of PDE4D4 were then TA cloned into 
the plasmid pCR®2.1 (Invitrogen). The recombinant pCR®2.1 containing the RT- 
PCR reaction products was transformed into INVaF’ One Shof*’’^  Competent E.coli 
(Invitrogen). Several colonies containing recombinant plasmid (selected by blue-
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white screening) were then picked and the inserts were sequenced (see section 2.3.9). 
Sequence alignment revealed 94.9% homology between HSPDE4D4 and the 
consensus sequence generated from the products of the RT-PCR reaction. Within the 
region of homology between PDE4D4 and PDE4D3, the amplified sequence aligned 
with the rat sequence at points of mismatch between rat and human sequences 
{Figure 3.13). The cDNA sequence of RNPDE4D4 was subsequently cloned by 
another group (accession number AF031373). The sequence of this cDNA matches 
that of the amplified fragment, providing further evidence to support the 
identification of the PDE4D isoform present in rat brain cytosol which can interact 
with SH3 domains as RNPDE4D4.
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Figure 3.12: RT-PCR o f  PDE4D from  Rat Brain
The figure shows the products o f RT-PCR reactions (from rat brain, total RNA) run 
on a 1.5% agarose mini-gel and visualized under UV illumination by staining with 
ethidium bromide. Lane 1 contains the products using primers designed to amplify 
PDE4D4 (predicted size 585 bp), lane 2 contains Hae IIIphiXl 74 DNA markers 
(bands are 1353, 1078, 872, 603, 310 and 276 bp), lane 3 contains the products 
using primers designed to amplify PDE4D3 (predicted size 561 bp).
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HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
7 7 0  7 8 0  7 9 0  3 0 0
I I I I
AaCc'.CTACCTCTACTGTCGCGCCATGGACCGCACCTCCmCGCGGTGG  
AG('GCTACCTGT7vCl'GTCGrGCCATGGACCGCACCTCCTACGCGGTGG 
AGCGCT/^CCTCrrACTG:'C'G rGCCATGGACCGCACCTCCTACGCGGTGG
8 1 0 8 2 0 8 3 0 8 40 8 5 0
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 { A F 0 3 1 3 7 3 ) b p  3 2 3 - 9 0 7
9 6 0
I
9 7 0 9 8 0 9 9 0
TTCTCCAAGCAAATTTTGTCCACAGTCAACGACGGGAGTCCTTCCTGT
TTCTCCAAGCAAACTTTGTGCACAGTCAACGf;CGGGAGTCCTTCCTGT
TTCTCCAAGCAAACTTTGTGCACAGTCAACGl’CGGGAGTCCTTCCTGT
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
1 2 0 0
I
1 21 0 1 2 2 0 1 2 3 0
TGTGCAACCAACCATCCATCAACAAAGCCACCATAACAGAGGAGGCCT 
T CTCCAACCAACCATCCAT CAACAAACCCACCATCACAGAGGAG G COT 
TGTGCAACCAACCATCCATCAACAAAGCCACCATCACAGAGGAGGCCT
1 2 4 0I 1 2 5 0 1 2 5 0 1 2 7 0 1 2 8 0
HSPDE4D4 ( L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
ACCAG7WVCTGGCCAGCGAGACCCTGGAGGAGCTGGACTGGTGTCTGG
ACCAGAAACTGGCCAGCGAGACCCTGGAGGAACTGGACTGGTGTCTGG
ACCAGAAACTGGGCAGCGAGACCCTGGAGGAGCTGGACTGGTGTCTGG
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Î
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
AGACCGGCCACCGGCCCGGCCTGAAGAAATCCAGGATGTCCTGGCCCT
ACACTCC'rCACCGCCC7\CGCCTGAACAAATCl'AGCATCTCCTCGCCCT
AGACTGGTCACCGGCCAGGCCTGAAGAAATCTAGQATGTCCTGGCCCT :î-
HSPDE4D4 ( L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
8 6 0
I
8 7 0 8 8 0 8 9 0 9 0 0
CCTCGTTCCAGGGACTCAGRCGTTTTGATGTGGAC7VATGGCACATCTG
CnTCTTTCCAGGGACTCAGACGTTTCGATGTGGACAATGGCACATCl'.G
C^’TCTTTCCAGGGACTCAGACGTTTu’GATGTGGACAATGGCACATCtG
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
9 1 0  9 2 0  9 3 0  9 4 0  9 5 0
I I  I I I
CGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGATCCGGGCTAA 
CGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGCTCTGGGCTAA 
CGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGf'TCrGGGCTAA
I
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
1 0 0 0  1 0 1 0  1 0 2 0  1 0 3 0  1 0 4 0
I I I  I I
ATCGATCCGACAGCGATTATGACCTCTCTCCAAAGTCTATGTCCCGGA 
ATCGATC7ÆACAGCGATTAT6ACCTCTCTCCAAAGTCTATGTCCAGGA 
ATCG.ATGAGACAGCGATTATGACCTCTCTCCAAAGTCTATGTGCAGGA
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o T ise n s u s  f r o m  R T -PC R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
1 0 5 0  1 0 6 0  1 0 7 0  1 0 8 0  1 0 9 0I ! I I I
ACTCCTCCATTGCCAGTGATATACACGGAGATGACTTGATTGTGACTC 
ACTCCTCGATTGCCAGTGATATACArGGAGATGACTTGATTGTGACTC 
ACTCCTCC.ATTGCCAGTGATATACA'rGGAGATGACTTGATTGTGACTC
HSPDE4D4 { L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
1 1 0 0  1 1 1 0  1 1 2 0  1 1 3 0  1 1 4 0
I I I I I
CATTTGCTCAGGTCTTGGCCAGTCTGCGAACTGTACGAAACAACTTTG 
CATTTGCTCAGGTCTTGGCCAGCCTrCGAACTGTAAGAAACAACTTTG 
CATTTGCTCAGGTCTTGGCCAG, :CT TCGAACTGTAAGAAACAACTTTG
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s  
RNPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7
1 1 5 0  1 1 6 0  1 1 7 0  1 1 8 0  1 1 9 0
I  I I I I
CTGCATTA1Û.CTAATTTGCAAG.ATCGAGCACCTAGCAAAA.GATCA.CCCA 
CTGCATTAACTAATTTGCAAGATCGCGCACCCAGCAAAAGATCACCCA 
CTGCATTAACTAATTTGCAAGATCGCGCACCCAGCAAAAGATCACCCA
1 2 9 0  1 3 0 0  1 3 1 0  1 3 2 0  1 3 3 0
I I I  I I
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  ACCAGCTAGAGACCCTACAGACCAGGCACTCCGTCAGT'lAGATt'GCCT
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s
RNPDE4D4 (A E 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7  ACCAGCTAGAGACCCT7.CAGACCAGGCACTCCGTCAGrGAGAT(V7CrT
1 3 4 0
I
HSPDE4D4 (L 2 0 9 6 9 )  b p  7 6 0 - 1 3 4 4  CCAACAAGT
C o n s e n s u s  f r o m  R T -P C R  P r o d u c t s
RKPDE4D4 (A F 0 3 1 3 7 3 )  b p  3 2 3 - 9 0 7  CC.AACAAGT
Figure 3.13: AUgnment o f the sequences o f HSPDE4D4, RNPDE4D4 and the 
products o f RT-PCR reactions from rat brain total RNA.
The figure shows a multiple alignment o f the sequences qfIiSPDE4D4 and 
RNPDE4D4 with the consensus sequence from the products o f RT-PCR reactions 
from rat brain total RNA using the primers SEiO and 2776. The sequences o f the 
primers are coloured blue and regions o f mismatch betvi'een the rat and human 
sequences are coloured red. Mismatch between the RT-PCR sequence and that o f  
RNPDE4D4 is coloured gi'een. This mismatch probably represents a point mutation 
which occurred during the PCR amplification step o f the RT-PCR.
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3.2.2 Optimisation of the puli down assay for protein-protein interaction
The RT-PCR data showed that RNPDE4D4, the rat homologue of HSPDE4D4, is 
expressed in rat brain. The immunoblot data showed that, of the 3 PDE4D 
immunoreactive species detected in rat brain cytosol, only I species, that co-migrated 
with HSPDE4D4 on SDS-PAGE, bound to the SH3 domains of Src and Fyn kinases. 
Taken together these data suggested that the PDE4D splice variant RNPDE4D4 is 
expressed in rat brain and that this species may be able to interact specifically with 
SH3 domains.
The model system of COS-7 cells transiently transfected to express recombinant 
PDEs has previously been used to investigate interactions between isoforms of 
PDE4A and SH3 domains. In these studies pull down assays were successfully used 
to assess the ability of transfected PDEs to interact with individual SH3 domains 
(141, 161, 162). I therefore decided to use this strategy to investigate further the 
interaction of PDE4D4 with SH3 domains.
I intended to use pull down assays to assess the ability of recombinant HSPDE4D4, 
expressed in COS-7 cells, to interact with a library of 22 GST fusion proteins so as to 
probe for possible protein-protein interactions with a variety of domains. Initially, 
however, I performed a series of control experiments to ensure that the pull down 
assay for protein-protein interaction was working in my hands.
3.2.2.1 Induction and purification offusion proteins
Fusion proteins were expressed in JM109 E.coli and purified by a single step of 
affinity chromatography using glutathione Sepharose resin. The purifications were 
monitored on Coomassie stained SDS-PAGE gels {Figure 3.14). With 17 of the 
fusion proteins a strong band of the predicted molecular weight was observed on the 
Coomassie stained gels. This indicated that the affinity chromatography step resulted 
in a reasonable degree of purification for of each of these fusion proteins.
In the cases of the fusion proteins representing full length Src kinase, the F‘ and 3"^  
WW domains of Nedd 4, the WW domain of FE65 and the WW domain of
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dystrophin, a strong band of the predicted molecular weight was not obseiwed on the 
Coomassie stained gels. In each of these cases, however, a band that co-migrated 
with GST was present. When the crude lysate from E.coli expressing these fusion 
proteins was visualised on a Coomassie stained gels strong, novel bands of the 
appropriate weights for these fusion proteins were present. This indicated that, under 
the conditions used, these fusion proteins were unstable and became degraded during 
the purification procedure. The reason that I was unable to purify these fusion 
proteins therefore was not due to premature termination or instability of the protein 
within the intact E.coli.
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Figure 3.14: Purification o f  GST fusion proteins
The figure shows Coomassie stained gels o f GSTfusion proteins purified by a single 
step o f affinity chromatography onto glutathione Sepharose resin. Panel A: lane 1 is 
molecular weight markers (New England Biolabs: MBP-b-galactosidase 175kDa, 
MBP-paramyosin SSkDa, Glutamic dehydrogenase 62kDa, Aldolase 47.5kDa, 
Triosephosphate isomerase 32.5kDa, b-Lactoglobulin A 25kDa, Lysozyme 16.5kDa); 
lanes 2-5 are GST fusions with full length Src, Src SH2/3, Src SH2 and Src SH3 
respectively: lane 6 is GST. Panel B: lane 1 is molecular weight markers (New 
England Biolabs); lanes 2-7 are GST fusions with Abl SH3, Csk SH3, Lck SH3, Crk 
SH3, Fyn SH3 and Lyn SH3 respectively; lane 8 is GST. Panel C: lane 1 is molecular 
weight markers (New England Biolabs); lanes 2-7 are GSTfusions with Grb-C SH3, 
Grb-NSH3, Cortactin SH3, Fodrin SH3, P53BP2 SH3 and PI3 Kinase SH3 
respectively; lane 8 is GST. Panel D; lane 1 is molecular weight markers (New 
England Biolabs); lanes 2—6 are GST fusions with Dystrophin WW, FE65 WW,
Nedd4 WW3, Nedd4 WW2 and Nedd4 WWl respectively; lane 7 is GST.
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3.2.2.2 Elution offusion proteins from glutathione Sepharose resin
Incomplete elution of the fusion proteins from the glutathione Sepharose resin during 
a pull down assay would have resulted in an underestimation of the amount of bound 
material. To assess the efficiency with which these GST fusion proteins could be 
eluted I performed batch elutions of 400pg of GST and of 400pg of GST-Lyn SH3 
from glutathione Sepharose resin (using lOOpl batches of lOmM glutathione as the 
elution buffer). As in the pull down assays, I incubated each batch of elution buffer 
with the resin for 15 minutes at 4‘^ C on an end over end mixer. The individual batches 
were kept separate and individually assayed.
Under the elution conditions used, more than 90% (assessed by digitally 
photographing Coomassie stained gels and counting pixels) of both GST and GST- 
Lyn SH3 was eluted in the first three lOOpl batchs {Figure 3.15). This suggested that, 
under the conditions used in pull down assays, a good recovery of PDE-fusion 
protein complexes could be expected.
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Figure 3.15: Elution o f  GST and GST-Lyn SH3 from  glutathione Sepharose resin
The figure shows Coomassie stained gels offusion proteins eluted from glutathione 
Sepharose resin in lOOjul batches by lOmMglutathione. Panel A: lanes 1-7 are 
fractions 1-7 in the elution o f GST, lane 8 is protein molecular weight markers (New 
England Biolabs: MBP-b-galactosidase 175kDa, MBP-paramyosin 83kDa, Glutamic 
dehydrogenase 62kDa, Aldolase 47.5kDa, Triosephosphate isomerase 32.5kDa, b- 
Lactoglobulin A 25kDa, Lysozyme 16.5kDa). Panel B: lanes 1-7 are fractions 1-7 
in the elution o f GST-Lyn SH3, lane 8 is protein molecular weight markers (New 
England Biolabs).
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3.2.2.3 Separation o f bound and unbound PDE
Incomplete separation of the bound from the unbound PDE would have increased the 
background noise and was therefore a potential source of error. To ensure that I could 
adequately remove the unbound PDE, I performed pull down assays between GST- 
Lyn SH3 and HSPDE4D4 expressed in the cytosol of transfected COS-7 cells. In 
these pull down assays I did not pool the wash fractions. Instead I individually 
probed each wash fraction for both PDE enzyme activity and immunoreactivity. This 
revealed that under the conditions used, more than 90% of both the activity and the 
immunoreactivity (assessed by digitally photographing immunoblots and counting 
pixels) that I was able to separate into the unbound fraction was released within the 
first two washing steps {Figure 3.16). This indicated that the washing regime 
employed in pull down assays was sufficient to achieve good separation of bound 
and unbound PDE.
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Figure 3.16: Separation o f  bound and unbound HSPDE4D4
The figure shows an immunoblot for FDE4D offractions from a pull-down assay. 
Lane 1 is 4pg cytosol from COS-7 cells overexpressing HSPDE4D4, lane 2 is the 
unbound fraction from the pull down assay, lanes 3-5 are washes 1-3 respectively, 
lane 6 is the bound fraction. An equal proportion o f each fraction (40%)) was loaded 
onto each lane. The weight shown is the apparent molecular weight o f the bands 
(kDa), calculated by plotting the R f values o f the bands and ofprestained molecular 
weight markers run on the same gel.
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3.2.2.4 Detection o f PDE activity in bound and unbound fractions
In their investigation of the interactions between RNPDE4A5 and SH3 domains 
O’Connell and others monitored both the immunoreactivity and the enzyme activity 
in the bound and unbound fractions to assess the interaction of this PDE with each 
SH3 domain. To increase the sensitivity of the enzyme activity assay, the incubation 
time was extended from 10 to 25 minutes in these experiments (162). 
Phosphodiesterase activities are unstable in vitro, for instance RNPDE4A1 enzyme 
activity has a half life of approximately 11 min at 50°C and the truncated, human 
PDE4A h6.1 enzyme activity has a half life of approximately 2 minutes at this 
temperature (200, 245). These assays were, however, performed in the absence of 
substrate and it is possible that the interaction of the enzymes with their substrate 
may serve to stabilise them. To ensure that a 25 min assay accurately represented the 
initial rate of cAMP hydrolysis by HSPDE4D4 I perfoimed time-course experiments 
{Figure 3.17).
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Figure 3.17:Phosphodiesterase activity assays:
The figure shows results from a representative time-course experiment assaying the 
hydrolysis of cAMP by HSPDE4D4. Assays were run under the conditions described 
in materials and methods (section 2.1.11). The experiment was performed three times 
using two separate preparations of PDE.
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3.2.2.5 Percentage recovery ofHSPDE4D4 in bound and unbound fractions
A marked loss of PDE activity occurred over the course of the pull down assays 
which I performed with HSPDE4D4. The total activity recovered in the bound and 
unbound fractions represented only 64% ± 2 of that which I initially added. 
Incomplete recoveiy of the PDE activity, horn pull down assays, was also 
encountered by O’Connell and others in their investigation of the interactions of the 
PDE4A isoform RNPDE4A5 with SH3 domains (161). In the previous study, 
optimisation of the method suggested that the observed loss of PDE activity was due 
to an inhibition of the PDE, caused by it’s immobilisation onto the glutathione 
Sepharose resin through interaction with an SH3 domain. Elution of the PDE-SH3 
domain complexes was found to result in a complete recoveiy of PDE activity.
The observed loss of PDE activity in the pull down assays that I performed with 
HSPDE4D4 was not, however, due to an inhibition of the PDE caused by its 
immobilisation onto the glutathione Sepharose resin. In all of the pull down assays 
that I performed the PDE-SH3 domain complexes were eluted horn the glutathione 
Sepharose resin prior to their assay for PDE enzyme activity.
A possible explanation for the observed loss of PDE enzyme activity is incomplete 
elution of the PDE-SH3 domain complexes from the glutathione Sepharose resin. 
Two lines of evidence, however, argue against this possibility. Firstly, under the 
conditions used in pull down assays, over 90% of the immobilised fusion protein was 
eluted from the glutathione Sepharose resin {Figure 3.15) therefore efficient recovery 
of PDE-fusion protein complexes can be expected. Secondly, control assays using 
either immobilised GST, washed resin alone or where no resin was included, were all 
subject to similar losses of activity. These results suggested that the observed loss of 
activity was neither due to incomplete elution of PDE-fusion protein complexes nor 
to the non-specific adsoiption of PDE onto the glutathione Sepharose resin {Figure 
3.18).
I do not believe the loss of activity was due to the degradation of the PDE by 
proteases present in the COS-7 cell cytosol as samples incubated on ice for the 
duration of the pull down assay were not subject to a similar loss of activity.
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Indeed, the total activity added was calculated from assays of samples so treated. 
Neither do I believe that the loss was due to the action of proteases present in the 
preparations of fusion protein, as similar losses were observed in control assays 
where no fusion protein or resin were included {Figure 3.18). For similar reasons I 
do not believe that other enzymatic reactions (such as dephosphorylation by 
phosphatases) or that the dissociation of regulatory molecules from the PDE can 
account for the observed losses in PDE activity.
I investigated the possibility of stabilising the PDE by inclusion of glycerol or 
protein in the assay mix . Neither the addition of glycerol nor of bovine serum 
albumin (BSA) prevented loss of activity over the course of pull down assays. 
Addition of BSA was, however, found to activate HSPDE4D4. This appeared to be a 
specific effect of BSA as neither casein nor soyabean trypsin inhibitor cause a similar 
activation.
I was not able to eliminate the losses in PDE enzyme activity over the course of pull 
down assays, however, the obsei*ved losses were reproducible and of equal 
magnitude in both control and test samples. To correct for these losses I have 
expressed the data generated in terms of the percentage of recovered activity present 
in the bound fraction (rather than as the percentage of the applied activity recovered 
in the bound fraction).
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I
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I suggest, therefore, that the observed loss of activity may be due to mechanical 
degradation of the PDE, or to it’s non-specific adsorption onto the walls of the 
Eppendorf tubes, or to both. This conclusion is consistent with the obseivation that 
PDE4D immunoreactivity, which co-migrates with HSPDE4D4, can be stripped 
from the walls of washed Eppendorf tubes in which HSPDE4D4 has been incubated 
{Figure 3.19).
To minimise any mechanical damage to the PDE, during the pull down assays, I 
performed all mixing of samples by gentle agitation and not by vortexing. I also 
minimised all centrifugation times and attempted to keep the samples at low 
temperatures whenever possible.
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Figure 3.18: Activity recovered in pull-down assays:
The bar chart shows data from control assays where the sample has been subjected 
to: no manipulations, all manipulations except for centrifugation steps, all 
manipulations: and from pull-down assays where the sample has been challenged 
with: glutathione Sepharose resin alone, immobilised GST and immobilised GST- 
Lyn SH3. Values are means of n separate assays. Error bars show standard error of 
the means.
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Figure 3.19: Stripping adsorbed HSPDE4D4 from  the walls o f  an Eppendorf tube
To investigate the possibility that a significant amount of non-specific adsorption 
onto the walls of the Eppendorf tubes occurs, HSPDE4D4 was incubated, end over 
end for 15 minutes at 4^C. The tube was then washed as in a pull-down assay, 
sample buffer was added and the tube heated at 10(PC for 5 minutes. The figure 
shows an immunoblot for PDE4D of the collected fractions. Lane 1 is unabsorbed 
HSPDE4D4, lane 2 is the pooled washes and lane 3 is sample buffer boiled in the 
washed tube. The immunoreactive bands migrated with apparent molecular weights 
of 108 kDa, calculated by plotting the Rf values of the bands and ofprestained 
molecular weight markers run on the same gel.
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3.2.3 Interaction of HSPDE4D4 with SH3 domains from various proteins
The long PDE4A isoforai, RNPDE4A5 showed specificity for the SH3 domains with 
which it could interact; for example, it appeared to associate well with the SH3 
domains of Src and of the related Src family protein kinases Lyn and Fyn, whereas 
little, if any, association was seen with the SH3 domains from the adapter proteins 
Grb2 and Crk (162). I therefore decided to investigate the ability of PDE4D4 to 
interact with the SH3 domains from a variety of different proteins.
I used recombinant HSPDE4D4, overexpressed in the cytosol of COS-7 cells as the 
source of enzyme for pull down assays with a variety of SH3 and other protein 
binding domains. I monitored both the immunoreactivity and the PDE enzyme 
activity in the bound and unbound firactions to assess the interaction of HSPDE4D4 
with each fusion protein. In all cases the endogenous phosphodiesterase activity of 
the COS-7 cells, determined by assaying an equivalent mass of mock transfected 
COS-7 cell cytosol, was less than 5% of the total PDE enzyme activity in tranfected 
cells.
3.2.3.1 Analysis o f eniyme activity data from pull-down assays
I needed some (semi) quantitative means of determining which of the fusion proteins 
interacted with HSPDE4D4 pull down assays. To do this I expressed PDE enzyme 
activity present in the bound fraction as a percentage of the total activity recovered in 
the assay. I then tested the data sets for significant differences in the mean percentage 
binding of HSPDE4D4 to each of the fiision proteins. The null hypothesis in each 
case was that the percentage binding of HSPDE4D4 to that fusion protein was equal 
to that of HSPDE4D4 to GST.
The two most commonly employed statistical tests for significant difference between 
sample means are Student’s t-Test and Analysis of Variance. When comparing 
differences between the means of more than two samples, Analysis of Variance is the 
prefeiTed test. This is because, when using t-Tests at (for instance) the 5% level of 
significance, there is a 1:20 chance of concluding the population means are different 
when in fact they are equal (a type I error). This probability of error applies to 
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each comparison made so, multiple comparisons greatly increase the risk of making
type I errors. The problem is exaggerated if only those pairs of sample means which 
show the greatest differences are examined, as this selects for type I errors. With
Analysis of Variance however, variation across the entire gi oup of sample means is 
examined and steps can be taken which set the error level for the entire analysis.
An important assumption underlying both t-Tests and Analysis of Variance is that 
each sample represents a normally distributed population, which has a mean of p and 
a standard deviation of a. As the sample sizes of the pull-down assay data were small 
(n<30) I could not appeal to the central limit theorem to support an assumption of 
normality (56). Instead I selected the two largest samples (pull-down assays with 
GST and with GST-Lyn SH3) and used the Chi-squared test to assess each for 
goodness of fit to a normal distribution. The value of Chi-squared in each case 
corresponded to a probability greater than 0.05 (0.626 with GST and 0.853 with 
GST-Lyn SH3). I therefore accepted the hypothesis, that these samples represent 
normality distributed populations, at the 5% level.
Another assumption made in applying Analysis of Variance (and the most commonly 
used form of the t-Test) is that the normally distributed populations all have an equal 
variance. To test this assumption I have performed an F-Test for equality of variance 
on the data sets generated for the binding of HSPDE4D4 enzyme activity to GST and 
to GST-Lyn SH3 (144). The calculated value of F corresponded to a probability of 
much less than 0.5%; that is to say, two samples drawn firom populations with an 
equal variance would be expected to show a difference in variance as large or larger 
than that observed less than 1 time in every 200 trials. I therefore rejected the 
hypothesis that these 2 samples represent normally distributed populations with an 
equal variance.
As Analysis of Variance is a more powerful method of analysis that Students t-Test, I 
also tested two transformations of the data (V(lOO-x) and log (100-x)) in an attempt
to meet the assumptions made in applying Analysis of Varianee. These -transformations, however, also failed to satisfy the assumption of equal variance.
This result means that an important assumption made when applying Analysis of
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As previously stated, performing multiple t-Tests leads to an increased risk of 
making type I enors. This problem can be somewhat alleviated by nominating, in 
advance of performing the experiments, a limited number of comparisons which will 
be made (166). Fortunately, when planning these experiments I had decided to run a 
negative control assay (with GST alone) in every experiment that I performed. I 
therefore felt justified in using t-Tests to compare the binding of HSFDE4D4 to each 
fusion protein with that of HSPDE4D4 to GST alone. To provide additional 
protection against type I errors I have also set the probability level at 1 % (rather than 
5%). This precaution is, however, at the expense of reduced sensitivity (increased 
risk of concluding that two means are equal when they are different, a type II enor).
The association of phosphodiesterase activity with GST fusion proteins representing 
the SH3 domains of Src, Lyn, Fyn, Csk, Abl, Fodrin and with a fusion protein 
representing both the SH2 and SH3 domains of Sre, was found to be significantly 
different from that with GST alone at the 1% level {Figure 3.20).
It is tempting to make comparisons of the relative amounts of binding of HSPDE4D4 
to each of the various fusion proteins and then to compare the rank order of binding 
seen using HSPDE4D4 to that using RNPDE4A5. For these 2 PDE4 isoforms 
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Variance is not safe for these data sets. Analysis of Variance should not, therefore, be 
used to analyse the enzyme activity data generated fi’om these pull down assays.
I have used t-Tests to assess the data for significant differences between sample 
means. In t-Tests the ratio of the observed difference between 2 sample means and 
the estimated standard error of this difference is evaluated. Usually the standard error 
of the difference is estimated from the pooled sample data; estimating the standard 
error of the difference in this way, however, relies on the assumption that the 2 
populations have a common variance. For these data sets such an assumption is not 
safe and the standard error of the difference must be estimated from the individual 
sample variances instead. The sample variances are themselves estimates of the true 
population variances and a drawback of using this method to estimate the standard 
error of the difference is that it reduces the number of degrees of freedom available 
with which to calculate the t-distribution.
have very different proline rich regions within their amino termini {Figure 3.8). 
Doing this would suggest that, although both HSPDE4D4 and RNPDE4A5 are able 
to specifically interact with SH3 domains in vitro, there seem to be differences in the 
rank order of preference for the domains tested. For instance RNPDE4A5 seems to 
be able to interact with the SH3 domain of Lyn kinase much more strongly (9.1±1.7 
times the binding to the SH3 domain of Src kinase) than it can interact with the SH3 
domain of Abl (0.48±0.09 times the binding to the SH3 domain of Src kinase) (162). 
The interaction of HSPDE4D4 with the SH3 domains of Lyn kinase and of Abl are 
not, however, significantly different (p=0.557). One must be circumspect about 
making comparisons such as these, however because of the increased risk of type I 
errors when multiple t-Tests are petformed. Nevertheless the differences seem to be 
quite pronounced and, considering the differences between the putative SH3 domain 
binding sites in these 2 proteins are perhaps not unexpected.
In addition to their interaction with SH3 domains, I have examined the abilities of 
both HSPDE4D4 and RNPDE4A5 to interact with the second WW domain fiom the 
ubiquitin protein ligase Nedd4.1 tested this domain because WW domains are 
another class of modular domains for protein-protein interaction which bind to 
proline rich regions within their target proteins (29). Neither HSPDE4D4 nor 
RNPDE4A5 were able to associate with this WW domain in pull down assays.
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Figure 3.20: Binding o f  HSPDE4D4 enzyme activity to domains fo r  protein-protein interaction
The bar chart shows data from pull-down assays to screen a library of SH3 and other protein 
binding domains for interaction with HSPDE4D4. The data is expressed as percentage of 
recovered activity present in the hound fraction. Values are means of n separate experiments. 
Error bars show standard error of the means. Columns coloured in red are judged to be 
significantly different from GST by t-Tests performed at the 1% level.
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3.2.3.2 Analysis o f immunoblot data from pull down assays
Due to the large volume of data generated by screening against a library of 17 
different fusion proteins and technical problems associated with performing 
quantitative immunoblots I have not performed a quantitative analysis of the 
immunoblot data generated from these pull-down assays. Instead I have used this 
data qualitatively to aid in the interpretation of the enzyme activity data.
With the exception of the fusion protein GST-Csk SH3, in all cases where the 
association of enzyme activity with a fusion protein was found to be significant, an 
immunoreactive band corresponding to HSPDE4D4 was readily detectable in the 
bound fraction from the pull down assay {Figure 3,21).
In pull down assays with fusion proteins representing the SH2 domain of Src, the 
SH3 domain of cortactin and the carboxyl-terminal SH3 domain of Grb, HSPDE4D4 
immunoreactivity was readily detectable in the bound fractions, however, the PDE 
enzyme activity in these fractions was not significantly different from that in the 
bound fractions of pull down assays using GST alone (at the 1% level) {Figure 3.20, 
Figure 3.21).
Where the immunoblot and enzyme activity data agree (in pull down assays with the 
SH3 domains of Src, Lyn, Fyn, Abl, and Fodrin) this is good evidence that 
HSPDE4D4 can interact in vitro with these domains. I therefore consider these 
proteins to be potential in vivo binding partners of HSPDE4D4. In the cases where 
there is a discrepancy between the immunoblot and the enzyme activity data (pull 
down assays with the SH2 domain of Src, the carboxyl terminal SH3 domain of Grb 
and of the SH3 domains of Csk and Cortactin) this is less convincing evidence for an 
interaction and, although these domains may have some affinity for HSPDE4D4, I 
consider these proteins to be poor candidates for in vivo binding partners of 
HSPDE4D4.
3.2.3.3 Effects o f binding to SH3 domains on PDE activity
Discrepancies between the enzyme activity and the immunoblot data from pull-down
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assays performed with RNPDE4A5 and certain of the tested fusion proteins were 
also reported (162). At the time it was suggested that these discrepmcies may have 
been due to changes in the catalytic activity of the PDE caused by it’s interaction 
with the SH3 domains.
To address the possibility that interaction with certain SH3 domains can affect the 
catalytic activity of HSPDE4D4 and RNPDE4A5,1 have assayed the cytosolic 
fraction of transiently transfected COS-7 cells, for PDE activity, in the presence of 
increasing concentrations of GST, GST-Lyn SH3 and GST-Crk SH3.1 have also 
performed a similar experiment using purified, affinity tagged HSPDE4D4, 
expressed in E.coli as the source of phosphodiesterase activity. Neither of the tested 
SH3 domain fusion proteins were found to effect the catalytic activity of either 
RNPDE4A5 or HSPDE4D4. These data do not support the hypothesis that 
interaction with these SH3 domains has an effect on the enzymatic activity of the 
PDE (see also section 3.2.5.4).
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Figure 3.21: Binding o f  HSPDE4D4 to a library o f  domains fo r  protein-protein  
interaction
The figure shows immunoblots o f HSPDE4D4 overexpressed in COS- 7 cells and 
“pulled down ” with the SH3 domains from various proteins expressed as fusion 
proteins with GST and immobilised on glutathione Sepharose. Panel A: lane 1 is 4pg 
cytosol from COS-7 cells overexpressing HSPDE4D4, lanes 2-9 are bound fractions 
from 40pg cytosol challenged with GST, GST—Src SH3, GST-Src SH2, GST-Src 
SH2/3, GST-Nedd4 WW2, GST-GrbC SH3, GST-P53BP2 SH3 and GST-Cortactin 
SH3 respectively. Panel B: lane 1 is 4pg cytosol from COS-7 cells overexpressing 
HSPDE4D4, Lanes 2-11 are bound fractions from 40pg cytosol challenged with 
GST, GST-Lyn SH3, GST-Fyn SH3, GST-Crk SH3, GST-Lck-SH3, GST-Csk SH3, 
GST-AblSH3, GST-GrbN SH3, GST-PI3K SH3 and GST-Fodrin SH3 respectively. 
The weights shown are the apparent molecular weight o f the bands (kDa), calculated 
by plotting the R f values o f the bands and ofprestained molecular weight markers run 
on the same gel.
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3.2.4 Mapping the region of HSPDE4D4 responsible for interaction with SH3 
domains
The putative sites of interaction between both HSPDE4D4 and RNPDE4A5 lie 
within the alternatively spliced, extreme amino-terminal regions of these isoforms 
(see section 3.1). This region of RNPDE4A5 is necessary for interaction with SH3 
domains as other PDE4A isoforms (RNPDE4A8, RNPDE4A1) and an engineered, 
truncated species (Met^ *^  RDI), all of which share identical sequence with 
RNPDE4A5 outside of the amino-teiminal spliced region, do not interact with the 
SH3 domain of Src in pull-down assays (162).
To assess the importance of the amino-terminal domain of HSPDE4D4 for 
interaction with SH3 domains I have assayed the PDE4D isoforms HSPDE4D3 and 
HSPDE4D5 for interaction with the SH3 domains of Src and Lyn kinases.
3.2.4.1 Pull down assays with HSPDE4D3 and HSPDE4D5 implicate the 
alternative spliced amino terminal region o f HSPDE4D4 in the interaction with SH3 
domains
Outside of their, alternatively spliced, amino-terminal regions the isoforms 
HSPDE4D3, HSPDE4D4 and HSPDE4D5 all share an identical primary structure. 
Neither HSPDE4D3 nor HSPDE4D5, however, were able to interact with the SH3 
domains of Src or Lyn kinases in pull down assays {Figure 3.22). This suggests that 
the alternatively spliced, amino-terminal region of HSPDE4D4 is necessary for it’s 
interaction with SH3 domains.
I have also expressed the extreme amino-terminal region of HSPDE4D4 as a fusion 
protein with maltose binding protein (MBP) (see sections 4.2.5.3-4.2.5.4). Using this 
fusion protein I have demonstrated that the alternatively spliced region of 
HSPDE4D4 is sufficient for interaction with the SH3 domain of Lyn {Figure 4.23, 
Figure 4.25). These results are consistent with the hypothesis that the interaction 
between HSPDE4D4 and SH3 domains is mediated by the proline rich motifs present 
in it’s extieme amino-terminal domain.
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Figure 3.22: Recombinant HSPDE4D3 and HSPDE4D5 do not bind to the SH3 
domains o f  Lyn or Src
The figure shows immunoblots o f HSPDE4D3 and HSPDE4D5 overexpressed in 
COS-7 cells and “pulled down ” with SH3 domains expressed as GSTfusion proteins 
and immobilised on glutathione Sepharose resin. Panel A: lane 1 is 20pg cytosol 
from COS-7 cells overexpressing HSPDE4D3, lanes 2-3 are unbound and bound 
fractions from 40pg cytosol challenged with glutathione Sepharose resin alone, 
lanes 4-5 are unbound and bound fractions from 40pg cytosol challenged with GST, 
lanes 6-7 are bound and unbound fractions from 40pg cytosol challenged with GST- 
Lyn SH3, lanes 8-9 are unbound and bound fractions from 40pg cytosol challenged 
with GST-Src SH3. Panel B: lane 1 is lOpg cytosol from COS-7 cells overexpressing 
HSPDE4D5, lanes 2-3 are unbound and bound fractions from 30pg cytosol 
challenged with glutathione Sepharose resin alone, lanes 4-5 are unbound and 
bound fractions from 40pg cytosol challenged with GST, lanes 6-7 are unbound and 
bound fractions from 40pg cytosol challenged with GST-Lyn SH3. The weights 
shown are the apparent molecular weight o f the bands (kDa), calculated by plotting 
the R f values o f the bands and ofprestained molecular weight markers run on the 
same gel.
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3.2.5 Characteristics of the association of HSPDE4D4 with SH3 domains
I decided to characterise the interaction of HSPDE4D4 with SH3 domains. As it was 
not practical to investigate the interactions of HSPDE4D4 with every SH3 domain 
which I had available I selected the SH3 domain of Lyn kinase to serve as an 
example of an SH3 domain from a Src family protein tyrosyl kinase. I chose this 
particular SH3 domain because both HSPDE4D4 and RNPDE4A5 interacted well 
with the GST-Lyn SH3 fusion protein in pull down assays, because both Lyn kinase 
and HSPDE4D4 are present in brain and because the GST-Lyn SH3 frjsion protein 
was expressed well in E.coli, which allowed the straightforward purification of large 
amounts of this protein.
I have performed assays to assess the stability of the interaction with SH3 domains in 
the presence of high ionic strength and of detergent and also the effects of 
interaction on the enzymatic activity of HSPDE4D4.1 have assayed for changes in 
the specific activity, the sensitivity to inhibition by rolipram and the affinity for 
magnesium ions of HSPDE4D4. Changes in one or more of these properties have 
previously been reported following modification (197) (82, 141) or truncation (95, 
108, 187) of the amino-terminal domains of long-fbim splice variants of PDE4A, B 
andD
3.2.5.1 Effect o f salt and detergent on the interaction between HSPDE4D4 and the 
SH3 domain o f Lyn kinase
The interaction between HSPDE4D4 and the SH3 domain of Lyn kinase was not 
disrupted by repeated washing with buffer (50mM Tris/HCl, pH 8.0), salt (0.5M 
NaCl) nor with detergent (0.5% Triton X-100) {Figure 3.23). In this respect the 
interaction of HSPDE4D4 with the SH3 domain of Lyn is similar to those of 
RNPDE4A5 and HSPDE4A4B (162).
3.2.5.2 Effect o f interaction with the SH3 domain o f Lyn on the affinity o f 
HSPDE4D4 for rolipram
Long isoforms of PDE4 can exist in at least 2 conformational states that can be
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distinguished by changes in the enzymes sensitivity to the drug rolipram (see section 
1.3.6). Interaction of the rat PDE4A isoform, RNPDE4A5 with the SH3 domain of 
Lyn kinase did not alter the enzymes sensitivity to inhibition by rolipram (162). In 
contrast to this, interaction of the human homologue of RNPDE4A5, namely 
HSPDE4A4B, with the SH3 domain of Lyn did cause a change in its sensitivity to 
inhibition by rolipram. This difference is linked to a hypeiwariable region of 
sequence called Linker Region 2 (LR2) that lies immediately amino terminal to the 
catalytic region in PDE4. The LR2 of human PDE4A contains a proline and arginine 
rich region of sequence that is not conserved in rat PDE4A (141). This region in 
HSPDE4A4B forms an additional site of interaction with SH3 domains. It is the 
binding of an SH3 domain to the LR2 region of HSPDE4A4B that causes the 
detected change in sensitivity to inhibition by rolipram (141).
I therefore decided to investigate whether the interaction of HSPDE4D4 with the 
SH3 domain of Lyn kinase caused a change in its sensitivity to inhibition by 
rolipram. To do this I performed PDE enzyme activity assays on the bound and the 
unbound fractions from pull down assays between HSPDE4D4 and GST-Lyn SH3 in 
the presence of a range of concentrations of rolipram. I then used the data from these 
assays to calculate the concentration of rolipram that caused a 50% inhibition of the 
PDE enzyme activity (ICgo) in each case. The ICgo values that I obtained in these 
assays were 0.08±0.02|liM and 0. l±0.02pM for the bound and the unbound fractions 
respectively {Figure 3.24). These values are not significantly different from each 
other (t-Test 5% level).
I also performed similar experiments to determine the ICgo value of rolipram for the 
inhibition of HSPDE4D4 in the crude cytosolic fraction of transfected COS-7 cells. 
The IC50 value that I calculated from these assays was 0.16±0.03pM {Figure 3.24).
These results show that the interaction of HSPDE4D4 with the SH3 domain of Lyn 
kinase did not cause a change in the sensitivity of this isoform to inhibition by 
rolipram.
3.2.5.3 Effect o f interaction with the SH3 domain o f Lyn on the enzyme activity o f
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To investigate whether interaction with SH3 domains affected the catalytic activity of 
PDE4 phosphodiesterase I have performed phosphodiesterase activity assays on the 
cytosolic fraction from COS-7 cells expressing either HSPDE4D4 or RNPDB4A5, in 
the presence of GST, GST-Lyn SH3 and of GST-Crk SH3.1 examined the SH3 
domain Crk as well as of Lyn kinase in these assays because there were discrepancies 
between the enzyme activity and immunoblot data generated in pull down assays 
with this SH3 domain for both HSPDE4D4 and RNPDE4A5 (see section 3.2.3.3). 
Assays were performed in the presence of 0, 12.5, 25, 50 and lOOpg fusion protein. 
No change in phosphodiesterase activity was obseiwed in the presence of either 
GST-Lyn SH3 or GST-Crk SH3 compared with that in the presence of GST {Figure 
3.25).
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Figure 3.23: Binding o f  HSPDE4D4 to the SH3 domain o f  Lyn is neither 
disrupted by repeated washing nor by washing in the presence o f  salt or detergent
The figure shows immunoblots, fo r PDE4D, offractions from pull-down assays 
performed with each o f three different washing regimes. Panel A shows fractions 
from an assay where the washing buffer was 50mM Tris/HCl (pH 8.0); panel B 
shows fractions from an assay where the washing buffer was 0.5M NaCl, 50mM 
Tris/HCl (pH 8.0); panel C shows fractions from an assay where the washing buffer 
was 0.5% Triton-XlOO, 50mM Tris/HCl (pH 8.0). In each o f the pannels; lanes 1—3 
are the unbound, the wash and the bound fractions respectively, from a pull-down 
assay with GST; lanes 4-6 are the unbound, the wash and the bound fractions 
respectively, from a pull-down assay with GST-Lyn SH3. The weights shown are the 
apparent molecular weight o f the bands (kDa), calculated by plotting the R f values o f 
the bands and o f prestained molecular weight markers run on the same gel.
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Figure 3.24: Inhibition o f  HSPDE4D4 by rolipram
The graph shows dose-response curves for the inhibition o f PDE activity by rolipram 
in the presence o f IpM  cAMP as substrate. Assays were performed on: the cytosolic 
fraction o f COS-7 cells overexpressing HSPDE4D4 (O)(IC50=0.16±0.05pM), the 
bound fraction from pull down assays with GST-Lyn SH3 (u)(IC50=0.08±0.02pM) 
and the unboundfraction fiom  pull down assays with GST-Lyn SH3 
(0)(IC50=0.10±0.02pM). 0% Inhibition is defined as the measured activity in the 
absence o f inhibitor. The data shown are from I representative experiment o f 3 
performed. Error bars shoM> the standard error o f the mean for each data point in the 
shown experiment.
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Figure 3.25: Effect o f  the SH3 domains o f  Lyn and Crk on the enzyme activity o f  
HSPDE4D4
Phosphodiesterase enzyme activity assays were performed on the cytosolic fraction 
from COS-7 cells expressing HSPDE4D4, in the presence o f GST, GST-Lyn SH3 
and o f GST-Crk SH3. Assays were performed in the presence o f 0, 12.5, 25, 50 and 
100pg fusion protein. The results are expressed as the percentage change in activity 
in the presence o f each concentration o f GST-SH3 domain fusion protein compared 
to the activity in the presence o f the equal amount o f GST. Each point represents the 
mean o f 2 separate experiments with standard errors shown.
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3.2.6 Subcellular distribution of HSPDE4D4
Both endogenously expressed PDE4D4 and recombinant HSPDE4D4 overexpressed 
in COS-7 cells occur partitioned between the soluble and particulate fractions of 
fractionated cells (P120±4%, P240±7%, S2 40±3%) (15, 98). The association of 
HSPDE4D4 with the particulate fraction requires is not disrupted by treatment with 
high ionic strength nor by washing with the non-ionic detergent triton X-100. These 
conditions also fail to dismpt the association of HSPDE4D4 with the SH3 domain of 
Lyn kinase in vitro. I therefore considered the possibility that HSPDE4D4 may be 
localised to some structure present in the particulate fraction of fractionated cells by 
interacting with SH3 domains present in one or more anchoring proteins.
3.2.6,1 Visualisation o f HSPDE4D4 by immunoflourescent staining and confocal 
microscopy
Fractionation of cells by differential centrifugation is a low resolution method of 
determining the subcellular distribution of a protein. To gain more insight into the 
distribution of HSPDE4D4 immunoflourescent staining and confocal microscopy 
was used to visualise recombinant HSPDE4D4 overexpressed in COS-7 cells.
The confocal pictures show that, in this system, HSPDE4D4 is not randomly 
distributed within the cell; rather it appears to be enriched in the perinuclear region 
and within processes at the plasma membrane {Figure 3.26). This distribution is 
similar to that seen for HSPDE4A4B overexpressed in transiently transfected COS-7 
cells (93). Unlike HSPDE4A4B, however, HSPDE4D4 did not appear to be enriched 
in the ruffles at the plasma membrane. I also noted that cells which had been 
transfected with HSPDE4D4 were extremely resistant to trypsin (used to dislodge the 
cells from the culture flask when preparing slides). Together with the enrichment of 
HSPDE4D4 within processes at the plasma membrane this may indicate that this 
isoform may have some involvement in regulating focal adhesions.
The antibody used for the immunoflourescent staining was raised against the 
carboxly-terminal region of PDE4D and can therefore detect all of the known splice 
variants of PDB4D. To show that the staining reflected the distribution of the
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transfected HSPDE4D4 and not of endogenous PDE4D isofonns, mock transfected 
COS-7 cells were also fixed and stained using this antibody. No staining was 
observed in the mock transfected cells under these conditions. Indeed the low
abundance of endogenous PDEs makes the immunoflourescent detection of these 
proteins very difficult in untransfected systems.
There must be concerns about the reliability of using an overexpressing, heterologous 
system to examine the distribution of a protein. To date, however, no cell lines that 
express endogenous PDE4D4 have been identified. Furthermore, a number of 
technical considerations suggest that the immunoflourescent detection of this isoform 
in untransfected cells is likely to be extremely technically challenging. These include 
(a) the low expression of endogenous PDEs in all cells thus far examined, (b) the 
only antibodies currently available that been successfully used for 
immunnfluorescent microscopy are not splice variant specific. I therefore feel that, as 
there is agreement between the fractionation data from transfected and natively 
expressed PDE4D4, these confocal pictures may give some useful information 
regarding the distribution of PDE4D4 in cells.
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The figure shows confocal microscope pictures o f a COS-7 cell transiently transfected 
to overexpress HSPDE4D4. Cells were fixed on coverslips 3 days after transfection 
then stained for immunofluorescence imaging. The primary antibody used was the 
monoclonal antibody 61D10E (Icos) which detects the common region ofPDE4D 
isoforms. The staining was detected using an anti-mouse IgG conjugated to the 
fluorescent dye Rhodamine. The photographs were taken using a X60 lens. Panel A 
shows a transmission/phase contrast photograph o f a typical cell overexpressing 
HSPDE4D4. Panel B shows a fluorescence image (taken by laser scanning confocal 
microscopy) o f a 0.2p section through the centre o f the same cell.
The immunostaning and confocal imaging o f these cells was performed by Dr E. 
Huston.
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3.2.7 Interaction of HSPDE4D4 with SH3 domains in vivo
The pull down assays that I have performed with recombinant HSPDE4D4 
overexpressed in COS-7 cells provide good evidence that this isoform can 
specifically interact with certain SH3 domains in vitro. I have also performed pull 
down assays, overlay assays and enzyme linked immunosorbent assays (ELISA) 
using a purified MBP fusion protein of HSPDE4D4 and GST-SH3 domain fusion 
proteins (see section 4.2.5). These assays support the hypothesis that HSPDE4D4 can 
directly bind to SH3 domains in vitro. In an attempt to address the question of 
whether HSPDE4D4 interacts with SH3 domains in vivo I have used the sti’ategy of 
immunoprecipitating either HSPDE4D4 or candidate interacting proteins fi’om cell 
lysates and probing the immunoprecipitated material for interacting proteins.
3.2.7.1 Immunoprécipitation ofHSPDE4D4 and Lyn from transfected COS-7 cells
I performed immunoprécipitations fiom RIPA buffer extracts of COS-7 cells which 
had been transiently transfected to overexpress HSPDE4D4.1 used RIPA buffer 
extracts because this buffer is able to solublise many membrane bound and 
cytoskeletal proteins which remain insoluble in less vigorous buffers (250). I 
immunoprecipitated from unsynchronised cells growing in the presence of 10% PCS, 
fiom cells which had been driven into stage Gq of the cell cycle by overnight serum 
starvation; from cells which had been serum starved overnight and then stimulated 
with IBMX (lOOpM) for 25 minutes and forskolin (lOpM) for 10 minutes prior to 
being harvested; from cells which had been serum starved overnight and then 
stimulated with epidermal growth factor (EGF) (50ng/ml) for 10 minutes prior to 
being harvested and from cells which had been serum starved overnight then
Stimulated with IBMX (lOOpM) for 25 minutes, forskolin (lOjaM) and epidermal 
growth factor (EGF) (50ng/ml) for 10 minutes prior to being harvested.
The stimulations with IBMX and forskolin were to raise intracellular cAMP and so 
activate pathways downstream of activated PKA. The stimulations with EGF were to 
activate tyrosine kinase signalling pathways downstream of the activated EGF 
receptor. I stimulated the cells in these ways to increase the chance of detecting
-4
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regulated protein-protein interactions which may only occur in certain activation 
states of the cell.
I decided to probe for in vitro interactions between HSPDE4D4 and Lyn kinase. I 
chose this protein as a potential binding partner of HSPDE4D4 because it is 
endogenously expressed in COS-7 cells and because I have shown that the fusion 
protein GST-Lyn SH3 interacts strongly with recombinant HSPDE4D4 in vitro.
I performed immunoprécipitations using antisera raised against Lyn kinase and also 
using antisera raised against the conserved, carboxyl-terminal region of PDE4D 
isoforms. I also performed negative control immunoprécipitations using pre-immune 
semm or with antisera raised against GST where no pre-immune serum was 
available. The immunoprecipitated material was separated by SDS-PAGE and 
immunoblotted using either a monoclonal antibody directed against PDE4D (anti- 
Lyn kinase immunoprécipitations) {Figure 3.27) or antisera raised against Lyn kinase 
(anti-PDE4D immunoprécipitations) {Figure 3.28). To ensure that the both Lyn 
kinase and HSPDE4D4 were immunoprecipitated by their respective antisera 
selected immunoblots were stripped and re-probed with antisera raised against the 
immunoprecipitated species.
Under these conditions HSPDE4D4 and Lyn kinase did not appear to co- 
immunoprecipitate. I have considered the possibility that an in vivo interaction 
between these proteins may exist but that it is disrupted by the detergents present in 
RIPA buffer. To address this possibility I performed pull down assays using samples 
prepared in RIPA buffer. In these assays recombinant HSPDE4D4 prepared in RIPA 
buffer was able to bind to the SH3 domain of Lyn kinase. This demonstrated that the 
interaction between HSPDE4D4 and the SH3 domain of Lyn kinase is not disrupted 
under the conditions similar to those in the immunoprécipitations.
That Lyn kinase and HSPDE4D4 did not appear to co-immunoprecipitate under any 
of the conditions that I tested tested suggests that these proteins do not interact in the 
RIPA buffer soluble fraction of transfected COS-7 cells. Although my 
immunoprécipitation data does not support an in vivo interaction between Lyn kinase 
and HSPDE4D4 1 can not exclude the possibility that HSPDE4D4 might be able 
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to interact with a pool of Lyn that may be present in the RIPA buffer insoluble 
fraction of the COS-7 cells.
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Figure 3.27: Immunoprécipitation o f endogenous Lyn from COS-7 cells
The figure shows immunoblots o f HSPDE4D4 in the RIPA buffer extracts, unbound 
fractions and bound fractions o f immunoprécipitations using antisera raised against 
Lyn, Panel A: lane 1 is 20pg extract from unstimulated COS-7 cells, overexpressing 
HSPDE4D4; lanes 2 and 4 are the unbound and bound fractions respectively o f an 
immunoprécipitation from unstimulated cells, using antisera raised against Lyn; lane 
3 is empty. Panel B: lane 1 is 20pg extract from unstimulated COS-7 cells, 
overexpressing HSPDE4D4; lanes 2 and 4 are the unbound and bound fractions 
respectively o f an immunoprécipitation from unstimulated, using antisera raised 
against GST; lanes 5 and 10 are 20pg extract from COS-7 cells, overexpressing 
HSPDE4D4 and stimulated with IBMX (100pM) and forskolin (lOpM); lanes 6 and 
8are the unbound and bound fractions respectively o f an immunoprécipitation from  
cells stimulated with IBMX and forskolin, using antisera raised against Lyn; lanes 
11 and 13 are the unbound and bound fractions respectively o f an 
immunoprécipitation from cells stimulated with IBMX and forskolin, using antisera 
raised against GST; lanes 4, 7, 9 and 12 are empty. Panel C: lanes 1 and 6 are 20pg  
extract from COS-7 cells, overexpressing HSPDE4D4 and stimidated with EGF 
(50ng/ml); lanes 2 and 4 are the unbound and bound fractions respectively o f an 
immunoprécipitation from cells stimulated with EGF, using antisera raised against 
Lyn; lanes 7 and 9 are the unbound and bound fractions respectively o f an 
immunoprécipitation from cells stimulated with EGF, using antisera raised against 
GST; lane 11 is 20pg extract from COS-7 cells, overexpressing HSPDE4D4 and 
stimulated with EGF, IBMX and forskolin; lanes 12 and 14 are the unbound and 
bound fractions respectively o f immunoprécipitations from cells stimulated with 
EGF, IBMX and forskolin, using antisera raised against Lyn; lanes 3, 5, 8, 10 and 13 
are empty. Panel D: lane 1 is 20pg extract from COS-7 cells, overexpressing 
HSPDE4D4 and stimulated with EGF, IBMX and forskolin; lanes 2 and 4 are the 
unbound and bound fractions respectively o f immunoprécipitations from cells 
stimulated with EGF, IBMX and forskolin, using antisera raised against GST; lane 4 
is empty.
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Figure 3,28: Immunoprécipitation o f  recombinant HSPDE4D4 from  COS-7 cells
The figure shows immunoblots o f Lyn in the RIPA buffer extracts, unbound fractions and 
bound fractions o f immunoprécipitations using antisera raised against PDE4D Panel A: 
lanes 1 and 6  are 20pg extract from unstimulated COS-7 cells, overexpressing HSPDE4D4; 
lanes 2 and 4 are the unbound and bound fractions respectively o f an immunoprécipitation 
from unstimulated cells, using antisera raised against PDE4D; lanes 7 and 9 are the 
unbound and bound fractions respectively o f an immunoprécipitation from unstimulated 
cells, using pre-immune antisera; lane I I  is 20pg extract from COS-7 cells overexpressing 
HSPDE4D4 and stimulated with IBMX (100pM) and forskolin (lOpM); lanes 12 and 14 are 
the unbound and bound fractions respectively o f an immunoprécipitation from cells 
stimulated with IBMX and forskolin, using antisera raised against PDE4D; lanes 3, 5, 8 , 10 
and 13 are empty. Panel B: lane 1 is 20pg extract from COS-7 cells overexpressing 
HSPDE4D4 and stimulated with IBMX and forskolin; lanes 2 and 4 are the unbound and 
bound fractions respectively o f an immunoprécipitation from cells stimulated with IBMX and 
forskolin, using pre-immune antisera; lanes 6  and 10 are 20pg extract from COS-7 cells 
overexpressing HSPDE4D4 and stimulated with EGF (50ng/ml); lanes 7 and 8  are the 
unbound and bound fractions respectively o f an immunoprécipitation from cells stimulated 
with EGF, using antisera raised against PDE4D; lanes 11 and 13 are the unbound and 
bound fractions respectively o f an immunoprécipitation from cells stimulated with EGF, 
using pre-immune antisera; lanes 3, 5, 9 and 12 are empty. Panel C: lanes 1 and 6  are 20pg 
extract from COS-7 cells, overexpressing HSPDE4D4 and stimulated with EGF, IBMX and 
forskolin; lanes 2 and 4 are the unbound and boundfractions respectively o f an 
immunoprécipitation from cells stimulated with EGF, IBMX and forskolin, using antisrea 
raised against PDE4D; lanes 7 and 9 are the unbound and bound fractions respectively o f an 
immunoprécipitation from cells stimulated with EGF, IBMX and forskolin, using pre-immune 
antisrea; lanes 3, 5 and 8  are empty.
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3.2.7.2 Immunoprécipitation ofHSPDE4D4 from metabolically labelled cells
I decided that attempting to co-immnnoprecipitate HSPDE4D4 with eveiy candidate 
interacting protein would be an inefficient strategy for identifying in vivo binding 
partners. Instead I performed immunoprécipitations from RIPA buffer extracts of 
methionine labelled COS-1 cells which I had transiently transfected to overexpress 
HSPDE4D4.1 performed immunoprécipitations from unsynchronised cells growing 
in the presence of 10% PCS, using an antisera raised against the conserved carboxyl- 
terminus of PDE4D isoforms. I also performed immunoprécipitations using pre- 
immune serum as a negative control.
I separated the immunoprecipitated material by SDS-PAGE, transferred it onto a 
nitrocellulose membrane and imaged the precipitated proteins using a Fujix Bas 1000 :phosphoimager {Figure 3.29 panel A). In a parallel experiment I performed similar
.. ;immunoprécipitations from RIPA buffer extracts of unlabeled cells, separated the 
immunoprecipitated material by SDS-PAGE and then immunoblotted using a 
monoclonal antibody directed against the carboxyl-terminal region of PDE4D 
isoforms {Figure 3.8 panel B).
Two strong bands, corresponding to frill length HSPDE4D4 and an amino-terminally 
truncated form of this enzyme were immunoprecipitated by the antisera raised 
against PDE4D. These bands were not precipitated by the pre-immune serum. Under 
these conditions, however, no bands which did not co-migrate with a PDE4D 
immunoreactive species and were not also precipitated by the pre-immune semm t
were clearly detected in the material immunoprecipitated by the anti PDE4D antisera.
It could be that HSPDE4D4 does interact with other proteins in COS-7 cells but that 
these proteins were poorly labelled by the regime employed and therefore below the 
limit of detection. I labelled the cells for 2 hours with a mixture of ^ S^ methionine 
and cystine before preparing the lysates. Alternatively it could be that proteins that 
interact with HSPDE4D4 are insoluble in RIPA buffer or that the interaction is 
dismpted by the RIPA buffer. Nevertheless a number of immunoprécipitation 
experiments have failed to provide evidence of an in vivo interaction between
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HSPDE4D4 and other proteins present in the RIPA buffer soluble fraction of COS-7 
cells.
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Figure 3.29: Immunoprécipitation o f  recombinant HSPDE4D4 from  metabolically 
labeled COS-1 cells
Panel A is a phosphoimage o f an immunoprécipitation from RIPA buffer extracts o f  
metabolically labeled COS-1 cells, using antisera raised against PDE4D: lane 1 is 
lOpg extract from metabolically labeled COS-1 cells overexpressing HSPDE4D4; 
lanes 2 and 3 are the unbound and bound fractions respectively o f an 
immunoprécipitation using antisera raised against PDE4D; lanes 4 and 5 are the 
unbound and bound fractions respectively o f an immunoprécipitation using pre- 
immne antisera. Panel B is an immunoblot for PDE4D o f an immunoprécipitation 
from RIPA buffer extracts o f metabolically labeled COS-1 cells, using antisera 
raised against PDE4D: lane 1 is lOpg extract from metabolically labeled COS-1 
cells overexpressing HSPDE4D4; lanes 2 and 3 are the unbound and bound 
fractions respectively o f an immunoprécipitation using antisera raised against 
PDE4D; lanes 4 and 5 are the unbound and bound fractions respectively o f an 
immunoprécipitation using pre-immne antisera.
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3.3 Conclusions
In this chapter I have shown that both endogenous RNPDE4D4, expressed in rat 
brain, and HSPDE4D4 expressed in COS-7 cells can interact in vitro with SH3 
domains. As is the case with the rat PDE4A isofbrm RNPDE4A5, HSPDE4D4 
shows a distinct specificity for the SH3 domains with which it can interact. These 
PDE4A and PDE4D isoforms appear, however, to have a different rank order of 
preference for interaction with the various SH3 domains that have been tested. 
Neither the PDE4A (RNPDE4A5) nor the PDE4D (HSPDE4D4) isoforms were able 
to interact with a WW domain fi'om the ubiquitin protein ligase Nedd4. WW domains 
are another class of modular domain for protein-protein interaction that binds to 
proline rich ligands. This supports the hypothesis that the interactions between these 
PDEs and SH3 domains are specific.
No changes in enzyme activity or in sensitivity to inhibition by the antidepressant 
drug rolipram were detected following the interaction of HSPDE4D4 with the SH3 
domain of Lyn kinase. Therefore the interaction between HSPDE4D4 and the SH3 
domain of Lyn kinase does not appeal' to cause any conformational change in the 
protein that is transmitted to the catalytic region.
The alternatively spliced, amino-terminal region of HSPDE4D4 is both necessary 
and sufficient for interaction with the SH3 domain of Lyn kinase. Furthermore, the 
purified fiision proteins GST-Lyn SH3 and MBP-HSPDE4D4 can interact with each 
other, as assessed by pull down assays, overlay assays and ELISA assays (see section 
4.2.5). This shows that HSPDE4D4 can bind directly to the SH3 domain of Lyn 
kinase in vitro.
The amino-terminal region of HSPDE4D4 is extraordinarily rich in proline residues. 
A putative site of interaction between HSPDE4D4 and SH3 domains lies within the 
region of sequence between Pro^  ^and Pro®® of HSPDE4D4 {Figure 3.8). This region 
in HSPDE4D4 rich in proline residues (66.7%). The amino terminal region of 
HSPDE4D4, however, is not rich in arginine residues. Conserved arginine residues 
that flank the PxxP core motif are an important feature of the optimal sequences
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for binding to several SH3 domains (1). I nevertheless feel that the proline rich 
region in the amino terminus of HSPDE4D4 is a good candidate for the site of 
interaction between HSPDE4D4 and certain SH3 domains. This is because the long 
stretches of proline residues present between Pro^ ® and Pro®® of HSPDE4D4 might be 
expected to foim a left handed PPII helical structure such as is required for 
interaction with SH3 domains. There are also 3 (basic) histidine residues in this 
region, one of which could be considered to be a conservative substitution for 
arginine in the motif RxxPxxP that has been suggested to be optimal for binding to 
several SH3 domains (see section 1.4.1). Indeed, in one study the SH3 domain of 
Lyn kinase selected 2 peptide sequences with histidine in this position from a biased 
phage display library (176).
To directly assess the importance of the proline rich region of sequence between 
Pro^  ^and Pro®® of HSPDB4D4 in the interaction of this protein with SH3 domains it 
would be useful to construct deletion mutants and truncations of HSPDE4D4. The 
amino terminal region of the cDNA encoding HSPDE4D4 is, however, a poor 
template for PCR reactions and several attempts to constmct such mutants have 
failed.
Using the strategy of immunoprecipitating HSPDE4D4 from transfected COS-7 cells 
I have not been able to demonstrate an in vivo interaction between HSPDE4D4 and 
another protein. Whether HSPDE4D4 does engage in physiologically relevant 
interactions with the SH3 domains of proteins in vivo remains to be deteimined.
Little is known about the tissue distribution and function of HSPDE4D4. It is 
therefore difficult to make predictions about which proteins are likely to interact with 
it in vivo. In the absence of a strong candidate interacting protein I feel that 
attempting to co-immunoprecipitate HSPDE4D4 with every protein containing an 
SH3 domain with which it can interact in vitro is likely to be an inefficient approach 
to identifying bona-fide HSPDÉ4D4 binding proteins. As more information 
regarding the tissue distribution and function of HSPDE4D4 becomes available this, 
together with the results of in vitro screens such as this one, will strengthen certain of 
the candidate interacting proteins. At that stage strategies such as immunoflourescent
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confocal microscopy to examine the subcellular distributions of HSPDE4D4 and 
potential interacting proteins, co-immunoprecipitation experiments from cells that 
endogenously express PDE4D4 and the use of antisense to down-regulate the 
expression of putative targeting proteins could be attempted to show which if any of 
these potential interactions are physiologically relevant.
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4, Purification of affinity tagged PDE4 expressed in E.coli
4.1 Strategies for the purification of PDE4
All cells and tissues thus far examined contain multiple forms of phosphodiesterase 
(PDE). A major obstacle to the study of the cyclic AMP (cAMP) specific, PDE4 
enzymes has been obtaining homogeneous preparations of the various forms of this 
PDE to address questions such as, initially, whether the high affinity, cAMP specific 
PDE activity in a cell represented a number of different enzymes or a single core 
enzyme associated with variable regulatory subunits (147, 151, 157). Latterly, 
homogeneous preparations of PDE4 have been required to address questions 
regarding the regulation, function and pharmacology of individual PDE4 enzymes. 
Examples of such questions include the regulation by phosphorylation, the structure 
of and the binding of other molecules (such as rolipram) to PDE4s (179, 197).
4.1.1 Endogenous PDE4
Initial attempts to purify endogenous cAMP specific PDE isofoims from tissues and 
primary cell cultures met with only limited success. Apparently pure preparations of 
high affinity, cAMP specific PDEs were obtained by a number of groups, however, 
the purifications employed were laborious and frequently resulted in low yields. A 
major source of concern was that, despite having obtained an apparently purified 
enzyme, the fold purification and specific activity of these preparations were often 
low {Table 4.4.1). Coupled with the observation that cAMP specific PDE activities 
were extremely heat labile and sensitive to proteolysis, this led to speculation that the 
purified enzymes may have been denatured or proteolysed during their preparation 
(59, 147, 151).
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Table 4,4.1: Purification o f endogenous PDE4
The table summarises the published data on the purification o f endogenous PDE4 
isoforms.
References are: (1) (232) (2) (59) (3) (136) (4) (135) (5) (173) (6 ) (172) (7) (151) (8 ) 
(147) (9) (164) (10) (157) (11) (6 8 ) (12) (40)
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The availability of cDNAs encoding mammalian PDE4 isoforms allowed researchers 
in the field to postpone the problem of PDE purification. Each newly cloned isoform 
was characterised in transiently transfected cell lines, such as COS-7, selected 
because of their low levels of endogenous PDE activity and the high efficiencies with 
which they could be transfected. In these systems enzyme purification was not 
necessary because of the relatively high levels of expression achieved. Indeed it was 
not uncommon for greater than 95% of the detectable PDE activity, present in the 
crude extracts of COS-7 cells transiently transfected with a recombinant PDE4 
isoform, under the control of a strong promoter, to represent the transfected PDE (15, 
16, 92, 93, 140, 194). The availability of sequence information fi'om the cloned PDEs 
has also allowed for the generation of subtype specific antisera, which has greatly 
facilitated the study of PDE4 isofoims in crude extracts fiom both transfected and 
untransfected cells.
4.1.2.1 Purification o f recombinant PDE4
The available immunological and molecular biological tools have allowed a great 
deal of progress to be made from the study of impure preparations of PDE4. There 
are, however, still a number of questions which will be very difficult to answer 
without first obtaining pure preparations of individual PDE4 isoforms. These include 
the 3 dimensional structure (108, 207), the interactions with inhibitors such as 
rolipram (179), the interactions with other proteins (252) and the acute
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4.1.2 Recombinant PDE4
In contrast to the slow progress made, during the 1980s, by groups using a 
biochemical approach to isolate and characterise cAMP specific PDE isoforms, a 
molecular biological approach to this problem proved extremely successful. In 1989 
Ron Davis et al used a cDNA firom the Drosophila dunce"^ gene to clone 
RNPDE4A1A (RDI), the first mammalian PDE4 cDNA to be reported. Additional 
PDE4 cDNAs were rapidly cloned and it soon became apparent that mammalian 
PDE4 activity represented a large enzyme family comprising the products of 4 
related but distinct genes, with additional diversity arising fi'om alternate mRNA 
splicing (38, 226)(see section 1.3).
regulation by post-translational modification (for example by phosphorylation), of 
PDE4 isoforms (197).
Recent attempts to purify recombinant isoforms of PDE4, expressed in heterologous 
cells, have been more successful than the earlier purifications of native PDE4 {Table 
4.4.2), This is probably due to the high levels of expression achieved in these 
artificial systems; although factors such as recent improvements in chromatography 
systems, improved protease inhibitors and the relative speed with which lysates can 
be prepared fi’om cell lines compared to tissues may also be significant. It should be 
noted, however, that problems such as the low specific activity of many preparations 
persist and that there is no cleai’ consensus on the criteria for acceptance of a 
preparation as being the correctly folded enzyme in a physiologically relevant state 
(186).
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Table 4.4.2: Purijîcation of recombinant PDE4
The table summarises the published data on the purification o f recombinant PDE4 
isoforms expressed in heterologous cells.
References are: (1) (245) (2) (241) (3) (169) (4) (178) (5) (179) (6 ) (108)
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4.2 Results and Discussion
I needed purified preparations of RNPDE4A5, HSPDE4A4 and HSPDE4D4 to 
investigate further the interactions of these isoforms with SH3 domains, I therefore 
decided to express the full length enzyme and truncated forms of each of these 
isoforms as fusion proteins. These were variously formed with maltose binding 
protein (MBP), with glutathione-S-transferase (GST) or as a 6 histidine motif (His^) 
tagged species and expressed in E.coli. Such fusion proteins were then purified by 
affinity chromatography. This strategy has been successfully employed for the 
purification and characterisation of RNPDE4D1 (a short isoform of rat PDE4D)
(108).
I chose to use E.coli, rather than mammalian cells, yeast or baculovirus, as the 
expression system because I was already experienced in the expression and 
purification of GST fusion proteins fïom E.coli (see sections 3.2.2. l-3.2.2,2). I was 
also attracted by the high levels of expression and the relative ease of purification 
which can often be achieved using this system.
4.2.1 Purification of affinity tagged FDE4A
I initially attempted to express the alternatively spliced, unique amino terminal 
regions from both the rat and the human PDE4A isoforms, RNPDE4A5 and 
HSPDE4A4B, as fusion proteins with carboxyl terminal, 6 histidine, zinc binding 
motifs (RNPDE4A5 His  ^and HSPDE4A4B Hisg). These fusion proteins had been 
constructed in the plasmid pET5 (Promega) which carries a T7 promoter. I therefore 
chose to use the E.coli strain BL21(DE) as the host cells for expression of these 
fusion proteins. This strain contains the gene for T7 RNA polymerase under the 
control of a lac UV5 promoter. This promoter is inducible by isopropyl-p-D- 
thiogalactopyranoside (IPTG). Addition of IPTG to a growing culture of BL21(DE3)
E.coli can be expected to induce T7 RNA polymerase expression and this will, in 
turn, transcribe any genes controlled by a T7 promoter.
Induction of BL21(DE3) E.coli transformed with either one of these plasmids
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(pET5R6 for RNPDE4A5 His^and pET5H46 for HSPDE4A4B HisJ did not, 
however, result in the appearance of any novel bands in the induced lane when the 
crude lysates from induced and uninduced E.coli were visualised on a Coomassie 
stained gel.
To serve as a positive control for the induction conditions I transformed BL21(DE3) 
E.coli with the plasmid pETl ITnC. This encodes the human heart muscle protein 
troponin C (TnC) under the control of an identical promoter to that which controlled 
the expression of the PDE HiSg fiision proteins in the plasmids pET5R6 and 
pET5H46.1 induced cultures of tliese bacteria under identical conditions to those 
under which the bacteria transformed with the PDE His  ^fiision proteins in pET5 
were induced. In these bacteria a novel band corresponding to TnC (predicted Mw 
18.4kDa) was clearly visible in the induced lane when lysates of the bacteria were 
visualised on a Coomassie stained gel {Figure 4.30).
There are several possible explanations for having failed to achieve detectable levels 
of expression of the PDE isoforms from these plasmids. These included: secondary 
structures which may have been present in the DNA or the RNA and which may have 
hindered the progress of the polymerase or the transcriptase; also any toxic effects of 
the expressed protein which may have lead to plasmid instability (due to the cultures 
becoming overgrown by cells which had shed the plasmid). I tried a number of 
different conditions including varying the temperature (30-37'’C), the concentration 
of IPTG (0.1-0.4mM) and the duration of the induction (0-14h) in an attempt to 
optimise the expression of these fusion proteins. I also addressed the possibility of 
plasmid instability by resuspending the bacteria in fresh growth medium containing 
ampicillin (lOOp/pl) just prior to induction of the cultures. This last strategy was 
intended to counteract the effects of p-lactamase, which degrades ampicillin and is 
secreted into the medium by ampicillin resistant bacteria, and so to maintain 
selection for a longer period of time during the induction. I was, however, unable to 
identify conditions under which detectable expression of the PDE Hisg fusion 
proteins was achieved {Figure 4.31).
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Figure 4.30: Expression o f  PDE4A in E.coli
The figure shows a Coomassie stained gel o f lysates from BL21(DE3) E.coli 
transformed with plasmids encoding TnC (pETl 1 TnC), the amino terminal o f  
RNPDE4A5 (residues 1-76) as a fusion with a 6  His motif (pET5R6) and the amino 
terminal ofHSPDE4A4B (residues 1—71) as a fusion with a 6  His motif (pET5H46). 
Lanes 1-2 are lysates prepared from growing cultures o f cells transformed with 
pETllTnC  before and 14h after induction with O.ljuMIPTG respectively, lanes 3-4 
are lysates prepared from cells transformed with pET5R6 before and 14h after 
induction with O.lpM IPTG respectively, lanes 5—6 are lysates prepared from cells 
transformed with pET5H46 before and 14h after induction with O.ljuM IPTG 
respectively, lane 7 is molecular weight markers (Sigma low range coloured 
markers). The arrows indicate the Mw (kDa) o f each marker.
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Figure 4.31: Time courses fo r  the expression ofproteins from  p E T  plasmids in 
BL21(DE3) K c o li
The figure shows Coomassie stained gels o f lysates prepared from BL21(DE3)
E.coli, transformed with pET plasmids at various time points following induction 
with 0.1 pM  IPTG. Panel A: lanes 1—5 are lysates prepared from cells transformed 
with the plasmidpET5R6 at 0, 3, 4, 5 and 6 h following induction respectively; lane 6  
is molecular weight markers (Sigma low range coloured markers). Panel B: lanes 1- 
5 are lysates prepared from cells transformed with the plasmid pETllTnC  at 0, 3, 4 , 
5 and 6 h following induction respectively; lane 6  is molecular weight markers 
(Sigma low range coloured markers). The arrows indicate the Mw (kDa) o f each 
marker.
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4,2. I J  Purification o f RNPDE4A5 as a fusion protein with MBP
I considered the possibility that the difficulties I had experienced in expressing 
RNPDE4A5 His  ^and HSPDE4A4B Hisg may have been related, in some way, to the 
sequences at the extreme 5’ ends of their open reading frames. I speculated that 
perhaps the bacterial transcription or translation machinery was inefficient at 
initiating either transcription or translation from these sequences and that a fusion 
protein, carrying an amino terminal tag which was known to be expressed well in 
bacteria, may be expressed at higher levels.
I decided to attempt to express and purify RNPDE4A5 as a fusion protein with MBP 
(MBP-RNPDE4A5). I chose to use MBP, rather than GST, as the affinity tag 
because I was intending to use this fusion protein in binding assays with GST SH3 
domain fusion proteins. I therefore considered that it would be essential for the PDE 
to carry a different affinity tag to that carried by the SH3 domains unless I 
proteolytically removed the GST moiety from at least 1 of these species. This 
consideration was especially important because PDEs are extremely sensitive to 
proteolysis and I anticipated problems in proteolytically cleaving the affinity tag 
from the purified RNPDE4A5 fusion protein (see section 4.1.1 and references 
therein).
I chose to use the JM109 strain of E.coli for these experiments because they were, at 
the time, the most commonly used E.coli strain in the laboratory and had proved to 
be a good, general purpose strain suitable for the production of fusion proteins. I 
transformed these cells either with the plasmid pMALR6, which encodes full length 
RNPDE4A5 as a fusion protein with MBP or with the plasmid pMAL-c2, which 
encodes MBP alone. I then induced cultures of these cells to express the recombinant 
proteins. I used a lower temperature, 30“C rather than the more commonly used 37“C, 
for the induction and expression of these proteins because this can often reduce the 
proportion of the recombinant protein which becomes incorporated into inclusion 
bodies.
Induction of JM109 E.coli, transformed with the plasmid pMALRô, resulted in an 
approximately 10 fold increase in the PDE activity present in the soluble
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fraction of the bacterial lysates over that observed in the lysates of bacteria 
transformed with pMAL-c2. A faint novel band which migrated with an apparent 
Mw of 176kDa on sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was visible in the induced lane when lysates of these bacteria were 
visualised on a Coomassie stained gel {Figure 4.32). The predicted Mw for the 
MBP-RNPDE4A5 fusion protein, based on the primary stricture, was 137.1kDa.
The difference between the observed and predicted Mw for this fusion protein can be 
accounted for by the anomalous migration of PDE4 isoforms on SDS-PAGE (15, 16, 
93, 108, 201).
I attempted to purify the MBP-RNPDE4A5 fusion protein by a single step of affinity 
chromatography using amylose resin (New England Biolabs). This resulted in a 27 
fold purification of the PDE enzyme activity. I also monitored the purification by 
SDS-PAGE. This revealed that the eluted material, containing the PDE activity, did 
not migrate as a single band but gave a ladder of bands on Coomassie stained gels 
{Figure 4.32).
To investigate whether the multiple bands observed on Coomassie stained gels 
represented truncated forms of the MBP-RNPDE4A5 fusion protein, I performed 
immunoblots using a polyclonal antisera raised against the carboxyl terminal region 
of rat PDE4A and also using a polyclonal antisera raised against MBP. Both of these 
antisera detected an immunoreactive species which co-migrated with the 176kDa 
band observed on Coomassie stained gels. This species therefore contained epitopes 
that would be predicted to occur at the amino terminal, detected by the anti MBP 
antisera, and also at the carboxyl terminal, detected by the anti rat PDE4A antisera, 
of the MBP-RNPDE4A5 fusion protein. The 176kDa species was therefore, in all 
probability, full length MBP-RNPDE4A5 as it contained epitopes located within 
both the amino and the carboxyl termini of this fusion protein {Figure 4.33).
In addition to the 176kDa band, the anti MBP antisera, but not the anti-rat PDE4A 
antisera, detected 4 faster migrating bands. These bands most likely represented 
carboxyl terminal truncations of the MBP-RNPDE4A5 fusion protein, generated by 
proteolysis or premature termination, which retained their MBP tags and hence co-
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purified with the full length fusion protein.
The PDE enzyme assay, and the immunological data supported the hypothesis that I 
had succeeded in expressing an active, full length, affinity-tagged PDE in the soluble 
fraction of JM109 E.coli. The affinity purification of this protein using amylose 
resin, however, resulted in a preparation with a low (1.84±0.1 Inmol/min/mg at IpM 
cAMP) specific activity, compared to that estimated for RNPDE4A5 expressed in the 
cytosolic fraction of COS-7 cells and which ran as a ladder of bands on Coomassie 
stained gels. Several of the bands detected by Coomassie staining were neither 
detected by an anti-MBP antisera nor by an anti-rat PDE4A antisera. The identity of 
these contaminating bands is therefore unclear. As I did not have ready access to a 
liquid chromatography system with which to further purify this fusion protein I 
decided not to pursue the purification and analysis of this fusion protein.
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Figure 4,32: Purification o f  RNPDE4A5 as a fusion protein with M BP
The figure shows a Coomassie stained gel offractions collected during the 
purification o f MBP-RNPDE4A5. Lane 1 is whole cell lysate from uninduced 
bacteria transformed with the plasmid pMALR6 ; lane 2 is whole cell lysate from 
bacteria transformed with the plasmidpMALR6 , which had been induced to express 
MBP—RNPDE4A5 by the addition o f 0.3mM IPTG; lane 3 is the soluble fraction o f 
the lysate from bacteria expressing MBP-RNPDE4A5 after incubation with amylose 
resin; lanes 4-6 are the material washed from the amylose resin by the 2^^ and 
3^^ washing steps respectively; lane 7 is the material eluted from the amylose resin; 
lane 8  is molecular weight markers (Bio-Rad broad range prestained SDS-PAGE 
standards). The arrows indicate the Mw (kDa) o f each marker.
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Figure 4,33: Immunological analysis o f  purified M BP and M BP-RNPDE4A5
The figure shows immunoblots ofpurified MBP and MBP-RNPDE4A5. Panel A 
shows an immunoblot that was probed with an antisera raised against the carboxyl 
terminal region o f rat PDE4A: lane 1 is 0.02pg purified MBP-RNPDE4A5, lane 2 is 
0.01 pg purified MBP. Panel B shows an immunoblot that was probed with an 
antisera raised against MBP: lane 1 is 0.02pgpurified MBP-RNPDE4A5, lane 2 is 
empty, lane 3 is 0.01 pg purified MBP. The arrows indicate the positions o f MBP- 
RNPDE4A5 and o f MBP; these proteins ran with apparant molecular weights o f 170 
kDa and 50 kDa respectively, calculated by plotting the R f values o f  markers run on 
the same gel.
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4.2.2 Purification of affinity tagged PDE4D
At the same time that I was attempting to express and purify MBP-RNPDE4A5,1 
also attempted to express and purify MBP fusion proteins of full length HSPDE4D4 
(MBP-HSPDE4D4) and also of the unique, amino terminal region (amino acids 1- 
166) of HSPDE4D4 (MBP-NT HSPDE4D4).
4,2.2.1 Purification offull length HSPDE4D4 as a fusion protein with MBP
I transformed JM109 E.coli with the plasmid pMALP39, which encodes full length 
HSPDE4D4 as a fusion protein with MBP. I then induced cultures of these cells to 
express the recombinant proteins. As with the MBP-RNPDE4A5 fusion protein I 
performed these inductions at 30°C in an attempt to maximise the proportion of the 
fusion protein expressed in the soluble fraction of the cells. This resulted in an 
approximately 75-fold increase in the PDE activity present in the soluble fraction of 
the bacterial lysates over that observed in the lysates of bacteria transformed with 
pMAL-c2. A faint novel band which migrated with an apparent Mw of 161±15.5kDa 
on SDS-PAGE was visible in the induced lane when lysates of the bacteria were 
visualised on a Coomassie stained gel {Figure 4.34). The predicted Mw for the MBP- 
RNPDE4D4 fusion protein, based on its primary structure, was 135kDa. As with the 
MB P-RNPDE4A5 fusion protein, the difference between predicted and the observed 
Mw for this fusion protein is likely to be accounted for by the anomalous migration 
of PDE4 isoforms on SDS-PAGE.
I attempted to purify MBP-HSPDE4D4 by a single step of affinity chromatography 
using amylose resin. This resulted in a 67-fold purification of the PDE enzyme 
activity. I also monitored the purification on Coomassie stained SDS-PAGE gels. 
The major band present in the eluted material migrated with an apparent Mw of 
152±3.3kDa and represented >98% of the stained protein, as assessed by scanning 
the gel and counting pixels {Figure 4.34).
To investigate further the identity of the major protein band present in the eluted 
material I performed immunoblots using a monoclonal antibody against the carboxyl 
terminal region of HSPDE4D4 and also using a polyclonal antisera against
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MBP. Both antibodies detected an immunoreactive band which co-migrated with the 
152kDa band visible on the Coomassie stained gels {Figure 435). The 
immunological data therefore supported the hypothesis that the major protein species 
present in the eluted material was full length MBP-HSPDE4D4.
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Figure 4.34 Purification o f  HSPDE4D4 as a fusion protein with M BP
The figure shows a Coomassie stained gel offractions collected during the 
purification o f MBP—HSPDE4D4. Lane 1 is whole cell lysate from uninduced 
bacteria transformed with the plasmid pMALP39; lane 2 is whole cell lysate from 
bacteria transformed with the plasmidpMALP39, which had been induced to express 
MBP—HSPDE4D4 by the addition o f 0.3mM IPTG; lane 3 is the soluble fraction o f  
the lysate from bacteria expressing MBP-HSPDE4D4 after incubation with amylose 
resin; lanes 4-6 are the material washed from the amylose resin by the 2^^ and 
3 rd -^ashing steps respectively; lane 7 is the material eluted from the amylose resin; 
lane 8  is molecular weight markers (Bio-Rad broad range prestained SDS-PAGE 
standards). The arrows indicate the Mw (kDa) o f each marker.
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Figure 4.35 Immunological analysis o f  purified M BP-HSPDE4D4
The figure shows immunoblots ofpurified MBP-HSPDE4D4. Panel A 
shows an immunoblot that was probed with a monoclonal antibody 
against the carboxyl terminal region o f human PDE4D: lane 1 is 0.2pg  
purified MBP—HSPDE4D4, lane 2 is 4pg cytosol from COS- 7 cells 
overexpressing HSPDE4D4. Panel B shows an immunoblot that was 
probed with an antisera raised against MBP: lane 1 is 0.2pg purified 
MBP—HSPDE4D4. The arrows indicate the positions o f MBP— 
HSPDE4D4 and o f recombinant HSPDE4D4 expressed in the cytosol o f 
transfected COS-7 cells; these proteins ran with apparant molecular 
weights o f 153 kDa and 112 kDa respectively, calculated by plotting the 
R f values o f markers run on the same gel.
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4.2.2.2 Purification o f the amino terminal region o f HSPDE4D4 as a fusion protein
with MBP
The amino terminal region of HSPDE4D4 does not include the catalytic site of the 
enzyme. I was therefore unable to use PDE enzyme activity assays to monitor the 
purification of this fusion protein. I monitored the expression and purification of this 
fusion protein on Coomassie stained SDS-PAGE gels and also by immunoblotting 
using a polyclonal antisera against MBP.
Induction of JM109 E.coli transformed with the plasmid pMALP39Al, which 
encodes amino acids 1-166 of HSPDE4D4 as a fusion protein with MBP, did not 
result in the appearance of a detectable novel band in the induced lane of Coomassie 
stained SDS-PAGE gels. I did, however, detect a novel band of anti-MBP 
immunoreactive material in the induced lane of immunoblots. I therefore proceeded 
with the purification of this fusion protein, by affinity chromatography, using 
amylose resin.
By starting with 800ml of induced culture, which is double the amount used for the 
purification of MBP-HSPDE4D4,1 was able to purify 108pg of material. The major 
band present in this eluted material migrated with an apparent Mw of 84±2.1kDa and 
represented >90% of the stained protein (assessed by scanning the gel and counting 
pixels) {Figure 4.36). The predicted Mw of this fusion protein was 61.8kDa.
Immunoblots of the eluted material, performed using a polyclonal antisera against 
MBP, revealed a major immunoreactive band which co-migrated with the 84kDa 
band visible on the Coomassie stained gel {Figure 4.36). The immunological data 
therefore supported the hypothesis that the major protein species present in the eluted 
material was a fusion protein between MBP and the amino terminal region of 
HSPDE4D4 (MBP-NT HSPDE4D4).
The difference between the predicted and the observed Mw of MBP-NT HSPDE4D4 
was unexpected. The anomalous migration of PDE4 isoforms on SDS-PAGE has 
previously been attributed to the concentration of acidic amino acids in the carboxyl 
terminal regions of these proteins (15, 16, 93, 108, 201). Indeed, carboxyl
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terminal deletion mutants of RNPDE4D1, expressed in and purified firom E.coli, 
migrated as predicted on SDS-PAGE whereas full length and amino terminal 
deletion mutants of RNPDE4D1 migiated with apparent Mw 6-9kDa higher than 
predicted from their primary structures (108). The situation is, however, complicated 
by the finding that the human homologue of this splice variant, HSPDE4D1, 
expressed in COS-7 cells, does not exhibit anomalous migration on SDS-PAGE 
(15). In the same study, however, the splice variant HSPDE4D2, the primary 
sequence of which is entirely contained within that of HSPDE4D1, did show 
anomalous migration on SDS-PAGE. This suggests that the expression system used 
and also sequence contained in the amino terminal of certain isoforms, may also 
affect their migiation on SDS-PAGE.
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Figure 4.36: Purification o ffu ll length and truncated HSPDE4D4 as fusion  
proteins with M BP
The figure shows SDS-PAGE analysis o f both full length and truncated HSPDE4D4 
as fusion proteins with MBP. Panel A shows a Coomassie stained gel ofpurified 
MBP fusion proteins: lane 1 is 4pg purified MBP, lane 2 is 3pg purified MBP- 
HSPDE4D4, lane 3 is 3pg purified MBP—NT HSPDE4D4, lane 4 is molecular 
weight markers (Bio-Rad broad range prestained SDS-PAGE standards). The 
arrows indicate the Mw (kDa) o f each marker. Panel B shows an immunoblot that 
was probed with an antisera raised against MBP: lane 1 is O.OSpg purified MBP-NT 
HSPDE4D4, lane 2 is 0.1 pg purified MBP-HSPDE4D4, lane 3 is 0.1 pg purified 
MBP. The arrows indicate the apparent Mw (kDa) each major band, calculated by 
plotting the R f values o f  markers run on the same gel.
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4.2.3 Characterisation of MBP-HSPDE4D4
On the basis of the immunological and the enzyme activity data, I had succeeded in 
purifying an intact fusion protein, between HSPDE4D4 and MBP, to apparent 
homogeneity. I next investigated whether this preparation accurately represented the 
correctly folded enzyme.
To address this question I performed a limited kinetic characterisation of MBP- 
HSPDE4D4.1 decided to compare the kinetics of cAMP hydrolysis and the 
sensitivity to inhibition by rolipram, a specific inhibitor of PDE4, of MBP- 
HSPDE4D4 to those of recombinant HSPDE4D4, expressed in the cytosolic fraction 
of COS-7 cells. I also decided to compare the data to those obtained for other 
isoforms of PDE4D which have been expressed in E.coli (Table 4.4.3) and also in 
COS-7 cells (15). It would have been desirable to compare the properties of this 
fusion protein to those of endogenously expressed HSPDE4D4, unfortunately it was 
not possible to do so because this isoform has not yet been isolated from 
untransfected cells or from tissue (15).
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Table 4.4.3: Expression of recombinant PDE4 isoforms in E.coli
The table summarises the published data on the properties o f recombinant PDE4 
isoforms expressed in E.coli.
References are: (1) (227) (2) (99) (3) (5) (4) (108) (5) (252)
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4.2.3.1 Kinetics o f cAMP hydrolysis by MBP—HSPDE4D4
I performed a kinetic analysis of the purified MBP-HSPDE4D4 fusion protein and 
also of recombinant HSPDE4D4 expressed in the cytosolic fraction of transfected 
COS-7 cells. For these studies I assayed the initial velocity of cAMP hydrolysis at 16 
different substrate concentrations over the range 0. l-SOpM cAMP. I calculated 
values for the constants Km and Vmax for each preparation, by fitting the kinetic 
data to the hyperbolic form of the Michaelis-Menten equation using the computer 
program Hyper 1.02a (see section 2.2.12). This analysis revealed that both 
preparations of HSPDE4D4 catalysed the hydrolysis of cAMP with kinetics that 
conformed well to the Michaelis-Menten model and that were linear when plotted in 
accordance with several linear transformations of the Michaelis-Menten equation 
{Figure 4.37, Figure 4.38).
The purified MBP-HSPDE4D4 catalysed the hydrolysis of cAMP with a Km of 
13.0±2.5pM and a Vmax of 1495±305pmol/min/mg. The unpurified preparation of 
recombinant HSPDE4D4, expressed in the cytosolic fraction of COS-7 cells, had a 
Km of 1.4±0.3pM for the hydrolysis of cAMP; the Vmax of this preparation was 
5.3±0.6pmol/min/mg cytosolic protein. It should be noted tliat the Vmax of 
unpurified preparations of PDEs, expressed in COS-7 cells, can vary widely between 
preparations because of differences in the individual ti ansfection efficiencies (see 
section 4.2.3.2).
The Km for cAMP of the purified MBP-HSPDE4D4 was approximately an order of 
magnitude higher than that of HSPDE4D4, expressed in the cytosolic fraction of 
COS-7 cells. The value for the Km that I obtained for HSPDE4D4, expressed in 
COS-7 cells, was in close agreement with that previously deteimined for this isoform 
in the same expression background and also with the published values of Km of 
several other isoforms of PDE4D, expressed in E.coli {Table 4.4.3) (15, 99, 108).
This suggested that the cAMP binding site of the MBP-HSPDE4D4 fiision protein 
may have been in a different conformation to that of the other preparations of this 
enzyme.
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It seemed likely that the difference in Km between these 2 preparations of 
HSPDE4D4 was due either to the MBP moiety of the fusion protein or to the 
prokaryotic expression system used for the production of MBP-HSPDE4D4. Other 
splice variants of PDE4D exhibit similar values of Km to themselves and to each 
other when expressed in either prokaryotic or eukaryotic cells. This shows that the 
observed difference in the Km of MBP-HSPDE4D4 is not simply because the cAMP 
binding site of PDE4D enzymes can not fold correctly in prokaryotes.
I
I
All of the active splice variants and tiimcations of PDE4D (with the exception of 
MBP-HSPDE4D4), thus far examined, exhibit a similar Km for cAMP. Indeed an 
MBP fusion protein of HSPDE4D5, expressed in and purified from E.coli, has a Km 
for cAMP of 5.1±0.4pM (252). This suggests that regions of the protein outside of 
the cAMP binding site have little influence on the conformation of this region. I 
therefore speculated that the MBP moiety of MBP-HSPDE4D4 may contact or 
sterically hinder the cAMP binding site of this protein. There were, however, various 
other possibilities that may have accounted for the difference in Km between 
HSPDE4D4 expressed in the cytosol of transfected COS-7 cells and MBP- 
HSPDE4D4 purified from E.coli. For example it could have been that the unique, 
alternatively spliced region of PDE4D4 does affect the binding of cAMP to this 
splice variant and that either some post-translational modification or the folding of 
this region is different when the protein is expressed in prokaryotic cells, as a fusion 
protein with MBP, compared to when the non-fusion protein is expressed in 
eukaryotic cells (see section 4.2.4.2).
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Figure 4.37: Kinetic analysis o f  purified MBP-HSPDE4D4
The figure shows graphical solutions o f the Michaelis-Menten equation for the 
hydrolysis o f cAMP by purified MBP-HSPDE4D4. The initial velocity o f catalysis 
was assayed at 16 different substrate concentrations and the data were fitted to the 
Michaelis-Menten equation using the computer program Hyper 1.02a. Panel A 
shows a graph for the hyperbolic form o f the equation. Panels B, C and D show a 
Hanes plot, a Lineweaver-Burkplot and an Eadie-Hofstee plot respectively. The 
graphs shown represent the results from a typical experiment o f 3 performed. These 
analyses revealed a Km for cAMP o f 13±2.5pM and a Vmax o f 
1495.5±304.7pmol/min/mg.
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Figure 4.38: Kinetic analysis o f  unpurified HSPDE4D4 expressed in the cytosoluc 
fraction o f  COS-7 cells
The figure shows graphical solutions o f the Michaelis-Menten equation for the 
hydrolysis o f cAMP by unpurified HSPDE4D4 expressed in the cytosolic fraction o f 
COS-7 cells. The initial velocity o f catalysis was assayed at 11 different substrate 
concentrations and the data were fitted to the Michaelis-Menten equation using the 
computer program Hyper 1.02 a. Panel A shows a graph for the hyperbolic form o f 
the equation. Panels B, C and D show a Hanes plot, a Lineweaver-Burk plot and an 
Eadie-Hofstee plot respectively. The graphs shown represent the results from a 
typical experiment o f 3 performed. These analyses revealed a Km for cAMP o f 
1.4±0.3pMand a Vmax o f 5.3^0.6pmol/min/mg.
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4.23.2 Estimated turnover number o f HSPDE4D4 for cAMP hydrolysis
The value of Vmax which I have calculated for HSPDE4D4, expressed in the 
cytosolic fraction of COS-7 cells, is expressed in terms of activity per pg cytosolic
protein. This value is therefore highly dependent upon the level of expression of 
HSPDE4D4 achieved in each particular transfection and should not be compared 
directly to the Vmax of other preparations.
To compare the activity of HSPDE4D4, expressed in the cytosolic fraction of COS-7 
cells, with that of purified MBP-HSPDE4D41 have performed quantitative 
immunoblots to estimate the molar concentration of HSPDE4D4 in the cytosolic 
fraction of a particular preparation of transfected COS-7 cells. I then calculated the 
turnover number (moles of cAMP hydr olysed per minute per mole of PDE) for 
cAMP hydrolysis by both MBP-HSPDE4D4 and of HSPDE4D4 expressed in the 
cytosolic fraction of COS-7 cells. This analysis revealed that MBP-HSPDE4D4 
catalysed the hydrolysis of cAMP with a turnover number of 201±41. Im in’ and that 
HSPDE4D4, expressed in the cytosolic fraction of COS-7 cells, catalysed the 
hydrolysis of cAMP with a turnover number of 106±11.9min‘ {Figure 4.39). These 
values are not significantly different at the 5% level (Student’s t-Test).
4-196M.B.Beard Purification o f affinity tagged PDE4 expressed in E. coli
'•was
• A#**#
. * 0 U f .  a m # 6 m w . » i K .  >
7 8 9 10 11 12 13 14
B
HSPDE4D4 Overexpressed in COS-7 Cells
300
20 40 60
Cell Protein (pg)
Purified MBP-HSPDE4D4
i> 100
0 .5  1 1 .5
Protein (pg)
Figure 4.39: Determination o f  the concentration o f  HSPDE4D4 present in the 
cytosolic fraction o f  transfected COS-7 cells
The figure shows a quantitative immunoblot, for PDE4D, o f the cytosolic fraction 
from COS-7 cells transiently transfected to overexpress HSPDE4D4 and o f purified 
MBP-HSPDE4D4. Panel A shows a phosphoimage o f the immunoblot. The primary 
antibody was the monoclonal antibody 61D10E (Icos) which binds to the carboxyl 
terminal region o f PDE4D isoforms. The secondary antibody was an conjugated 
anti-mouse IgG. Lanes 1-6 are 2, 4, 8 , 16, 32 and 64pg cytosol from COS-7 cells 
overexpressing HSPDE4D4 respectively; lane 7 is empty; lanes 8-14 are 0.02, 0.04, 
0.08, 0.16, 0.32, 0.64 and 1.28pgpurifiedMBP-HSPDE4D4 respectively. Panels B 
and C are graphs showing band intensity against material loaded for HSPDE4D4 
expressed in the cytosol o f COS- 7 cells and for purified MBP-HSPDE4D4 
respectively. The data shown represent the results from a typical experiment o f 3 
performed.
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4.23.3 Inhibition o f MBP-HSPDE4D4 by rolipram
The antidepressant drug rolipram in a potent and specific inhibitor of PDE4 enzyme 
activity (87). Indeed, sensitivity to inhibition by rolipram is often used as a 
diagnostic test for the presence of PDE4.1 therefore compared the sensitivity of 
purified MBP-HSPDE4D4 to inhibition by rolipram to that of HSPDE4D4 expressed 
in the cytosolic fi*action of COS-7 cells.
I calculated values for the IC50 of rolipram on the hydrolysis of cAMP by both 
purified MBP-HSPDE4D4 and by unpurified HSPDE4D4, expressed in the cytosolic 
jfraction of COS-7 cells. For these studies I assayed the initial rate of cAMP 
hydrolysis, at a substrate concentr ation close to the Km of the preparation, in the 
presence of 8 different concentrations of rolipram over the range O-lOOpM. I used 
the computer program Kelidagraph to fit these data to an equation describing a 
sigmoidal curve and so derived the concentration of rolipram required to inhibit 50% 
of the activity observed in the absence of rolipram (see section 2.2.12) {Figure 3.17 
and Figure 4.40). This analysis revealed that rolipram inhibited MBP-HSPDE4D4 
with an IC50 of 0.215±0.001pM (at lOpM cAMP) and that it inliibited unpurified 
HSPDE4D4, expressed in the cytosolic fraction of COS-7 cells, with an IC50 of 
0.160±0,Q29pM (at IpM cAMP). These values are not significantly different at the 
5% level (Student’s t-Test).
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Figure 4.40: Inhibition of MBP-HSPDE4D4 by rolipram
The figure shows a dose-response curve for the inhibition o f MBP-HSPDE4D4 PDE 
enzyme activity by rolipram in the presence o f lOpM cAMP as substrate. The initial 
rate o f cAMP hydrolysis was measured in the presence o f 8  different concentrations 
o f rolipram over the range 0-100pM  and the percent inhibition was calculated with 
0% inhibition defined as the measured activity in the absence o f inhibitor. The data 
shown are from a representative experiment o f 3 performed.
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4.2.4 Proteolytic cleavage of MBP-HSPDE4D4
3
I have investigated the possibility of proteolytically cleaving the MBP moiety of 
MBP-HSPDE4D4 to produce a purified nonfusion protein of HSPDE4D4. The 
possibility of obtaining this species was especially attractive because of the 
difference in Km between the fiision protein and other preparations HSPDE4D (see 
section 4.2.3.1). If this difference was due to the MBP moiety contacting or sterically 
inhibiting the cAMP binding site of the PDE then cleavage of the fiision protein, to 
remove the MBP moiety, might be expected to yield a nonfusion HSPDE4D4 with a 
Km similar to that of other preparations of PDE4D enzymes.
4.2.4.1 Cleavage o f MBP-HSPDE4D4 with factor Xa
The plasmid pMALN (derived fi*om pMAL-c2), which was used to construct the 
MBP-HSPDE4D4 fusion protein, encodes a recognition site for the protease factor 
Xa that lies just upsti eam of the of the polylinker region of the plasmid. Cleavage of 
the MBP-HSPDE4D4 fusion protein with factor Xa at this site would be expected to 
produce firee MBP (predicted Mw 42.5kDa) and an untagged HSPDE4D4 with only 
10 vector derived amino acids at its extreme amino terminal (predicted Mw 92.3kDa, 
based on primary structure). Following cleavage a further step of affinity 
chromatography using amylose resin would be expected to remove the released MBP 
moiety and leave the purified, untagged HSPDE4D4 in the flow through.
I used the computer program Gene Jockey to search the peptide sequence of 
HSPDE4D4 for motifs which matched the recognition site of factor Xa (lie-Glu-Gly- 
Arg). This search revealed no good matches for the recognition sequence. I therefore 
proceeded to treat 30pg MBP-HSPDE4D4 with Ipg factor Xa at 4°C. I monitored 
the digestion by taking 5pg aliquots at 0, 0.2, 0.5, 1.0, 3.8 and 20h time points, for 
analysis by SDS-PAGE. I also performed a mock digestion in which I incubated Spg 
MBP-HSPDE4D4 in the absence of factor Xa for 2Oh at 4“C.
The digestion of MBP-HSPDE4D4 by factor Xa resulted in the gradual appearance 
of 5 major bands with apparent Mw 105.0±0.6, 91.7±0.7, 76.7±0.7, 65.7±0.3 and 
47.0±0.0kDa on Coomassie stained gels. The appearance of these bands
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coincided with the disappearance of the 152kDa MBP-HSPDE4D4 {Figure 4.41).
I investigated the identity of the novel bands produced by digesting MBP- 
HSPDE4D4 with factor Xa for 20 hours at 4°C by immunoblotting using a 
monoclonal antibody against the carboxyl terminal of HSPDE4D4 and also using a 
polyclonal antisera raised against MBP. The anti-MBP antisera detected a single 
major band of immunoreactivity in each lane. In the uncut and mock digested (no 
protease) lanes this immunoreactivity had an apparent Mw of 153kDa and co­
migrated with the major protein bands visible in these lanes on Coomassie stained 
gels. In the factor Xa digested lane this immunoreactivity had an apparent Mw of 
45kDa and co-migrated with the smallest of the 5 major novel bands visible on 
Coomassie stained gels {Figure 4.42).
The anti-PDE4D4 monoclonal antibody detected 2 major immunoreactive species 
with apparent Mw 223kDa and 156kDa in the uncut and in the mock digested lanes. 
The 223kDa species was not present in every experiment which I performed and 
probably represented an aggregated form of MBP-HSPDE4D4, which was not 
disrupted by the Laemmli’s buffer. The 156kDa species was most likely monomeric 
MBP-HSPDE4D4. The factor Xa digested lane contained 3 major and several 
additional minor immunoreactive bands of anti PDE4D immubnoreactivity. The 3 
major bands had apparent Mw of 106, 92 and 78kDa. These bands co-migrated with 
the 3 of the protein bands detected on Coomassie stained gels {Figure 4.42).
An important question was whether one of the bands, produced by the digestion of 
MBP-HSPDE4D4, represented full length, untagged HSPDE4D4. To address this 
question I ran factor Xa digested MBP-HSPDE4D4 on the same gel as HSPDE4D4, 
expressed in the cytosolic fraction of COS-7 cells, and detected these species by 
immunoblotting using an anti-PDE4D monoclonal antibody. This showed that the 
largest of the major immunoreactive bands, present in the digested lane, migrated 
with an apparent Mw which was lower than that of HSPDE4D4, expressed in the 
cytosolic fraction of COS-7 cells. A minor immunoreactive band which was present 
in the factor Xa digested lane but not in the mock digested lane, however, co­
migrated with HSPDE4D4 expressed in the cytosolic fraction of COS-7 cells {Figure
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4.43). This result suggested that full length, untagged HSPDE4D4 is not one of the 
major species produced by the digestion of MBP-HSPDE4D4 with factor Xa.
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Figure 4.41: Clevage o f  M BP-HSPDE4D4 with factor Xa
The figure shows a Coomassie stained gel o f the fractions collected during the 
proteolytic digestion ofpurified MBP-HSPDE4D4 by factor Xa. I  incubated 30pg 
MBP-HSPDE4D4 with 1 pg factor Xa at 4°C and collected 5pg aliquots at various 
time points. Lanes 1-6 are the aliquots collected at 0, 0.2, 0.5, 1.0, 3.8 and 20h time 
points respectively; lane 7 is a 20h mock digestion (no protease) o f MBP- 
HSPDE4D4; lane 8  is molecular weight markers (Bio-Rad broad range prestained 
SDS-PAGE standards). The arrows indicate the Mw (kDa) o f each marker.
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Figure 4.42: Immunological analysis o f  the digestion o f  M BP-HSPDE4D4 by 
factor Xa
The figure shows immunoblots offractions collected during the proteolytic digestion 
ofpurified MBP-HSPDE4D4 by factor Xa. Panel A shows an immunoblot that was 
probed with a monoclonal antibody against the carboxyl terminal region o f PDE4D: 
lanes 1  and 2  are 0.5pg aliquots collected at 0  and 2 0 h time points respectively; lane 
3 is a 0.5pg aliquot from a 20h mock digestion (no protease) o f MBP-HSPDE4D4. 
Panel B shows the same immunoblot which has been stripped and re-probed using a 
polyclonal antisera raised against MB P. The arrows indicate the apparent Mw (kDa) 
o f each major band, calculated by plotting the R f values o f markers run on the same 
gel.
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Figure 4.43: Comparison o f  the factor Xa digested M BP-HSPDE4D4 with 
HSPDE4D4 expressed in the cytosolic fraction o f  COS-7 cells
The figure shows an immunoblot ofpurified MBP-HSPDE4D4, which had been 
digested by factor Xa, and o f HSPDE4D4 expressed in the cytosolic fraction o f COS- 
7 cells. Lane 1 is 1.6pg cytosol from COS-7 cells transiently transfected to 
overexpress HSPDE4D4, lane 2 is empty and lane 3 is a 0.1 pg aliquot collected 
after a 20h digestion o f MBP-HSPDE4D4 by factor Xa at 4°C. Each arrow 
indicates the apparent Mw (kDa) o f that band, calculated by plotting the R f values o f  
markers run on the same gel.
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4.2.4.2 Cleavage o f MBP—HSPDE4D4 with TEVprotease
A potential solution to the problem presented by the apparent cleavage of 
HSPDE4D4 itself by factor Xa was provided by the tobacco mosaic virus protease 
(TEV) (Gibco BRL). The TEV protease is considered to exhibit higher fidelity than 
factor Xa (53, 237). I therefore investigated the possibility of engineering a sequence 
encoding a TEV protease recognition site (Glu-Asn-Leu-Tyr-Phe-Gln-Gly) into the 
plasmid pMALP39.
As a preliminary experiment I incubated 20pg MBP-HSPDE4D4 with 10 units TEV 
protease at 4°C. I monitored the digestion by taking 5pg aliquots at 0, 2.5, 4.5 and 
12.5 hour time points for analysis by SDS-PAGE. Even at the longest time point 
examined there was no detectable digestion of MBP-HSPDE4D4 by TEV protease 
{Figure 4.44). This result suggested that the strategy of inserting a TEV protease site 
into the MBP-HSPDE4D4 fusion protein might provide a convenient way of 
removing the MBP tag from this fusion protein without also degrading the 
HDPDE4D4 moiety.
The plasmid pMALP39 had been constructed by cloning the open reading frame of 
HSPDE4D4 into the Not I site of the plasmid pMALN, which is itself a derivative of 
pMALc2 containing a Not I site inserted into the polylinker region of the plasmid.
All 3 of these plasmids contain an Xmn I site which lies at the extreme 5’ end of their 
polylinker regions. I was therefore able to engineer a TEV protease recognition site 
into pMALP39 immediately downstream of the factor Xa site already present.
I digested the plasmid pMALP39 with Xmn I to produce a blunt ended, linear 
molecule. I then used Taq polymerase to ligate adenosine overhangs onto the 3’ end 
of each DNA strand. Next Ï annealed the complementary, synthetic oligonucleotides 
MB4 and MB5 together. This produced a double stranded DNA molecule which 
encoded a TEV protease recognition site and which had thymidine overhangs at the 
3’ end of each DNA strand {Figure 4.45). I ligated the annealed oligonucleotides 
with the linear, Taq polymerase treated pMALP39.1 then transformed competent 
XLl blue E.coli with the products of the ligation reaction and used PCR to screen for 
colonies which contained the recombinant plasmid (pMALP39xEv)- Finally I
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sequenced across the inserted region to confirm the presence and the orientation of 
the inserted sequence.
I transformed JM109 E.coli with the plasmid pMALP39xEv then expressed and 
purified the fusion protein as before (see section 4.2.2.1). I then proceeded to treat 
25pg MBP-HSPDE4D4tev with 20 units TEV protease at 4®C. I monitored the 
digestion by taking 5pg aliquots at 0, 1, 2,4,5 and 20h time points, for analysis by 
SDS-PAGE. I also performed a mock digestion in which I incubated 5pg MBP- 
HSPDE4D4jev in the absence of TEV protease for 2Oh at 4°C. This digestion 
resulted in the gradual appearance of 2 bands with apparent Mw 120.7kDa and 
47.8kDa on Coomassie stained gels. The appearance of these bands coincided with 
the gradual disappearance of the 152kDa MBP-HSPDE4D4xev {Figure 4.46). The 
upper of these novel bands was probably untagged HSPDE4D4 with 11 vector 
derived amino acids remaining at it’s amino terminus (Gly-Ile-Ser-Glu-Phe-Cys-Gly- 
Arg-Arg-Pro-Arg-). The lower novel band was probably the MBP moiety of the 
fusion protein.
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Figure 4.44: Treatment o f  M BP-HSPDE4D4 with TEV protease
The figure shows a Coomassie stained gel o f the fractions collected during the 
treatment ofpurified MBP-HSPDE4D4 with TEV protease. I  incubated 20pg  
MBP—HSPDE4D4 with 10 units TEV protease at 4°C and collected 5pg aliquots 
at various time points. Lanes 2-6 are the aliquots collected at 0, 2.5, 4.5 and 
12.5h time points respectively: lane 7 is a 12.5h mock digestion (no protease) o f 
MBP—HSPDE4D4: lanes 1 and 8  are molecular weight markers (Bio-Rad broad 
range prestained SDS-PAGE standards). The arrows indicate the Mw (kDa) o f 
each marker.
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Figure 4.45: Insertion o f  a TEVprotease site into MBP-HSPDE4D4
The figure shows the cloning strategy which I  used to engineer a TEVprotease site 
into MBP-HSPDE4D4. Panel A shows the preparation o f the plasmid pMALP39, 
which encodes MBP—HSPDE4D4, for ligation with a DNA fragment encoding a TEV 
protease site. First I  digested pMALP39 with the restriction endonuclease Xmn I. 
This cut the plasmid at a single site which lay within the open reading frame o f 
MBP-HSPDE4D4 and was immediately downstream o f the last codon o f the factor 
Xa site. This produced a linear, blunt ended, double stranded molecule. I  treated the 
digested plasmid with Taq polymerase to ligate adenosine overhangs onto the 3 ' end 
o f each DNA strand. This was both to increase the efficiency o f the subsequent 
ligation reaction and also to prevent the plasmid from re-circularising without 
incorporating the DNA fragment. Panel B shows the DNA fragment encoding a TEV 
protease site which I  ligated into pMALP39.1 generated this molecule by annealing 
2 complementary oligonucleotides (MB4 and MB5). These oligonucleotides had been 
designed to produce a double stranded molecule with thymidine overhangs at the 3 ’ 
end o f each DNA strand. The oligonucleotide MB 5 was phosphorylated at i t’s 5 ' end. 
This was to allow the formation o f bonds between the 5 ’ end o f MBS and the plasmid 
DNA in addition to bonds between the 3 ’ ends o f both MB 4 and MBS and the 
plasmid DNA during the ligation.
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Figure 4.46: Cleavage o f  MBP-HSPDE4D4j2v TEV protease
The figure shows a Coomassie stained gel o f the fractions collected during the 
proteolytic digestion o f  purified MBP-HSPDE4D4p£v^y factor Xa. I  incubated 
20pg MBP—HSPDE4D4f£y with 20 units TEV protease at 4°C and collected 5pg 
aliquots at various time points. Lanes 1-5 are the aliquots collected at 0, 1, 2, 4.5 
and 20h time points respectively: lane 6 is a 20h mock digestion (no protease) o f  
MBP-HSPDE4D4: lane 7 is molecular weight markers (Bio-Rad broad range 
prestained SDS-PAGE standards). The arrows indicate the Mw (kDa) o f each 
marker.
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4.2.4.3 Characterisation o f purified, un tagged HSPDE4D4 p£ y
To test the hypothesis that the difference in Km between HSPDE4D4 expressed in 
the cytosol of COS-7 cells and purified MBP-HSPDE4D4 was due to some effect of 
the MBP moiety on the conformation of the protein, I digested purified MBP- 
HSPDE4D4xev with TEV protease overnight at 4®C. I then removed both the released 
MBP moiety, using amylose resin, and the protease (which was His tagged), using a 
NT chelate resin. I then assayed the initial velocity of cAMP hydrolysis by the 
untagged, purified enzyme at 13 different substrate concentrations over the range 
0.1“20pM cAMP. I calculated values for the constants Km and Vmax for this 
preparation by fitting the kinetic data to the hyperbolic form of the Michaelis-Menten 
equation, using the computer program Hyper 1.02a. This analysis revealed that the 
untagged HSPDE4D4jev catalysed the hydrolysis of cAMP with kinetics that 
conformed well to the Michaelis-Menten model and that were linear when plotted in 
accordance with several linear transfoimations of the Michaelis-Menten equation 
{Figure 4.47).
The purified, untagged HSPDE4D4tev catalysed the hydrolysis of cAMP with a Km 
of 2.3pM and an apparent Vmax of 3490pmol/min/mg.
The Km for cAMP of the purified, untagged HSPDE4D4jev was 6 fold lower that of 
purified MBP-HSPDE4D4. It was, however, in close agreement with the Km for 
cAMP of HSPDE4D4 expressed in the cytosolic fraction of COS-7 cells and with 
those of other preparations of PDE4D isoforms (see section 4.2.3.1).
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Figure 4.47: Kinetic analysis o f  purified, untaggedHSPDE4D4j^y
The figure shows graphical solutions o f the Michaelis-Menten equation for the 
hydrolysis o f cAMP by purified, untagged HSPDE4D4fpy. The initial velocity o f  
catalysis was assayed at 16 different substrate concentrations and the data were 
fitted to the Michaelis-Menten equation using the computer program Hyper 1.02a. 
Panel A shows a graph for the hyperbolic form o f the equation. Panels B, C and D 
show a Hanes plot, a Lineweaver-Burkplot and an Eadie-Hofstee plot respectively. 
The graphs shown represent the results from a typical experiment o f 3 performed. 
These analyses revealed a Km for cAMP o f 2.3 pM  and a Vmax of3490pmol/min/mg
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4.2.5 Use of MBP—HSPDE4D4 fusion proteins to study protein-protein
interactions
Both RNPDE4A5 (HSPDE4A4B) and HSPDE4D4 are able to interact with tlie SH3 
domains of certain proteins (see chapters 3 and 5). I have used the purified MBP 
fusion proteins of full length HSPDE4D4 and also of the unique, amino terminal 
region (amino acids 1-166) of HSPDE4D4 to further characterise these interactions.
I performed these experiments using a purified GST fusion protein of the SH3 
domain of Lyn kinase, which I selected as an example of an SH3 domain fi'om a Src 
family tyrosyl kinase (see section 3,2.5).
4.2.5.1 Pull down assays with full length HSPDE4D4 as a fusion protein with MBP
The pull down assays that I have described in chapter 3 of this thesis were performed 
using unpurified preparations of PDE. As such they did not address the question of 
whether the detected interactions between the PDEs and the SH3 domains 
represented direct interactions between these species. An equally likely possibility 
was that the PDEs and the SH3 domains each bound to a mutual, third species. To 
address this question I have performed pull down assays using purified preparations 
of MBP-HSPDE4D4 and of GST-Lyn SH3. In these assays I examined the binding 
of both MBP—HSPDE4D4 and of MBP alone to GST-Lyn SH3 and to GST alone.
IIn the pull down assays using MBP-HSPDE4D4 and either GST-Lyn SH3 or GST 
alone I was able to monitor the binding of both immunoreactivity and of PDE 
enzyme activity. In these assays, where GST-Lyn SH3 was used as the “bait”,
49.3±7.6% of the recovered PDE enzyme activity was present in the bound fraction.
This compared to only 3.2± 1.1% of the recovered activity present in the bound 
fraction of pull down assays where the “bait” was GST alone. The binding of MBP- 
HSPDE4D4 enzyme activity to GST-Lyn SH3 was therefore significantly different 
fi’om that to GST alone at the 1% level (Student’s t-Test). As an additional control I 
also performed a pull down assay using purified MBP-HSPDE4D3 as the “prey” and ^
either GST-Lyn SH3 or GST alone as the “bait”. In this assay only 3.5% and 2.2% 
of the recovered activity was present in the bound fractions with GST-Lyn SH3 and 
with GST alone respectively. Although this is the result of only 1 trial and
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should therefore be treated with caution it is in agreement with the data that I 
generated from pull down assays using the crude cytosolic fraction of COS-7 cells 
transiently transfected to overexpress HSPDE4D3 which suggested that HSFDE4D3 
does not interact with this SH3 domain (see section 3.2.4).
The immunoblots that I generated from these pull down assays show an 
immunoreactive band corresponding to MBP-HSPDE4D4 in the bound fraction of 
the pull down assays using GST-Lyn SH3 but not of those using GST alone. This 
demonstrated that MBP-HSPDE4D4 immunoreactivity, as well as enzyme activity, 
bound to GST-Lyn SH3 {Figure 4.48).
In the pull down assays between MBP alone and either GST-Lyn SH3 or GST alone 
I was only able to monitor the binding of immunoreactivity. The immunoblots 
generated from these assays show that only trace amounts (>0.5%) of the recovered 
immunoreactivity was present in the bound fractions of pull down assays using either 
GST-Lyn SH3 or GST alone. This demonstrated that the detected interaction 
between MBP-HSPDE4D4 can not be attributed to the binding of MBP to the GST 
fusion protein {Figure 4.51),
These data show that MBP-HSPDE4D4, but not MBP alone, can bind directly to 
GST-Lyn SH3 but not to GST alone. This supports the hypothesis that HSPDE4D4 
can bind directly to SH3 domains.
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Figure 4.48: Binding o f  M BP-HSPDE4D4 to GST and GST-Lyn SH3
The figure shows an immunoblot for PDE4D offractions from pull-down assays 
between purified MBP-HSPDE4D4 and GST and purified MBP-HSPDE4D4 and 
GST-Lyn SH3. Lane 1 is 0.2pg purified MBP-HSPDE4D4; lanes 2 and 4 each 
contain 11% o f the total unbound fractions from O.Spg MBP-HSPDE4D4 
challenged with GST and with GST-Lyn SH3 respectively, 11%; lanes 3 and 5 each 
contain 53%) o f the bound fractions from these pull down assays with GST and GST- 
Lyn SH3 respectively. The arrow indicates the apparent Mw (kDa) o f the bands, 
calculated by plotting the R f values o f markers run on the same gel.
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4.2.5.2 Overlay assays
As an independent method to assess whether MBP-HSPDE4D4 could bind directly 
to SH3 domains I performed “overlay” assays, using a method based upon that 
commonly used to probe for protein kinase A anchoring proteins (AKAPs) (27, 28). 
In these experiments I subjected purified GST and GST fusion proteins of various 
SH3 domains to SDS-PAGE. I transferred these proteins from the gel onto a 
nitrocellulose membrane which I then blocked and probed with eithei* purified MBP 
or MBP-HSPDE4D4.1 washed the membrane, to remove any unbound probe, and 
then performed an immunoblot to detect the bound probe. Finally, I used Ponceau S 
stain to visualise the position of the GST fiision proteins on the nitrocellulose.
In these experiments MBP-HSPDE4D4, but not MBP alone, was able to interact 
with the SH3 domains of Src, Lyn and Fyn but not with those of Lck, Crk, Csk, Abl, 
P53BP2, Fodrin, PI3 Kinase, Cortactin, the SH2 domain of Src, GST alone nor with 
a fusion protein containing both the SH2 and the SH3 domains of Src. This supports 
the hypothesis that MBP-HSPDE4D4 can bind directly to the SH3 domains of Src, 
Lyn and Fyn kinases {Figure 4.49, Figure 4.50).
Recombinant HSPDE4D4, expressed in the cytosol of COS-7 cells, can interact with 
the SH3 domains of Abl and Fodrin, in pull down assays, to a similar extent as that to 
which it can interact with the SH3 domains of Src, Lyn and Fyn. It was therefore 
surprising to find that MBP-HSPDE4D4 did not interact with these domains in the 
overlay assays. Furthermore, although MBP-HSPDE4D4 did interact with GST-Src 
SH3, it was unable to interact with GST-Src SH2/3 in these overlay assays. A 
possible explanation for these results is that the overlay assay method relies on the 
“bait” proteins renatureing after being transferred firom the SDS gel onto the 
nitrocellulose membrane. It may be the case that although certain proteins can 
renature under these conditions, others can not and that, with these proteins, no 
interaction is detected. An alternative explanation is that the interaction between 
HSPDE4D4 and certain SH3 domains depends upon the presence of other molecules 
that are present in the cytosolic fraction of COS-7 cells but not in the overlay assay. I 
therefore suggest that, although interactions detected in overlay assays can be
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regarded as supporting evidence for a direct interaction between 2 species, the failure 
of 2 proteins to interact in an overlay assay should not be regarded as evidence that 
these species can not interact in solution.
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Figure 4.49: Direct interaction o f  M BP-HSPDE4D4 with SH3 
domains
The figure shows an overlay assay for direct protein-protein 
interactions. GST and GSTfusion proteins o f various SH3 domains 
were subjected to SDS-PAGE, transferred to a nitrocellulose membrane 
and probed with MBP—HSPDE4D4. The bound probe was detected by 
immunoblotting and the fusion proteins were visualised using Ponecau 
S stain. Panel A is an immunoblot to detect the bound probe. Panel B is 
the nitrocellulose filter stained with Ponceau S: lanes 1-14 in both 
panels are GST, GST-Src SH2, GST-Src SH3, GST-Src SH2/3, GST-Lyn 
SH3, GST-LckSH3, GST-Fyn SH3, GST-CrkSH3, GST-CskSH3, 
GST-AblSH3, GST-P53BP2 SH3, GST-Fodrin SH3, GST-PI3Kinase 
SH3 and GST-Cortactin SH3 respectively. The arrows indicate the 
position o f molecular weight markers run on the same gel.
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Figure 4.50: Direct interaction o f  M BP with SH3 domains
The figure shows an overlay assay for direct protein-protein interactions. 
GST and GSTfusion proteins o f various SH3 domains were subjected to 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with 
MBP. The bound probe was detected by immunoblotting and the fusion 
proteins were visualised using Ponecau S stain. Panel A is an immunoblot 
to detect the bound probe. Panel B is the nitrocellulose filter stained with 
Ponceau S: lanes 1-14 in both panels are GST, GST-Src SH2, GST-Src 
SH3, GST-Src SH2/3, GST-Lyn SH3, GST-LckSH3, GST-Fyn SH3, GST- 
CrkSH3, GST-CskSH3, GST-Abl SH3, GST-P53BP2 SH3, GST-Fodrin 
SH3, GST-PI3Kinase SH3 and GST-Cortactin SH3 respectively. The 
arrows indicate the position o f molecular weight markers run on the same 
gel.
M.B.Beard Purification o f affinity tagged PDE4 expressed in E. coli 4-220
■ I
4.2.53 Pull down assays with the amino terminal region ofHSPDE4D4 as a fusion
protein with MBP
The “long” PDE4D isoforms HSPDE4D3, HSPDE4D4 and HSPDE4D5 all share an 
identical primary structure outside of their alternatively spliced, amino terminal 
regions. Unlike HSPDE4D4, neither HSPDE4D3 nor HSPDE4D5 were able to 
interact with the SH3 domains of Src or Lyn kinase in pull down assays. This 
suggested that the unique, alternatively spliced, amino terminal region of 
HSPDE4D4 was necessary for it’s interaction with these SH3 domains (see section 
3.2.4.1).
To investigate whether the alternatively spliced, amino terminal region of 
HSPDE4D4 was also sufficient for interaction with SH3 domains I performed pull 
down assays using purified preparations of MBP-NT HSPDE4D4. In these assays I 
examined the binding of both MBP-NT HSPDE4D4 and of MBP alone to GST-Lyn 
SH3 and to GST alone.
The amino terminal region of HSPDE4D4 does not include the catalytic site of the 
enzyme, therefore I was not able to use PDE enzyme activity assays to monitor the 
binding of these species; instead I performed quantitative immunoblots, using a 
polyclonal antisera against MBP {Figure 4.51). In the pull down assays where MBP- 
NT HSPDE4D4 was the “prey” and GST-Lyn SH3 was the “bait”, 18.2±8.6% of the 
recovered immunoreactivity was present in the bound fraction. This compared with 
0.3±0.1% of the recovered immunoreactivity present in the bound fractions of assays 
where the “bait” was GST alone. In the pull down assays where MBP alone was the 
“prey”, less than 0.2±0.2% of the recovered immunoreactivity was present in the 
bound fraction of assays with either GST-Lyn SH3 or GST alone as the “bait”
{fig. 4.2 3).
These results demonstrated that amino acids 1-166 of HSPDE4D4 can bind directly 
to the SH3 domain of Lyn kinase. This supports the hypothesis that the unique, 
alternatively spliced, amino terminal region of HSPDE4D4 is both necessary and 
sufficient for the interaction of HSPDE4D4 with SH3 domains.
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Figure 4.51: Binding o f  M B P -N T  HSPDE4D4 to GST and GST-Lyn SH3
The figure shows a quantatative immunoblot for MBP offractions from pull-down 
assays between purified MBP—NT HSPDE4D4, GST-Lyn SH3 and GST alone and 
between purified MBP GST-Lyn SH3 and GST alone. Lanes 1—5 are 0.5, 0.1, 0.05, 
0.01 and 0.005pg purified MBP respectively; lanes 6  and 7 are the unbound 
fractions from 5pg MBP-NT HSPDE4D4 challenged with GST-Lyn SH3 and with 
GST respectively, 1% o f each fraction was run; lanes 8  and 9 are the unbound 
fractions from 20pg MBP challenged with GST-Lyn SH3 and with GST respectively, 
O.lVo o f each fraction was run; lane 10 is empty; lanes 11 and 1 2  are the bound 
fractions from the pull down assays o f MBP-NT HSPDE4D4 with GST-Lyn SH3 and 
GST respectively, 13% o f each fraction was run; lanes 13 and 14 are the bound 
fractions from the pull down assays o f MBP with GST-Lyn SH3 and GST 
respectively, 27%) o f each fraction was run. The arrows indicates the apparent Mw 
(kDa) o f the bands, calculated by plotting the R f values o f markers run on the same 
gel.
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4.23.4 ELISA for protein-protein interaction
As a third, independent method of examining the interaction between HSPDE4D4 
and SH3 domains I performed a series of ELIS As (enzyme linked immune adsorbant 
assays), using purified MBP and GST fusion proteins. A similar approach has 
previously been used to investigate the interaction between HSPDE4D5 and RACKl 
(receptor for activated C kinase 1) (252).
I initially performed ELISAs in which either GST-Lyn SH3 or GST alone were 
immobilised on Reacti-Bind glutathione coated ELISA plates (Pierce) as the “bait” 
species. The immobilised GST fusion proteins were then challenged with either 
MBP-HSPDE4D4 or with MBP alone. These assays, however, resulted in an 
extremely liigh background due to the nonspecific binding of MBP-HSPDE4D4 to 
the wells of the ELISA plate.
I therefore decided to attempt ELISAs in which either MBP-HSPDE4D4 or MBP 
alone were immobilised as the “bait” species and challenged with either GST-Lyn 
SH3 or with GST alone. In these assays GST-Lyn SH3 bound both to MBP-
HSPDE4D4 and to MBP-NT HSPDE4D4 in an apparent dose dependent fashion 
with EC50 values of 0.392±0.104pM and of 1179pM respectively. The binding of 
GST-Lyn SH3 to MBP alone and of GST alone to MBP-HSPDE4D4, to MBP-NT 
HSPDE4D4 or to MBP alone were typically about 5 fold lower than that of GST- 
Lyn SH3 to MBP-HSPDE4D4 or to MBP-NT HSPDE4D4 in these assays {Figure 
4.52Figure 4.53). These data support the hypothesis that HSPDE4D4 can interact 
with SH3 domains and that the unique, amino terminal (amino acids 1-166) of the 
molecule are sufficient for this interaction.
If this system could be shown to be at equilibrium then, fi-om modeling the kinetics 
of adsorption, it would follow that the measured EC50 for binding would be equal to 
the ratio between the dissociation and the association constants for this interaction 
(ie. the equilibrium constant (Ks)) (154).
I therefore performed time course experiments to measure the binding of GST-Lyn 
SH3 to MBP-HSPDE4D4 with time. This showed that, even after 20 hours, the
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system had not reached equilibrium (Figure 4.54). The measured EC50 of binding for 
these ELISAs is therefore a non-equilibrium measurement and will depend not only 
upon the ratio between the dissociation constant and the association constant of the 
interaction but also upon the time of interaction (before separation of bound and 
unbound “prey”).
4-224M.B.Beard Purification of affinity tagged PDE4 expressed in E. coli
MBP-HSPDE4D41.8 -
1.6 -
1.4 -
0. 8 "
0.6 - MBP
0 .4 -
0.2 J
0 2000 4000 80006000 10000
[GST-Lyn SH3] (|iM)
Figure 4.52: Binding o f  MBP~HSPDE4D4 and o f  M BP to GST-Lyn SH3
The figure shows results from an ELISA for interaction between MBP-HSPDE4D4 
and GST-Lyn SH3. l.Spmol MBP—HSPDE4D4 or MBP was immobilised in each 
well o f a 96 well plate. The wells were then blocked and probed with a concentration 
range o f either GST-Lyn SH3 or GST alone for 3 hours at room temperature. After 
rapid washing at 4°C the bound probe was fixed using paraformaldehyde and 
detected immunologically. The binding o f GST alone at each concentration was used 
as the baseline value for the binding o f GST-Lyn SH3 to the immobilised ligand.
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Figure 4.53: Binding o f MBP-NT HSPDE4D4 and o f MBP to GST-Lyn SHB
The figure shows results from an ELISA for interaction between MBP-NT 
HSPDE4D4 and GST-Lyn SH3. l.Spmol MBP-NTHSPDE4D4 or MBP 
immobilised in each well o f a 96 well plate. The wells were then blocked and probed 
with a concentration range o f either GST~Lyn SH3 or GST alone for 3 hours at room 
temprature. After rapid washing at 4°C the bound probe was fixed using 
paraformaldehyde and detected immunologically. The binding o f GST alone at each 
concentration was used as the baseline value for the binding o f GST-Lyn SH3 to the 
immobilised ligand.
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Figure 4,54: Time course for the binding o f MBP~~HSPDE4D4 and o f MBP to 
GST-^Lyn SH3
The figure shows results from an ELISA for interaction between MBP-HSPDE4D4 
and GST-Lyn SH3. L5pmol MBP—HSPDE4D4 or MBP was immobilised in each 
well o f a 96 well plate. The wells were then blocked and probed with either GST-Lyn 
SH3(300nM) or GST alone (SOOnM) for various periods o f time. After rapid washing 
at 4°C the bound probe was fixed using paraformaldehyde and detected 
immunologically. The binding o f GST alone at each time point used as the 
baseline value for the binding o f GST-Lyn SH3 to the immobilised ligand.
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4.3 Conclusions
In this chapter I have shown that it is possible to express active, full length isoforms 
of PDE4 in E.coli as fusion proteins with MBP. Each of the “long” splice variants 
from the PDE4D gene can now be expressed, as an MBP fusion protein, and rapidly 
purified to near homogeneity, by a single step of affinity chromatography using 
amylose resin, I have demonstrated the purification of the HSPDE4D4 isoform in 
this chapter and the purification of the HSPDE4D3 and the HSPDE4D5 isoforms 
have been reported in a study by Yarwood and others (252).
I have also shown, at least in the case of MBP-HSPDE4D4, that by engineering a 
TEV protease site into the MBP-PDE fusion protein it is possible to separate the 
MBP and PDE moieties by limited proteolysis without degrading the PDE moiety. It 
seems likely that this strategy could now be used to produce purified, untagged 
preparations of each of the splice variants of PDE4D.
I have shown that the purified MBP-HSPDE4D4 is an active PDE4D enzyme, as 
judged by the criteria of PDE enzyme activity, immunoreactivity, and sensitivity to 
inhibition by the PDE4 selective inhibitor rolipram. This fusion protein catalyses the 
hydrolysis of cAMP with kinetics that conform well to the Michaelis-Menten model. 
The Km for cAMP of MBP-HSPDE4D4 is, however, approximately 10 fold higher 
than that of HSPDE4D4 expressed in the cytosolic fraction of COS-7 cells. This 
suggested that there were differences in the cAMP binding site of MBP-HSPDE4D4 
compared to that of HSPDE4D4 expressed in the cytosolic fraction of COS-7 cells.
I determined the true Vmax of MBP-HSPDE4D4 to be 1496±305|imol/min/mg and 
also calculated the turnover number to be 201±41 min ’. I then used quantitative 
immunoblots to calculate the molar concentration of HSPDE4D4 in the cytosolic 
fraction of transfected COS-7 cells (using purified MBP-HSPDE4D4 as a standard) 
and so estimated the turnover number for cAMP hydrolysis of this preparation of 
HSPDE4D4 to be 106±12 min'. These values were not significantly different at the 
5% level (Student’s t-Test). This suggested that although the affinity of MBP- 
HSPDE4D4 for cAMP was reduced compared to that of the wild type enzyme
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the speed with which the active sites of the 2 enzymes were able to catalyse the 
hydrolysis of cAMP was similar. I therefore speculated that the elevated Km of the 
fusion protein may have been due to the MBP moiety either sterically hindering 
access of cAMP to the active site or altering the conformation of the active site in 
some way and so reducing it’s affinity for cAMP. I therefore decided to pursue the 
proteolytic cleavage of the MBP tag from the fusion protein.
By engineering a TEV protease recognition site into the MBP-HSPDE4D4 fiision 
protein I was able to purify HSPDE4D4 as an untagged protein with just 11 vector 
derived amino acids remaining at its amino terminus. This protein was kinetically 
identical to recombinant HSPDE4D4 expressed in the cytosolic fraction of COS-7 
cells.
I have used purified preparations of the MBP fusion proteins of HSPDE4D4 and also 
of the unique, amino terminal region of HSPDE4D4 (amino acids 1-166) to show 
that this isoform can bind directly to the SH3 domain of Lyn kinase and that the 
unique, amino tenninal region of HSPDE4D4 is sufficient for this interaction. I 
demonstrated this interaction by 3 independent methods: pull down assays, overlay 
assays and ELIS As. Taken together with the data presented in chapter 3 of this thesis, 
which shows that HSPDE4D4 but neithei’ the HSPDE4D3 nor HSPDE4D5 can 
interact with SH3 domains, this supports the hypothesis that the unique, amino 
terminal region of HSPDE4D4 is both necessary and sufficient for the interaction of 
HSPDE4D4 with the SH3 domain of Lyn kinase.
5. Mapping the sites within the amino terminal of 
RNPDE4A5 responsible for SH3 domain association and for 
targeting
5.1 Introduction
There are 3 distinct splice variants of rat PDE4A that have so far been characterised, 
RNPDE4A1, RNPDE4A5 and RNPDE4A8 (200) (16, 140, 201). In addition to these, 
another 2 splice variants, rPDE66 [G. Bolger and others, unpublished] and also the 
rat homologue of HSPDE4A10 [M. Houslay and others, unpublished] have been 
cloned but not yet characterised. The alternative splicing of rat PDE4A, as with all 
known active PDE4s, takes the form of 5’ domain swaps such that all the members of 
this family share an identical primary structure outside of their alternatively spliced 
amino terminal regions.
5.1.1 Characteristics of RNPDE4A5
The splice variant RNPDE4A5, originally cloned from an adult rat brain cDNA 
library, is a long isoform of rat PDE4A (17). The alternatively spliced amino 
terminal region of this protein comprises 102 residues (including the initiating 
methionine) and does not share homology with any other known rat PDE. This 
region of RNPDE4A5 is, however 89% homologous with the spliced, amino terminal 
region of HSPDE4A4B, the human homologue of RNPDE4A5.
5.1.1.1 Interaction o f RNPDE4A5 with SH3 domains
An isoform specific property of RNPDE4A5 is that it can selectively bind to the SH3 
domains of certain proteins, namely those of the Src family tyrosyl kinases Src, Fyn, 
Lyn and of the cytoskeletal protein fodrin (see section 3.1.2.4). The alternatively 
spliced, amino terminal 102 residues of RNPDE4A5 are necessary for its interaction 
with these SH3 domains. This region of RNPDE4A5 contains 3 motifs that conform
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to the PxxP consensus sequence that is proposed to confer an ability to interact with 
SH3 domains (see section 1.4.1). One or more of these motifs are likely to be the site 
of the interaction between RNPDE4A5 and SH3 domains. These PxxP motifs are 
also well conserved in HSPDE4A4B, the human homologue of RNPDE4A5 ().
5.1.1.2 Cleavage o f RNPDE4A5 by caspase-3
The spliced amino terminal region of RNPDE4A5 contains a pair of motifs that 
conform to the consensus sequence for cleavage by the members of a family of 
cysteine proteases called caspases. This family of proteases, which are required for 
the initiation of apotosis, are synthesised as inactive zymogens and are proteolyticaly 
activated in a cascade similar to that of the immune complement system.
RNPDE4A5 is a substrate for the ubiquitously expressed caspase-3 and is cleaved by 
this caspase at an early stage during the initiation of apotosis [Huston and others, 
manuscript in preparation].
The cleavage of RNPDE4A5 by caspase-3 does not result in a change in the catalytic 
activity of RNPDE4A5, nor does it cause any conformational change in the protein 
which can be detected by a change in its sensitivity to the PDE4 specific inhibitor 
rolipram (see section 1.3.6). The truncated foim of RNPDE4A5, produced by 
cleavage with caspase-3 does, however, exhibit an altered intracellular distribution, 
as assessed by immunofluoresent staining and confocal microscopy, compared to the 
full length enzyme. The region of the RNPDE4A5 that is removed by caspase-3 
cleavage is that which contains the 3 putative SH3 domain binding regions within the 
amino terminal of RNPDE4A5. The truncated RNPDE4A5 also shows a marked 
reduction in its ability to interact with SH3 domains and this has lead to speculation 
that the interaction of RNPDE4A5 with an SH3 domain may be involved in its 
subcellular targeting. It may be the case that the disruption of this targeting following 
the cleavage of RNPDE4A5 by caspase-3 is important in the progression of the 
apoptotic pathway of programmed death in cells where RNPDE4A5 is expressed 
[Huston and others, manuscript in preparation]
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Figure 5.55: Alignments of the 3 proline and arginine rich regions o f sequence 
contained within the alternatively spliced amino termini of RNPDE4A5 and of 
HSPDE4A4B
The figure shows alignments o f the 3 regions ofproline and arginine rich sequence, 
within the alternatively spliced amino termini o f RNPDE4A5 and HSPDE4A4B, that 
conform to the consensus motif PxxP. The numbering above and below the sequences 
refer to the amino acid number in the deduced amino acid sequences o f these 
proteins.
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5.2 Results and Discussion
The only differences between the primary structures of RNPDE4A5 and of the other 
rat PDE4A isofoims are in their alternatively spliced, amino terminal regions. This 
suggests that sequences contained within the amino termini of these proteins are 
responsible for the splice variant specific properties and regulation of each isoform. 
To define in detail the regions within the amino terminal of RNPDE4A5 that are 
necessary for certain of its splice variant specific properties I decided to construct a 
series of amino terminal truncations in RNPDE4A5 and to investigate which of the 
RNPDE4A5 specific properties each truncation retained. The properties that I 
intended to characterise were: which regions (a) conferred interaction with SH3 
domains, (b) conferred association with the particulate cell fi’actions and (c) might 
affect the enzyme activity.
5.2.1 Construction of amino-terminal truncations in RNPDE4A5
The plasmid pSP0RTrPDE6 encodes RNPDE4A5 under the control of an SV40 
promoter. This plasmid has previously been used to achieve high levels of expression 
of RNPDE4A5 in transiently transfected COS-7 cells (140, 162). I used the Quick 
Change method of mutagenesis (Stratagene) to construct a series of deletions and 
point mutations in pSPOTRrPDE6 that encoded a series of amino terminal 
truncations and also a point mutation of RNPDE4A5 (R6A1— R6A7 and R6P7-A) 
(Figure 5.56, Figure 5.57).
The Quick Change method of mutagenesis relies upon the polymerase chain reaction 
(PCR) to construct and amplify each mutated plasmid (see section 2.4.6). I performed 
these PCR reactions using Pfu polymerase (supplied with the Quick Change kit).
This polymerase has proof reading activity and hence shows approximately 5 fold 
greater fidelity than the non proof reading polymerase Taq (Promega), however, even 
using Pfu polymerase, the possibility of unplanned mutations arising during the PCR 
amplification should not be ignored. I therefore sequenced the entire open reading
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The plasmids pSPORTR6A l- pSPORTR6A3 were constructed to encode truncations 
of RNPDE4A5 which lacked each of the 3 putative SH3 domain binding motifs that 
occur within the amino terminal region of this protein (residues 1-10 (R6A1), 1-42 
(R6A2) and 1-67 (R6A3) of the wild type protein respectively). The point mutation 
p8P ORTR6P7 - A was constructed to encode a mutation of RNPDE4A5 in which the 
residue Pro  ^of the wild type enzyme was mutated to Ala (R6P7-A). This mutation 
was intended to disrupt the first of the putative SH3 domain binding motifs (residues 
4-10, PxxPxxR) by changing the second Pro in the motif to Ala (Figure 5.S6, Figure 
5.57).
?
.The deletions pSPORTR6A4-pSPORTR6A7 were constructed to encode truncations 
of RNPDE4A5 which lacked putative functional domains within the amino terminal 
of this isoform. The truncation pSPORTR6A4 encoded a species in which the unique, 
spliced region of RNPDE4A5 was deleted (residues 1-103 (R6A4)). The truncation 
pSPORTR6A5 encoded a species that was truncated up to the beginning of upstream 
conserved region 1 (UCRl) (residues 1-134 (R6A5)). The truncation pSPORTR6A6 
encoded a species that was truncated up to the end of UCRl (residue s 1-197 
(R6A6)). The truncation pSPORTR6A7 encoded a species that was truncated up to 
the beginning of upstream conserved region 2 (UCR2) (residues 1-219 (R6A7))
(Figure 5.56, Figure 5.57).
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Figure 5.56: Truncation mutants in RNPDE4A5
The figure shows a diagram representing 3 o f the splice variants from the rat 
PDE4A gene. The start sites o f the engineered truncations R6A1 (residue 11 in 
RNPDE4A5), R6A2 (residue 43 in RNPDE4A5), R6A3 (residue 6 8  in 
RNPDE4A5)^ R6A4 (residue 103 in RNPDE4A5), R6A5 (residue 135 in 
RNPDE4A5), R 6 A 6 (residue 197 in RNPDE4A5), R6A7(residue 218 in 
RNPDE4A5) and Mef^RDl (previously engineered by our group (200)) 
(residue 260 in RNPDE4A5) are indicated by arrows. The hashed boxes show 
the positions o f UCRl and ofUCR2 and the grey box represents the conserved, 
catalytic region which is present in all known mammalian 3 ’5 ’ 
phosphodiesterases.
NB. This figure is not drawn to scale.
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R6A1Met G1 n Pro Pro Ala Ala Pro Ser Gin Arg Ser Leu Ser Leu Ser Leu Pro Gly 18
1403 ATG GAG iC ï CCG GCC Gàc i t t i TÙG GAA AGG AGC CTG TCT CTC TCT CTT CCG GGG
Pro Arg Glu Gly Gin Ala Thr Lys Pro Pro Gin His Trp Gin 361457 CCC CGG GAG GGC CAG GCC ACC CTG
R6A2
AAG CCG CCC CCC CAG CAC CTG TGG CGG CAG
Pro Arg Thr Pro lie Arg lie Gin Gin Arg Gly Tyr Asp Ser Ala Glu Arg 541511 CCG AGG ACC CCG ATC CGC ATC CAG CAA CGC GGC TAC CCG GAC AGT
R6A3
GCC GAG CGC
Ser Glu Thr Glu Arg Ser Pro His Arg Pro lie Glu Arg Ala Asp Ala Val Asp 72
1565 TCA GAG ACA GAG CSC TCÀ ecQ exc CSB CCC TTA SAG "CISC GCC GAC GCC GTG GAC
Thr Gly Asp Arg Pro Gly Leu Arg Thr Thr Arg Met Ser Trp Pro Ser Ser Phe 90
1619 ACT GGC GAC CGG CCA GGC CTG CGG ACT ACC CGC ATG TCC TGG
R6A4
CCC TCG TCC TTC
His Gly Thr Gly Thr Gly Gly Gly Ser Ser Arg Arg Leu Glu Ala Glu Asn Gly 1081673 CAC GGC ACC GGT ACC GGC GGA GGC AGC ACT AGG CGC TTG GAG GCA GAA AAT GGG
Pro Thr Pro Ser Pro Gly Arg Ser Pro Leu Asp Ser Ala Ser Pro Gly Leu 126
1727 CCA ACG CCA TCC CCT GGC CGC AGC CCC CTG
R6A5
GAC TCG CAG GCG AGC CCG GGG CTT
Val Hla Ala Gly Ala Thr Thr Ser Gin Arg Arg Glu Ser Phe Tyr Arg 1441781 GTG CTG CAT GCT GGG GCC ACC ACC AGC CAG CGC CGC GAG TCC TTC CTC TAC CGC
Ser Asp Ser Asp Tyr Asp Met Ser Pro Lys Ala Val Ser Arg Ser Ser Ser Val 1621835 TCA GAC AGC GAC TAT GAC ATG TCA CCG AAG GCT GTG TCC AGG AGC TCG TCT GTC
Ala Ser G1 u Ala His Ala Glu Asp lie Val Thr Pro Phe Ala Gin Val Leu 180
1889 GCC AGC GAA GCG CAC GCT GAG GAC CTC ATT GTG ACA CCA TTT GCC CAG GTG CTGR6A6A1 a Ser Arg Set Val Arg Set As n Phe Ser Leu Thr Asn Val Pro lie 198
1943 GCC ACT CTC CGC AGC GTT CGA AGC AAC TTC TCA CTC TTA ACC AAT GTG CCC ATC
Pro Ser Lys Arg Ser Pro Leu Gly Gly Pro Pro Ser Val Cys Lys Ala Thr 216
1997 CCC AGC AAC
R6A7
AAG AGG TCT CCA CTG GGT GGC CCA CCC TCT GTC TGC AAG GCC ACA
Leu Ser Glu Glu Thr Cys Gin Gin Leu Ala Arg Glu Thr Leu Glu G1 u Leu Asp 2342051 CTS TCA GAG SAG ACG TGC CAG CAG CTG GCC CGG GAG ACC CTG GAA GAG CTG GAT
Trp Cys Leu G1 u Gin Glu Thr Met Gin Thr Tyr Arg Ser Val Ser Glu Met 2522105 TGG TGC CTG GAG CAG CTG GAG ACC ATG CAG Met^SRDl ACC TAC CGC TCT GTC AGC GAG ATGAla His Ly s Phe Lys Arg Met. Arg Glu Thr HI s Ser Glu 2702159 GCC TCA CAC AAG TTC AAA AGG ATG CTG AAC CGT GAG CTC ACA CAC CTG TCG GAA
Met Ser Arg Ser Gly Gin Val Glu Tyr lie Ser Thr Phe Asp 2882213 ATG AGC AGG TCA GGA AAC CAG GTC TCA GAG TAC ATT TCC AAC ACA TTC CTG GAC
Lya Gin Glu Val Glu lie Pro Ser Pro Thr Pro Arg Gin Arg Ala Phe Gin 3062267 AAG CAG AAT GAA GTG GAG ATC CCC TCA CCC ACA CCT CGG CAG A6A GCC TTC CAG
Gin Pro Pro Pro Ser Val Leu Arg Gin Ser Gin Pro Met Ser Gin lie Thr Gly 324
2321 CAG CCC CCG CCG TCA GTG CTG CGA CAG TCC CAG CCC ATG TCT CAG ATC ACA GGG
Figure 5.57: Positions o f  the truncations and point mutation in RNPDE4A5
The figure shows the amino acid and the nucleotide sequence o f part o f the open 
reading frame o f RNPDE4A5. The positions o f the truncations R6Al-R6A7and o f 
M e RDI  are shown by red arrows. These truncations were constructed in the 
plasmid pSP0RTrPDE6 by deletion o f the nucleotide sequence lying between the 
initiating A TG o f RNPDE4A5 and the position indicated here by the red arrows. The 
position o f the point mutation R6P7-A is shown by the red box. This mutation was 
constructed by mutation o f the codon CCC to GCC. The regions o f sequence 
coloured in gt een indicate regions conserved between all PDE4s. These are UCRl 
(residues 135 196 in RNPDE4A5), UCR2 (residues 218 298 in RNPDE4A5) and the 
catalytic region (residues 318-674 in RNPDE4A5). The numbers along the right 
hand .side o f the figure indicate the codon number in the open reading frame o f 
RNPDE4A5. Ihe numbers along the left hand side o f the figure indicate the 
nucleotide number in the genbank .sequence for RNPDE4A5 (accession number 
L27057).
M.B.Beard Mapqjing the sites within the amino terminal of RNPDE4A5
responsible for SH3 domain association and for targeting
5-236
5.2.1.1 Expression o f the engineered truncations in RNPDE4A5
To establish that each of the mutated plasmids did indeed encode for an active PDE, 
I transiently transfected COS-7 cells with each plasmid. I then performed both PDE 
enzyme activity assays and immunoblots, using a polyclonal antisera raised against 
the carboxyl terminal region of RNPDE4A5, on the cmde cytosolic fraction of the 
transfected cells. In all cases the PDE enzyme activity in the cytosolic fraction of the 
transfected cells was 50-100 times that in the cytosolic fraction of mock transfected 
cells (no DNA). The immunoblots revealed a novel band of immunoreactivity 
present in the cytosolic fraction, of cells transfected with each plasmid, that migrated 
with an apparent Mw 9-16kDa higher, depending upon the deletion, than that 
calculated from the predicted primary structure of each mutant (see section 2.4.10) 
{Figure 5.58 and Table 5.5.1). This is consistent with the observed anomalous 
migration of RNPDE4A5 and other isoforms of PDE4 on sodium dodecyl sulphate 
polyacrylamide gel electrophroesis (SDS-PAGE) (15, 16, 93, 108, 140, 201).
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B
R6A3 R6A4 R6A5 R6A6 R6A7 Met^^ROl
Figure 5.58:Expression o f  amino terminal truncated form s o f  RNPDE4A5 in 
COS-7 cells
The figure shows immunoblots o f truncation mutants o f RNPDE4A5 expressed in the 
cytosolic fraction o f transiently transfected COS-7 cells. In panel A: lanes 1-4 are 
sufficient o f the cytosolic fraction o f transfected COS-7 cells to contain 8 EU o f  
RNPDE4A5, R6P7-A, R6A1 and R6A2 respectively. In panel B: lanes 1—6 are 
sufficient o f the cytosolic fraction o f transfected COS-7 cells to contain 8 EU o f 
R6A3, R6A4, R6A5, R 6 A6 , R6A7 and Met^^RDI respectively. The arrows indicate 
the apparent Mw (kDa) o f that band, calculated by plotting the R f values o f markers 
run on the same gel.
M.B.Beard Mapping the sites within the amino terminal of RNPDE4A5
responsible for SH3 domain association and for targeting
5-238
Apparent Mw on SDS-PAGE
Construct Amino acids Calculated
(kDa)
Observed
(kDa)
RNPDE4A5 844 93 108 + 1
R6P7-A 844 93 108 + 1
R6A1 835 93 102+ 2
R6A2 803 89 98± 3
R6A3 778 86 99+2
R6A4 743 82 98 + 1
R6A5 711 79 94±3
R6A6 649 72 86+1
R6A7 627 70 82 + 1
Met^®RDl 585 65 81+1
Table 5.5.1: Molecular weights o f  truncations and a poin t mutation in RNPDE4A5
The table shows the predicted and the observed Mw o f truncations and a point 
mutation in RNPDE4A5. The sequence analysis o f these proteins was done using the 
computer program Gene Jockey and in all cases the initiating methionine o f the 
peptide sequence has been included in the analysis. The observed Mw o f each protein 
was determined by comparing the R f value o f the immunoreactive bands on 
immunoblots to those o f molecular weight markers run on the same gels. Each 
reported value is the mean o f at least 3 determinations and the reported errors are 
the standard error o f each mean.
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5.2.2 Mapping the regions of sequence within RNPDE4A5 necessary for 
interaction with SH3 domains
Unlike RNPDE4A5, neither RNPDE4A8 nor Met^^RDl can interact with the SH3 
domains of either Src or Lyn kinase in pull down assays (162). This suggested that 
the unique amino terminal region of RNPDE4A5 was necessary for its interaction 
with these SH3 domains. The extreme amino terminal region of RNPDE4A5 
contains 3 motifs which conform to the PxxP consensus sequence for binding to SH3 
domains. It has been suggested (162) that one or more of these motifs may be 
responsible for the detected interaction between RNPDE4A5 and SH3 domains (see 
sections 1.3.2.2). I therefore decided to use the amino terminal truncations in 
RNPDE4A5: R6A1, R6A2, R6A3, R6A4, Met^^RDl {Figure 5.56) and also the point 
mutation R6P7-A {Figure 5.55) to define the sub-region within the amino terminal 
of RNPDE4A5 that is involved in binding to the SH3 domain of Lyn kinase.
I transiently transfected COS-7 cells to express either wild type (full length) 
RNPDE4A5 or one of the amino terminal truncations or the R6P7-A point mutation 
in this protein. I then used the cytosolic fi-action fi*om the transfected cells as the 
source of enzyme for pull down assays with either purified GST-Lyn SH3 or with 
GST alone. I used both PDE enzyme activity assays and immunoblots to monitor the 
binding of each construct to GST-Lyn SH3 and to GST alone {Figure 5.59, Figure 
5.60).
In my previous study of the interactions between HSPDE4D4 and SH3 domains from 
various proteins, I had found that the data which I generated in those pull down 
assays was unsuitable for analysis by ANOVA (see section 3.2.3.1). I therefore 
designed this set of experiments in such a way that I was able to analyse the data 
using paired t-Tests (166).
I performed the pull down assays as a series of (tightly) paired determinations where, 
in each experiment, I measured the percentage binding of a construct to GST-Lyn 
SH3 and to GST alone. I then tested to see if the mean difference between these pairs
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was significantly different from 0 at the 5% level.
This analysis revealed that, of the proteins examined, only R6A4 and Met^^RDl 
failed to interact significantly with the SH3 domain of Lyn kinase {Figure 5.59). This 
was an unexpected result because the construct R6A3 does not contain any of the 3 
putative SH3 domain binding PxxP motifs that are present in full length RNPDE4A5 
yet it was still able to interact with the SH3 domain of Lyn kinase.
Inspection of the data showed that there appeared to be a large decrease in the mean 
percentage binding of R6A1 to GST-Lyn SH3 compared to that of full length 
RNPDE4A5. Further truncations in the unique, alternatively spliced region of 
RNPDE4A5 (R6A2 and R6A3) did not, however, appear to fiirther reduce the binding 
to GST-Lyn SH3 in pull down assays {Figure 5.59).
That the truncated form R6A1 showed a large decrease in binding to GST-Lyn SH3 
compared to that of full length RNPDE4A5 (48% and 19% respectively) suggested 
that the first 10 amino acids of RNPDE4A5 were important for the interaction of 
RNPDE4A5 with the SH3 domain of Lyn kinase {Figure 5.57 and Figure 5.59).
That the truncated forms R6A2 and R6A3 showed little further reduction in their 
binding to GST-Lyn SH3 (12% and 14% respectively) than did R6A1 suggested that 
the 2 PxxP motifs contained in the region between residues 11-68 of RNPDE4A5 are 
not important for the interaction of RNPDE4A5 with the SH3 domain of Lyn kinase 
{Figure 5.57 and Figure 5.59).
The truncated form R6A4 did not show significant binding to GST-Lyn SH3. This 
implicates the region between residues 68-102 of RNPDE4A5 as being involved in 
the interaction with the SH3 domain of Lyn kinase {Figure 5.57 and Figure 5.59).
I perfoimed pull down assays using the point mutation R6P7-A to examine the effect 
of disrupting the putative SH3 domain binding motif that is present in the region of 
RNPDE4A5 deleted in the truncation mutant R6A1. The mean percentage binding of 
this point mutation to GST-Lyn SH3 appeared to be reduced compared to that of
5-241M.B.Beard Mapping the sites within the amino terminal o f RNPDE4A5
responsible for SH3 domain association and for targeting
RNPDE4A5. This is consistent with the hypothesis that the PxxP motif between 
residues 4—7 of RNPDB4A5 is involved in the interaction of this protein with SH3 
domains {Figure 5.57 and Figure 5.59).
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Figure 5.59: Rinding o f  wild type, a pm nt mutation o f  and truncations in 
RNPDE4A5 to the SH3 domain o f  Lyn kinase
The bar chart shows data from ptdl down assays to screen a point mutation o f  and a 
series o f truncations in RNPIWÂA5 for interaction with the SH3 domain o f lyn  
kinase. Ihe data are expressed as the percentage o f recovered PDE enzyme activity 
present in the bound fraction. Ihe values are the means o f n separate determinations 
with error bars showing the standard error o f the means. Columns coloured in red 
indicate that the mean binding to GST-Lyn SH3 is sigtiifwantly different from that to 
GST alone (paired t-Test, 5% level).
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A
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Figure 5.60: Binding o f  truncation mutants in RNPDE4A5 to the SH3 domain o f  
Lyn kinase
The figure shows immunoblots for rat PDE4A o f the bound fractions from pull-down 
assays between truncation mutants in RNPDE4A5 and either GST or GST-Lyn SH3. 
In panel A: lanes 1-4 are the bound fractions from pull down assays between GST- 
Lyn SH3 andRNPDE4A5, R6P7-A, R6A1 and R6A2 respectively; lane 5 is empty; 
lanes 6-9 are the bound fractions from pull down assays between GST and 
RNPDE4A5, R6P7-A, R6A1 and R6A2 respectively; lanes 10—13 are 20pg cytosolic 
fraction from transfected COS-7 cells expressing RNPDE4A3, R6P7-A, R6A1 and 
R6A2 respectively. In panel B; lanes 1-3 are the bound fractions from pull down 
assays between GST-Lyn SH3 and Met^^RDl, R6A3 and R6A4 respectively; lane 5 
is empty; lanes 6-8 are the bound fractions from pull down assays between GST and 
Met^^RDl, R6A3 and R6A4 respectively; lane 9 is empty; lanes 10-12 are 20pg 
cytosolic fraction from transfected COS-7 cells expressing Met^^RDI. R6A3 and 
R6A4 respectively.
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5.2.3 Mapping the regions of sequence within the amino terminal region of 
RNPDE4AS that are necessary to targeting the protein to the particulate 
fraction of COS-7 cells
When expressed in transiently transfected COS-7 cells both RNPDE4A5 and 
RNPDE4A8 are found in both the soluble and the particulate cell fractions. This is 
also true for the RNPDE4A5 like species that is present in preparations of rat brain 
(16, 140). Another splice variant from the rat PDE4A gene, RNPDE4A1, is found 
associated exclusively with the paiticulate fraction of both transfected COS-7 cells 
and of rat brain preparations (140). This is in contrast to the tmncated species 
Met^^RDl, which occurs as an exclusively cytosolic species when expressed in COS- 
7 cells (see section 1.3.2.1) (200). It therefore appears that the alternatively spliced, 
amino terminal regions of PDE4A splice variants are both necessary and, at least in 
the case of RNPDE4A1, sufficient for the association of these enzymes with the 
particulate fraction of cells (194).
Differences between the sub-cellular distributions of RNPDE4A5 and RNPDE4A8, 
as assessed by the fractionation of transfected COS-7 cells, have previously been 
reported (16). The primary structures of these 2 proteins, which are identical outside 
of their amino terminal regions, converge at residue 103 in RNPDE4A5 (residue 22 
in RNPDE4A8). This suggested that sequences contained within the first 103 amino 
acids of RNPDE4A5 may be responsible for splice variant specific sub-cellular 
targeting of this isoform.
The association of RNPDE4A5 with the particulate fraction of COS-7 cells is not 
disrupted by washing with buffers containing high concentrations of salt, nor of the 
nonionic detergent Triton X-100. Neither is the association disrupted by washing 
with buffers containing both high concentrations of salt and of Triton X-100 (140). 
The interaction of RNPDE4A5 with SH3 domains in pull down assays is also not 
disrupted under these conditions. This has lead to speculation that the targeting of 
RNPDE4A5 into the salt and Triton X-100 insoluble pellet may involve its binding 
to an SH3 domain (162). The fraction of RNPDE4A8 which is found associated with 
the particulate fraction of transfected COS-7 cells is, however, also resistant to
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solubilisation by salt and Triton X-100. This observation does not support the 
involvement of an SH3 interaction in the salt and Triton X-100 insolubility of 
RNPAE4A5. Rather it suggests that the region of sequence that is conserved between 
RNPDE4A5 and RNPDE4A8 may be, at least partly, responsible for the observed 
salt and detergent insolubility of these proteins (16).
I therefore decided to use the amino terminal truncation mutants in RNPDE4A5 to 
define the sub-regions of sequence within the amino terminal of RNPDE4A5 that are 
involved in mediating association with the particulate fractions of cells.
5.2.3.1 Assessment o f the subcellular distribution o f recombinant proteins by 
fractionation
I transiently transfected COS-7 cells to express either wild type (full length) 
RNPDE4A5 or one of the amino terminal truncations of this protein. I then 
fi*actionated the cells by differential centrifugation to produce a low speed (850g) 
pellet fraction (PI), a high speed (lOOOOOg) pellet fraction (P2) and a high speed 
(lOOOOOg) supernatant firaction (S2). This method of fractionation has been routinely 
used by members of our group as a rapid means of determining whether a protein has 
the propensity to interact with subcellular structures (15, 140, 193).
I used lactate dehydrogenase (a marker enzyme for cytosol) enzyme activity assays to 
monitor the efficiency of this fractionation procedure (see section 2.3.4). This 
analysis revealed that, under these conditions, I was able to achieve >96% cell 
breakage and <1% contamination of the pellet fractions by cytosolic proteins.
To assess the distribution of each recombinant PDE between the cell fi-actions I 
performed both PDE enzyme activity assays and semi-quantitative inununoblots on a 
known proportion of each fraction. This allowed me to calculate the percentage of 
both the total PDE enzyme activity and of the total anti-PDE4A immunoreactivity 
present in each fraction.
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5.23.2 Distribution ofRNPDE4A5, RNPDE4A8 and ofMet^^RDl in transfected 
COS-7 cells
First I compared the percentages of the total PDE that were present in each fraction 
of the cells. This revealed that there were significant differences (5% level) in the 
distributions of these species as determined both by semi-quantitative 
immunoblotting and by PDE enzyme activity assays. I then proceeded to partition the 
treatment sums of squares for each fraction and to compare the percentage of 
Met^^RDl present in each fraction with the percentage of the other PDE species, 
taken together, present in that fraction, I did this because there is strong evidence that 
Met^^RDl exists as an exclusively soluble species in transfected cells (140, 171, 200, 
201). This comparison should therefore reveal any propensity of these species to 
associate with the particulate fractions of the cells.
The analysis revealed that the distribution of Met^^RDl, as assessed by semi- 
quantitative immunoblotting, was significantly different (5% level) from those of 
RNPDE4A5 and of RNPDE4A8 but that the distributions of these latter 2 species
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Preliminary experiments indicated that, in my hands, the deletion mutant R6AP4 was 
present in the PI, as well as in the P2 and the S2 fractions of transfected COS-7 cells. 
This was a surprising result because R6AP4 is truncated up to the point at which the 
primary structures of RNPDE4A5 and RNPDE4A8 converge and it has previously 
been reported that only trace amounts of RNPDE4A8 were found associated with the 
PI fraction of transfected COS-7 cells (16), I therefore decided to examine the 
distributions of RNPDE4A5, RNPDE4A8 and of Met26RDl before proceeding with 
the analysis of the other truncation mutants.
I assayed the distributions of both the anti PDE4A immunoreactivity and of the PDE 
enzyme activity between the PI, the P2 and the S2 fractions of COS-7 cells 
transiently transfected with RNPDE4A5, with RNPDE4A8 and with Met^^RDl 
{Figure 5.61). I then used ANOVA to compare the distributions of these PDEs (as 
determined by semi-quantitative immunoblotting and also by PDE enzyme activity 
assays).
were not significantly different fi:om each other (5% level) {Table 5.5.2, Table 5.5.3, 
Table 5.5.4). I then applied this analysis to the distributions of these species as 
assessed by PDE enzyme activity assays. This revealed that whilst the distributions 
of Met^^RDl and of the other 2 species were still judged to be significantly different 
(5% level), there was also a significantly (5% level) greater proportion of the 
RNPDE4A8 than of the RNPDE4A5 present in the S2 fraction and a significantly 
(5% level) smaller proportion of the RNPDE4A8 than of the RNPDE4A5 present in 
the P2 fi-action {Table 5.5.5, Table 5.5.6, Table 5.5.7). It therefore appears that there 
are differences between the distributions of RNPDE4A5 and RNPDE4A8 in 
transfected COS-7 cell fractions but that, in my hands, both of these proteins are 
significantly associated with the PI, as well as with the P2, cell fraction.
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RNPDE4A5
RNPDE4A8
Met^RDl
Distribution of 
Immunoreactivity
PI ^  10±3.7% 
P2 B  14±3.2% 
S2 □  74±6.4%
PI M 14±2.3% 
P 2 B  6±3.4% 
S2 □  80^2.6%
Distribution of 
Enzyme Activity
2± 1.0%
P 2 ®  2±1.1%
S2 □  96±1.3%
PI ^  7±0.5% 
P2 ■  25±2.5% 
S2 □  68± 2.6%
PI ^  7±0.8% 
P2 ■  8±0.7% 
S2 □  85±1.3%
PI M 2±0.6% 
P2 ■  2±0.7% 
S2 □  96±1.4%
Figure 5.61: Distribution o f  PDE4A immunoreactivity and o f  PDE enzyme activity 
in transfected COS-7 cells
The figure shows the percentages o f the total PDE4A immunoreactivity and o f the 
total PDE enzyme activity that were present in the low speed pellet (PI), the high 
speed pellet (P2 ) and the high speed supernatant (S2 ) fractions o f transfected COS-7 
cells. Ihe reported values are the means o f at least 3 determinations with standard 
errors shown.
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Table 5.5.2: ANOVA ofpercentage o f anti PDE4A immunoreactivity in the PI
fraction of transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 269.23 2 134.62 3.00 No
Met^^RD 1 / others 243.84 1 243.84 5.43 Yes
Others 25.39 1 25.39 0.57 No
Error 448.78 10 44.88
Total 718.01 12
Table 5.5.3: ANOVA ofpercentage o f  anti PDE4A immunoreactivity in the P2 
fraction o f  transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p~O.OS
All treatments: 373.46 2 186.73 4.84 Yes
Met^^RD 1 /others 259.30 1 259.30 6.72 Yes
Others 114.16 1 114.16 2.96 No
Error 386.00 10 38.60
Total 759.45 12
Table 5.5.4: ANOVA ofpercentage o f  anti PDE4A immun oreactivity in the S2 
fraction o f  transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p-0.05
All treatments: 1159.04 2 579.52 4.55 Yes
Met^^RD 1 /others 1102.44 1 1102.44 8.65 Yes
Others 56.60 1 56.60 0.44 No
Error 1274.74 10 127.47
Total 2433.78 12
M.B.Beard Mapping the sites within the amino terminal o f RNPDE4A5
responsible for SH3 domain association and for targeting
5-250
M.B.Beard Mapping the sites within the amino terminal of RNPDE4A5
responsible for SH3 domain association and for targeting
5-251
Table 5.5.5: ANOVA ofpercentage o f PDE enzyme activity in the PI fraction of
transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 78.77 2 39.38 17.84 Yes
Mef^RD 1 /others 77.80 1 77.80 35.24 Yes
Others 0.97 1 0.97 0.44 No
Error 19.87 9 2.21
Total 98.63 11
Table 5.5.6: ANOVA ofpercentage o f  PDE enzyme activity in the P2 fraction o f  
transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 953.66 2 476.83 80.55 Yes
Met^ ^RD 1 /others 417.25 1 417.25 70.48 Yes
Others 536.41 1 536.41 90.61 Yes
Error 53.28 9 5.92
Total 1006.93 11
Table 5.5.7: ANOVA o f  percentage o f  PDE4 enzyme activity in the S2 fraction o f  
transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 1438.61 2 719.30 66.34 Yes
Met^ ^RD 1 / others 855.74 1 855.74 78.92 Yes
Others 582.87 1 582.87 53.76 Yes
Error 97.58 9 10.84
Total 1536.19 11
5.2.33 Distribution ofRNPDE4A truncation mutants in COS-7 cells
I then proceeded to use the amino terminal truncations in RNPDE4A5, namely R6A3,
R6A4, R6A5, R6A6, R6A7 and Met^^RDl to locate the regions, within the amino 
termini of long form PDE4A splice variants, that are involved in their association 
with the particulate fraction of COS-7 cells. For this analysis I needed to set criteria i
for a truncation to be regarded as retaining the ability to associate with particulate 
cell fr actions. I set this as there being a significantly greater proportion of a species 
present in a particulate cell fraction than of Met^^RDl in that fraction, I decided on 
this criteria because there is strong evidence that Met '^^RDl exists as an exclusively 
soluble species in transfected COS-7 cells (140, 171, 200, 201).
'Ef
As with my previous analysis of the distributions of RNPDE4A5, RNPDE4A8 and 
Met^^RD 1,1 transfected COS-7 cells to express transiently each of the proteins. I 
then fractionated the cells by differential centrifugation to produce a PI, a P2 and an 
S2 fraction. I compared the distributions of each protein, as determined by semi- 
quantitative immunoblotting and also by PDE enzyme activity assays, by using the 
technique of ANOVA {Figure 5.62, Table 5.5.8, Table 5.5.9, Table 5.5.10, Table 
5.5.11, Table 5.5.12, Table 5.5.13).
I first compared the percentages of the total PDE that were present in each cell 
fraction. After this I proceeded to paitition the treatment sums of squares for each 
fraction and to compare the percentage of Met^^RDl present in each fraction with the 
percentage of the other PDE species, taken together, present in that fr action (Table 
5.5.8, Table 5.5.9, Table 5.5.10, Table 5.5.11, Table 5.5.12, Table 5.5.13). This 
analysis revealed that, although there were significant differences (5% level) between 
the distributions of the truncations R6A3, R6A4, R6A5, R6A6 and R6A7 (as judged 
by PDE enzyme activity assays) all of these species satisfied the criteria for being 
regarded as associated with the particulate fractions of the cells.
That the truncation R6A7 is found associated with the particulate fractions of COS-7 
cells shows that amino acids 1-217 in RNPDE4A5 are not necessary for the 
association of this protein with the particulate cell fractions. Furthermore, taken
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with the observation that Met^^RDl does not associate with the particulate cell
fractions, my analysis shows that the region between amino acids 218-259 in %RNPDE4A5 is involved in targeting the protein to the particulate cell fractions.
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R6AP3
R6AP4
R6AP5
R6AP6
R6AP7
Met^^RDl
Distribution of 
Immunoreactivity
PIQ 10±3.7% 
P2I3 14±3.2% 
S2D 74±6.4%
PIO 12±3.2% 
P21B 18±5.2% 
8 2 0  70±7.7%
PIO 8±2,8% 
P2E 8±0,3% 
8 2 0  84±3.1%
PIO 9±4,1% 
P 20  11±2.7% 
8 2 0  80±3.8%
PIQ 20±4.9% 
P 2 0  14±4.1% 
8 2 0  65±4.1%
PIO 20±2.1% 
P 20  16±2.6% 
8 2 0  64±0.5%
PIO 2±1.0% 
P2H 2±1.1% 
8 2 0  96±1.3%
Distribution of 
Enzyme Activity
PIQ 7±0.5% 
P 20  25±2.5% 
8 2 0  68±2.6%
PIQ 9±0.7% 
P2H 17±1.2% 
8 2 0  74±1.9%
PIQ 5±0,7% 
P2B 8±0.4% 
8 2 0  87d=0.9%
PIO 6±0.5% 
P2B 23±3.1% 
8 2 0  72±2.7%
PIO 5±0.9% 
P 2 0  16±1.0% 
8 2 0  79±1.5%
PIO 4±0.2% 
P2Q 12±0.7% 
8 2 0  83±0.7%
PIO 2±0.6% 
P2B 2±0.7% 
8 2 0  96±1.4%
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Figure 5,62: Distribution o f  PDE4A immunoreactivity and o f  PDE enzyme activity 
in transfected COS-7 cells
The figure shows the percentages o f the total PDE4A immunoreactivity and o f the 
total PDE enzyme activity that were present in the low speed pellet (PI), the high 
speed pellet (P2) and the high speed supernatant (S2) fractions o f transfected COS-7 
cells. The reported values are the means o f at least 3 determinations with standard 
errors shown.
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:Table 5,5.8: ANOVA ofpercentage of anti PDE4A immunoreactivity in the PI
fraction of transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 1002.10 6 167.02 2.43 No
Meri^RD 1 /others 456.02 1 456.02 6.64 Yes
Others 546.08 5 109.22 1.59 No
Error 1373.63 20 68.68
Total 2375.73 26
Table 5,5.9: ANOVA ofpercentage o f  anti PDE4A immunoreactivity in the P2 
fraction o f  transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen
t p=0.05
All treatments: 674.03 6 112.34 1.87 No
Met^^RDl/others 519.71 1 519.71 8.64 Yes
Others 154.33 5 30.87 0.51 No
Error 1203.27 20 60.16
Total 1877.31 26
Table 5,5,10: ANOVA ofpercentage o f  anti PDE4A immunoreactivity in the S2 
fraction o f  transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 2914.313 6 485.72 3.80 Yes
Met^ *^ RD 1 /others 2006.55 1 2006.55 15.71 Yes
Others 907.76 5 181,55 1.42 No
Error 2554.50 20 127.73
Total 5468.82 26
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Table 5,5.11: ANOVA ofpercentage o f PDE enzyme activity in the PI fraction o f
transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=O.OS
All treatments: 106.00 6 17.67 13.82 Yes
Met^^RD 1 /others 63.77 1 63.77 49.90 Yes
Others 42.22 5 8.44 6.61 Yes
Error 21.73 17 1.28
Total 127.72 23
Table 5.5.12: ANOVA ofpercentage o f  PDE enzyme activity in the P2 fraction o f  
transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 1478.76 6 246.46 16.96 Yes
Met^^RD 1 / others 753.12 1 753.12 51.83 Yes
Others 725.64 5 145.13 9.99 Yes
Error 247.04 17 14.53
Total 1725.8 23
Table 5,5.13: ANOVA o f  percentage o f  PDE4 enzyme activity in the S2 fraction o f  
transfected COS-7 cells
Sources of variation Sums of 
squares
Degrees
of
Mean
squares
F Differen 
t p=0.05
All treatments: 2209.19 6 368.20 25.75 Yes
Met^^RD 1/others 1242.10 1 1242.10 86.88 Yes
Others 967.09 5 193.42 13.53 Yes
Error 243.06 17 14.30
Total 2452.24 23
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5.2.4 Mapping the regions of sequence within the amino terminal of 
RNPDE4A5 which affect the PDE enzyme activity
Regions of sequence contained within the amino termini of PDE4 isoforms have 
been suggested as affecting the kinetic properties of these enzymes (16, 87). This 
implies that the amino terminal regions of these isoforms, although not necessary for 
catalysis, nevertheless, may influence the conformation of the active site. Truncation 
of both PDE4A and PDE4D isoforms at the amino terminal causes an increase in the 
Vmax of the enzyme which, in the case of rat PDE4A, appears not to be 
accompanied by any change in the Km for cAMP (84, 93, 95, 140, 200). I therefore 
decided to use the truncations R6A1-Met^^ RDI to define more precisely the regions 
within the amino terminus of RNPDE4A5 that affect the rate of cAMP hydrolysis.
I transfected COS-7 cells to express either wild type (full length) RNPDE4A5 or one 
of the amino terminal truncations of this protein. I then performed PDE enzyme 
activity assays on a known amount of the cytosolic fraction fi*om each transfection, 
and used semi-quantitative immunoblots to correct for differences in the levels of 
expression of the various preparations {Table 5.5.14),
I used paired t-tests to determine whether the coiTected specific activity of each of the 
truncated mutants was significantly different fi'om that of wild type RNPDE4A5.
This analysis revealed that, of the truncations that Ï examined, only Met^^RDl was 
significantly more active than wild type RNPDE4A5. This finding agrees with 
previous studies in which the relative Vmax of Met^^RDl was found to be 7 fold 
higher than that of RNPDE4A5 and with another study in which the relative Vmax of 
R6A3 was found not to be significantly different from that of RNPDE4A5 (16, 140)[ 
Huston and others, manuscript in preparation].
These data suggest that the region of RNPDE4A5 between residues 218-259 is 
important in regulating both the catalytic activity and the sub-cellular targeting of the 
enzyme.
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Construct Relative specific 
activity 
(arbitrary units)
Different from 
RNPDE4A5 
(5% level)
RNPDE4A5 1 No
R6A1 1.5±0.10 No
R6A2 1.6±0.09 No
R6A3 1.5±0.08 No
R6A4 1.4±0.14 No
R6A5 1.83=0.26 No
R6A6 1.33=0.20 No
R6A7 1.73=0.15 No
Mct^RDl 2.93=0.57 Yes
Table 5,5.14: Relative specific activities o f truncations in RNPDE4A5
The table shows the relative specific activities o f a series o f truncations in 
RNPDE4A5. A known amount o f the cytosolic fraction o f transiently transfected 
COS-7 cells expressing either full length RNPDE4A5 or one o f the truncations in this 
species was assayed for PDE enzyme activity. Semi quantitative immunoblots were 
then used to correct for differences in the levels o f expression between preparations. 
The specific activity o f each truncation is shown relative to that offull length 
RNPDE4A5 (arbitrarily set at I). Paired t-tests were used to test whether the 
corrected specific activity o f each truncation was significantly different from that to 
full length RNPDE4A5. The reported values o f relative specific activity are the 
means o f at least 2  determinations with standard errors shown.
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5.3 Conclusions
In this chapter I have mapped regions of sequence within the amino terminal of 
RNPDE4A5 that are necessary for the interaction of this isoform with the SH3 
domain of Lyn kinase, are involved in the targeting of RNPDE4A5 and of 
RNPDE4A8 to the particulate fractions of COS-7 cells and are involved in regulating 
the activity of rat PDE4A isoforms.
5.3.1 Interaction of RNPDE4A5 with SH3 domains
The extreme amino teiminal region of RNPDE4A5 (residues 1-103) is necessary for 
its interaction with the SH3 domain of Lyn kinase. Within this region the first 10 
residues seem to be especially important for the interaction. Deletion of residues 1- 
10 caused a large decrease in the degree of binding observed in pull down assays 
(443=5% binding of RNPDE4A5, 193=3% binding of R6A1 ). Deletion of these 10 
residues removes the first of the 3 PxxP motifs that occur in the amino terminal 
region of RNPDE4A5. Two further truncations in the amino terminal region of 
RNPDE4A5 that remove the first 42 residues (R6A2) and the first 67 residues 
(R6A3), did not seem to produce much further reduction in binding to the SH3 
domain of Lyn kinase. The deletion R6A2 removes the first 2 of the 3 PxxP motifs 
and the deletion R6A3 removes all 3 of the PxxP motifs that occur in the amino 
terminal region of RNPDE4A5.
The first 10 residues of RNPDE4A5 contain the motif PAAPSER. This conforms to 
the consensus PxxP that has been suggested as being able to confer binding to SH3 
domains. It therefore seems plausible that this motif in RNPDE4A5 may represent 
the primary site of interaction between RNPDE4A5 and the SH3 domain of Lyn 
kinase in these assays. This region of sequence is well conserved in HSPDE4A4B, 
the human homologue of RNPDE4A5 {Figure 5.55). The results that I have obtained 
with R6A1 are in good agreement with the finding that a truncated form of 
HSPDE4A4B, in which residues 1-14 are deleted, called lOA, also shows a marked
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reduction in binding to SH3 domains compared to full length HSPDE4A4B (87).
The lower but, nevertheless significant, degree of binding between the truncations 
R6A1 "  R6A3 and the SH3 domain of Lyn kinase may be due to additional contacts 
between the PDE and the SH3 domain. Specific interactions between SH3 domains 
and regions outside of the core PxxP motif have been demonstrated using biased, 
dodecapeptide, phage display libraries and it is possible that regions of sequence 
even further removed fi'om the core PxxP motif may also interact with an SH3 
domain (61, 176).
The truncated form R6A4, in which the entire 102 residue, alternatively spliced 
region of RNPDE4A5 was deleted, did not interact significantly with the SH3 
domain of Lyn kinase. This is consistent with the finding that another long form 
splice variant of PDE4A, namely RNPDE4A8, did not interact with the SH3 domain 
of Lyn kinase in pull down assays (162) as the amino acid sequence of R6A4 is 
entirely contained within that of RNPDE4A8. Taken together these findings 
implicate the region between residues 68-102 of RNPDE4A5, that is to say the 
region that is present in R6A3 but deleted in R6A4 {Figure 5.56), as being involved 
in the interaction between RNPDE4A5 and SH3 domains.
Another possibility that can not be excluded is that deletion of the first 10 residues of 
RNPDE4A5 may alter the stiucture of some other region within the protein that is the 
tiue site of the interaction with the SH3 domain of Lyn kinase. Under this model 
deletion of residues 1-10 in RNPDE4A5 would alter the structure of the SH3 domain 
binding region so as to reduce the strength of the interaction and the deletion of 
residues 1-103 would either further alter the structure of or delete this region so as to 
completely abolish the interaction.
5.3.2 Targeting of PDE4 isoforms
There has previously been speculation that the targeting of RNPDE4A5 to the 
particulate firactions of cells may involve its binding to an SH3 domain contained
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targeting of this enzyme.
Of all the truncations in RNPDE4A5 that I have examined, only Met^^RDl did not 
become associated with the particulate cell fractions. This implicates residues 218- 
259 of RNPDE4A5 {Figure 5.56) as being involved targeting the protein to the 
particulate cell fractions. It does not, however, show that residues 218-259 are either 
necessary or sufficient for this tar geting.
To address the question of whether the region between residues 218-259 is necessary 
to target RNPDE4A5 to the particulate cell fractions it will be necessary to construct 
a internal deletion mutant of RNPDE4A5 in which just these residues are deleted. To 
address the question of whether the region between residues 218-259 is sufficient to 
target RNPDE4A5 to the particulate cell fractions it will be necessary to construct 
chimeric proteins comprising this region of RNPDE4A5 and some heterologous, 
normally soluble protein such as GST or chloramphenicol acetyltransferase (CAT). 
This approach has been used previously to demonstrate that the alternatively spliced, 
amino terminal region of RNPDE4A1 is sufficient to target proteins to the particulate 
fr actions of cells (194).
On the basis of the currently available evidence it remains entirely possible that more 
than one region within the amino terminal of RNPDE4A5 may be involved in the 
sub-cellular targeting of this isoenzyme. Indeed, analysis of the sub-cellular 
distributions of RNPDE4A5 and of R6A3 by immunofiourescent confocal 
microscopy has shown differences between the sub-cellular distributions of these
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within an anchoring protein that is itself located to those cell fractions.
In this study I have shown that the region of sequence that is necessary for the 
interaction of RNPDE4A5 with the SH3 domain of Lyn kinase is not also necessary 
for the targeting of RNPDE4A5 to particulate cell fractions. This shows that the 
ability of RNPDE4A5 to become associated with the particulate fractions of cells is 
not solely mediated by its binding to an SH3 domain. It is important to note, 
however, that these data do not exclude the possibility that an interaction between
RNPDE4A5 and an SH3 domain may nevertheless be involved in the sub-cellular
enzymes [Huston and others, manuscript in preparation]. This finding suggests that 
the extreme amino teiminal region of RNPDE4A5, although not necessary for 
targeting to the pai ticulate cell fractions, does have some effect on the sub-cellular 
targeting of RNPDE4A5.
5.3.2.1 The region implicated in the subcellular targeting o f RNPDE4A5 
corresponds to the amino terminal portion ofUCR2
The amino termini of all long isoforms of PDE4 are characterised by the presence of 
2 highly conserved regions of sequence, namely UCRl and UCR2. Short isoforms of 
PDE4 do not contain UCRl but do contain either the entire of or, in the cases of 
PDE4A1 and PDE4D2, just the carboxyl terminal portion of UCR2 (see sections
1.3.1 and 6.1). The region of sequence between residues 218-259 in RNPDE4A5, 
that my data has implicated as being involved subcellular targeting, corresponds to 
the amino terminal portion of UCR2. This region of sequence is therefore well 
conserved in other members of the PDE4 enzyme family. The only known, active 
PDE4 splice variants that do not contain this region of sequence are PDE4A1 and 
PDE4D2.
Examination of the subcellular distributions of other PDE4 splice variants makes it 
seem unlikely that the sequence between residues 218-259 of RNPDE4A5 can be 
sufficient for the targeting of a protein to the particulate fi*actions of cells {Figure
5.63). The short form PDE4B splice variant PDE4B2 contains an intact UCR2 and 
this species is able to associate with the particulate fractions of COS-7 cells (26%P1, 
12%P2, 61%S2) (92). The short form PDE4D splice variant PDE4D2 does not 
contain the amino terminal portion of UCR2 and this species is entirely soluble in 
transfected COS-7 cells (15). The short foim PDE4D splice variant PDE4D1, 
however, contains an intact UCR2 region and this species is also entirely soluble in 
COS-7 cells (15). This last example is not consistent with the amino terminal portion 
of UCR2 being sufficient for the association of PDE4 with the particulate fractions of 
cells.
A further complication arises because there appear to be species differences between
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the sub-cellular tai'geting of rat and human PDE4A isoenzymes. The cDNA clone 
HSPDE4A4C (h6.1) encodes for an amino terminal truncation in human PDE4A that 
includes an intact UCR2, catalytic region and carboxyl terminal region of the enzyme 
(residues 210-886 in HSPDE4A4B). As such this species can be considered to be a 
human homologue approximating to the rat PDE4A species R6A7. The sub-cellular 
distribution of HSPDE4A4C is, however, markedly different from that of R6A7. 
HSPDE4A4C is present in the PI and the S2 fractions (approximately 23% and 76% 
respectively) but only trace amounts are present in the P2 fraction (approximately 
1%) of transfected COS-7 cells (141).
Although HSPDE4A4C is targeted to the PI fraction of transfected COS-7 cells this 
targeting is not mediated by the amino terminal portion of UCR2. Rather, the 
association of HSPDE4A4C with the PI fraction is dependent on a proline and 
arginine rich motif, that is located within LR2 (residues 305-331 in HSPDE4A4B) 
(141) but that is not conserved in rat PDE4A isoforms (see sections 1.3.1 and 
1.3.2.2). In addition to its role in sub-cellular targeting, the proline and arginine rich 
motif in the LR2 region of human PDE4A is both necessary and sufficient for the 
interaction of HSPDE4A4C with SH3 domains such as those of Src and Lyn kinase. 
Internal deletions that delete this motif abolish the association of the HSPDE4A4C 
with both the PI cell fraction and with SH3 domains (141). It therefore appears that, 
although the amino terminal portion of UCR2 in rat PDE4A has a role in targeting 
the enzyme to the particulate fractions of cells, the presence of this region in human 
PDE4A is not sufficient to target these enzymes to either the PI or to the P2 cell 
fractions.
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Sub-cellularDistribution
Pî P2 S2
R6A7 20% 16% 64%
Met^RDl 2% 2% 96%
HSPDE4B2 26% 12% 61%
HSPDE4D1 4% 3% 93%
HSPDE4D2 2% 4% 94%
Figure 5.63: Comparison o f  the sub-cellular distributions o f  various PDE4 species
The figure shows a comparison o f the sub-cellular distributions o f various short form  
splice variants and amino terminally truncatedforms o f PDE4. The legends along 
the left hand side o f the figure identify each protein. The green hieroglyphics 
represent the portion o f UCR2 that is present in each o f the proteins. In the cases o f 
R6A7, HSPDE4B2 andHSPDE4D1 a large green box is drawn to indicate that these 
species each contain and intact UCR2. In the cases o f  Me RDI and HSPDE4D2 a 
smaller green box is drawn to indicate that these species each contain only the 
carboxyl terminal region o f UCR2. None o f the boxes representing these species are 
closed at the right hand sides; this is to indicate that these proteins all contain 
sequence that lies carboxyl terminal to UCR2 . The boxes representing HSPDE4B2 
and HSPDE4DI are not closed at the left hand side; this is to indicate that these 
proteins contain sequence that lies amino terminal to UCR2. The numbers along the 
right hand side o f the figure refer to the proportion o f each species that fractionates 
with the PI, P2 and S2 cell fractions (as assessed by quantitative immunohloting).
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5.3.3 Regulation of the catalytic activity of PDE4 isoforms
The observation that certain truncations and deletions within the amino termini of 
PDE4 isoforms led to an increase in the activity of certain of these enzymes has 
prompted the suggestion, by Conti and co workers, that UCR2 of PDE4 isoforms is 
an autoinhibitory region (41, 99, 122). This hypothesis is based largely on the results 
of work on the human PDE4D isofoims HSPDE4D1, HSPDE4D2 and HSPDE4D3. 
These studies located the region of sequence necessary for the inhibitory effect as 
that lying between amino acids 167-212 in HSPDE4D3 (99, 108, 122). This 
corresponds to the carboxyl terminal portion of UCR2 (amino acids 134-212 in 
HSPDE4D3).
The published data concerning the HSPDE4D isoforms support a relatively simple 
model in which a sub-domain within UCR2 is responsible for constraining the 
activity of the catalytic region. It is more difficult, however, to extend this model to 
accommodate the published data concerning the other PDE4 enzyme families 
(discussed below).
A study conducted on full length and truncated forms of HSPDE4A4A, expressed in 
yeast, supported (as do all relevant studies of which I am awar e) the involvement of 
sequence, lying amino terminal to the catalytic region of PDE4 enzymes, in an 
inhibition of the catalytic activity (95). The location of the sequence necessary for the 
inhibition, in this case however, was not within UCR2 but it within the poorly 
conserved LR2, between UCR2 and the catalytic region. Indeed, truncation of 
HSPDE4A4A up to the end of UCR2 (amino acid 305) resulted in a marked 
inhibition of this truncation compared to full length protein.
It should be noted, however, that the clone HSPDE4A4A encodes a protein that 
differs at 9 amino acids fi'om the clone, HSPDE4A4B. The clone HSPDE4A4B is 
widely accepted as representing the true, wild type sequence of this human PDE4A 
isofoim. In contrast, HSPDE4A4A is thought to represent either a cloning artefact or 
a mutated enzyme (224). It should also be noted that the Km for cAMP of full length 
HAPDE4A4A, in this study, was determined to be lOpM (95). This value is rather
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higher than the values of Km determined for the truncations of HSPDE4A4A 
examined in the same study (3pM). The value of lOgM for the Km of full length 
HSPDE4A4A is also higher than that reported by Livi and others (3pM) in the 
original report of this clone, where HSPDE4A4A was expressed in COS-1 cells 
(125).
The situation regarding human PDE4A is fuiiher complicated by the observation that 
the human PDE4A clone, HSPDE4A4C, has a relative Vmax that is 11 fold higher 
than that of HSPDE4A4B when each is expressed in COS-7 cells (224) (93). As 
HSPDE4A4C retains the entire of UCR2 this observation does not support a simple 
model in which part of UCR2 acts as the sole inhibitoiy domain contained in the 
amino terminal region of PDE4 (122).
Tmncations within UCR2 of rat PDE4A do not appear to have the same effect on 
activity as do equivalent truncations in the human enzyme. In this regard the 
truncation in rat PDE4A, R6A7, that corresponds to the human species HSPDE4A4C, 
was not activated relative to full length RNPDE4A5 {Table 5.5.14).
The published data concerning isoforms of HSPDE4B (92) are also at variance with a 
simple model in which a subdomain within UCR2 is solely responsible for the 
inhibitory action of the amino termini of PDE4 isoforms (122). This is because the 
short form PDE4B splice variant HSPDE4B2 contains an intact UCR2 but 
nevertheless exhibits a Vmax that is approximately 4 fold higher than that of the long 
form splice variant HSPDE4B1 (92). This suggests that some region within the 
amino terminal of HSPDE4B1 other than UCR2 is involved in constraining the 
catalytic activity of this isoenzyme.
Therefore, although sequence lying amino teiminal to the catalytic region of PDE4 
isoforms seems to be able to influence the conformation of the active site and can 
cause a reduction in enzyme activity it is difficult, on the basis of the evidence 
currently available, to formulate a simple model to explain this effect.
In interpreting the available data it should be noted that comparing data fi'om these
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different studies is complicated by a number of potential problems. These include (a) 
the folding of the catalytic region of truncated enzymes may be altered compared to 
the full length species (b) differences in the expression backgrounds used between 
the various studies may have resulted in differences the post-translational 
modifications of the enzymes (c) differences in the expression backgrounds may 
have resulted in differences in the interaction of these enzymes with regulatoiy 
molecules.
If there is some common mechanism for constraining the activity of PDE4 isofonns 
that is associated with the amino termini of these proteins, then the sequence 
responsible for this must be located within the carboxyl terminal region of UCR2 as 
this is the only conserved region outside of the catalytic domain that is present in all 
known, active, PDE4 splice variants.
One possibility is that regions within the amino termini of individual PDE4 isoforms 
may regulate the interaction between an autoinhibitory region, located in the 
carboxyl terminal of UCR2, and the catalytic site of the enzyme. If this were the case 
then differences in the phosphorylation state, for instance, of a PDE4 that was 
examined in one of 2 different expression backgrounds might result in there being 
differences in the effects of truncating this species depending upon which expression 
background was used.
Another possibility is that more that one region within the amino termini of 
individual PDE4 isoforms may be able to interact directly with the catalytic unit to 
regulate its activity. If this were the case then a truncation in the enzyme that 
removed one of the regulatory regions might or might not result in a change in the 
enzyme activity, depending upon the interactions between the catalytic region and 
other regions of the protein. These, in turn, may vary depending upon the 
phosphorylation state and other regulatory influences on the PDE in the particular 
expression background used.
It is also possible that deletions and truncations may affect the quaternary structures 
of PDE4 isoforms that exist as dimers or as higher order oligomers. Such changes
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could be, at least partially, responsible for the observed changes in activity. In this 
regard splice variants of PDE4D and of PDE4B have been found to form dimers or 
higher order oligomers in cells (40, 108, 178, 179). In contrast to this the human 
PDE4A clone HSPDE4A4C has been found to exist as a monomeric species (245).
It has been argued that effects on quaternary structure are unlikely to account for the 
effects of amino terminal truncations in PDEs on their catalytic activity because the 
regions important for dimerization of PDE4s have been putatively mapped to the 
carboxyl termini of the proteins (122). It seems to me, however, entirely plausible 
that a region within a multi subunit protein may affect its quaternary structure 
regardless of whether or not it is necessary for the oligmerization of that protein. 
Furthermore, although the carboxyl terminal regions of PDE4s are implicated in the 
foimation of dimers and tetramers (108), regions in the amino terminal of both 
PDE4B and PDE4D have been implicated in the formation of higher order oligimers 
(108, 178, 179). This suggests that the amino termini of PDE4 isoforms can have an 
effect on the quaternary structures of these proteins.
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6. Electrostatic interactions between UCRl and UCR2
6.1 Introduction
The sequences of all known mammalian 3’5’ cyclic nucleotide phosphodiesterases 
(PDEs) share homology with one another over a region of approximately 300 
residues that are located towards the carboxyl terminal end of the proteins. This 
represents the only region of sequence that is conserved between all mammalian 
PDEs and there is good evidence that this is the location of the catalytic site of these 
enzymes (31, 95, 99). In addition to the catalytic region, the members of individual 
PDE enzyme families often share other conserved regions of sequence. In the case of 
the PDE4 enzyme family, that is encoded by 4 genes, there are 2 regions of sequence 
that are highly conserved. These aie called Upstream Conserved Regions 1 and 2 
(UCRl and UCR2) and are present in the amino termini of these proteins {Figure
6.64) {\3, 14).
These UCRl and UCR2 of PDE4s appear to form distinct, modular entities as they 
are separated from each other by a region of poorly conserved sequence and they do 
not show homology to one another. Indeed, neither UCRl nor UCR2 shares 
homology with any other sequence in the Swissprot database (last searched 28/9/99). 
The sequences of UCRl and UCR2 show strong evolutionary conservation 
throughout the mammalian PDE4s and even between species as distantly related as 
Drosophila and humans. This suggests that UCRl and UCR2 are important as 
sequences that are strongly conseiwed in evolution are often of functional 
significance.
Further evidence to suggest that UCRl and UCR2 may have functional significance 
is that a major point of splicing in mammalian PDE4 genes, and in the dunce gene of 
Drosophila, lies between the exons that encode UCRl and UCR2. Alternative 
splicing in this region leads to the production of either long PDE4 isoforms, that 
include UCRl, or short PDE4, isofonns that do not include UCRl, but that contain
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all or apart of UCR2 (see section 1.3.1).
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Figure 6.64: Structures of UCRl and UCR2
The figure shows the positions o f conserved regions o f sequence within PDE4 
isoforms. Panel A shows a schematic diagram o f the 5 mRNA transcripts from the 
human PDE4D gene. The grey bar indicates sequences homologous to those in other 
PDE4 families. The regions o f strongest conservation, the catalytic region, UCRl 
and UCR2 are indicated by the red box each o f the 2 cross hatched areas 
respectively. The black bars represent the regions o f sequence that are unique to 
each isoform. The black boxes represent the positions o f the initiating ATG o f each 
splice variant and the black star represents the termination codon o f the open 
reading frames. Panel B shows an alignment o f the amino acid sequences o f the 
common amino terminal regions o f the human PDE4 isoforms and o f the dunce PDE 
o f Drosophila melanogaster. The alignment begins at the point at which the 
sequences ofHSPDE4D3, HSPDE4D4 and HSPDE4D5, in the human PDE4D 
family, converge and it extends to the beginning o f catalytic region. The numbering 
o f the alignment corresponds to the amino acid sequence o f HSPDE4D3. Regions o f 
sequence that are conserved between PDE4 isoforms and the dunce PDE are 
coloured green. Residues that have been mutated in various o f the constructs used in 
this study are indicated by bold type and also by arrows. The regions o f sequence 
that were included in the MBP-UCRl, the MBP-UCRl-C and the GST~~UCR2 fusion 
proteins are underlined in red, blue and yellow respectively.
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g6.1.1 Sequence analysis of UCRl and UCR2
Sequence analysis of the primary structures of UCRl and of UCR2 reveals that these 
regions have very different predicted characteristics. UCRl (residues 50-109 in 
HSPDE4D3) comprises a polai' amino terminal region (residues 50-84 in 
HSPDE4D3) and an apolar carboxyl terminal region (residues 85-109 in 
HSPDE4D3). In contrast to this the entire of UCR2 (residues 134-212 in 
HSPDE4D3), is composed predominantly of residues with polar side chains. This
1region is predicted to be hydrophilic in nature.
Within the polar, amino terminal portion of UCRl, 37% of the residues have charged 
side chains. The occurrence of positive and negatively charged side chains in this 
region, however, is evenly balanced and the net charge is 1 positive. Secondary 
structure predictions indicate that this portion of UCRl is likely to be highly flexible. 
In contrast, 63% of the residues within the carboxyl terminal portion of UCRl have 
apolar side chains. Helical wheel analysis of this region suggests that it may be able 
to form an amphipathic helix with the few charged groups that do occur here focused 
on a discrete side of the molecule (87).
Secondary structure predictions of UCR2 indicate that it may foim a series of 3 
helical regions. The first and the third of these putative helical regions are predicted 
to be negatively charged (anionic) whilst the second of the putative helical regions is 
predieted to have a slightly positive net charge (cationic) (87).
6.1.2 Putative functions of UCRl and UCR2
Although the functional significance of UCRl and UCR2 has not yet been resolved f
putative functions for each of these regions have been proposed. These include 
possible roles for regions within UCR2 in the targeting of PDE4 isoforms and in 
constraining the catalytic activity of these enzymes, also a role for UCRl as a site of 
regulation by protein kinase A (PKA) has been shown for PDE4D3. UCRl is 
possibly a site for regulation by PKA in other long PDE4 isoforms as well (see 
sections 5.3.2-5.3.3) (122).
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6.1.2.1 Regulation ofHSPDE4D3 activity by phosphorylation within UCRl
A consensus motif, of the form RRxS, for phosphorylation by PKA is present at the 
amino terminal end of UCRl (residues 51-54 in HSPDE4D3). There is strong 
evidence that PDE4D3 can be phosphoiylated, in vivo, by PKA at this site and that 
this results in an activation of the enzyme (see section 1.3.5.3) (2, 82, 197, 198).
As the PKA recognition motif within UCRl is conserved in all long isoforms of 
PDE4 one might expect that these enzymes would also be substrates for PKA. There 
are, however, no published reports to date that PKA can phosphorylate other PDE4 
isofoims at this site. In the initial reports of the phosphoiylation, by PKA, of 
PDE4D3 it was reported that splice variants of PDE4A and PDE4B that contain 
UCRl were not significantly activated following treatment with PKA and Mg^^ATP 
(2, 197). It has recently been shown, however, that long PDE4B, PDE4C and PDE4D 
isoforms can be phosphoiylated on a serine residue (Ser^ ^^  in HSPDE4D3) by ERK2 
and that this causes an inhibition of the enzyme activity of these isoforms. The 
subsequent phosphorylation of these proteins by PKA causes a recovery of their 
activities to basal levels [Bailliey and MacKenzie personal communication]. As this 
effect of PKA on HSPDE4D3 is due to its phosphorylation of Seri'  ^(the PKA site in 
UCRl) this suggests that this site in other long PDE4 isoforms may also be a 
substrate for PKA (see section 1.3.5.4). To my knowledge, however, no study has 
directly examined the phosphorylation of this motif by PKA in any isoform other 
than PDE4D3.
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Various portions of the HSPDE4D3 cDNA were cloned into the two-hybrid vector 
pLEXAN and such constructs were then used as baits in two-hybrid screens. All of 
the constructs that included the amino terminal half of UCRl produced very high
 ^This project was conducted in collaboration with Prof. G. Bolger, University o f Utah who 
constructed all o f  the plasmids used in this project and who also performed all o f  the yeast two-hybrid 
screens described in this chapter, subsequent to discussions with m yself and my supervisor. 6-276 
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6.2 Results and Discussion^
There is precedent for interactions between regions within the amino termini of 
PDE4 isoforms and other proteins. Examples of this include: the interaction of PDE 1 
isoforms with calmodulin; the interaction of the a  and p subunits of PDE6 isofoims 
with their y subunits; the interactions of the PDE4 isofbrms HSPDE4A4B and "'■fiHSPDE4D4 with SH3 domains and the interaction of HSPDE4D5 with RACKl (7,
70, 141, 252). UCRl and UCR2 seemed to be good candidates for forming 
regulatory regions of PDE4 enzymes as PKA regulates at least 1 PDE4 isoenzyme by 
phosphorylating a serine residue located within UCRl. It therefore seemed plausible 
that either one or both of UCRl and UCR2 might interact with the catalytic region of 
the enzyme. It was speculated that UCRl and UCR2 might even interact to create a 
regulatory module within the enzyme.
6.2.1 Isolation of UCR2 as and interaction partner for UCRl in a two-hybrid 
screen
The two-hybrid screen is a powerful genetic approach for the isolation of cDNAs 
encoding proteins that can interact with a protein of interest. It was by this method 
that the interaction between PDE4D5 and RACKl was first identified (252). In 
collaboration with our laboratory Prof. G. Bolger decided to use a two-hybrid method 
to screen for cDNAs encoding potential interacting partners for UCRl or UCR2.
Subsequently, mutated forms of UCRl and UCR2 were also tested after discussions &
between myself, my supervisor and Prof. Bolger.
6.2.1.1 The carboxyl terminal half o f UCRl interacts with another region within 
PDE4D
background “noise” (false positives) in these two-hybrid assays and therefore could 
not be used as baits in a screen. The reasons for the high background noise associated 
with these constructs were not established but it was speculated that the 
concentration of charged, acidic residues in the amino teraiinal region of UCRl may 
have been sufficient to produce transcriptional transactivation activity when coupled 
to the LexA DNA binding domain, even in the absence of the normal activation 
domain.
To circumvent the problem of high background noise associated with baits 
containing the amino terminal portion of UCRl, the plasmid pLEXAUlD was 
constructed. This plasmid encoded just the carboxyl terminal portion of UCRl 
(residues 80-116 in HSPDE4D3) as a fusion protein with the LexA DNA binding 
domain. This construct produced a sufficiently low background in control assays to 
be used as the bait in a two-hybrid screen.
A HeLa cell cDNA library was selected for the screen because several PDE4D 
species are present in HeLa cells. It was, therefore, considered likely that proteins 
which interact with UCRl of PDE4D might also be present in this library (15). Of a 
total of 6x10^ recombinants that were screened, approximately 220 were HIS+, and 
of these, 82 were also LacZ+. Only 9 of the 82 LacZ+ recombinants were still 
positive after retrieval of the library fi'om the yeast cells and the subsequent re-testing 
for interaction with pLEXAUlD. Five of these 9 remaining positives encoded non 
physiological fusion proteins, in which the open reading firame incorporated in the 
GAL4 fusion was different fiom that of the protein encoded naturally by the cDNA. 
All of these were discarded. All 4 of the remaining plasmids encoded an identical 
insert, consisting of a truncated PDE4D cDNA that encoded all of UCR2 and the 
catalytic region of the protein, but none of UCRl. This suggested that the carboxyl 
terminal region of UCRl potentially interacted with other regions of the PDE4D 
protein located in UCR2, the catalytic region or the extreme carboxyl terminal of the 
protein.
To obtain supporting data that the interaction detected in this two-hybrid screen was 
specific, yeast two-hybrid p-galactosidase assays were used to test the two-hybrid
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positive clone with a variety of baits expressed as LexA fusions. These included 
lamin, casein kinase II, Ras, Raf, several transcription factors and the DNA binding 
region of LexA itself (not fused to another protein). The plasmid pLEXAU 1D was 
also tested with these proteins expressed as GAL4 fusions and with the GAL4 a
activation domain itself (not fused to another protein). No interactions were detected
under conditions that demonstrated an interaction between pLEXAU 1D and the 
positive from the screen. This suggested that the interaction detected in the screen 
was unlikely to be explained by non specific interactions between UCRl and other 
proteins.
6 .2.1.2 The carboxyl terminal half o f UCRl interacts with the amino terminal third 
ofUCR2
To provide further evidence in support of the results from the two-hybrid screen and 
also to determine more precisely which regions of PDE4D3 interacted with the 
cai’boxyl terminal half of UCRl, various portions of the HSPDE4D3 cDNA were 
cloned into pGADN, to encode fusion proteins with the GAL4 activation domain. 
Yeast two-hybrid p-galactosidase assays were then used to test these constructs for 
interaction with the carboxyl terminal half of UCRl, called UCRl-C.
These assays were performed both with the pLEXAUlD construct encoding the 
carboxyl terminal portion of UCRl (residues 80-116 in HSPDE4D3) and with 
another construct, pLEXAU IE that corresponded more closely to the carboxyl 
terminal portion of UCRl (residues 80-109 in HSPDE4D3). The results of the assays 
using either one of these baits demonstrated that the carboxyl terminal portion of 
UCRl interacted with a small portion of the PDE4D protein, located within the 
amino terminal half of UCR2 (residues 134-170 in HSPDE4D3).
It was also noticed that the carboxyl terminal half of UCRl was unable to interact g
with any of the portions of HSPDE4D3 that contained UCRl, even if that portion 
also included UCR2. These results were interpreted as competition for the LexA- 
UCRl binding site on the PDE4D-GAL4 fusion protein by the UCRl already present 
in those constructs.
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6.2.2 Biochemical analysis of the interaction between UCRl and UCR2
Although positives from two-hybrid screens can be taken as indicative of a protein- 
protein interaction, it is crucial to be able to demonstrate such an interaction 
biochemically in order to provide strong evidence for the interaction. Furthermore 
biochemical analysis was requires to test full length UCRl as a potential interacting 
partner for UCR2. To provide such biochemical evidence in support of the 
interaction between UCRl and UCR2 that had been discovered by the two-hybrid 
method I decided to use fusion proteins of both full length and the carboxyl terminal 
portion of UCRl with maltose binding protein (MBP). I decided to perform pull 
down assays with truncated forms of HSPDE4D3, expressed in the cytosolic fraction 
of transiently transfected COS-7 cells.
6.2.2.1 UCRl and UCR2 interact in pull down assays
The fusion proteins that I used for these studies were MBP-UCRl, a fusion protein 
between MBP and residues 17-136 of HSPDE4D3, and MBP-UCRl-C, a fusion 
protein between MBP and residues 80-116 of HSPDE4D3.1 expressed each of these 
fusion proteins, and also MBP alone, in JM109 E.coli then purified each one by 
affinity chiomatography on amylose resin. I monitored the purification of these 
fusion proteins by sodium dodecyl sulphate polyacrylamide electiophoresis (SDS- 
PAGE). In neither the purified MBP-UCRl nor the MBP-UCRl-C was a single 
band obseiwed. This indicated that these preparations were not homogeneous. There 
was, however, a major band in each case that migrated more slowly than did MBP 
alone and this was presumed to be the chimeric MBP-UCRl species. The uppermost 
band in each preparation migrated with an apparent Mw of 75kDa and of 70kDa for 
MBP-UCRl and for MBP-UCRl-C respectively. These values compared to an 
apparent Mw of 60kDa for MBP itself. The faster migrating bands in these 
preparations probably represent carboxyl terminally truncated forms of these fusion 
proteins. These may have resulted either from premature termination or from 
proteolysis of the full length fusion protein during the purification {Figure 6.65).
I used these fusion proteins as the baits in pull down assays with either full length 
HSPDE4D3 or amino terminal truncations in this protein that were expressed in
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the cytosolic fraction of transiently transfected COS-7 cells. I present here 2 typical 
immunoblots showing the bound and the unbound fractions from such pull down 
assays {Figure 6 .6 6 ). These immunoblots show that the full length and the 
truncations in HSPDE4D3 were detected as single immunoreactive bands in both the 
bound and the unbound fractions of these pull down assays. I used both semi- 
quantitative immunoblots and PDE enzyme activity assays to assess the binding of 
these species {Figure 6.67, Figure 6 .6 8 ). In all cases where I performed a semi- 
quantitative analysis of immunoblot data I also ran control lanes, on the same blot, 
that contained a known amount of HSPDE4D3. This was to show that, over the range 
of band intensities analysed, there was a linear relationship between band intensity 
and the amount of immunoreactive protein loaded. I analysed this data by performing 
t-tests to see if the mean difference between the binding of each of the truncations in 
HSPDE4D3 to each of the MBP-UCRl fusion proteins was significantly different 
from the binding of that truncation to MBP alone. This analysis revealed that both 
MBP-UCRl and MBP-UCRl-C were able to bind to UCR2+Cat, a truncation in 
HSPDE4D3 that lacked UCRl but still contained UCR2. In contrast to this neither of 
the MBP-UCRl fusion proteins were able to bind to full length HSPDE4D3 
(NT+Ul+U2+Cat+C) nor to a truncation in HSPDE4D3 that contained only the 
catalytic and the extreme carboxyl terminal regions of the protein (Cat+C).
In separate experiments I also examined the binding of a fusion protein between GST 
and UCR2 (residues 134-212 in HSPDE4D3), expressed in COS-7 cells, to the 
MBP-UCRl fusion proteins. These experiments showed that the GST-UCR2 fusion 
protein, but not GST alone, was able to bind to both MBP-UCRl and to MBP- 
UCRl-C but not to MBP alone in pull down assays {Figure 6.69)
Together theses data confirm the two-hybrid data that the carboxyl terminal portion 
of UCRl can interact with UCR2. In particular they confirm that exogenous UCRl 
can only interact with UCR2 when UCRl is not present in the construct. In addition 
to this they demonstrate that full length, as well as just the carboxyl terminal portion 
of UCRl can interact with UCR2,
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Figure 6.65: Fusion proteins on UCRl y U CRl-C  and poin t mutations in UCRl 
with M BP
The figure shows Coomassie stained gels ofpurified MBP fusion proteins. In panel A 
lanes 2-9 are 3pgpurified MBP, MBP-UCRl, MBP-UCRlS54T, MBP— 
UCR1R51R52A, MBP-UCR1R98A, MBP-UCRlR101 A, MBP-UCR1E53A, MBP- 
UCRl S54D respectively; lanes 1 and 10 are molecular weight markers (Bio-Rad 
broad range prestained SDS-PAGE standards). The arrows indicate the Mw (kDa) o f 
each marker. In panel B lanes 1—7 are 3pgpurified MBP, MBP-UCRl-C, MBP- 
UCR1R98A, MBP-UCRl RIO I A, MBP-UCR1S5A, MBP-UCRl R98R101 A; lane 8  is 
molecular weight markers (New England Biolabs broad range prestained SDS- 
PAGE standards). The arrows indicate the Mw (kDa) o f each marker. The apparent 
Mw o f the slowest migrating band in each preparation was calculated by plotting R f  
values; this was ôOkDa, 70kDa, 75kDa and 75kDa for MBP, for MBP-UCRl-C, for  
MBP—UCRl and for the point mutations in MBP-UCRl respectively.
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Figure 6.66: M B P -U C R l interacts with the UCR2 o f  truncations in HSPDE4D3y 
in p u ll down assays
The figure shows immunoblots for PDE4D, o f aliquots (8 % and 16% respectively) 
from the bound and the unbound fractions from pull down assays o f MBP—UCRl and 
MBP-UCRl-C fusion proteins with truncations in HSPDE4D3 expressed in the 
cytosolic fraction o f transiently transfected COS-7 cells. Panel A shows analysis o f 
the truncation UCR2+Cat and o f the Catalytic and carboxyl terminal region o f 
HSPDE4D (Cat). Lanes 1 and 2 are standards for UCR2+Cat (D3-N2) and for Cat 
(D3-N3). Lanes 3-8 are unbound fractions and lanes 9-14 are bound fractions from  
pull down assays. The bait and prey pairs were: lanes 3 and 9, UCR2+Cat and 
MBP-UCRl ; lanes 4 and 10, Cat and MBP-UCRl ; lanes 5 and 11 UCR2+Cat and 
MBP; lanes 6  and 12 Cat and MBP; lanes 7 and 13 UCR2^Cat and MBP-UCRl-C; 
lanes 8  and 14 Cat and MBP-UCRl-C. Panel B shows analysis o f full length 
HSPDE4D3 (D3) and ofUCR2+Cat (D3-N2). Lanes 1—4 are unbound fractions and 
lanes 5-8 are bound fractions. The bait and prey pairs were: lanes 1 and 5 
UCR2+Cat and MBP-UCRl; lanes 2 and 6 , full length HSPDE4D3 and MBP- 
UCRl; lanes 3 and 7, UCR2+Cat and MBP; lanes 4 and 8 , UCR2+Cat and MBP. 
Full length HSPDE4D3 migrated as a 98kDa species, UCR2+Cat as an 84kDa 
species and Cat as a 70kDa species in these experiments. These data are typical o f  
those from experiments performed on 3 separate occasions.
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Figure 6.67: Senti quantitative analysis o f  bound immunoreactivity in pull 
down assays
The figure shows a histogram o f the percentage binding in pull down assays 
between MBP, MBP—UCRl and MBP-UCRl-C as the baits and full length 
HSPDE4D3, the truncations UCR2+Cat and Cat. The data show the 
proportion o f the prey captured in the bound fraction as a percentage o f total 
amount recovered. This was assessed by semi quantitative immunoblots for  
PDE4D. The figures represent the means o f 3 separate experiments with 
standard errors shown.
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Figure 6.68: Analysis o f  bound PDE enzyme activity in pu ll down assays
The figure shows a histogram o f the percentage binding in pull down assays 
between MBP, MBP—UCRl and MBP-UCRl-C as the baits and full length 
HSPDE4D3, the truncations UCR2+Cat and Cat. The data show the 
proportion o f the prey captured in the bound fraction as a percentage o f total 
amount recovered. This was assessed by PDE enzyme activity assays. The 
figures represent the means o f 3 separate experiments with standard errors 
shown.
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Figure 6.69: MBP—UCRl interacts with GST—UCR2y in p u ll down assays
The figure shows immunoblots, with an antibody against GST, o f aliquots (8 % and 
16% respectively) from the bound and the unbound fractions from pull down assays 
o f MBP—VCR with GST—UCR2 expressed in the cytosolic fraction o f transiently 
transfected COS-7 cells. In panel A is a standard for GST-UCR2, lane 2 is empty, 
lanes 3-5 are the unbound fractions and lanes 6 - 8  are the bound fractions. The bait 
and prey pairs were: lanes 3 and 6 , MBP and GST-UCR2; lanes 4 and 7 MBP- 
UCRl and GST-UCR2, lanes 5 and 8 , MBP-UCRl-C and GST-UCR2. Panel B 
shows an experiment done to show that MBP-UCRl did not bind to GST in these 
assays. The immunoblot shows the bound fractions only ofpull down assays in which 
the bait and prey pairs were: lane 1, MBP and GST; lane 2, MBP and GST-UCR2; 
lane 3, MBP-UCRl and GST; lane 4, MBP-UCRl and GST-UCR2. These data are 
typical o f those from experiments performed on 3 separate occasions.
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6.2.3 Two charged amino acids within UCRl are necessary for its interaction 
with UCR2
The carboxyl terminal of UCRl is mainly composed of amino acids with apolar side 
chains. The few charged residues that occur within this region are D83, D84, R98 
and RlOl (numbers indicate the position of the residue in HSPDE4D3). These 
residues are highly conserved among all the mammalian PDE4 isoforms and in the 
dunce PDE of Drosophila (Figure 6.64). In contrast, the amino terminal portion of 
UCR2 (residues 134-179 in HSPDE4D3) is very hydrophilic and contains numerous 
amino acids with negatively charged side chains. It therefore seemed likely that the 
interaction between these 2 regions would involve the chai'ged residues in the UCRl.
6.2.3.1 Yeast two-hybrid analysis o f charged residues within UCRl
The involvement of the charged residues within the carboxyl terminal region of 
UCRl was first investigated by the yeast two-hybrid method. The codon for each of 
the 4 charged residues in this region of UCRl was mutated, separately and in various 
combinations, to encode alanine, in the plasmid pLEXAUlD. Two-hybrid assays 
were then used to test the mutants for their ability to interact with UCR2. The results 
of these assays demonstrated that both the R98 and the RlOl individual mutants 
partially attenuated the interaction and that the R98,R101 double mutant completely 
blocked the interaction. In contrast to this neither the D83 nor the D84 mutations 
produced any detectable change in the interaction.
6 .2.3.2 Biochemical analysis o f charged residues within UCRl
To provide biochemical evidence in support of this two-hybrid data I expressed and 
purified 3 separate mutants of the MBP-UCRl construct, in which the residues R98 
and RlOl had been mutated to alanine singly and in combination. I used these 
proteins as baits in pull down assays with the truncation in HSPDE4D3, UCR2+Cat, 
as the prey. I monitored binding in these experiments both by immunoblots and by 
PDE enzyme activity assays (Figure 6.70, Figure 6.71). I analysed this data by 
performing t-tests to see if the mean difference between the binding of UCR2+Cat to 
each of the MBP-UCRl fusion proteins was significantly different from its 
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binding to MBP alone. This analysis revealed that mutation of either R98 or RlOl to 
alanine partially attenuated the interaction and that the R98, RlOl to alanine double 
mutation completely blocked the interaction.
Together with the results from the yeast two-hybrid experiments these data show that 
the positively charged arginine residues R98 and RlOl are necessary for the 
interaction between UCRl and UCR2 in these assays. This supports the hypothesis 
that the side chains of these residues project out from a generally hydrophobic region 
within UCRl and that they are necessary for the binding of UCRl to UCR2 in the 
full length PDE.
i
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Figure 6.70: Specific amino acids (R98 and R lO l) in U CRl 
mediate its interaction with UCR2
The figure shows an immunoblot, for PDE4D, o f aliquots from 
the bound fractions ofpull down assays between constructs o f 
MBP—UCRl with various mutations, as baits, and the cytosolic 
fraction from transiently transfected COS-7 cells expressing 
UCR2+Cat (D3-N2) as prey. The mutations in the MBP- 
UCRl construct used in these pull down assays were: lane 1, 
R98A; lane 2, RlOl A, lane 3, wild type; lane 4, R98A,R101A. 
These data are typical o f those from experiments performed on 
3 separate occasions.
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Figure 6.71: Analysis of bound PDE enzyme activity and of bound anti PDE4D 
immunoreactivity in pull down assays
The figure shows a histogram o f the percentage binding in pull down assays between 
MBP, MBP-UCRl, MBP-UCR1R98A, MBP-UCRIRIOIA andMBP- 
UCR1R98R101A as the baits and full length UCR2+Cat as the prey. The data show 
the proportion o f the prey captured in the bound fraction as a percentage o f total 
amount recovered. This was assessed both by semi quantitative immunoblots (solid 
bars) and by PDE enzyme activity assays (cross hatched bars). The figures represent 
the means o f 3 separate experiments with standard errors shown.
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6.23.3 Yeast two-hybrid analysis o f specific charged residues within UCR2
Further yeast two-hybrid analysis were then performed to determine which residues 
within UCR2 were necessary for the interaction with UCRL Site directed 
mutagenesis was used to mutate various combinations of glutamic acids or aspartic 
acids within the amino terminal region of UCR2 to alanine. These mutants were then 
tested for their abilities to interact with pLEXAU IE in two-hybrid tests. The results 
of these assays demonstrated that the simultaneous mutation of 3 amino acids (El 46, 
E l47 and D149) to alanine significantly attenuated the interaction between UCRl 
and UCR2. In contrast to this, the mutation of other combinations of charged amino 
acids, such as the double mutant pairs E143, E146 or D153, E l56 to alanine had no 
detectable effect on the interaction.
To determine if the positively charged arginine residues R98 and RlOl in UCRl 
might specifically interact with the negatively charged glutamic and aspartic acids 
E l46, E l47 and D149 in UCR2 further two-hybrid assays were performed. These 
assays tested the ability of the single R98 to alanine and the RlOl to alanine mutants 
in UCRl to interact with vaiious combinations of mutations that changed El 46,
El 47 and D 149 to alanine. These results showed that the combination of mutating 
RlOl in UCRl and D149 in UCR2 to alanines blocked the interaction, although each 
of these single mutants alone did not.
These data show that specific charged residues are important for the interaction 
between UCRl and UCR2. This supports the hypothesis that UCRl and UCR2 
interact by electrostatic interactions between positively charged arginines within the 
carboxyl terminal portion of UCRl and the negatively charged glutamic and aspartic 
acid residues in the amino terminal portion of UCR2. Indeed these data are consistent 
with, although do not prove, a putative direct interaction between residue RlOl in 
UCRl and one or both of the residues El 46, E147. To further test this hypothesis it 
would be desireable to construct mutant proteins in which these residues were 
swaped and then to test whether these constructs could interact with each other.
6.2.4 Effect of phosphoi*ylation at Ser54 on the interaction between UCRl and
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UCRl
The long PDE4D isoform PDE4D3 is activated upon phosphorylation by PKA (82,
197, 198). There are 2 distinct sites within PDE4D3 that conform to the consensus 
RRxS motif for phosphorylation by PKA (SI 3 and S54 in HSPDE4D3). Both of 
these sites in PDE4D3 are substrates for PKA in vitro and in vivo PKA (82, 197,
198). The phosphorylation of PDE4D3 at S54 leads both to activation of the enzyme 
and to a change in its sensitivity to inhibition by rolipram (197). The effects of 
phosphorylation at S54 on both the enzyme activity and its sensitivity to rolipram are 
completely mimicked by the mutation of S54 to aspartic acid (82). As the residue 
S54 in HSPDE4D3 lies within UCRl, I decided to investigate whether the 
phosphorylation of this residue affected the interaction between UCRl and UCR2.
6.2.4.1 Effect o f mutations in the PKA consensus phosphorylation motif in UCRl on 
the interaction between UCRl and UCR2
■Ï
I decided to use mutations within the PKA phosphorylation motif in UCRl as an 
initial strategy to investigate whether the phosphorylation of S54 was likely to affect 
the interaction of UCRl with UCR2. This was because, by using mutations, rather 
than in vitro phosphorylated MBP-UCR-1, 1 could be confident that all of the bait 
fusion protein in the assays contained the modification. Another potential 
disadvantage associated with the alternative strategy of using in vitro phosphorylated 
MBP-UCRl for the initial investigation was the possibility that residues other than 
S54 may have been modified under the conditions used for the in vitro 
phosphorylation of the fusion protein.
I expressed and purified 5 separate mutants of the MBP-UCRl construct in which 
the residue S54 was mutated to an alanine, an aspartic acid, or a threonine residue 
(MBP-UCRl S54A, MBP-UCRl S54D and MBP-UCRl S54T respectively) or the 
residue E53 was mutated to an alanine (MBP-UCR1E53 A) or the residues R51 and 
R52 were both mutated to alanines (MBP-UCR1R98R101 A). I used these proteins 
as baits in pull down assays with UCR2+Cat, as the prey. I monitored binding in 
these experiments both by immunoblots and by PDE enzyme activity assays {Figure 
6.72, Figure 6 .73). I analysed this data by performing t-tests to see if the mean
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difference between the binding of UCR2+Cat to each of the MBP-UCRl fijsion 
proteins was significantly different from its binding to MBP alone.
The effect of these mutations in full length HSPDE4D3 suggests that the 
phosphorylation of wild type HSPDE4D3 at S54 leads to at least 2 distinct 
conformational changes in the enzyme. One of these is suggested to result in 
activation and the other to yield a change in the enzymes sensitivity to inhibition by 
rolipram (82).
It has been proposed that the conformational change in HSPDE4D3 that is detected 
by a change in its sensitivity to inhibition by rolipram is caused by the disruption of a 
hydrogen bond involving the side chain hydroxyl group of S54. Consistent with this 
proposal, mutation of S54 in the full length enzyme to threonine, which preserves the 
hydrogen bonding potential at this site, does not cause a change in the enzymes 
sensitivity to rolipram. The conformational change in full length HSPDE4D3 that 
leads to enzyme activation was suggested to be due to the disruption of an ion pair 
interaction involving the negatively charged E53. Consistent with this proposal, 
mutation of E53 to alanine in the full length enzyme resulted in a species that was 
constitutively activated compared to the unphosphorylated, wild type enzyme but 
that did not display an altered sensitivity to inhibition by rolipram (82).
Mutation of S54 to either alanine or aspartic acid in MBP-UCRl disrupted the 
interaction between UCRl and UCR2 in pull down assays. These mutations in full 
length HSPDE4D3 both caused a change in the sensitivity of the enzyme to rolipram. 
In contrast to this, the effects of these mutations on the activity of HSPDE4D3 are 
different; with mutation of S54 to aspartic acid but not to alanine causing activation 
of the enzyme. Mutation of S54 to threonine in MBP-UCRl did not disrupt the 
interaction between UCRl and UCR2 in pull down assays. This mutation in full 
length HSPDE4D3 does not cause a change in sensitivity to rolipram {Figure 6.72, 
Figure 6 JS) (82).
Mutation of E53 to alanine in MBP-UCRl did not disrupt the interaction between 
UCRl and UCR2 in pull down assays. This mutation in full length HSPDE4D3 does 
cause activation but does not affect the sensitivity of the enzyme to inhibition by
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rolipram. The double mutation of R51 and R52 to alanines (which disrupts the 
phosphorylation motif for PKA) in MBP-UCRl did not disrupt the interaction 
between UCRl and UCR2 in pull down assays. This mutation in full length 
HSPDE4D3 did not affect either the sensitivity of the enzyme to inhibition by 
rolipram, nor did it cause activation compared to the unphosphorylated wild type 
enzyme {Figure 6.72, Figure 6 .73) (82).
Together these data suggest that a change in the conformation in full length 
HSPDE4D3 that follows the phosphorylation of S54 by PKA and that results in a 
change in the sensitivity of this enzyme to inhibition by rolipram involves the 
disruption of an interaction between UCRl and UCR2.
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Figure 6.72: The effect o f  mutations within the PKA consensus phosphorylation 
m otif in UCRl on the interaction between UCRl and UCR2 in p u ll down assays
The figure shows an immunoblot, for PDE4D, o f aliquots from the bound fractions o f 
pull down assays between constructs o f MBP-UCRl with various mutations, as 
baits, and the cytosolic fraction from transiently transfected COS-7 cells expressing 
UCR2+Cat (D3-N2) as prey. The mutations in the MBP-UCRl construct used in 
these pull down assays were: lane 1, S54D; lane 2, S54A, lane 3, wild type; lane 4, 
S54T; lane 5, the double mutation R51R52A; lane 6 , E53A. These data are typical o f 
those from experiments performed on 3 separate occasions.
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Figure 6.73: Analysis of bound PDE enzyme activity and of bound anti 
PDE4D immunoreactivity in pull down assays
The figure shows a histogram o f the percentage binding in pull down assays 
between MBP, MBP-UCRl, MBP-UCRS54A, MBP-UCR1S54D, MBP- 
UCRl S54T, MBP-UCR1E53A and MBP-UCRl R51RS 2A as the baits and full 
length UCR2+Cat as the prey. The data show the proportion o f the prey 
captured in the bound fraction as a percentage o f total amount recovered.
This was assessed both by semi quantitative immunoblots (solid bars) and by 
PDE enzyme activity assays (cross hatched bars). The figures represent the 
means o f 3 separate experiments with standard errors shown.
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6,3 Conclusion
In this chapter I have presented biochemical evidence to support the results of elegant 
yeast two-hybrid experiments perfomied in the laboratory of Prof. G. Bolger, 
Together these data suggest that UCRl and UCR2 of PDE4 can interact and that this 
interaction is stabilised by electrostatic bonds between specific residues located in the 
carboxyl terminal portion of UCRl and in the amino terminal portion of UCR2.1 
have also presented data which suggest that the interaction between UCRl and 
UCR2 can be regulated by phosphoiylation at a PKA consensus motif located within 
the amino terminal of UCRl.
6.3.1 UCRl and UCR2 may form authentic domains within the amino termini 
of PDE4 isoforms
The sequences of UCRl and UCR2 can be regarded as unique signatures of the 
PDE4, cAMP specific phosphodiesterase family. These conserved regions are located 
in the amino termini of PDE4s and are clearly separate firom the catalytic regions of 
these enzymes. The data presented in this chapter are consistent with the hypothesis 
that both UCRl and UCR2 act as authentic protein domains. That is to say that 
UCRl and UCR2 each seem able to fold into independent modules that retain their 
structures in a variety of contexts. This is demonstrated by the data showing that 
UCRl can interact with UCR2 when each is expressed as a fusion with one of several 
different proteins. These include the DNA binding domain of LexA and MBP for 
UCRl and GST or the GAL4 activation domain for UCR2. This is reminiscent of 
SH2 and SH3 domains, that are also independently folding domains able to 
participate in protein-protein interactions (141, 162, 168).
6.3.2 Conformational change in PDE4D3 following phosphorylation on Ser^ '^
The data on the effect of mutations within the PKA phosphoiylation site in UCRl 
provide additional insight into the mechanism of the regulation of PDE4D3 by PKA. 
Conti and co-workers have demonstrated that PDE4D3 can be phosphorylated and 
activated by PKA in vivo. The critical phosphorylation site for this activation is 854
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(197-199). This residue lies within the amino terminal portion of UCRl.
Phosphorylation of S54 in PDE4D3 produces both a change in the enzymatic activity 
(change in relative Vmax) and a change in the sensitivity of the enzyme to inhibition 
by rolipram. A study by Hoffmann and others that used mutants within the PKA 
phosphorylation sites in HSPDE4D3 showed that the changes in enzyme activity and 
in sensitivity to rolipram that followed modification of this region could be separated 
from one another. This study provided evidence to suggest that S54 and the adjacent 
E53 were each involved in forming bonds that influenced the structure of the 
catalytic site of the enzyme. The proposed model was one in which the side chain of 
E53 was involved in an ion pair that constrained the catalytic activity of the enzyme 
but that did not influence the sensitivity of the enzyme to inhibition by rolipram. The 
side chain hydroxyl group of S54 was suggested to be involved in a hydrogen bond 
that did not constrain the activity of the enzyme but that did influence the 
conformation of the catalytic site in a way that could be detected by a change in its 
sensitivity to inhibition by rolipram (82).
In this chapter I have shown that mutations in UCRl that cause a change in the 
sensitivity of full length HSPDE4D3 to inhibition by rolipram also dismpt the 
interaction between UCRl and UCR2 in pull down assays (MBP-UCRl S54A and 
MBP-UCR 1S54D). Mutations in UCRl that do not cause a change in the sensitivity 
of HSPDE4D3 to inhibition by rolipram do not, however, disrupt the interaction 
between UCRl and UCR2 in pull down assays (MBP-UCRl S54T, MBP- 
UCRl E53 A and MBP-UCR1R51R52A). This is regardless of whether or not they 
cause activation of full length HSPDE4D3.
These data support the hypothesis that the change in sensitivity to inhibition by 
rolipram but not the activation of PDE4D3, following phosphorylation by PKA on 
S54, is linked to the disruption of an interaction between UCRl and UCR2 in the 
enzyme.
It would be desirable to perform pull down experiments using a wild type UCRl 
fusion protein that was phosphorylated on S54 to support the results of these pull 
down assays using mutated fusion proteins. It would also be interesting to
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further test the hypothesis, that the interaction between UCRl and UCR2 affects the 
sensitivity of the enzyme to rolipram but not its activity, by characterising the effect 
of mutations in full length HSPDE4D3 that disrupt this interaction in pull down 
assays. Full length HSPDE4D3 in which R98 and RlOl were mutated to alanines, for 
instance, would be predicted to show an altered sensitivity to inhibition by rolipram 
compar ed to the wild type enzyme.
The data presented in this chapter are consistent with a model for PDE4 structure 
where UCRl and UCR2 in the full length protein each comprise 1 or more 
independently folding domains and that these domains interact with other regions of 
the enzyme. An important example of such an interaction is the electrostatic 
interaction between positively charged residues in the carboxyl terminal of UCRl 
and negatively charged residues within the amino terminal of UCR2. It is proposed 
that this interaction is modulated by PKA phosphorylation of a serine residue in the 
extreme amino terminal region of UCRl. This portion of UCRl is not necessary for 
the interaction with UCR2 in pull down or in two-hybrid assays. It might therefore 
not interact directly with UCR2. It is possible that the amino and the carboxyl 
teiminal portions of UCRl affect one another in such a way that the loss of hydrogen 
bonding capacity at S54 prevents the carboxyl terminal of UCRl from interacting 
with UCR2. Under this model UCRl and UCR2 can be thought of as forming a 
regulatory module that in turn regulates the catalytic site of long PDE4 isoforms. 
Structural analysis of PDE4 enzymes will, however, be needed to gain a full 
understanding of the molecular mechanisms of this regulation.
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7. General discussion
An important aspect of the regulation of cAMP signalling within a cell is the spatial 
organisation of the components of this signalling pathway. Enzymes that catalyse 
each step of the cAMP signalling pathway are targeted to specific locations within 
the 3 dimensional interior of the cell. This creates a potential for the establishment of 
localised increases in cAMP concentration that could selectively activate PKA in that 
region but not affect other, functionally distinct, pools of PKA anchored in other 
regions of the cell.
In chapter 3 of this thesis I have shown that the type 4 phosphodiesterase (PDE4) 
splice variant PDE4D4 can specifically interact with Src homology 3 (SH3) domains
Ï-
The 3’,5’ cyclic adenosine monophosphate (cAMP) signalling pathway plays a 
central role in cellular signalling. As I have discussed, in detail, in the inti'oduction of 
this thesis, signalling through cAMP is classically considered to involve the 
activation of protein kinase A (PKA) which then phosphorylates downstream 
proteins to bring about both acute changes in cellular physiology and also longer 
term changes in the transcription of cAMP responsive genes. In addition to causing 
activation of PKA, cAMP can also act to affect cell function by directly binding to 
certain ion channels and by binding to and activating the guanine nucleotide 
exchange factor Epac (exchange protein directly activated by cAMP). Once 
activated, Epac causes the activation of Rap-1 which can then feed into the mitogen 
activated kinase (MAPK/ERK) signalling pathways.
In addition to the direct actions of activated PKA on downstream proteins, every 
stage in the classical cAMP signalling pathway presents opportunities for crosstalk 
between the cAMP and other intracellular signalling pathways. Signalling through 
cAMP should therefore be thought of as an integrated part of the signal transduction 
potential of a cell. The cellular response to any single stimuli will depend not only 
upon the class of receptor that it activates and the signalling pathway that it couples 
to but also, in various and subtle ways, on the activation status of many, if not all, 
other signal transduction pathways within the cell.
' :
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in vitro and that it appears to show a selectivity for interaction with the SH3 domains 
of the Src family tyrosyl protein kinases Src, Lyn and Fyn. This finding is significant 
because it raises the possibility that, in vivo, PDE4D4 may become recruited into
In chapter 4 of this thesis I have shown, for the first time, that recombinant, full
signalling complexes by interacting with an SH3 domain and that this may serve to 
regulate local cAMP concentrations in the immediate vicinity of such complexes.
length HSPDE4D4 can be expressed in E.coli as a fusion protein with maltose 
binding protein (MBP) and purified to near homogeneity by affinity chromatography. 
By using purified preparations of MBP-HSPDE4D4 and also of just the amino 
terminal region of HSPDE4D4 as a fusion protein with MBP I was able to 
demonstrate that both full length HSPDE4D4 and the alternatively spliced, amino 
terminal region of HSPDE4D4 alone can interact directly with SH3 domains.
By engineering a sequence encoding a recognition site for the viral protease TEV 
into the MBP-HSPDE4D4 fusion protein I was able to express and purify a fusion 
protein that included this protease recognition site. This enabled me to separate 
proteolytically the MBP moiety of the fusion protein from the HSPDE4D4 moiety. 
Doing this I obtained a purified recombinant HSPDE4D4 with only 11 vector derived 
amino acids remaining at its amino terminus.
The production of a bacterially expressed, highly purified, full length PDE is a 
significant advance as, in the past, the purification of these enzymes has proven to be 
extremely problematic. This has allowed me to perform a limited characterisation of 
purified HSPDE4D4. This was the first time that a purified preparation of 
HSPDE4D4 had been chaiacterised. It is likely that the method I developed for the 
expression and the purification of untagged, full length, HSPDE4D4 will be 
generally applicable to the purification of other PDE4 isoforms. The ability to easily 
produce relatively large quantities of purified PDE4 isoenzymes will be of major 
importance to future investigations into the regulation and the structure of these 
proteins.
In chapter 5 of this thesis I investigated the interaction of another PDE4 isoform, 
RNPDE4A5, with SH3 domains. It had already been shown that RNPDE4A5
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can specifically interact with SH3 domains and that the alternatively spliced, amino 
terminal region of the protein was necessary for this interaction. This region of 
RNPDE4A5 is characterised by 3 regions of proline and arginine rich sequence that 
each conform to the PxxP, minimal consensus sequence for binding to SH3 domains. 
By using a strategy of sequential amino terminal truncations in RNPDE4A5 I 
implicated the most amino terminal of these putative SH3 domain binding motifs as 
being of importance in the interaction between RNPDE4A5 and SH3 domains. I also 
used the truncation mutants in RNPDE4A5 to identify a region of sequence within 
the mnino terminal region of this protein that is involved in the subcellular targeting 
of this enzyme. These findings will be important in planning further experiments to 
examine the roles of protein-protein interactions and of subcellular targeting in the 
regulation of cAMP signalling by RNPDE4A5.
In chapter 6 of this thesis I turned my attention from the intermolecular protein- 
protein interactions of PDE4s to investigate an intramolecular interaction between 
the UCRl and UCR2 of long foim PDE4 splice variants. I provided biochemical 
evidence to support preliminaiy yeast 2 hybrid data that demonstrated an interaction 
between the UCRl and the UCR2 of HSPDE4D3. In a collaboration with Prof. G. 
Bolger I then proceeded to investigate the roles that specific residues within UCRl 
and UCR2 play in regulating the interaction of these 2 regions. This investigation 
showed that specific charged residues located in the carboxyl terminal portion of 
UCRl and the amino terminal portion of UCR2 were important for stabilising the 
interaction between UCRl and UCR2. Furthermore, I showed that the interaction 
between UCRl and UCR2 could be regulated by the phosphorylation of a serine 
residue located within a PKA recognition motif that lies within UCRl (Ser^ '^  in 
HSPDE4D3). This residue is found in all long PDE4 isoforms where it is an 
authentic substrate for modification by PKA in vivo.
UCRl and UCR2 are unique “signature” regions of all long PDE4 isoforms. 
Phosphorylation of a serine residue within UCRl can activate at lease one PDE4 
isoform, namely HSPDE4D3. This modification also serves to dismpt the interaction 
between UCRl and UCR2.1 propose, therefore, that UCRl and UCR2 may act as 
signal transducing modules within PDE4 enzymes that can interact with each other
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and can also transmit the effects of regulatory post-translational modifications to the 
catalytic region of the enzyme {Figure 7.74).
Taken together the work presented in this thesis represents a significant contribution 
to the understanding of the role of regulated protein-protein interactions in the 
control of cAMP signalling by PDE4.
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Figure 7.74: Proposed model fo r  the regulation o f  PDE4
The figure shows a diagram representing the proposed roles for regions within long 
PDE4 isoforms. The green boxes represent regions that are conserved between all 
long isoforms ofPDE4. These are Upstream Conserved Regions 1 and 2 (UCRl and 
UCR2) and the catalytic region. It is suggested that the interactions o f certain 
isoforms o f PDE4A (162) and PDE4D (Chapter 3 o f this thesis) with SH3 domains 
and the interaction o f HSPDE4D5 with RACK-1 (252) may play a role in subcellular 
targeting. It is also suggested that UCRI and UCR2 may interact to form a signal 
integration module that co-ordinates the effects o f regulatory inputs and transmits 
these to the catalytic region. The phosphorylation o f MMPDE4A5, downstream o f  
p70S6 kinase (132) and o f HSPDE4D3 by both PKA (197) and ERK2 (81) are shown 
as examples o f regulatory inputs.
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